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Summary
The complement system is implicated in a number of diseases where it exacerbates or 
triggers pathology. The majority of the anti-complement agents inhibit systemically, risking 
infection and immune complex disease with long-term use in humans. Many of these have a 
short half-life in vivo, necessitating repetitive administration. To overcome these limitations, 
two types of reagents were generated. Both target late stages of complement activation, 
preventing membrane attack complex (MAC) formation, which is implicated in many 
diseases.
The saliva of the soft tick, Ornithodoros moubata, contains a powerful complement inhibitor 
(OmCI) which has been developed by others for therapy. Recombinant OmCI rapidly binds 
circulating C5 when given to animals, completely inhibiting complement. However, excess 
agent is excreted within minutes, making long-term therapy with this agent problematic. To 
overcome this, I fused OmCI to the Fc domain of murine IgG2a, generating OmCI-Fc, an 
anti-complement therapeutic with extended in vivo half-life. OmCI-Fc efficiently inhibited 
the terminal pathway in vitro and, by binding C5 following resynthesis, also provided 
prolonged inhibition in vivo.
A second group of agents comprised CD59, a powerful MAC inhibitor, and the murine 
complement receptor of the immunoglobulin superfamily (CRIg). CRIg binds complement 
activation fragments, thus has potential to deliver therapy directly to tissues attacked by 
complement. An antibody hinge domain was engineered between the two moieties in 
CD59-CRIg to promote dimerisation and increase avidity for target tissue. The dimeric 
agent localised efficiently to the surface of complement-attacked cells in vitro and 
specifically targeted diseased tissue ex vivo.
I have created novel anti-complement reagents designed to deliver effective therapy locally, 
or where inhibition is long-term, to target only the terminal stages of complement. These 
agents have exciting potential to effectively treat complement-mediated diseases and to 
retain other crucial biological functions of complement such as opsonisation and immune 
complex solubilisation.
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Chapter 1. Introduction
In this chapter I will present a general overview of the literature relating to complement 
suppression in the context of disease. The chapter starts by describing the complement 
system and its physiological role in health. I will provide detailed information about 
complement regulatory molecules and give an overview of clinical conditions in which 
pathology is triggered by altered complement regulation. The focus is then moved to anti­
complement therapy where previously generated complement blocking drugs are 
comprehensively discussed. Finally, this chapter introduces the objectives of the current 
study.
1.1. The Complement system
Complement is a part of innate immunity with a crucial role in promoting inflammation, 
facilitating elimination of pathogens and maintaining homeostasis. Complement also has a 
role in modulation of adaptive immunity. The complement system consists of at least 30 
proteins. Some of the proteins circulate in a proenzymatic form and are only activated after 
proteolytic cleavage by earlier components in the cascade. Normal host tissues are protected 
from complement attack by complement control proteins; therefore failure in complement 
control mechanisms may result in damage to host cells. Complement activation occurs 
through three pathways: the classical (CP), lectin (LP) and alternative pathway (AP). This is 
illustrated in fig 1.1.
15
Lectin pathwayAlternative pathwayClassical pathway
MASPs
'•Z i
M B U Ficolin  
/  C4 I C4-bp
MASPs
Faclor B
Factor H 
Factor I
F actorDDAF
MCP
CR1
DAF
MCP
CR1
Properdi
CT C
'  C3a
□ 3 0
t C ' 3 b
C3
C4bC2a C3-convertase C3-con vert ase
C4bC2a
C5
C5aC5b
C6
- C D  C8C7
CD59
Membrane Attack Complex
Fig.1.1 Complement system. The CP is initiated by the binding of the C l complex to antibodies 
bound to antigens. C ls first cleaves C4, which binds covalently to the bacterial surface, and then 
cleaves C2. C4b and C2a forms C3-converatase (C4b2a) of the CP. The LP is initiated by binding of 
the complex of mannose-binding lectin or ficolins and the serine proteases mannose-binding lectin- 
associated proteases 1 and 2 (MASP1 and MASP2) to sugars on the pathogen surfaces. MASP2 acts 
in a fashion similar to that of C ls  to lead to the formation of the C3 convertase. MASP1 may be able 
to cleave C3 directly. The AP is initiated by the covalent binding of a small amount of C3b to 
hydroxyl groups on cell-surface carbohydrates and proteins and is activated by low-grade cleavage 
of C3 in plasma. C3b binds factor B and forms a C3bB complex. Factor D cleaves factor B bound to 
C3b to form the AP C3-convertase (C3bBb). The binding of properdin stabilizes this enzyme. The 
C3-convertases cleave C3 to C3b, which bind covalently around the site of complement activation. 
Some of this C3b binds to the C4b and C3b in the convertase enzymes of the CP and AP, 
respectively, forming C5-convertase. These enzymes cleave C5 to C5a and C5b, which initiates the 
formation of the membrane-attack complex (MAC). MAC is assembled of C5b, C6, C7, C8 and 
multiple C9 molecules.
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1.1.1. Activation pathways
1.1.1.1. Classical pathway (CP)
The CP is initiated by binding of Cl to antibodies produced during the humoral response 
(IgG and IgM), to natural antibodies, and other molecules generated as a result of an 
inflammatory reaction such as C-reactive protein (CRP) or serum amyloid protein (SAP), as 
well as pathogen-associated molecular patterns, such as lipopolysacharide (LPS). Cl is a 
multi-molecular complex comprising Clq and serine proteases Clr and Cls (ClqClr2Cls2) 
[1]. The activation of the pathway occurs when Clq within the Cl complex binds one of the 
above mentioned target molecules. Ligands for Clq are listed in table 1.1.
Ligands for Clq:
Immunoglobulins Fc domain of IgM and IgG (IgG3, IgGl 
and IgG2)
Gram-negative bacteria Lipid A of LPS, Porins
Gram-positive bacteris Lipoteichoic acid
Viruses Moloney virus, Vesicular stomatitis virus, 
DNA polyoma virus, HIV-1
Polyanions Heparin, Chondroitin-4-sulphate 
Polynucleotides, Single stranded and 
double stranded DNA, Cardiolipin and 
other anionic polyanions in vesicles or on 
apoptotic cells
Other proteins Ligand bound pentraxins: CRP and SAP 
(bound to bacterial and host cell 
breakdown products such as chromatin)
Table 1.1 Clq ligands
The complex then binds C4 and activated Cls cleaves it to C4b. Surface attached C4b
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interacts with C2. C2 is then cleaved by the activated Cls into C2a and C2b. C4b and C2a 
fragments form the C3 convertase that cleaves the third component of complement, C3. 
Activation of C3 results in generation of C3a and C3b fragments. As seen in Fig. 1.1, C3b 
forms a complex with C4b and C2a to generate the C5 convertase that will cleave C5 to C5a 
and C5b [1]. C3a and C5a are anaphylatoxins that mediate multiple reactions in the acute 
inflammatory response, such as smooth muscle contraction, changes in vascular 
permeability, histamine release from mast cells, neutrophil chemotaxis, platelet activation 
and aggregation. C5a is the most potent, followed by C3a and C4a.
1.1.1.2. Lectin pathway (LP)
The LP has features in common with the CP but is evolutionary much older [2, 3]. 
Activation of the LP occurs through recognition of oligosaccharide-based or actetyl-based 
pathogen-associated molecular patterns by either mannan binding lectin (MBL) or ficolins in 
associations with MBL-associated serine proteases (MASPs). MBL and ficolins are plasma 
proteins that recognise carbohydrates motifs found on bacteria, viruses, fungi or altered self­
molecules (Table. 1.2) [4]. In humans there are three MASPs (MASP-1, -2 and 3) and an 
alternative splicing fragment of MASP-2 called Map 19 [5]. These enzymes are very similar 
to Clr and Cls of the CP. Upon binding to the target, the MASPs are activated and can 
cleave C4 and C2, this allows the generation of the CP C3 convertase (C4bC2a).
1.1.1.3. Alternative pathway (AP)
In contrast to the CP and LP, AP has no recognition proteins similar in structure to Clq, 
MBL or ficolins. However a low level of C3 activation (1% of total C3 per hour) takes place 
in the blood. A spontaneous hydrolysis of thioester bond in C3 occurs resulting in the 
generation of C3(H20), a molecule with similar properties to C3b. C3(H20) is capable of 
binding to factor B (fB).
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Target Pathogens for MBL and ficulins
Bacteria E.coli
Salmonella sp.
Pseudomonas aruginosa 
Haemophilus influenzae 
Neiserria meningitidei and N. 
gonorrhoea
Viruses Herpes simplex virus 
HIV-1 and HIV-2 
Influenza A Virus
Fungi Candida albicans 
Saccharomyces cerevisiae 
Aspergillus fumigatus
Endogenous ligands Dying cells 
Ischemic tissue 
Transformed cells 
Nucleic acids 
Phospholipids
Table 1.2. Pathogens recognised by MBL and ficolins
Upon the binding fB changes conformation and can be then cleaved by serum protease 
factor D (fD) into Ba and Bb. The Bb fragment remains associated with the complex to form 
“initiation” C3-convertase (C3(H20)Bb) and through its own serine protease domain cleaves 
additional C3 molecules into small fragment C3a and large fragment, nascent C3b. This 
process leads to conformational changes and exposure of an internal thioester bond, which 
following nucleophilic attack by a surface group, allows covalent association of C3b with 
pathogen surfaces. C3b associates with fB to generate C3-convertase of the AP (C3bBb). 
This process is known as the tickover mechanism of the alternative pathway as it constantly 
generates low levels of activated C3b-like molecules capable of forming a convertase. The 
C3 convertase is stabilized by the binding of an oligomeric protein known as properdin [6, 
7]. Cleavage of C3 and binding of this additional C3b to the convertase (forming a C3b 
‘dimer’) gives rise to the C5 convertase of the alternative pathway. This enzyme activates 
C5.
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Another mechanism of activation of the alternative pathway has been recently proposed. 
Spitzer and colleagues have shown that properdin can directly bind to some target surfaces 
such as yeast cell wall and Neisseria gonorrhoeae and recruit fluid-phase C3b to the surface 
[8]. Properdin-bound C3b associates with fB in a similar fashion as the nascent C3b.
The alternative pathway also serves as an “amplification loop” for CP and LP [9, 10]. The 
C3b molecules, generated by the activation of CP or LP, bind fB. Similarly to the tickover 
process, fB is then cleaved and activated by fD.
1.1.2. Terminal pathway
All three pathways of complement activation converge at the level of C3. Activation of C3 
followed by C5 activation triggers the terminal pathway of the complement system. The 
terminal pathway and the assembly of the Membrane Attack Complex (MAC) are illustrated 
in figure 1.2. The terminal pathway starts when C5 is split into the chemo-attractant, C5a, 
and C5b by the C5 convertase. C5a is a potent anaphylatoxin that mediates inflammatory 
responses at the site of injury by stimulating neutrophils, eosinophils, phagocytes and 
endothelial cells [11]. C5b forms a complex with C6 and the subsequent binding of C5b6 to 
C7 induces a hydrophilic to amphipilic transition that allows C5b7complex to bind the target 
lipid bilayer membranes. Incorporation of C8 and multiple C9 molecules allows the complex 
to penetrate the lipid bilayers creating complete transmembrane channels resulting in 
osmotic lysis of the cell.
C5b-7 is cytolytically inactive and does not form a pore in the cell membrane, whereas C5b- 
8 and C5b-9 are pore-forming complexes. C5b-8 pores range from 0.4 to 3nm in diameter 
and a large number is required to lyse erythrocytes and nucleated cells [12]. The diameter of 
C5b-9 pores can range from 1 to 11 nm [13, 14].
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Fig. 1.2 Schematic diagram of terminal complement pathway and MAC formation. C5
convertase binds and cleaves C5 into C5b and C5a. C5a (anaphylatoxin) is released in the 
fluid phase. C5b binds C6. Upon the binding C6 undergoes conformational changes that 
allows binding to the lipid bilayer. C7 and then C8 sequentially bind to C5b and insert into 
the lipid bilayer, forming C5b-7 and C5b-8 complexes, respectively. One molecule o f C9 
binds to C8, which is followed by polymerisation of multiple C9 molecules, forming the 
C5b-9 complex.
Papadimitriou and colleagues have demonstrated that MAC lytic activity is characterized by 
a rapid increase in intracellular Ca2+, followed by loss of mitochondrial polarity and adenine 
nucleotide pools (ADP and ATP) [15]. Multiple C5b-9 complexes are required to kill 
nucleated cells, resistance to MAC-mediated killing being dependent on the ability o f the 
cells to eliminate C5b-9 complexes and repair the cellular membranes. Insufficient numbers 
of C5b-9 complexes form short-lived channels that can easily be eliminated through 
endocytosis and exocytosis without causing any cell lysis. This sublytic dose o f C5b-9 can 
induce cell-cycle progression by activating signal transduction pathways, transcription 
factors and various components o f the cell-cycle machinery [16-19].
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1.1.3. Physiological role of the complement system in health
Complement participates in different steps of inflammatory reactions to protect the host 
against infection and from chemical or physical injury.
1.1.3.1. Host defence against infection
Complement is a major component of innate immunity that takes part in host defense against 
foreign pathogens. Activation of complement results in opsonisation, chemotaxis and 
activation of leukocytes and cytolysis of pathogens by MAC, all processes are responsible 
for pathogen removal.
1.1. 3.1.1. Opsonisation
Activation of the CP, LP and the AP converge at the level of C3 cleavage. Proteolytic 
cleavage of C3 into C3a and C3b results in conformational changes exposing the internal 
thioester bond and allowing covalent association of C3b with pathogen surfaces (bacterial, 
viral and protozoal) or circulating immune complexes. Further proteolysis of C3b results in 
formation of opsonins iC3b and C3dg and these can be recognized by different receptors on 
phagocytes promoting uptake of microbes coated with opsonins [20]. This process is known 
as opsonisation.
Complement receptors (CR) on leukocytes form an important link to the complement 
system. The receptors are discussed in section 1.5. Briefly, Complement Receptor type 1 
(CR1, CD35) binds the opsonin fragments C3b and C4b and promotes phagocytosis and 
clearance of antigen-antibody complexes [21]. Complement Receptor type 2 (CR2, CD21) 
binds iC3b and C3dg. This receptor is part of the B cell receptor (BCR) complex; binding of 
antigen-complement complexes to CR2 increases the sensitivity of the B cell to antigen by 
up to a thousand fold. Complement Receptor type 3 (CR3, CDl lb/CD 18, MAC-1) and 
Complement Receptor type 4 (CR4, CDl 1 c/CD 18, p i50.95) are integrin molecules that bind 
iC3b, p-glucan, intercellular adhesion molecule-1 (ICAM-1), and fibrinogen. These
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molecules serve as complement receptors, adhesion molecules and transmembrane 
signalling adapters. As complement receptors, CR4 and CR3 bind iC3b opsonised pathogens 
and trigger phagocytosis and degranulation of the effector cells [22, 23]. CR3 is the primary 
receptor responsible for phagocytosis of opsonised bacteria by neutrophils [24]. In addition 
to its complement-related function, CR3 binding to ICAM-1 expressed by stimulated 
endothelium allows monocytes, macrophages, neutrophils, NK and dendritic cells to adhere 
to blood vessel walls and move into the tissues at the site of inflammation [25, 26].
CRIg (Complement receptor of the immunoglobulin superfamily) is another complement 
receptor that recognizes C3 cleavage products. It binds opsonins C3b and iC3b and 
facilitates the clearance of pathogens. Although the Kupffer cells express CR3, CRIg is the 
main complement phagocytic receptor in liver. CR3 does not participate in immediate 
recognition of iC3b-coated pathogens, but contributes to the clearance indirectly by 
recruitment of neutrophils through interaction with ICAM-1 on neutrophils [27]. Moreover 
CR3 only binds iC3b, while CRIg can recognise also C3b, the first C3 cleavage product and 
thus ensures immediate pathogen recognition.
I.I.3.I.2. Chemotaxis and activation of leukocytes
Upon complement activation, small molecules C3a, C4a and C5a (~9kDa; 74-77 residues), 
known as anaphylatoxins are released. The anaphylatoxins exhibit important 
proinflammatory activities such as increase in vascular permeability, smooth muscle 
contraction, leukocyte recruitment and promoting production and release of other 
inflammatory mediators such as histamine [28]. C5a has been shown to be the most potent 
and C4a to be the weakest [29]. The functional response of the anaphylatoxins are mediated 
through interaction with seven-transmembrane G-protein-coupled receptors (C3aR for C3a, 
C5aR and C5L2 for C5a) expressed on the effector cells such as granulocytes, mast cells, 
monocytes and macrophages. It has been demonstrated that together with C3a and bacterial 
formylated peptides, C5a attracts phagocytes to the site of infection [30]. It can modulate the 
activity of a number of cell types such as eosinophils, basophils, neutrophils, monocytes and 
macrophages [31-35]. C5a, upon interaction with the C5a receptor (C5aR, CD88), can
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stimulate oxidative burst (release of reactive oxygen species) in neutrophils and enhances 
phagocytosis and release of granule enzymes [36, 37].
I.I.3.I.3. Lysis of bacteria and cells
Activation of the complement cascade results in formation of the membrane attack complex, 
which can disrupt the integrity of the bacterial cell wall, especially in Gram-negative 
bacteria (Neisseria meningitidis), which have an outer lipid membrane. However, Gram- 
positive bacteria resist this attack by the fact that their cell membrane is shielded by a thick 
cell wall [38] which prevents the C5b-9 complex from penetrating the thick peptidoglycan 
layer. The elimination of Gram-positive bacteria occurs via phagocytosis.
1.1.3.2. Disposal of waste
1.1.3.2.1. Clearance of immune complexes from tissues
Complement plays a role in maintaining homeostasis and removing antigen-antibody 
complexes generated during the adaptive immune response. This prevents immune complex 
(IC) deposition within the tissues and subsequent inflammatory reactions induced by these 
complexes. In humans and other primates, erythrocytes express CR1 organized in clusters on 
the cell surface, which bind C3b and/or C4b opsonised IC. The red blood cells transport 
these IC to the spleen and liver where they are cleared by macrophages [39, 40]. In 
autoimmune disease such as SLE (systemic lupus erythematosus) the number of CR1 on 
erythrocytes is reduced [41, 42]. This leads to failure in IC disposal and their deposition in 
the glomeruli and small vessels, which can trigger inflammation.
1.1.3.2.2. Clearance of apoptotic cells
Apoptosis is a genetically-controlled programmed cell death, which plays a crucial role in 
maintaining tissue homeostasis and eliminating aberrant cells. This process is associated
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with morphological changes such as shrinkage, plasma membrane blebbing, chromatin 
condensation followed by cellular fragmentation and formation of apoptotic bodies. Self­
derived dead cells are a source of autoantigens therefore the apoptotic cells need to be 
rapidly cleared from the body. The apoptotic cells have the ability to activate the 
complement system and this facilitates the clearance of the cells through phagocytosis. 
Binding of Clq to apoptotic cells and apoptotic debris induces complement activation and 
C3b and iC3b deposition followed by clearance of the dying cells by macrophages through 
binding to specific receptors immune [43-46]. CRP also binds apoptotic cells and can 
activate the complement cascade resulting in opsonisation [47].
1.1.3.3. Link between innate and adaptive immunity
Complement provides a link between innate and adaptive immunity. It is involved in 
regulation of the humoral and T cell response.
Complement modulates humoral immunity by augmentation of the antibody response and 
enhancement of immunological memory. In vitro and in vivo studies have demonstrated that 
deficiency in C3, C4 or CR1/2 (CR1 and CR2 are product of a single gene in mice, 
explained in section 1.5.2.1) results in a less efficient humoral response to T-independent 
and T-dependent antigens [48-51]. B cells express complement receptors CR1 and CR2. 
Complement receptor CR2 on B-cells forms a co-receptor together with CD 19 and CD81. 
Co-ligation of the co-receptor with the BCR through C3dg-coated antigens has been found 
to enhance downstream signaling and the amount of antigen required to activate B cells and 
to induce antibody response in vitro and in vivo [52-55]; thus the complement system acts as 
an adjuvant.
Follicular dendritic cells (FDC) are involved in modulation of the humoral response. FDC 
are stromal cells which produce B lymphocyte chemoattractant chemokines and participate 
in organisation of germinal centers in the B cell follicles [56]. They also express 
complement receptors CR1 and CR2 and are involved in modulation of the humoral memory 
by binding and harboring C3-tagged antigens and immune complexes over the long term to 
be presented to the antigen specific B cell [57-60]. This event is important for clonal
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selection of B cells within the germinal center and efficient maintenance of long-term 
antibody responses and memory. Complement also plays a role in immunoglobulin class- 
switching by modulating cytokine production. For example, Clq deficiency in mice resulted 
in a blocking of class-switching to IgG2a and IgG3 due to reduction of IFN-y production 
[61,62].
Complement participates in regulation of T cells. For example, C3 deficient mice 
demonstrated reduced anti-influenza CD4+ and CD8+ T-cell responses in the context of 
viral infection [63]. Furthermore complement has been found to play a role in development 
of induced regulatory T cells. Crosslinking of membrane cofactor protein with CD3 on 
CD4+ T cell induces regulatory T-cell phenotype with 11-10 production [64].
1.2. Complement regulation and regulators
Complement is a powerful component of the innate immune system and modulator of the 
adaptive response. However it also has a potential to damage host tissues. For this reason, 
control of complement activation is crucial. Distinguishing self and non-self or altered self is 
the first point of control. For example the CP is initiated by antibody recognition of a 
microbial target and the LP recognizes patterns specific for pathogen surfaces. Once 
activated, complement is controlled by a number of membrane-bound (Table 1.3) and 
soluble (Table 1.4) complement regulators described below. The regulators inactivate 
complement at different stages of the cascade, mainly at the level of the convertases and at 
MAC-assembly.
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Regulator Genes/ 
alternative splicing
Membrane
attachment
Molecular size and 
structure
Expression Ligands Complement inhibitory 
function and 
mode of action
CR1 Peripheral blood cells and Decay accelerating
Human 1 gene/ no TM 23-37 SCRs; 180-280kDa; FDC, astocytes, podocyte activity;
C4b, C3b, iC3b Co-factor I activity;
Mouse 1 gene/ yes CR2 TM 21 SCRs-CRl B cells, FDC Clearance of IC, stimulate
15 SCRs-CR2 phagocytosis;
Crry Decay accelerating
(rodents only) 1 gene/ no TM 5 SCRs; 65kDa Broad C4b, C3b activity;
Mouse Co-factor I activity;
MCP C4b, C3b
Human 1 gene/yes TM 4SCRs; Broad Co-factor I activity;
58-68kDa with STP (Except erythrocytes)
48-56kDa no STP
Mouse 1 gene/yes TM 4SCRs; 60kDa In the testis
DAF Decay accelerating
Human 1 gene/no GPI-, secreted 4 SCRs; 70kDa (membrane Broad activity;
associated) C4b, C3b
Mouse 2 genes/yes GPI-, secreted, 4 SCRs; 70kDa (membrane Broad for GPI-DAF1
transmembrane associated) Testis for TM-DAF2
CD59 Prevents insertion of C9
Human 1 gene/yes GPI 20kDa Broad C5b-8 complex molecules into
the cell membrane and
Mouse 2 genes/no GPI 20kDa CD59a-broad inhibits MAC formation;
CD59b-testis
Table 1.3. M em brane bound complement regulators in hum an and mouse. GPI, gycophosphatidyl inositol anchored; TM, transmembrane; STP, 
region enriched in serines, threonine and prolines;
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Regulator Molecular size and structure Ligands Function
Factor H 150kDa; 20 SCRs C3b Accelerates the decay of AP 
convertases and acts as a cofactor 
for the factor I-mediated cleavage 
of C3b.
C4bp 500kDa
Human: 8 SCRs in a-chain, seven 
a-chains, 3 SCRs in p-chain, one 
p-chain;
Mouse-: no p-chain
C4b
Non-complement ligands: 
heparin,serum amyloid P 
component and protein S;
Cofactor for factor I-mediated 
cleavage for C4b;
Link complement and coagulation 
system;
C l inhibitor Human 104kDa/Mouse 96 kDa Cl and MBL-MASP complexes
Non-complement ligands: factor 
XII and kalikrein, factor XI and 
thrombin tissue, plasminogen 
activator and plasmin;
Dissociates Clr and Cls from the 
Cl and MASPs from the MBL- 
MASPs complex.
Non-complement function- 
Blocks contact system, 
coagulation system and 
fibrinolytic system;
Factor I Serine protease, 88kDa C3b, C4b, Factor H, C4bp, MCP, 
CR1
Cleaves C4b and C3b (in 
cooperation with essential 
cofactors)
Table 1.4 Soluble complement regulators
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Two different regulatory mechanisms have evolved to control the complement convertases. 
The first one prevents the formation of active convertase by catabolism of C3b and C4b via 
factor I cleavage (Fig. 1.3). Factor I requires cofactors such as membrane cofactor protein 
(MCP), CR1 and factor H (fH) and the rodent specific regulator Complement receptor 1- 
related/gene protein y (Crry), for its proteolytic activity and thus this regulatory mechanism 
is known as “cofactor activity”. The second mechanism of regulation is the dissociation of 
inappropriately formed convertase (Fig. 1.4). There are several complement inhibitors that 
exhibit a decay accelerating activity. These are the decay accelerating factor (DAF), CR1, 
fH, C4-binding protein (C4bp) and Crry.
1.2.1. Factor I
Factor I consists of noncatalytic heavy chain linked by a disulfide bond to a catalytic chain. 
It is a soluble complement regulatory serine protease that cleaves three peptide bonds in a- 
chain of C3b and two bonds in the a-chain of C4b and inactivates these proteins in presence 
of cofactors such as factor H, MCP, C4bp and CR1 [65]. C3b is cleaved into iC3b and C3f 
[66]. Further C3 degradation to C3c and C3dg is observed in presence of CR1 as a co-factor 
of factor I [67]. C4b is cleaved to C4c and C4d in presence of C4bp, MCP and CR1 [68, 69].
1.2.2. Regulators of complement activation (RCA) gene cluster
Many of the complement regulators are encoded by a cluster of genes located on the long 
arm of chromosome 1 (lq32), this region is known as Regulators of Complement Activation 
(RCA) gene cluster [70, 71]. In humans these are proteins from the factor H family, C4bp, 
DAF, MCP and CR1. Another member of this family is CR2.
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Fig. 1.3 Schematic diagram of factor I mediated cleavage and generation of C3 and C4 
fragments. A. Factor I cleaves and inactivates C3b and C4b in presence of cofactor activity. 
This includes MCP, fH, CR1 and C4bp. MCP is illustrated as an example. B. Cleavage of 
C3 and generation of C3 fragments. C3 is activated by the C3 convertase to generate C3a 
and C3b. C3b is inactivated by cleavage with factor I into inactive iC3b and C3dg. Co­
factors for factor I cleavage are shown below the arrows. C. Cleavage of and generation of 
C4 fragments. C4 is activated by the C l complex to generate C4a and C4b. C4b is 
inactivated by cleavage with factor I to generate C4d and C4c. Co-factors for factor I 
cleavage are shown below the arrows.
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Fig. 1.4 Decay accelerating activity. The example illustrates the decay of the CP C3 
convertase (C4b2a) by DAF. DAF binds the C4b units of the convertase and dissociates C2a 
from the enzyme.
Figure 1.5 shows schematic diagrams o f RCA members. CR1 and CR2 are explained in 
detail in section 1.5.1.1. The proteins within the RCA family interact with C3 or C4 
activation products and have similar structures. They are organized in tandem structural 
units known as short consensus repeats (SCR). Each SCR consists o f 60-70 amino acids 
including four invariant cysteine residues and one conserved tryptophan. Several glycines 
and prolines are also present in fixed positions in most SCRs. The cysteines form two 
disulphide bonds, which hold the SCRs in rigid triple-loop structure [72, 73].
I.2.2.I. Factor H family
Factor H family includes Factor H (fH), factor H-like 1 (fH Ll) and five factor H-related 
proteins (fHRl to 5). Factor H is a 150 kDa fluid phase regulatory protein that binds C3b of 
the alternative pathway C3 convertase (C3bBb) accelerates its decay and acts as co-factor 
for the factor I-mediated proteolytic inactivation of C3b [74, 75]. fH can act in fluid phase 
and on the cellular surface. It is o f particular importance for the protection o f cells that lack 
surface-bound regulators. Self and non-self discrimination depends on the composition of 
the surface to which C3b is bound [76-78].
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mCRl
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D Membrane *
Fig.1.5 Schematic diagram of membrane bound and soluble members of RCA
A. Soluble members: fH and C4bp. B. Membrane bound members: MCP, Crry and DAF. C. 
Mouse CR1 and CR2. C3 binding sites are indicated.
fH attaches to the surface through binding with glycosaminoglycans on the host cells. fH is 
composed of 20 SCR [79] (Fig. 1.5A). It has three C3b binding sites. The binding site in 
SCR1-4 is essential for the factor I co-factor activity of factor H [80-83].
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fHLl protein (42kDa) is an alternative splicing of the gene encoding fH. It contains the 
seven N-terminal domains of fH and four unique amino acids at the C-terminus. Similar to 
fH, fHLl has cofactor and decay accelerating activity [84]
The five fHR proteins are encoded by separate genes, located in the RCA cluster, adjacent to 
the fH  gene. These proteins are composed of four to nine SCRs. They show homology with 
SCRs 6-9 and SCRs 19-20 of fH thus having binding sites for heparin, CRP and some 
microbial surface proteins. Although they have no homology with the SCRs 1-4 of fH, fHR3 
and fHR4 proteins have been found to enhance the fH cofactor activity [85] and fHR5 has 
shown a weak cofactor and decay activity [86, 87].
1.2.2.2. Membrane cofactor protein (MCP, CD46)
MCP is a cofactor for factor I-mediated cleavage of C3b and C4b generated in the CP, LP 
and AP [88]. Cleavage of C3b generates iC3b. Cleavage of C4b produces C4c and C4d. 
MCP is broadly expressed on most human cells, but it is absent from erythrocytes. Its 
expression in mice is restricted only to testis. There is no homology between the sequences 
of the mouse and human MCP cytoplasmic domains. MCP consists of four SCRs with 
binding sites for complement components C3b and C4b (Fig. 1.5 B). The SCRs are followed 
by an O-glycosylation region, enriched with serine, threonine and proline residues (STP 
domain). Next are small segment of 12 amino acids of undefined function, followed by a 
transmembrane domain, cytoplasmic anchor and one of two non-homologous cytoplasmic 
tails. The tails contain signalling motifs and drive differential processing of isoforms [89]. 
MCP is most effective in regulation of the amplification loop of the AP [88, 90]. As a 
cofactor for the factor I-mediated cleavage, it prevents C3b deposition on the host cells [88, 
90]. In addition to its complement inhibitory activity, MCP is also a receptor for some 
pathogens including measles virus, human herpes virus 6, group A Streptococci, group B 
and D adenoviruses, Neisseria gonorrhoae and Neisseria meningitidis [91-96]. Infection 
with these pathogens leads to down-regulation of MCP expression and this enhances 
complement activity [97]. As demonstrated by Schnorr and co-workers, cells infected with 
measles virus had enhanced sensitivity to complement-mediated killing due to the down 
regulation of MCP. This molecule also plays an important role in cell signalling.
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Crosslinking of MCP leads to cell activation and regulation of T-cell immune function [64, 
98-102].
1.2.2.3. Decay accelerating factor (DAF, CD55)
DAF is composed of four SCRs followed by glycosylated stalk and a glycosyl phosphatidyl 
inositol (GPI) anchor [103-105] (Fig. 1.5 B). DAF accelerates decay of Bb from the AP 
convertase and C2a from the CP enzyme (Fig. 1.4). Together with MCP, DAF protects host 
cells from opsonisation and complement-mediated damage by inactivating the convertases 
[106, 107]. It is expressed on tissue and peripheral blood cells: erythrocytes, granulocytes, 
T-cells, B-cells, monocytes and platelets, it is also found on bone marrow mononuclear cells 
and erythroid progenitors [108-110]. A secreted form of DAF has been found in plasma, 
tears, saliva, urine, synovial and cerebrospinal fluids [111]. This soluble DAF is likely to be 
a product from alternative splicing of the DAF gene [104]. In the mouse there are two forms 
of DAF encoded by different genes: GPI-anchored and a transmembrane form. Whilst the 
mouse GPI-anchored DAF is broadly expressed [112], expression of the transmembrane 
form is restricted to mouse testis [113]. An additional soluble form of DAF was also 
described [114]. Like MCP, DAF is a ligand for pathogens such as enteroviruses, some 
picofnaviruses (Coxsackieviruses) and uropathogenic E. coli [115,116].
I.2.2.4. C4b-binding protein
C4b-binding protein is a 500-kDa glycoprotein, composed of seven identical a-chains and a 
P-chain linked together by a central core (Fig. 1.5 A). The a-chains contain eight and the P- 
chain contains three SCRs [117, 118]. It inhibits the CP by acting as a cofactor to the serine 
proteinase factor I in the proteolytic inactivation of C4b [117], preventing the assembly of 
the classical and lectin C3-convertase (C4b2a) and accelerating the natural decay of the 
complex [119]. It has been suggested that C4bp also acts as factor I cofactor in the cleavage 
of C3b in the fluid phase thereby inhibiting to some extent the AP of complement but it is 
not as efficient as fH. C4bp interacts not only with C4b and C3b, but also with heparin 
[120], SAP and protein S (PS) [121], [122]. PS is a vitamin K-dependent anticoagulant and
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the interaction with C4bp links the complement and the blood coagulation systems. C4bp 
circulates in complex with vitamin K-dependent PS, which provides the C4bp with the 
ability to interact with negatively charged phospholipid membranes.
1.2.2.5. Complement receptor 1-related/gene protein y (Crry)
Crry is a 65 kDa-complement inhibitor broadly expressed in rodents. It contains five SCRs 
in mice and seven in rats (Fig.l.5B). It inhibits the CP and AP C3 convertases by 
dissociating the enzymes or by factor I-mediated activity [123]. Crry, together with MCP, 
exerts a co-factor activity for the factor I-mediated cleavage of C3b and C4b. MCP 
expression is restricted to male germ cells in mouse and rat, therefore Crry remains the main 
regulator with cofactor activity in these animals. Similarly to DAF, Crry accelerates the 
decay of the CP C3 convertase and to a lesser extent the AP C3 convertase [124].
1.2.3. Cl-inhibitor
Cl inhibitor is a plasma protein that belongs to the serine protease inhibitor (serpin) family 
of inhibitors [125]. Upon the interaction with Cl-inhibitor, the protease cleaves a peptide 
bond at the reactive center loop of the Cl-inhibitor. This results in a molecular 
rearrangement that leads to the formation of a covalent bond between the inhibitor and the 
active site of the serine protease. The Cl-inhibitor inactivates complement proteases Clr, 
Cls and MASP2 and thus regulates the CP and LP [126-129]. In addition to the complement 
proteases, it also controls the activity factor XII, plasma kallikrein, factor XI, plasmin, and 
tissue plasminogen activator [130]
1.2.4. CD59
CD59 is a GPI-linked glycoprotein with molecular weight of ~20 kDa. It regulates the 
terminal pathway and inhibits inappropriate MAC formation on host cells. It binds the a-
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chain of C8 within the C5b-C8 complex, preventing binding of more than one copy of C9 to 
the complex and subsequent insertion of C9 into the membrane [131, 132]. CD59 contains 
five intrachain disulphide bonds which maintain the disc shape of the molecule [133], CD59 
is broadly expressed being identified on all circulating cells [134]. Two forms of CD59 
(CD59a and CD59b) exist in mice, as a result of duplication of the CD59 gene. CD59a is 
found in almost all mouse tissues whereas CD59b is identified exclusively in testis [135, 
136].
1.3. Complement receptors
C3 is a central player in the complement cascade and its breakdown products have multiple 
functions in immunity. The C3 derived molecules perform their effector functions through 
interactions with other molecules. For example, pathogens, immune complexes and dying 
cells opsonised with C3 fragments can be recognised by complement receptors. Three 
different C3 receptor families will be described in this section. The RCA gene cluster codes 
for CR1 and CR2. CR3 and CR4 belong to p2 integrin family. The recently identified C3 
receptor termed Complement receptor of the immunoglobulin superfamily (CRIg) is a type 1 
transmembrane Ig molecule.
1.3.1. Receptors encoded by the RCA gene cluster
This group includes two members: CRl and CR2. Like other members of this family, the 
extracellular region of CRl and CR2 is composed of SCRs.
I.3.I.I. Complement receptor type 1 (CRl)
Human CRl is a -200 kDa single chain transmembrane glycoprotein that binds C3b and 
C4b with high activity and iC3b and C3dg with low affinity [39, 67,137]. It inhibits both CP 
and AP C3 and C5 convertase due to its decay accelerating activity and co-factor activity for
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the factor I-mediated cleavage of C3b to iC3b, C3c and C3dg and of C4b to C4c and C4d. 
CRl is expressed on erythrocytes, a subset of T cells, mature B cells, follicular dendritic 
cells, kidney podocytes, granulocytes and monocytes. A soluble form of CRl, released from 
the cell membrane by proteolytic cleavage, was found at low concentration in the blood 
[138-140].
The most common CRl allotype consists of 30 SCRs. All except the two carboxyl terminal 
SCRs (SCRs 29 and 30) form large repetitive units called long homologous repeats (LHRs). 
LHRs A, B and C (but not LHR D proximal to the cell membrane) contain seven SCRs and 
bear binding sites for C3b and/or C4b, products of complement activation [141]. There are 
two functional sites interacting with these products or the complement convertases, located 
in the three amino-terminal SCRs of the LHRs [141-144]. Site 1 (SCRs 1-3), located in LHR 
A binds C4b and very weakly C3b [143]. Site 2 in LHR B (SCRs 8-10) and LHR C (SCRs 
15-17), binds C3b and with lower affinity C4b [145].
In addition to its complement inhibitory function, CRl also plays a major role in immune 
complex clearance due to its affinity for C3b and C4b. CRl expressed on erythrocytes is 
able to capture complement-bound immune complexes and transports them to the liver and 
spleen where they are eliminated through the action of macrophages [146-148]. CRl 
expressed on macrophages and neutrophils binds complement opsonised immune complexes 
and mediates phagocytosis.
I.3.I.2. Complement receptor type 2 (CR2)
CR2 is a 145kD protein that comprises 15 or 16 SCRs. It binds C3dg and with lower affinity 
iC3b [149-152]. CR2 is expressed on mature B-cells, thymocytes, a subset of CD4+ and 
CD8+ peripheral T-cells and FDCs, basophils, mast cells, keratinocytes and epithelial cells. 
CR2 together with CD 19 and CD81 acts as a B-cell co-receptor complex for antigen 
receptor mediated signal transduction. Studies using antigens coated with C3d/C3dg to co- 
ligate CR2 with surface IgM demonstrated that CR2 contributes in B cell activation, 
generation of immunologic memory and Ig class switching. Uptake of C3dg-coated antigen 
by B cells results in enhanced signaling via the B cell antigen receptor, lowering the 
threshold of B cell activation and providing an important survival signal [54].
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In addition to C3 fragments, CR2 also binds the Epstein-Barr virus glycoproteins gp350 and 
gp220. This interaction contributes to the viral infection [153].
1.3.1.3. Murine complement receptor type 1 and complement receptor type 2
Murine type 1 and type 2 complement receptors are products of alternative splicing of single 
gene Cr2. Mouse CRl comprises 21 SCRs while mouse CR2 contains 15 SCRs (Fig.l.5C). 
There are two C3b binding sites in the murine CRl-within SCRs 1-2 and SCRs 7-8, and one 
in CR2 (SCRs 1-2) [154] [155, 156]. One C3d binding site is found in both molecules- 
SCRs7-8 in CRl and SCRs 1-2 in CR2. Mouse CRl and CR2 are expressed on B 
lymphocytes, follicular dendritic cells and activated T cells [156,157].
1.3.2. 02 -Integrin family
Two complement receptors belong to the P2-integrin family. Complement receptors type 3 
and type 4 are transmembrane heterodimers composed of a  subunit (CDllb or CDllc 
respectively) and a common CD 18 (P) chain. CR3 and CR4 are expressed mainly on 
leukocytes. Both of these receptors bind iC3b and facilitate phagocytosis of iC3b-opsonised 
particles [158, 159]. CR3 and CR4 are also involved in leukocyte adhesive, migratory, 
phagocytic activities in response to inflammatory stimuli, events that facilitate the host- 
defence against bacterial pathogens [160].
1.3.3. Type 1 transmembrane Ig superfamily
Complement receptor of the immunoglobulin superfamily (CRIg) also known as V-set and 
Ig domain-containing 4 (VSIG4) is a recently identified member of the type 1 
transmembrane Ig superfamily [161]. Two alternative spliced forms were found in human 
(long and short) whereas only one form exists in mouse. The longer human form 
(huCRIg(L)) also known as Z39Ig consists of V and C2-type Ig domain and the short human 
form and the mouse CRIg contain only a single V-type Ig domain. CRIg is expressed at high
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levels in liver macrophages (Kupffer cells), intraperitoneal macrophages, neutrophils and 
activated dendritic cells. Low level of expression was detected in human adrenal gland 
macrophages, alveolar macrophages, synovial macrophages in the joints, foam cells in 
atherosclerotic plaques and lamina propria histiocytes [161-163]. CRIg binds surface 
attached C3b and iC3b and facilitates the phagocytosis in the liver and plays an important 
role in removal of intracellular and extracellular pathogens as well as complement-opsonised 
platelets from the circulation [161, 164,165]. CRIg binds the p-chain of the C3 fragment but 
not the a, as other complement receptors do [166]. CRIg expressed on the cell surface does 
not affect complement activation. However, a study using CRIg-Fc fusion protein 
demonstrated that binding of CRIg to C3b, a subunit of the AP C3 and C5 convertases, 
results in complement inhibition [166]. Interestingly, CRIg does not exhibit either decay 
accelerating or co-factor I mediated activities. Its mode of action is different; it prevents 
binding of C3b within the convertase to its ligands C3 and C5. The role of CRIg as a 
complement inhibitor has been confirmed in vivo in models of arthritis [167]. In addition to 
its role as a complement receptor and regulator, CRIg inhibited T-cell proliferation and 11-2 
production [163]. Administration of CRIg-Ig fusion protein reduces cytotoxic T-and B-cell 
response to viral antigen in animals immunized with cytomegalovirus glycoprotein [163].
1.4. Complement and diseases/pathology
The human body is constantly exposed to pathogens and infectious agents and consequently 
has developed complex, highly efficient immune mechanisms to fight foreign invaders. As a 
part of the immune system complement plays a key role in enemy elimination. However, 
when the host’s anti-pathogen response is not properly controlled and regulated, the immune 
system and complement in particular can attack and damage self-tissues. The delicate 
balance between the self-protective and self-destructive mode of complement is discussed in 
this section.
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1.4.1. Infectious disease and pathogen evasion of complement
The complement system plays a major role in host defense against invading bacteria, fungi, 
multicellular organisms and viruses. It facilitates phagocytosis of pathogens, stimulates the 
humoral immune response and chemotactic attraction of immune cells to the sites of 
infection, stimulates cytokine and histamine synthesis and directly lyses targets. Deficiencies 
in the terminal pathway components are associated with increased susceptibility to 
meningococcal infections caused by the Gram-negative bacteria Neisseria meningitides 
[168]. On the other hand, parasites and pathogens, which successfully cause infections and 
diseases, often protect themselves from host defense by using specific immune escape 
strategies. Many pathogens have developed mechanisms to break the host’s defense barrier 
and to evade complement attack. Pathogens have learnt how to control and prevent 
complement recognition and inhibit effector function. There are three main strategies used 
by pathogens to evade the host complement system.
Some pathogens, such as group B streptococci and gram-negative bacterium P. aeruginosa 
secrete proteases which inactivate products of complement activation: C5a and C3b 
respectively [169]. Another common complement escape mechanism is binding soluble 
complement regulators from the host (such as factor H, C4bp) to the pathogen surface [170- 
172], The regulators block complement activation and protect the pathogen’s surface from 
complement attack. Some of the proteins secreted by pathogens have the ability to directly 
inhibit complement activation. For example, Staphylococcos aureus produces a 
staphylococcal complement inhibitor (SCIN) that blocks the three pathways of complement 
activation by binding to surface-bound convertases [169, 173]. This bacterium secretes 
another complement inhibitor, extracellular fibrinogen binding protein, which binds the 
thioester containing C3dg domain of C3b and prevents C3b deposition on to sensitized 
surfaces. Ticks also produce complement inhibitors. Several anti-complement proteins are 
found in saliva of blood feeding acari, including Ixodes sp. and Ornithodoros moubata.
During a blood meal Ornithodoros moubata secretes a salivary gland “protein cocktail” able 
to modulate the host immune and homeostatic system. Some of these proteins belong to a 
family termed lipocalins. This family is characterised by an eight-stranded anti-parallel P- 
barrel closed off at one end by an N-terminal helix and stabilised by a C-terminal a-helix 
that packs against the side of the barrel [174]. The lipocalins are found to modulate the host
40
inflammatory response by blocking histamine and serotonin, to inhibit platelet and 
neutrophil aggregation and vasoconstriction, and to block the complement system. The 
complement inhibitor identified in Ornithodoros moubata is termed Omithodores moubata 
Complement Inhibitor (OmCI). OmCI is a 17kDa nonglycosylated protein that belongs to 
the lipocalin family [175]. It inhibits C5 activity in a broad range of species including 
rodents and humans without generating immune response [176]. A structural study revealed 
that the binding of OmCI to C5 does not block the convertase cleavage site but rather leads 
to conformational changes in C5 molecule which stabilise its global structure [177]. These 
properties of OmCI could be employed as a therapy in complement mediated disease. This 
matter will be further discussed in the thesis.
1.4.2. Complement dysregulation and disease
The complement response of the host to infectious agents is a double-edged sword -despite 
the protective role of complement against microbial invasion, inappropriate activation of the 
system may have pathological consequences. When complement is not properly controlled it 
can turn its power towards self-tissues to cause diseases. These include immune complex 
and autoimmune diseases (such as SLE, autoimmune arthritis and myasthenia gravis), 
neurodegenerative disorders (such as Alzheimer’s disease and multiple sclerosis), 
cardiovascular diseases (atherosclerosis) and acute conditions such as sepsis and ischaemia 
reperfusion (IR) injuries. Diseases and animal models involving complement are listed in 
Table 1.5. Some of these will be discussed in this Chapter.
1.4.2.1. Acute conditions
Although complement activation is often not the primary cause, the tissue damage in certain 
conditions is complement-mediated. A number of studies provide compelling evidence to 
implicate complement in IR injury [178-182]. IR injury is a pathological tissue damage 
caused when blood supply returns to a tissue following a period of ischaemia. IR injury can 
occur in various clinical situations including myocardial infarction, stroke, haemorrhagic 
and septic shock [183-185]. Membrane phospholipids and mitochondrial proteins exposed
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during the ischaemia serve as neoantigens which activate complement during the reperfusion 
phase [178, 179]. Restoration of circulation results in complement activation via CP, LP 
and/or AP [186, 187]. Complement activation triggers release of anaphylatoxins C3a and 
C5a and MAC formation on the target cells. C3a and C5a can activate endothelial cells and 
leukocytes. C5a was found to attract inflammatory cells to the site of injury [188]. The 
incorporation of MAC alters normal function of the target cell by causing direct tissue 
damage or by modulating the transcription of genes coding for proinflammatory mediators 
[189, 190]. MAC insertion triggers activation of endothelial nuclear factor kB and increases 
the expression of number of adhesion molecules; expression of 11-8 and monocytes 
chemoattractant protein-1; and activation of platelets, contributing to platelet-leukocyte 
aggregation. In addition cleavage of C3b results in deposition of iC3b on the target 
endothelial cells and acts as ligand for CR3. CR3 is usually upregulated in activated 
leukocytes and contributes to the accumulation of these cells in the extravascular 
compartment.
In transplantation, the products generated upon the complement activation can modulate the 
graft rejection by binding to the graft or by modifying the response of macrophages, T and B 
cells of the recipient. Donor specific antibodies in the blood of the recipient can bind to the 
vascular endothelium of the transplant and activate complement through the CP. The 
complement cascade can be also activated through the LP in transplants. MBL binds 
apoptotic and injured endothelial cells and may be activated by cells undergoing apoptosis 
[191-194].
1.4.2.2. Autoimmune diseases
Complement has been found to be a key player in the pathology associated with many 
autoimmune diseases. Autoimmune diseases occur when the immune response is directed 
against self-antigens and are often characterized by high levels of circulating autoantibodies
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Human disease Models Evidence for complement implication
Rheumatoid arthritis Antigen-induced (AIA, antigen-methylated BSA); 
Collagen type Il-induced (CIA);
Anti-collagen type II Ab transfer (CAIA);
K/BxN serum transfer;
Elevated levels of complement activation products 
in synovial fluid; Enhanced local production of 
complement proteins in synovial tissue; 
Complement deficiency (C3, fB) and complement 
inhibition (anti-C5 mAb, sCRl) have protective 
effect;
Multiple sclerosis EAE, ADEAE, Biozzi (antibody high, ABH); Elevated levels of complement activation products 
C3a, C4a and soluble C5b-9 in CSF;
Complement deficiency and complement 
inhibition have protective effect;
Antiphospholipid antibody syndrome Anti-phospholipid antibody transfer Complement deficiency (Clq, C4, C3, fB) and 
complement inhibition (Crry-Ig, anti-fB mAb) 
have protective effect;
Lupus nephritis MRL/lpr strain; 
NZB/WF1
Complement proteins in the glomerulus, 
predominantly those of the CP;
Cl, C2 and C4 deficiency predispose to SLE;
Myasthenia gravis Active immunisation with Acetylcholine receptor 
(AChR) from Torpedo electric organ of young 
Lewis rats (acute and chronic phase) and mice 
(C57bl6);
Passive transfer of anti-AChR Abs
Complement deficiency (C5) and complement 
inhibition (anti-Clq Ab, OmCI, anti-C5) have 
protective effect;
Table 1.5 Examples for disease associated with complement activation. Animal models and evidence for the role of complement in the 
disease pathology
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Human disease Models Evidence for complement implication
Small vessel vasculitis:
Cryoglobulinemic vasculitis (immune complex 
mediated)
CP activation; Complement consumption;
LP and AP activation; C3, properdin and MAC
Henoch-Schonlein purpura/ IgA nephropathy - deposition in the mesangium;
Anti-neutrophil cytoplasmic autoantibody- 
associated vasculitis (autoimmune disease)
Passive transfer of anti-MPO antibody C3 and MAC deposition in glomeruli; 
Complement deficiency and complement 
inhibition are protective
Asthma Sensitisation with allergen (OVA, ragweed) in 
aluminium hydroxide followed by inhalation;
Elevated levels of C3a and C5a in 
bronchoalveolar lavage fluid;
Complement deficiency (C3, C3aR, fB) and 
complement inhibition (anti-fB mAb, sCRl, 
futhan) has protective effect and blocked the 
inflammatory response and airway responsiveness 
to the allergen;
Atypical haemolytic uremic syndrome fH deficient mice, with fH SCR1-15 transgenic Association with “loss-of function” mutation in 
MCP, fH and fl and “gain of function” mutation in 
fB; mutation in C3;
Type II membranoproliferative glomerulonephritis 
(Dense Deposit Disease)
fH deficient mice Deposition of C3 activation products within the 
glomerular basement membrane; Reduced 
circulating C3 levels due to complement 
consumption; Association with loss-of function 
mutation in factor H
Table 1.5 (continued) Examples for disease associated with complement activation. Animal models and evidence for the role of complement 
in the disease pathology
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Human disease Models Evidence for complement implication
Macular degeneration Laser-induced Choroidal neovascularization 
Chronic oxidative damage (model of dry AMD)
C3, C5 and MAC deposition in the retinal lesions; 
Association with fH polymorphism (Tyr402His); 
Deficiency in fD and fDprotective from visual 
loss;
Traumatic brain/spinal cord injury Mice Increased complement deposition (Clq, C4, fB, 
MAC) on neurons and oligodendrocytes; 
Complement deficiency (C4, C3, fB) and 
complement inhibition (CRl-Cny) has protective 
effect to injury;
Guillain-Barre syndrome Passive immunisation with anti-ganglioside IgM 
Ab and normal human serum (mice)
Elevated levels of complement activation products 
in CSF;
Complement deficiency (C6) and complement 
inhibition (sCRl) have protective effect to nerve 
injury;
Paroxysmal nocturnal haemoglobinuria - Complement-mediated intravascular haemolysis 
due to the lack of GPI anchored protein CD59 and 
CD55;
Table 1.5 (continued) Examples for disease associated with complement activation. Animal models and evidence for the role of complement 
in the disease pathology
45
and the presence of auto-reactive T cells in the affected organs. Complement plays a dual 
role in the development of autoimmunity. Uncontrolled or excessive complement activation 
contributes to the pathogenesis of many autoimmune diseases. For example immune 
complexes accumulate in glomeruli of patients with SLE and activate complement through 
the CP leading to tissue damage [195]. On the other hand, lack of early complement 
components facilitates the development of autoimmunity especially SLE [45, 196]. The late 
complement components have also been associated with the pathogenesis of autoimmune 
diseases. Increasingly, evidence implicates the terminal pathway as a disease mediator in 
rheumatoid arthritis and multiple sclerosis. It has been demonstrated that MAC contributes 
to joint destruction in arthritis and myelin loss in multiple sclerosis. Rheumatoid arthritis and 
multiple sclerosis will be discussed here.
I.4.2.2.I. Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects mainly peripheral 
joints. Joint inflammation in RA is a complex process. Strong evidence from both animal 
and clinical studies demonstrates that complement contributes to the development of the 
disease [197-199]. RA is characterised by presence of autoantibodies to a variety of antigens 
such as collagen type II and glucose-6- phosphoisomerase [200]. These are able to form 
immune complexes within the joints and thus may activate the CP of complement. In 
addition, AP activation has been also reported in RA [198, 201-203]. It has been found that 
collagen type II, exposed during the course of disease can activate complement in vitro in 
absence of C4 [201]. Different studies have shown elevated levels of complement activation 
products in synovial fluids of RA patients [204, 205]. Once activated, complement releases 
C3a and C5a, causing local inflammation and triggers MAC formation resulting in joint 
destruction. Increased level of soluble MAC was found in synovial fluid of RA patients 
[197, 205]. The participation of the terminal pathway in RA was further investigated using 
animal models. Two models for inflammatory arthritis associated with the terminal 
complement pathway have been developed. These include collagen-induced arthritis (CIA) 
and antigen-induced arthritis (AIA). CIA, the most widely used model of arthritis, is induced 
in a limited number of susceptible inbred strains (DBA/1 and B10.RIII) by immunisation 
with collagen type II [206]. The disease progression is mediated by cellular and humoral
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autoimmune response to the collagen challenge. Both T and B cells play a role in disease 
pathogenesis. During the early stages of disease, anti-collagen antibodies are generated and 
bind to the joint cartilage and thus activate complement. The role of complement was 
confirmed using complement deficient animals. For example C3 deficient mice and mice 
lacking factor B developed only mild arthritis [207, 208]. The relationship between the 
terminal pathway and arthritis was also assessed. DBA1 mice lacking C5 were resistant to 
CIA [209]. Furthermore, blocking C5 with anti-C5 antibody prevented disease onset and 
ameliorated already established disease [210]. In contrast to CIA, which is poly-articular 
inflammatory arthritis, in ALA the inflammation is localized in a single joint. When ALA was 
induced with methylated bovine serum albumin, CD59-/- mice were found to have 
significantly greater joint swelling, tissue damage and MAC deposition compared to the 
wild type control mice [211].
Other models used to explore the role of complement in RA are listed in Table 1.5.
I.4.2.2.2. Multiple sclerosis
Multiple sclerosis (MS) is another example of a complex autoimmune disease where the 
terminal complement pathway contributes to the pathology. MS is a complex, T-cell 
mediated disease in which myelin and the myelin forming cells are targets. It starts with the 
formation of acute inflammatory lesions and breakdown of the blood-brain barrier (BBB). 
The complement system is another important contributor to the pathogenesis of MS, it was 
implicated in the killing of oligodendrocytes and neurons [212, 213]. Complement activation 
products such as Clq, C3d and C5b-9 have been detected in white matter lesions in patients 
with MS [214]. Activation of complement in MS occurs either by antibodies against myelin 
proteins found in MS patients [215], or directly by myelin and oligodendrocytes themselves 
[216, 217]. Once complement is activated it triggers MAC formation. MAC is possibly one 
of the demyelinating effectors in MS. Its assembly on myelin and oligodendrocytes and can 
induce myelin loss and cell death. Soluble C5b-9 was absent in human cerebrospinal fluid 
(CSF) from normal donors. However presence of soluble C5b-9 and decreased level of C9 
were found in CSF of MS patients, suggestive for C9 consumption due to terminal pathway 
activation in the central nervous system [218-220]. Wing et al provided other evidence for
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involvement of the terminal pathway in MS pathology. Incorporation of human CD59 in rat 
oligodendrocytes (lacking rat CD59) increased the cell survival when exposed to human 
complement [221]. The role of the terminal complement pathway in disease pathology was 
further explored in animal models of MS. Experimental autoimmune encephalomyelitis 
(EAE) is an acute model of MS used to evaluate the role in complement in MS. The disease 
is induced either by active immunization with proteins or peptides from the myelin sheath 
such as myelin oligodendrocyte glycoprotein (MOG), alone or in combination with anti- 
MOG demyelinating monoclonal antibodies (antibody dependent EAE, ADEAE) [222]. 
ADEAE induced in rats showed correlation between MAC deposition and spinal cord 
demylination [223]. This observation was confirmed by using C6 and CD59 deficient 
animals [224, 225]. C6 deficient rats failed to develop demyelination and axonal injury after 
induction of ADEAE, whereas mice lacking the MAC regulator CD59 showed enhanced 
disease severity. Whereas, these findings demonstrate that the MAC acts as an effector in 
demyelination and axonal damage, other studies suggest that sublytic C5b-9 may also be 
beneficial and promote oligodendrocyte survival under certain circumstances [226, 227]. 
Sublytic dose of C5b-9 inhibited the mitochondrial pathway of apoptosis in 
oligodendrocytes and contributed to their regeneration [226-228]. The conclusion is 
therefore that complement plays both proinflammatory and neuroprotective roles in MS.
1.4.2.3. Cardiovascular disease
Complement is involved in the pathogenesis of various cardiovascular diseases including 
atherosclerosis, arterial aneurism and diabetic angiopathy [229, 230]. When the endothelium 
lining the luminal side of blood vessels loses its integrity (damage) complement activation 
occurs and destroys the target cells or promotes cell cycle activation and cell survival [231].
Atherosclerosis is a disease associated with endothelial dysfunction and plaque formation. 
Atherosclerotic lesions (atheroma) consist of cells, connective-tissue elements, lipids and 
debris [232, 233]. Plaque rupture and thrombosis take place as disease progresses. In 
atherosclerosis, complement activation via the AP can be provoked by enzymatic-modified 
low-density lipoprotein (LDL) [234-236]. In addition, immobilized immunoglobulins, 
pentraxins (CRP), cholesterol crystals and apoptotic cells can also trigger the complement
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cascade in atherosclerotic lesions. Complement activation products and complement 
receptors have been detected in atherosclerotic lesions [237, 238]. For example C5b-9 was 
found on smooth muscle cells in early lesions while in advanced lesions it colocalised with 
apoptotic cells in human atherosclerotic lesions. In advanced lesions the C5b-9 was 
associated with intact macrophages and macrophage derived debris [239, 240]. As revealed 
from in vivo experiments complement plays a complex role in the disease development 
however it was clearly shown that terminal pathway plays a crucial role in this pathological 
process. Schmiedt and colleagues found that C6 deficient rabbits were protected from aortic 
lesion formation [241]. The role of complement and the terminal pathway in particular was 
evaluated using mice with targeted deletion of the gene for apolipoprotein E (ApoE-/-). 
These animals develop severe hypercholesteterolemia and atherosclerosis especially when 
the mice are fed on a high fat diet. The pathology was reversed when ApoE-/- was crossed 
with C6-/- mice. C6 deficiency significantly reduced plaque area and disease severity while 
the lack of CD59 had an opposite effect and exacerbated the disease [242]. This finding 
clearly demonstrates the association of the terminal pathway with the pathology in 
atherosclerosis. In contrast no difference was observed in disease development in presence 
or absence of C5 [243]. A different animal model was also developed and used to elucidate 
the role of complement in atherosclerosis. Mice deficient in LDL receptors were crossed 
with Clq deficient mice. In contrast to the terminal pathway, the early complement 
component Clq was found to be protective. Clq deficient mice had larger atherosclerotic 
plaques with more apoptotic cells compared to the wild type controls. This is likely due to 
inability of these mice efficiently to clear cell debris and immune complexes in the plaques.
1.4.2.4. Disease with genetically defined mutations of complement inhibitors and/or 
complement proteins
Complement-related diseases can also be triggered by alterations in the expression and 
function of complement components and regulators. This group of disorders includes 
membranoproliferative glomerulonephritis type II (MPGN type II), Atypical haemolytic 
uremic syndrom (aHUS), Paroxysmal nocturnal haemoglobinuria (PNH) and age-related 
macular degeneration (AMD). These diseases are examples of complement activity against 
self-tissues as a result of abnormal complement regulation.
49
I.4.2.4.I. Membranoproliferative glomerulonephritis type II
Membranoproliferative glomerulonephritis (MPGN) is characterised with proliferation of 
mesanglial and endothelial cells and by thickening of the capillary walls due to immune or 
intramembranous dense deposits. Three types of MPGN have been described. Type I and III 
are immune complex mediated disease and type II has no association with immune 
complexes [244]. MPGN type II, also referred to as dense deposit disease (DDD), is a 
progressive renal disease often leading to kidney failure. It is characterised with low serum 
C3 levels, intramembranous dense deposits and C3b and MAC deposition in kidney 
glomeruli and in vascular walls. Over 80% of the patients are positive for autoantibodies, 
known as nephritic factors, able to prolong the half-life alternative pathway convertase and 
thus increase the complement activation. The abnormal complement activation is also 
accounted for by mutations in the gene encoding fH (the N terminus in particular) that 
impair the secretion or function of fH and influence the regulation of C3 in circulation [245- 
248]. The inability of fH to control C3 activation is likely to be a cause of MPGN type II.
I.4.2.4.2. Atypical haemolytic uraemic syndrome
The typical form of Haemolytic uraemic syndrome (HUS) is an epidemic disease that 
follows a gastrointestinal infection with particular strains of E. coli. However, in 5-10% of 
cases there is no associated E. coli infection and this is termed atypical HUS (aHUS). In 
aHUS the disease occurs in a familial pattern. In contrast to MPGN type II where C3 
fragments are accumulated along the glomerular basement membrane, aHUS is 
characterised by endothelial cell injury and thrombosis leading to haemolytic anemia, 
thrombocytopenia and renal failure. aHUS is associated with mutation or polymorphisms in 
genes encoding complement regulators (factor H, factor I and CD46) and complement 
components (factor B and C3) leading to complement dysregulation [249-252]. The 
mutations in fH linked to aHUS are clustered at the carboxy-terminus of the protein and thus 
affect the binding of fH to heparin, C3b and endothelium but not the plasma C3 regulation 
[253-257]. This prevents overactivation but allows enough complement activity to attack 
target cells.
50
I.4.2.4.3. Paroxysmal nocturnal haemoglobinuria
Paroxysmal nocturnal haemoglobinuria (PNH) is an intravascular haemolytic anemia 
characterised by episodic haemoglobinuria, occurring predominantly at night [258, 259]. 
PNH is an acquired disease caused by a somatic mutation of the phospatidylinositol glycan 
complementation class A (PIGA) gene in a hematopoietic stem cell and the expansion of the 
abnormal haematopoietic clone [260]. This mutation blocks the synthesis of GPI anchors in 
proteins including CD55 and CD59. Resultant red blood cells, leukocytes and platelets have 
thus a reduced ability to protect themselves against complement attack. The increased 
sensitivity to complement results in chronic haemolysis.
To conclude, complement mediates injury and causes diseases either by formation of lytic 
MAC or by the releasing of the anaphylatoxins C3a and C5a. The MAC may cause 
inappropriate cell lysis or may activate pro-inflammatory mechanisms to induce cell- 
activation and thus production of inflammatory chemokines. C3a and C5a induce damage by 
attracting and activating immune effector cells such as neutrophils, eosinophils and mast 
cells.
1.5. Anti-complement therapeutics
To prevent complement-mediated destruction of host cells and tissues, complement must be 
strictly controlled. As described above, despite the presence of a large number of 
complement regulatory proteins on cells and in fluids, complement may become 
inappropriately activated in the context of disease. For this reason complement is a 
promising therapeutic target. A number of anti-complement therapeutics have been 
developed and tested in vitro and in vivo.
1.5.1. Cobra Venom Factor
Cobra venom factor (CVF) was the first anti-complement reagent tested in models. It is a 
structural and functional analogue of C3b found in cobra venom. It binds factor B and forms
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a stable AP C3 convertase (CVFBb). Compared to C3bBb the complex has an extended 
half-life, 7 hours compared to 1.5 minutes, and is resistant to fluid phase regulation [261]. 
When given to experimental animals, CVFBb continuously activates the AP and consumes 
all plasma C3. Such complement depletion in vivo was useful proof of principle to 
demonstrate that knocking out the complement system is relevant to many pathologies. 
However, its use as a long term therapeutic is limited because of its immunogenicity. To 
address this issue, the C-terminal region of human C3 was replaced with the corresponding 
region derived from CVF to generate chimeric CVF-like molecule. This “humanised CVF” 
was less immunogenic with reduced ability to generate neutralizing antibodies [262, 263]. 
Furthermore, “humanised CVF” with no C5 activating properties has been developed which 
prevents the release of the pro-inflammatory C5a anaphylatoxin. This reagent was shown to 
protect from complement-mediated myocardial IR injury in mice [264, 265].
1.5.2. Polyanionic agents
Polyanionic molecules such as low molecular weight heparin, dextran sulphate, polyvinyl 
sulphate, polylysine and suramin, have been shown to inhibit complement in vitro [266]. 
Heparin inhibits complement at various points including activation of the CP (by binding to 
Clq), assembly of the C3 convertase and the MAC [267-272]. In vivo low molecular weight 
heparin was used as an anti-coagulant in patients with shock syndromes and to coat 
extracorporeal circuits in dialysis and cardiopulmonary bypass. Part of its effect in such 
situations may be due to its properties as a complement inhibitor [273, 274], however its 
anti-complement capacity in vivo has not been fully studied.
1.5.3. Small molecule inhibitors
A number of natural or synthetic small molecules inhibit complement in vitro as well as in 
vivo. One such molecule is K-76COOH which blocks complement at the C5 stage and thus 
inhibiting disease in several complement dependent animal models [275]. Nafamastat 
mesilate (FUT-175) is an example of a synthetic protease inhibitor. It inhibits complement
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by blocking Clr, Cls, fD and the Bb fragment of C3/C5 convertase [276]. Its anti­
complement function has been demonstrated in a rat model of adjuvant arthritis [277]. 
Furthermore, FUT-175 in combination with K-76COOH prolonged graft survival in rats 
[278]. Other small molecule inhibitors are listed in table 1.6. Together with the advantages 
(low cost, good tissue penetration, oral administration) they have disadvantages. Usually 
these molecules are enzyme inhibitors, which have non-specific effects acting on all serine 
proteases rather than just those of the complement system. Their usage is also limited by 
their short half-life in vivo resulting in their rapid clearance from the body, making them 
unsuitable for long-term anti-complement therapy in chronic inflammatory conditions.
Molecule Level of inhibition
K76COOH C5
(K76)
An organic acid
FUT-175 Cls
(Furan) fD
An organic C3/C5 convertases.
compound
BCX-1470 fD
An organic Cls
compound
Compstatin C3 (prevents cleavage)
A cyclic peptide
F-OpdChaWR C5aR (antagonist)
A cyclic peptide
Table 1.6 Small molecule anti-complement inhibitors.
1.5.4. Peptide inhibitors
A number of complement inhibitory peptides have been selected from phage display peptide 
libraries. It has been demonstrated that a peptide interacting with the IgG binding site within 
Clq inhibits the CP in vitro [279]. Another anti-complement peptide derived from a phage 
display library is compstatin. It was identified from a search for C3 binding peptides by
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Sahu et al. [280]. The authors showed that this 13-amino acid cyclic peptide was able to bind 
C3 and to prevent the cleavage of C3 to C3a and C3b in reversible manner in human serum 
and in a pure protein system (AP). Other studies independently confirmed the complement 
inhibitory activity of compstatin on the CP and the AP [281]. Compstatin blocks exclusively 
human and primate C3 while no binding is observed in mice, rats, guinea pigs and rabbits 
[280, 282] and thus limiting its characterisation in vivo. However, the ability of compstatin 
to block C3 cleavage was demonstrated ex vivo in a model for potential pig to human 
xenotransplantation. The presence of this peptide significantly increased the survival time of 
pig kidneys perfused with human complement compared to the controls [283, 284].
Another promising peptide with complement inhibitory potential is C5aR antagonist (Ac- 
Phe-[Om-Pro-dCha-Trp-dArg]) [285]. By blocking the binding of C5a to C5aR, this peptide 
blocked C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro 
and inhibited neutropenia associated with septic shock induced by lipopolysaccharide in rats 
[286, 287]. In addition, the C5aR antagonist peptide suppressed the reverse-passive Arthus 
reaction and endotoxin shock in rats [288, 289], Its protective role was further proved in a 
model of intestinal IR injury [290]. The number of in vivo studies supporting the therapeutic 
effect of C5aR antagonist is currently increasing. Jacob et al. have successfully 
demonstrated that the treatment with the peptide blocks C5a/C5aR signaling while leaving 
the upstream complement protective events intact and thus decreasing the brain pathology in 
the MRL/lpr lupus mouse model [291].
1.5.5. Recombinant complement receptor 1
Anti-complement reagents based on naturally occurring complement regulators have been 
developed. Examples for such therapeutics and their application are given in table 1.7 and 
table 1.8.
Soluble complement receptor 1 (sCRl) was the first recombinant complement regulator 
developed for therapy. It consists of the extracellular domains of the naturally occurring 
membrane-associated regulator CR1 (Figl.6A). sCRl inhibits complement at C3 and C5 
level.
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Reagent Moieties and linker Expression 
system (host 
cells)
Mode of action Anti-complement effect 
in vitro
Anti-complement effect in vivo
sCD59 rCD59 (no GPI) Yeast {Pichia 
pastoris)
Inhibits MAC formation Cell (erythrocytes) 
protection from 
complement mediated 
lysis;
NA
CD59-Crry extracellular domain of rat 
CD59 (no GPI) linked to rCrry 
(SCRsl-5)
Yeast {Pichia 
pastoris)
Multiple hit: Inhibit MAC 
formation and inhibition of 
convertases by decay 
acceleration and cofactor 
activity
Cell (erythrocytes) 
protection from 
complement mediated 
lysis (greater than the one 
achieved by CD59)
NA
CRIg-Fc
Long-lived
Mouse form: mCRIg 
(extracellular) linked to 
mlgGl
Human form: hCRIg mutated 
from phage display library 
(extracellular) linked to 
mlgGl
CHO
Inhibits the AP convertases 
by blocking substrate 
binding
Targets C3 fragments and 
protect cells from 
complement-mediated 
lysis;
Protective effect in intestinal IR injury; 
Protection in arthritis (CIA and CALA); 
Modified human form-protective in 
K/BxN serum transfer mouse model of 
arthritis;
sCRl (TP 10) hCRl (SCRsl-30) CHO Decays the convertases (CP 
and AP) by decay 
acceleration and cofactor 
activity
Protects cells from
complement-mediated
lysis
Protection in models of IR injury: heart, 
skeletal muscle, intestine, liver; models 
of acute and chronic inflammatory 
disease: dermal vascular reaction, 
trauma, myasthenia gravis, 
glomerulonephritis, MS, allergic 
reactions, asthma; Clinical trials: 
reducing mortality in males on CBP;
Table 1.7 Summary of the recombinant soluble anti-complement reagents. Extracellular-extracellular domain; r-rat, m-mouse; fa- 
human; NA-not assessed;
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Reagent Moieties and linker Expression 
system (host 
cells)
Mode of action Anti-complement effect 
in vitro
Anti-complement effect in vivo
OmCI
Soft tick 
protein
Recombinant OmCI Yeast (Pichia 
methanolica)
Inhibits C5 activation and 
MAC
Protects cells from 
human, mouse and rat 
complement mediated 
lysis
Protection in models of myasthenia 
gravis
CD59-Fc
Long-lived
mCD59 linked to Fc of 
mIgG2a
CHO Inhibits MAC formation Protects cells from 
complement mediated 
damage;
Protection in mouse model of CNV
DAF-Fc
Long-lived
rDAF(SCRsl-4) linked to Fc 
ofhlgGl
CHO Inhibits complement by 
decay accelerating activity;
Protects cells from 
complement mediated 
damage;
Protection in rat model of ALA;
Crry-Fc
Long lived
rCrry(SCRsl-4) linked to Fc 
of rIgG2a
mCrry(SCRl-5) linked to Fc 
of mlgGl
CHO
NS/0
Inhibits the convertases by 
decay acceleration and 
cofactor activity
Cofactor activity; 
Protects cells from 
complement mediated 
damage;
The mouse form inhibits 
C3 deposition on 
zymosan particles;
Protection in rat model of myasthenia 
gravis;
Mouse form has protective effect in 
nephrotoxic nephritis, mesenteric IR and 
neurological improvement in traumatic 
brain injury;
Table 1.7 (continued) Summary of the recombinant soluble anti-complement reagents. Extracellular-extracellular domain; r-rat, m-mouse; 
h-human; NA-not assessed;
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It accelerates the decay of the convertases and has cofactor activity for factor I mediated 
cleavage of C3b and C4b. sCRl at nanomolar concentrations is able to inhibit complement in 
vitro and in vivo. Its ability to inhibit complement activation has been tested in a variety of 
animal models such as myocardial, skeletal muscle and intestinal I/R, graft rejection, 
myasthenia gravis, multiple sclerosis, glomerulonephritis and arthritis [185, 292-304]. 
Treatment with this reagent reduced the infarct size by 44% in a rat model of myocardial IR 
injury [185], reduced clinical severity, and also inhibited inflammation and blocked 
demyelination in a model of multiple sclerosis [300]. sCRl has been shown to diminish C 
haemolytic activity in a model of glomerulonephritis and thus significantly reduce the 
morphological and functional consequences of disease pathology [302]. sCRl (named TP-10) 
has been tested in phase I and II clinical trials for respiratory distress syndrome and in 
patients on cardiopulmonary bypass (CPB) [305, 306]. While 5mg/kg of sCRl inhibits 
complement and reduces the mortality in males on bypass, no beneficial effect was found in 
female patients [307]. In another study, the use of sCRl in lung transplantation reduced the 
number of patients requiring intubation and also decrease the time on ventilation and stay in 
intensive care [308].
sCRl has been further modified and its half-life increased. Makrides and colleagues extended 
the half-life of sCRl by adding an albumin binding site from streptococcal protein G to the 
C-terminus of the drug. The binding of sCRl to albumin enabled the reagent to remain longer 
in the circulation and increased its half-life from 103 to 297 minutes [309]. A targeted CR1 
reagent has also been developed. To target sCRl to cells, Sialyl-lewis X (sLeX) 
tetrasaccharide groups have been attached to sCRl. These groups are present on neutrophils 
and bind P-, E- and L-selectins which are upregulated on endothelial surfaces during 
inflammation. In addition to its complement inhibitory function, the targeted therapeutic was 
more efficient in reducing neutrophil accumulation than the unmodified sCRl in a rat model 
of lung injury [310, 311].
A second strategy has been applied to develop a highly potent membrane-targeted anti­
complement therapeutic derived from CR1 known as APT070 (Fig. 1.6A). Three N-terminal 
SCRs of sCRl have been fused to a peptide containing positively charged amino acids to 
bind the phospholipid membrane and a terminal myristoyl group to insert into the membrane 
bilayer. This modification allowed the reagent to target a variety of cells [312].
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Reagent Moieties and linker Expression 
system 
(host cells)
Target Mode of action Anti-complement effect 
in vitro
Anti-complement effect in vivo
Targeting using complement receptor
CR2-CD59 hCR2 (SCRsl-4) linked to 
hCD59 (extracellular) via 
SS(GGGGS)3 or (GGGS)2 
linker
CHO iC3b and 
C3dg
Inhibits MAC 
formation
Inhibition of complement- 
mediated cell (CHO and 
erythrocytes) lysis
NA
CR2-DAF hCR2 (SCRsl-4) linked to 
hDAF (SCRsl-4) via 
SS(GGGGS)3 or (GGGS)2 linker
CHO iC3b and 
C3dg
Inactivates the 
convertases by 
decay
acceleration
Inhibition of complement- 
mediated cell (CHO and 
erythrocytes) lysis
Targeting complement activation 
in SLE mouse models
CR2-Crry mCR2 (SCRsl-4) linked to 
mCrry (SCRs 1-5) via 
(GGGGS)2 linker
NSO iC3b and 
C3dg
Inactivates the 
convertases by 
decay
acceleration and 
cofactor activity
Targeting complement 
activation ex vivo 
(opsonised cells, FACS);
Inhibition of complement- 
mediated cell (CHO) lysis;
Targeting complement activation 
in intestinal IR injury;
Protection in intestinal IR injury; 
Improved the disease in CIA;
CR2-fH mCR2 (SCRsl-4) linked to Freestyle iC3b and Inactivates the Targeting C3 opsonised Disease reduction in CAIA;
mfH(SCRsl-5) via 
(GGGGS)2 linker
293 cell or 
CHO
C3dg AP convertases 
by decay 
acceleration and 
cofactor activity
zymosan particles; Protection in laser-induced 
choroidal neovascularisation and 
intestinal IR injury;
Table.1.8 Summary of the recombinant targeted anti-complement reagents. Extracellular-extracellular domain; r-rat, m-mouse; h-human; 
NA-not assessed
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Reagent Moieties and linker Expression 
system 
(host cells)
Target Mode of action
Targeting using antibody specificity
IgG-DAF 1. Anti-dansyl Ab (m variable 
and h constant region) linked to 
hCD59 (extracellular) via 
SG4 SG4 SG4 S linker
TWS2 cells Dansyl
(Model
system)
Inhibits the 
convertases by 
decay
acceleration
IgG-CD59 1. Anti-dansyl Ab (m variable 
and h constant region) linked to 
hDAF (SCRs2-4)
SG4 SG4 SG4 S linker
1.TWS2
cells
1. Dansyl
(Model
system)
Inhibits MAC 
formation
2. K9/9 scFv linked to 
rCD59 via GGGGS 
linker
2. P.
pastoris
(yeast)
2.Unidentifie
d Ag on rat
glomerular
and proximal
tubular
epithelial
cells
IgG-Crry K9/9 scFv linked to rCrry via 
GGGGS linker
P. pastoris 
(yeast)
Unidentified
Ag on rat
glomerular
and proximal
tubular
epithelial
cells
Inhibits the 
convertases by 
decay
acceleration and 
cofactor activity
Anti-complement effect 
in vitro
Anti-complement effect in vivo
Targeting and complement 
protection of dansyl- 
labeled CHO cells;
1. Targeting and 
complement protection of 
dansyl-labeled CHO cells;
2. Targeting and 
complement protection of 
rat proximal tubular 
epithelial cells;
NA
NA
2. Protection in rat model of 
puromycine-induced nephrosis;
Targeting and complement 
protection of rat proximal 
tubule epithelial cells 
(PTEC);
Protection in rat model of 
puromycine-induced nephrosis;
Table.1.8 (continued) Summary of the recombinant targeted anti-complement reagents. Extracellular-extracellular domain; r-rat, m- 
mouse; h-human; NA-not assessed
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Reagent Moieties and linker Expression Target 
system
Mode of action Anti-complement effect Anti-complement effect in vivo 
in vitro
Targeting using membrane address tag
CD59
Targeted
hCD59 with membrane address tag: 
N-(myristoyl)
KSSKSPSKKKKKKPGDC-(S-2- 
thiopyridyl) C-amide (APT3146)
rCD59 with N-
(myristoyl)GSSKSPSKKKKKKPG 
DC-(S-2-thiopyridyl) C-amide 
(APT542)
E. coli Cell
membrane
Inhibits MAC formation Protects erythrocyte 
from complement- 
mediated lysis; 
Human form 
protects PNH- 
erythrocytes from 
complement- 
mediated lysis;
Protection in rat model of 
AIA;
CR1 1. sCRl glycosylated with SLex 1. CHO l.E- and 1.Decays the convertases 1. Binds cell 1. Protection in various
Targeted (TP20) producing 
enzyme that 
incorporates 
sialylated 
and
fucosylated 
tetrasacchar 
ide sialyl 
Lewis
P-selectin (CP and AP) by decay 
acceleration and cofactor 
activity;
expressing E- 
selectin; Protect 
cells from 
complement 
mediated lysis; 
Inhibition of 
neutrophil 
recruitment and 
activation;
preclinical models: mouse 
stroke, rat lung injury, rat 
lung allograft, rat myocardial
IR;
2. ATP070 (hCRl SCR 1-3) with 
membrane address tag
2. E.coli 2.Membra
ne
targeting
2.Decays the convertases 
(CP and AP) by decay 
acceleration and cofactor 
activity;
2. Binds variety of 
cells;
2. Protection in a model of 
anti-basement membrane 
disease; protective effect in 
kidney transplantation 
models and AIA;
Crry
Targeted
Rat Crry (SCRsl-4) 
GSGGGSGC-linker 
Membrane address tag (APT542)
E. coli Cell
membrane
Inhibits the convertases by 
decay acceleration and 
cofactor activity
Targeting and 
complement 
protection of 
erythrocytes;
NA
Table.1.8 (continued) Summary of the recombinant targeted anti-complement reagents. Extracellular-extracellular domain; r-rat, m- 
mouse; h-human; NA-not assessed
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APT070 has demonstrated highly protective effect in rat models o f vascular shock, kidney 
I/R and in AIA [313, 314]. It has also shown neuroprotective effect by preventing MAC 
formation in a model o f Miller-Fisher syndrome [315].
3 N-terminal 
SCRs ofCRl
Plasma membrane
APT070
Mouse anti-dansyl 
variable region
Human IgG4 
constant region
CD59
Hinge-CD59 Ch3-CD59Ch1-CD59
Fig. 1.6. Diagrammatic representation of recombinant anti-complement reagents. A.
sCRl and APT070 are reagents based on CR1. sCRl contains the extracellular domain of 
CR1. APT070 is composed o f three N-terminal SCRs of CR1 linked to a charged peptide 
(that binds to the membrane) and a myristoyl tag (which inserts the membrane). B. CRIg-Fc 
is long-lived reagent, composed o f the extracellular domain of CRIg linked to Fc o f an 
antibody. C. The four N-terminal SCRs o f CR2 are linked to the extracellular domain of 
Crry to generate targeted reagent CR2-Crry. D. IgG-CD59 fusion proteins. The extracellular 
domain of human CD59 was joined to an antibody at the end o f ChI, the hinge or after the 
entire human IgG4 constant region. Each construct contains human IgG constant region 
joined to a mouse anti-dansyl variable region.
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1.5.6. Complement regulator-Fc fusion proteins
A common strategy employed to increase the half-life of therapeutics is the generation of Fc 
fusion proteins. The biologically active molecule is attached to Fc domain of antibody. 
When expressed in mammalian cells the fusion proteins are often secreted as disulfide- 
linked homodimers due to interchain disulfides that form between cysteine residues located 
in the IgG hinge region. The antibody-like structure of the Fc fusion proteins increases their 
size and circulating half-lives. Small molecules with molecular weight <30 kDa are rapidly 
filtered by the glomerulus and then excreted. As the molecular weight increases (>30 KDa), 
the capacity of a protein for glomerular filtration decreases [316]. In addition to that, the 
interaction of Fc to the neonatal receptor (FcRn) in the endothelial cells is responsible for 
the long half-life of the Fc-fusion proteins. Similarly to antibodies, Fc fusion proteins could 
internalise into the cells via pinocytosis and enter the early endosomes where FcRn 
expression is localised. The Fc protein bound to FcRn is recycled back to the plasma 
membrane of the endothelial cells and released back in to circulation. Proteins that are not 
able to bind FcRn enter the lysosomes and are degraded [317, 318].
This approach has been used to generate various anti-complement therapeutics: Crry-Fc, 
CRIg-Fc, DAF-Fc and CD59-Fc.
1.5.6.1. Crry-Fc
A mouse Crry-Fc fusion protein has been generated by linking the major rodent complement 
regulator Crry to Fc of mouse IgGl [319]. The therapeutic has been shown to have a half- 
life of 40 hours. The authors demonstrated that treatment with Crry-Fc inhibited 
complement in vivo and reduced renal injury in a mouse model of glomerulonephritis [319]. 
The protective effect of mouse Crry-Fc has been further demonstrated in other animal 
models such as intestinal IR injury [320], antiphospholipid antibody-induced fetal loss 
[321], SLE [322], and traumatic brain injury [323]. Recently, our group generated a rat Crry- 
Ig containing the Fc of rat IgG2a [324]. The therapeutic has been found to abrogate disease 
in a rat model of myasthenia gravis.
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1.5.6.2. CRIg-Fc
The extracellular domain of human complement receptor/regulator, CRIg, has been attached 
to the Fc portion of mouse IgGl to generate a CRIg-Fc fusion protein (Fig.l.6B) [161]. 
CRIg-Fc has been tested in collagen- and antibody-induced models of arthritis. Treatment 
with this reagent reversed inflammation and bone loss by inhibiting the AP of complement 
in the joint [167]. Mutant CRIg-Fc with increased C3b binding capacity has recently been 
created and showed greater therapeutic efficacy compared to the wild type fusion protein 
when tested in a K/BxN serum transfer model of arthritis [325]. The therapeutic effect of 
mouse CRIg-Fc has also been studied in a mouse model of intestinal IR injury [326]. It was 
demonstrated that the treatment with CRIg fusion prior to surgery reduced C3 deposition 
and cell infiltration and prevented local and remote tissue injury (damage of distant organs).
I.5.6.3. DAF-Fc
A rat DAF-Fc fusion protein has been generated by linking the four SCRs of DAF to human 
Fc. This reagent has prolonged half-life. It has been found to inhibit the disease in a rat 
model of AIA [327].
I.5.6.4. CD59-Fc
A mouse CD59-Fc protein has been developed by joining a mouse terminal pathway 
inhibitor CD59a with the Fc portion of mouse IgG2a. Bora and colleagues have examined 
the impact of this reagent on disease pathology in a mouse model of choroidal 
neovasculisation (CNV, laser-induced mouse retinal degeneration model) where the 
administration of the agent 24 hours before the laser intervention inhibited the development 
of CNV [328].
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1.5.7. Complement regulator-complement receptor fusion proteins
Therapeutic targeting as defined by Smith “implies a relatively selective delivery of a 
pharmacologically active agent to a disease site, which increases the therapeutic ratio of that 
agent” [329].
Complement regulators have been targeted to the sites of complement activation by joining 
them with a complement receptor and thus providing an effective local concentration of the 
drug with low levels of systemic inhibition. The use of such fusion proteins has been shown 
to reduce susceptibility to infections due to systemic complement inhibition especially in a 
long-term treatment of chronic diseases. Various CR2-Complement receptors fusion proteins 
have been developed (CR2-DAF, CR2-CD59, CR2-Crry and CR2-fH) [330-332]. CR2 is a 
complement receptor that binds iC3b and C3dg deposited at sites of complement activation.
1.5.7.1, CR2-DAF
Song and co-workers linked the four N-terminal SCRs of human CR2 to the N- or C- 
terminus of the extracellular domain of human complement inhibitor DAF [330]. In vitro 
studies demonstrated that the fusion protein containing CR2 linked to the N-terminus of 
DAF bound C3dg with a higher affinity than the fusion protein with CR2 at the C-terminus. 
This orientation was also found to be more effective in terms of complement inhibition in 
vitro. CR2-DAF at concentration of 18nM was able to provide 50% protection to CHO cells 
from complement-mediated killing while 74 nm DAF-CR2 was required to achieve the same 
effect. CR2-DAF was taken further into in vivo studies. The authors showed that human 
CR2-DAF targeted to sites of C activation in vivo reduced the clinical score in a mouse 
model of lupus nephritis [330].
1.5.7.2. CR2-CD59
Human CR2-CD59 fusion proteins have been generated. Similarly to CR2-DAF described 
above, the four N-terminal SCRs of human CR2 were attached to the N- or C-terminus of
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the extracellular domain of human CD59. The targeted CD59 and the N-terminal CD59 in 
particular was significantly more effective than the nontargeted CD59 in protecting 
erythrocytes and CHO cells from complement mediated lysis in vitro [330].
I.5.7.3. CR2-Crry
To target the major rodent complement inhibitor, Crry, to the sites of complement activation, 
the extracellular domain of the mouse regulator was linked to the four N-terminal SCRs of 
mouse CR2 (Fig.l.6C) [331]. CR2-Crry has been successfully targeted to the sites of local 
and remote complement activation following intestinal IR injury. Significantly lower dose of 
CR2-Crry was required to achieve equivalent protection compared to non-targeted, long- 
lived Crry-Ig. In a different in vivo study, CR2-Crry improved the neurological recovery and 
reduced pathology in murine ischaemic stroke and spinal cord injury to a level to that seen in 
C3 deficient animals [333]. Complement inhibition with CR2-Crry was protective in a 
model of hepatic IR injury [334]. Conversely, complement inhibition and more precisely 
blocking production of C3a-des-Arg (acylation-stimulating protein [ASP]) had a negative 
effect on the liver regeneration in the context of massive liver resection (procedure for 
removing primary and secondary liver tumors). In a combined model of hepatic IR injury 
and partial hepatectomy (liver resection), a high dose of CR2-Crry resulted in steatosis, 
severe hepatic injury and mortality, whereas a low dose of the reagent was found to be 
protective and improved liver regeneration compared to the control groups [334]. In other 
words, complement plays a dual role in health and disease. Therefore a balance between 
complement activation and inhibition has to be considered when developing therapeutic 
strategies.
I.5.7.4. CR2-fH
Factor H-targeted reagents CR2-fH and CR2-fHfH have been generated by joining mouse 
CR2 with one or two repeats of the first five N-terminal SCRs of mouse fH [332]. The SCRs 
1-4 contain the AP inhibitory activity. It was demonstrated that CR2-fH targeted the site of 
injury and reduced tissue C3 deposition in the intestine [332]. Both CR2-fH and CR2-fHfH
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protected from local intestinal and remote (distant) lung injury in a mouse model of 
intestinal IR injury. Effective targeting and AP inhibition has been also observed in animal 
model of CIA [335]. The capacity of CR2-fH to target complement activation has also been 
demonstrated in a model of CNV [336]. Even delayed treatment after injury provided 
protection and effectively reduced the choroidal neovascularization in mice [336].
1.5.8. Antibody targeting
Fab arms of antibodies have been used to generate anti-complement therapeutics, which 
target to different sites. This is a targeting strategy that utilizes the antigenic specificity of 
monoclonal antibodies to deliver anti-complement protection to specific cells. Such reagents 
were generated by linking complement inhibitors such as CD59, DAF and Crry to the C- 
terminus of an antibody recognizing specific cell surface antigens.
I.5.8.I. IgG-CD59
An antibody-targeted CD59 reagent has been generated by linking antibody fragments 
specific for the hapten 5-dimethylaminonaphtalene-t-sulfonyl (dansyl) to CD59 functional 
unit (Fig.l.6D) [337]. Using a model system, Zhang and co-workers demonstrated that this 
reagent successfully targeted dansyl-labeled CHO cells and inhibited complement-mediated 
lysis. More effective protection was achieved when small antibody fragments comprising 
just the first antibody constant region (CHI) were used [337] (Fig.l.6D). This indicates that 
CD59 must be close to the cell surface for effective function.
I.5.8.2. IgG-DAF
The approach used for generating IgG-CD59 has also been applied to target DAF to a 
surface [338]. SCRs 2-4 of human DAF were used. The IgG-DAF proteins targeted 
dansylated CHO cells and were able to inhibit complement deposition and cell lysis in vitro. 
This experiment revealed that the construct containing only the CHI region was the most 
effective at inhibiting complement deposition, presumably due to spacing from the target
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membrane [338]. Spitzer et al have used similar targeting strategy to generate a human DAF 
(SCRsl-4) reagent that bound specifically to mouse red blood cells and showed its 
protective effect from complement mediated killing in vitro and in vivo [339].
I.5.8.3. IgG-Crry
These in vitro studies using IgG-CD59 and IgG-DAF have demonstrated the feasibility of 
the antibody targeted approach to complement inhibition [337, 338]. The same strategy has 
also been employed for rat Crry [340]. To target the complement inhibitor to the kidney, the 
extracellular domain of rat Crry was linked to a single chain variable region of antibody 
specific for an unidentified antigen on rat glomerular and proximal tubular epithelial cell. 
The reagent, termed tCrry, has been tested in rat model of experimental nephritic syndrome
[340]. The administration of tCrry resulted in reduction of tubulointerstitial injury, 
complement deposition and enhancement in the renal function when compared to the 
nontargeted Crry.
1.5.9. Blocking antibodies
Many monoclonal antibodies (mAbs) are now in clinical use. The first mAb approved for 
human use was a murine anti-CD3 mAb, used for the treatment of organ transplant rejection
[341]. However, it became evident that murine mAbs have a short half-life, high 
immunogenicity and suboptimal effector functions when used in humans. To overcome 
these limitations, mouse mAbs have been engineered to generate chimeric and humanized 
antibodies [342-344]. The former contains the variable regions of a mouse antibody and the 
constant regions of a human antibody, while in a humanized mAb, only the complementarity 
determining regions (CDRs) are of a murine origin. Fully human mAb have been generated 
by phage display [345]. An alternative approach is the use of human immunoglobulin 
transgenic mice to generate human antibodies [346]. Monoclonal antibodies against 
complement have been generated and have emerged as promising therapies.
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1.5.9.1. Anti-C5
The terminal pathway and MAC formation have been implicated in pathology of many 
diseases such as MS, RA and PNH. Neutralizing C5 will inhibit the terminal pathway 
without interfering with other crucial complement functions such as opsonisation. Inhibition 
of complement at C5 level in the context of clinical complications can be achieved by using 
specific anti-C5 antibodies.
Monoclonal antibodies to mouse, rat and human C5 which inhibit C5a generation and 
membrane attack complex formation have been developed. The efficiency of this has been 
proved in a number of animal models of diseases where complement is implicated in the 
pathology. Furthermore, two antibody-based therapeutics have been developed for use in 
humans and have reached the clinic.
Different research groups have developed anti-C5 mAbs that block complement [347, 348]. 
The mouse anti-C5 monoclonal antibody (BB5.1) prevents cleavage of C5 in vitro and in 
vivo and effectively abrogates disease or tissue damage in a wide range of animal models 
including nephritis, CIA and myocardial IR injury [210, 348]. Girardi and co-workers 
studied the effect of C5 inhibition in a murine model of anti-phospholipid syndrome [349]. 
The researchers found that pre-treatment with anti-C5 antibody is protective against 
pregnancy loss. BB5.1 administration has improved the function of the lower airways and 
ameliorated intrapulmonary inflammation in an asthma model [350]. In a murine model of 
CIA, anti-C5 therapy delays the onset of disease and ameliorates established disease [210].
The C5 blocking capacity of various single chain anti-human C5 antibodies has been 
demonstrated in preclinical studies. Anti-human C5 scFv clone N19-8 has been shown to 
prevent C5b-9 deposition in mouse hearts perfused with human plasma [351]. An anti-C5 
scFv: TS-A12/22 (reacting with the a-chain of C5 at the C5 convertase cleavage site and 
inhibits C5 lytic activity and C5a release) and TS-A8 (inhibiting only the C5 lytic activity) 
have been isolated from a human phage display library [352, 353]. Administration of these 
two anti-C5 scFv reduced joint swelling, cell count and TNFa levels in synovial lavage fluid 
in a model of antigen-induced arthritis in rats [352, 353].
68
Two different human-specific reagents based on mouse anti-C5 antibody (h51 -1) have been 
created [354] and tested in clinical trials. These are humanized monoclonal antibody 
(Eculizumab, Soliris®, Alexion Pharmaceuticals) and its single chain version (scFv) lacking 
the constant region (Pexelizumab, Alexion Pharmaceuticals).
The scFv humanized fragment of the murine antibody, Pexelizumab is short-lived reagent 
and has good tissue penetration. Pexelizumab has been shown to prevent C-mediated 
myocardial damage during myocardial IR injury and currently two large clinical trials are 
underway in patients with acute myocardial infarction and undergoing coronary artery 
bypass surgery [355]. Administration of Pexelizumab reduces total C activity, soluble C5b- 
9 formation and leukocyte activation in a human phase I trial with patients undergoing 
coronary artery bypass grafting requiring CPB. It has a beneficial effect on inflammatory 
markers, myocardial infarction rate and postoperative death rates [356]. The benefit of 
Pexelizumab on adverse clinical outcomes has been further confirmed in a phase II study in 
cardiac surgery patients [357]. Moreover, a phase III double-blinded, placebo-controlled 
study confirmed the impact of Pexelizumab on infarct and mortality reduction in cardiac 
artery bypass grafting surgery [358-360].
The second humanized anti-C5 reagent, Soliris® is suitable for treatment of chronic diseases 
and is now approved for treatment of patients with PNH. Its effect has been initially 
evaluated in a pilot trial for PNH [361]. The effect of the antibody treatment has been 
measured by a reduction in serum lactate dehydrogenase levels. Blocking C5 using Soliris® 
has inhibited haemolysis and thus prevented the transfusion requirements of PNH patients. 
Because of patient improvement, the study has been extended [362]. The efficacy of 
Soliris® in treatment of PNH has been further confirmed in a double-blind, randomized, 
placebo-controlled phase III clinical trial [363, 364]. Currently Soliris® is the only treatment 
for this disease that reduces haemolysis. The use of Soliris® in other diseases is under 
investigation. Clinical trials are initiated to evaluate the therapeutic effect of Soliris® in 
aHUS, DDD, kidney transplantation, myasthenia gravis, anti-phospholipid syndrome and 
other neurological and haematological disorders.
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1.5.10. Recombinant CD59
An alternative strategy for blocking the self-destructive capacity of complement whilst 
leaving the early key complement functions intact, is the use of the terminal pathway 
regulator CD59. Soluble recombinant CD59, consisting the extracellular domain of the 
inhibitor, is itself a poor inhibitor of complement in whole serum because of its small size 
(12kDa) and rapid clearance from the circulation in the kidney. However, generation of 
forms with long half-life or targeted reagents has meant that this complement regulator has 
become a potential therapeutic. Membrane targeting of recombinant CD59, using the same 
lipid targeting peptide as discussed for CR1/APT070, has improved the specific activity to 
the level of the native protein [365]. Fraser and colleagues demonstrated that membrane 
targeted CD59 blocked MAC deposition in joints and markedly suppressed disease in a rat 
model of AIA. This targeting strategy has been applied to human CD59 [366]. The targeted 
human CD59 bound to PNH erythrocytes in vitro and restored CD59 levels to those of 
normal erythrocytes. Furthermore, these CD59-‘coated’ PNH erythrocytes were protected 
from complement-mediated lysis when transfused into CD1 mice.
As discussed in section 1.5.8.1, CD59 has been targeted to different cell types by fusion of 
the protein with a cell-specific antibody or antibody fragment. The rapid clearance of soluble 
CD59 in vivo was overcome by generation of CD59-Fc fusion proteins as explained 
previously in section 1.5.6.4. Mouse CD59a fused to the Fc of mouse IgG2a generated a 
reagent that inhibited the development of choroidal angiogenesis in a mouse model of CNV 
[328]. The deposition of MAC was prevented as well as MAC-mediated release of 
angiogenic growth factors such as VEGF, p-FGF and TGF-p2.
1.5.11. Recombinant OmCI
The soft tick lipocalin OmCI, also known as rEV576, was introduced in 1.4.1. Its low 
immunogenicity and the ability to block MAC formation and C5a release, similarly to the 
therapeutic anti-C5 antibody described above, suggests that OmCI could be a powerful 
therapeutic in disease mediated by complement activation. This was proved in vivo by us 
and others. OmCI was able to protect rats from clinical signs of disease in passive and active
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models of myasthenia gravis (the models are explained in table 1.5) [176, 367]. A marked 
reduction in C3 and C9/MAC deposition at the neuromuscular junction and a significant 
decrease, in cellular infiltrate was observed in the animals that received OmCI compared to 
control rats [176]. Therefore the OmCI-based anti-complement therapy offers a powerful 
approach for preventing complement-mediated damage in disease. However the usage of 
OmCI as a therapeutic is limited due to its short half-life of few minutes. Given to 
experimental C5 sufficient animals, OmCI circulates in complex with C5, however the free 
OmCI was rapidly cleared in absence of C5 [176]. Thus extending the half-life of OmCI 
would be rewarding and such long-living inhibitor would be a potent drug, an alternative to 
anti-C5 antibody treatment, for complement-associated diseases.
1.5.12. Optimal target for complement inhibition
As discussed in this chapter, blocking complement is beneficial in a variety of diseases. 
However as a part of immune system, complement provides resistance towards infectious 
agents, eliminates IC and dying cells and helps the development of optimal adaptive immune 
response, events crucial for maintain the health of a living organism. Each of these important 
complement functions might be affected with chronic complement inhibition. Evidence for 
this was provided by findings in humans and experimental animals with complement 
deficiency. For example, patients and animals lacking early complement components are 
unable to efficiently process apoptotic cells and immune complexes and prone to develop 
autoimmune disease [196, 368, 369]. Clq and MBL were shown to bind directly to 
apoptotic blebs resulting in their opsonisation via the activation of C4 and C3. Deficiencies 
in Clq, C2 and C4 in humans are associated with SLE. The absence of Clq in mice results 
in apoptotic bodies and immune deposits accumulation in the glomeruli and the animals 
develop glomerulonephritis. Furthermore deficiency in Cl and C4, affects the uptake of 
apoptotic bodies by macrophages [45]. Another key complement component for 
maintenance of the body homeostasis is C3. C3 bind covalently to IC and thus allowing their 
solubilisation (transforming big complexes in to small) and transport via the erythrocytes to 
the liver and spleen for removal by phagocytes. C3b deposited on the pathogens surface 
facilitates their removal by phagocytosis and clearance.
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In contrast to the deficiency in the activation pathways, deficiency or inhibiting complement 
at later stages does not alter IC clearance or humoral immunity but only results in increase 
susceptibility to gram-negative bacteria and Neisseria meningitidis in particular. However 
Neisseria infection is not a major issue since the bacterium is susceptible to antibiotic 
treatment. Vaccination against this pathogen is another option to prevent the infection.
1.6. Project Aims
The conclusion therefore is that complement is a host defence system that plays an important 
role in both innate and adaptive immunity. Besides its beneficial effect in health, 
complement has a destructive role in various pathological conditions where complement 
dysregulation can cause tissue damage. In such disorders, complement activation via one of 
the three activation pathways, occurs leading to the generation of MAC, which can result in 
tissue damage and cell activation. Therapeutic intervention of complement in the context of 
disease has aroused enormous interest. Many anti-complement reagents and approaches 
have been developed and some of them translated into the clinic. Previous research findings 
revealed the importance to balance the benefit from inhibiting the complement system with 
potential side effects, such as increased susceptibility to gram-negative bacteria and 
autoimmune disease caused by poor clearance of IC and cell debris. To avoid complications, 
only the self-destroying power of the complement should be turned off while leaving 
untouched crucial function such as opsonisation of pathogens and clearance of immune 
complexes. This makes the terminal pathway a valuable location for therapeutic 
intervention.
Therefore, this research effort is to develop anti-complement therapy that does not simply 
turn the complement off, but modulates its activity. The overall aim of this project is to 
generate targeted and soluble long-lived reagents which specifically block terminal pathway 
activity at the level of MAC assembly or C5 activation respectively. The specific aims for 
this study are:
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1.6.1. To generate the optimal targeted CD59-CRIg reagent.
The major side effect of anti-complement therapeutics is the systemic action many of the 
reagents have on complement and leaving an individual susceptible to infection. This was 
addressed by developing targeted anti-complement reagents. For example targeted CR2-Crry 
reagent did not affect the susceptibility of the experimental animals to infections, while the 
animals that received the non-targeted version, Crry-Fc, lost their pathogen resistance due to 
inefficient bacterial clearance [331].
A similar approach is applied here to target the terminal pathway inhibitor CD59 to the site 
of pathology. As noted earlier in this chapter, sCD59 is a poor complement inhibitor in 
whole serum, probably due to interactions with serum proteins. In vivo, sCD59 because of 
its small size is efficiently cleared by filtration in the kidney, thus targeting CD59 to sites of 
complement activation and disease is very likely to improve its efficacy. Furthermore the 
targeting CD59 may reduce the side effect of complement inhibition such as infections with 
Neisseria, particularly in long-term complement suppression. An accurate delivery of CD59 
will be achieved by linking the extracellular domain of mouse CD59 to the extracellular 
region of the mouse complement inhibitor CRIg. CD59-CRIg chimeric molecule is likely to 
provide good protection to host cells attacked by complement. Targeted human CR2-CD59 
reagent has been already developed but its function has been little explored in vivo. CR2 
binds C3 degradation products iC3b, C3dg and C3d. CRIg binds iC3b and it also interacts 
with C3b. The advantage of CRIg over CR2 as targeting molecule is that binding of CRIg to 
the first C3 activation fragment C3b is very likely to provide cell protection earlier in time 
than CR2 targeted reagents. C3b deposited on cell surface is converted to iC3b (both 
molecules binds CRIg) by complement regulators. However, in diseases associated with 
complement dysregulation and absence of complement regulators, the generation of C3 
breakdown products iC3b and C3dg will be affected and thus leaving C3b a main target for 
C3 targeted therapeutics. In such situations CRIg is likely to provide more efficient targeting 
than CR2.
It has been shown that the orientation of CD59 towards the cell membrane and the other 
counterpart of the chimeric molecule is of a high importance for the function of the reagent. 
Such an orientation, in which CD59 is placed close to the membrane has been found 
beneficial for the activity of CD59 present in chimeric proteins containing DAF or antibody
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portion [337, 370]. Another example emphasising the impact of the orientation on the 
protein function was given by Song et al, where the authors demonstrated that CD59 and 
DAF linked to the C-terminus of CR2 provided better cell protection [330]. Here CD59- 
CRIg fusion proteins in a different orientation are generated and their functions are analysed 
and compared.
To enhance targeting potential, dimeric forms of CD59-CRIg reagents are generated which 
incorporate an antibody hinge to link the two moieties and promote dimerisation. To the best 
of my knowledge, the use of antibody hinge to create dimeric forms of reagents targeting 
complement activation is a novel approach for improving drug efficiency.
1.6.2. To generate a long-lived soluble anti-CS drug: OmCI-Fc.
C5 is another promising target when blocking the terminal pathway. C5 neutralizing mAbs 
have been developed and shown their therapeutic effect in preclinical and clinical studies. 
Moreover anti-C5 mAb is used as a therapy in PNH. Another molecule able to block C5 
activation is OmCI. Similarly to anti-C5 mAb, OmCI prevents MAC formation and the 
release of C5a anaphylatoxin.
As discussed in this Chapter, OmCI is able block the activity of C5 from various species 
including human, mouse and rat. For this reason the anti-complement effect of OmCI can be 
validated in preclinical models. The protective role of OmCI was already demonstrated in 
vivo. However, as a small molecule, OmCI is rapidly cleared from the circulation, which 
necessitates frequent administration and thus limits its clinical utility. To address this issue 
OmCI is ligated to Fc portion of IgG molecule. The construction of Fc chimeric proteins has 
been shown to improve pharmacokinetics of therapeutic agents including anti-complement 
drugs.
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1.6.3. To study the capacity of these therapeutics to inhibit complement in vitro.
One of the objectives of this study is to assess the ability of CD59-CRIg fusion proteins to 
target complement activation and protect the target cells from complement-mediated killing. 
Based on this result, the optimal reagent will be selected and taken for in vivo analysis.
Insertion of the Fc fragment could cause conformational change and render the OmCI 
functionally inactive. To assess this, the complement inhibitory activity of OmCI-Fc is first 
analysed in vitro and compared to OmCI.
1.6.4. To test the therapeutic value of the reagents ex vivo and in vivo in mice.
Reagents shown to be effective in vitro, will be tested for their ability to target complement 
activation ex vivo and in vivo.
It is expected that the reagents generated in this project will have the potential to deliver 
substantial therapeutic benefit and offer a very attractive option for treatment of 
complement-mediated disease. When humanized, these anti-complement agents may 
provide a medical solution for patients who have not responded to other treatments. I believe 
that the results revealed in this study will have implications for improvements in drug design 
and therapeutic approaches.
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Chapter 2. Materials and methods
This chapter will focus on the research methods to be used within the proposed study.
Unless otherwise stated all chemicals were from Sigma Chemical Company or Fisher 
Scientific UK Ltd.
2.1. Preparation of plasmids encoding the anti-complement therapeutics-molecular 
biology
The RNA preparation was carried out using diethylpyrocarbonate treated tips and tubes. The 
DNA manipulations were performed using autoclaved plasticware and solutions.
2.1.1. Solutions
Table 2.1
Solution Contents
TAE 40mM Tris, 40mM acetic acid, ImM EDTA pH 7.2
Agarose gel loading 
buffer
20% glycerol (v/v) in lOx TAE with bromphenol blue
Lauria-Bertani (LB) 1% tryptone (w/v), l%NaCl (w/v), 0.5% (w/v) yeast
broth extract in water
SOC 2% tryptone (w/v), 0.5%yeast extract (w/v), 0.05% NaCl 
(w/v), 2.5mM KC1, lOmM MgCl2 and 20mM glucose
2.1.2. RNA preparation
Mouse liver (BalbC) was harvested and RNA was isolated using GenElute™ Mammalian 
Total RNA Purification Kit (Sigma) according to the manufacturer’s protocol. In brief, the 
liver was homogenised in guanidine thiocyanate and 2-mercaptoethanol to release RNA and 
inactivate RNase. The homogenate was spun through a filtration column to remove cellular 
debris and shear DNA. The filtrate was applied to a silica column to bind RNA, followed
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by washing and elution. The concentration of the purified RNA was determined by 
measuring the absorbance 260nm.
2.1.3. Reverse transcriptase PCR (RT PCR)
cDNA was prepared from the RNA isolated from mouse liver using TaqMan Reverse 
Transcription reagents (Applied Biosystems, Warrington, UK).
The reaction consisted of:
0.5pg RNA
0.5pi random hexamers 
1 pi lOxRT buffer 
2.2pl 25mM MgCl2 
2pl dNTPs
0.2pl RNAse inhibitor
0.25pl Reverse Transcriptase Multiscribe
RNAse free water to take the reaction to volume to lOpl
The reaction mix was incubated as follows:
25°C for 10 minutes (to allow the primers to anneal)
42°C for 45 minutes (to extend the DNA)
95°C for 5 minutes (to denature the enzyme)
cDNA was stored at -20°C.
2.1.4. PCR
PCR was used to amplify DNA to be cloned into a vector or to screen bacterial colonies 
containing plasmids encoding protein of interest. The primers used for amplification,
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screening and sequencing were purchased from Invitrogen Life Technologies. The primers 
were reconstituted using dH20 to obtain a concentration of lOOpmol/pl.
PCR was performed to generate DNA encoding OmCI and the extracellular domains of 
murine CRIg and CD59 for cloning.
The reaction contained: 
lOOng template DNA (2pl)
15pmol forward primer (1 pi)
15pmol reverse primer (lpl)
IX Platinum ® Blue PCR SuperMix (Invitrogen life technologies) (21 pi)
Platinum ® Blue PCR SuperMix contains recombinant Taq DNA polymerase, Platinum ® 
anti- Taq DNA polymerase antibody, Mg , dNTPs, glycerol and blue tracking dye. 
Platinum® Blue PCR SuperMix is supplied at l.lx  concentration to allow approximately 
10% of the final reaction volume to be used for the addition of primer and template 
solutions.
PCR steps:
1. 94°C-4 minutes (Specific binding of the anti-7a# antibody inhibits polymerase activity at 
room temperature. Activity was restored after this denaturation step)
2. 94°C-30 seconds (Denaturation)
3. 5 8-65°C-45 seconds (Annealing; temperature dependent upon melting temperature of the 
primers)
4. 72°C -1.30 minutes (Elongation; times may vary depending on the size of the PCR 
product, 1 minute per kb)
5. 72°C -15 minutes (Final extension)
Steps from 2 to 4 formed 1 PCR cycle. Each PCR consisted 30 cycles.
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2.1.5. Screening PCR (see also Bacterial screening)
f m  t      ’T 'X /f
For screening PCR, BioMix Red (Bioline) was used. BioMix Red is a 2x reaction mix 
containing an ultra-stable Taq DNA polymerase, dNTPs, MgCk and inert red dye that 
permits easy visualisation and direct loading onto a gel. Each reaction contained reagents as 
followed:
2jnl bacterial DNA
25pmol forward primer
25pmol.reverse primer
12.5 nl BioMix™Red
dF^O to take the final volume to 25 pi
The PCR was performed as above.
2.1.6. Agarose Gel electrophoresis
Agarose Gel electrophoresis was used to visualise DNA fragments and PCR products. 
Agarose (Sigma) was melted in lxTAE buffer using microwave. The percentage agarose 
used depends on the size of the DNA fragments. The agarose was allowed to cool to 60-56° 
and lOOng/ml ethidium bromide was added. An agarose gel was cast using BioRad casting 
system. The gel was allowed to set and placed into electrophoresis tank (BioRad or Thermo 
Electron corporation). PCR products containing gel loading buffer or DNA samples with gel 
loading buffer added were loaded into the gel. DNA size markers were also used. Gels were 
run at 100V. The DNA bands were visualised using a UV transilluminator (BioRad, 
ChemiDoc). Images were captured on a digital camera using BioRad Gel Documentation 
system.
2.1.7. Purification of PCR products
PCR products were purified using a QIAquick PCR purification kit (Qiagen) and a 
QIAquick Gel Extraction Kit (Qiagen) was used to purify DNA from agarose gels when 
plasmid DNA was used as a template. The manufacturer’s protocol was used for the PCR
purification. In brief, the DNA was bound to a silica membrane in a high-salt buffer, washed 
and then eluted with low-salt buffer. The concentration was determined by measuring the 
absorbance at 260nm on a Nanodrop spectrophotometer ND-1000. For accuracy, the reading 
should be between G.l and 1.0. An absorbance of 1 unit at 260nm corresponds to 50pg 
double stranded DNA per millilitre. To purify PCR products from an agarose gel, DNA was 
extracted from the gel and purified using manufacturer’s protocol in which the agarose gel 
was dissolved in a gel-dissolving buffer, the DNA bound to a silica matrix, washed and 
eluted with lOpl of elution buffer. The concentration was determined as above.
2.1.8. Restriction digests
The restriction enzymes used for digestion PCR products or plasmid DNA were purchased 
from Promega. For digesting 5pg DNA, 3 pi (24-30 units) of relevant enzyme was used with 
7pi of the recommended buffer and 7pl of 0.1% BSA. The final volume was taken to 70pl 
with distilled water. All digests were incubated for 2 hours at 37°C. DNA was purified after 
each digesting step using a QIAquick® PCR purification kit and eluted with 56pl elution 
buffer provided in the kit.
2.1.9. Ligation
The digested PCR products were ligated into the expression vector pDR2AEFla (gift from 
Dr. I. Anegon, INSERM U437, Nantes, France) using T4 DNA ligase (Promega). To 
generate OmCI-Fc, a ligation step in to Signal pig plus vector (R&D systems) was also 
performed. For ligation, 90ng plasmid was used and 3-fold molar excess of insert. This was 
calculated by:
3X(90ng vector x size of insert in kb)/size of vector in kb
Each ligation reaction contained also lpl lOx ligase buffer (Promega, 300mM Tris-HCl pH
7.8, lOOmM MgCl2, lOOmM DTT and lOmM ATP), lplT4 DNA ligase and dH20  to adjust
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the final reaction volume to IOjlxI. This was then incubated at 16°C overnight. The ligated 
DNA was transformed into bacteria.
2.1.10. Transformation
Chemically competent DHa bacterial cells (Invitrogen Life Technologies) were transformed 
with ligated DNA by heat shock, lpl of ligated DNA was added to 50pl of bacterial cells 
and mixed gently. The competent cells were incubated on ice for 30 minutes followed by 
incubation for 60 seconds at 42°C. The cells were immediately transferred back on ice and 
incubated for 2 minutes. 950pl of SOC medium was added and the cells were incubated at 
37°C for 1 hour in a shaking incubator. 200pl of the bacterial suspension were plated onto 
LB ampicillin plate (LB containing 1.5% agar and lOOpg/ml ampicillin plated into a Petri 
dish) and incubated for 16 hours at 37 °C.
2.1.11. Bacterial colony screening
Bacterial colonies were screened by PCR to detect the efficiency of ligation insert into 
plasmid. In order to check the orientation of the insert in the vector “internal” and “external” 
primers were used. “Internal” is one of the primers used to amplify the insert. The “external” 
primer is specific for the pDR2AEFla plasmid. All the primers used for screening are listed 
in Table 2.2. Single colonies were picked with a sterile pipette tip and resuspended into 20pl 
of dFLO. lpl of the suspension was spotted onto an LB amp plate. The remaining 19pl was 
boiled for 10 minutes on a heating block to lyse the bacteria. The tubes were cooled down by 
incubation on ice followed by a centrifugation at 13000 rpm for 8 minutes. 2pi of the 
supernatant containing plasmid DNA was used as a template for the screening PCR. The 
PCR products were visualised on agarose gel and colonies containing the insert in the 
correct orientation and size were identified. These were picked from the LB amp plate and 
seeded in 10ml LB broth and incubated in a shaking incubator for 16 hours (overnight) at 
37°C.
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Construct Cloning step External
primer
Internal primer Annealing
temperature
(C°)
OmCI-Fc OmCI into Sig pig plus 5’pIgpDR2 OmCI 3’ 60
CD33sp-OmCI into pDR 5’ OmCI 3’ 60
pDR2AEFla
CRIg-CD59* CRIg into pDR2AEFla pDR 5’ CRIg amino 3’ 62
CD59 into pDR 5’ CD59carboxy 3’ 60
CRIg/pDR2 AEF1 a
CD59-CRIg* CD59 into pDR2AEFla pDR 5’ CD59 amino 3’ 62
CRIg into pDR 5’ CRIg carboxy 3’ 62
CD59/pDR2AEF 1 a
Table 2.2 Cloning steps and primers used for DNA screening
*An additional screening step was performed for the reagents containing antibody hinge. 
The insertion of the hinge was confirmed by PCR using pDR5’ (external) and the reverse 
primer specific for the hinge (internal).
2.1.12. Plasmid isolation
The overnight bacterial culture was spun down at 1300xg for 10 min. The supernatant was 
discarded. The plasmid DNA was isolated from the bacterial pellet using QIAprep Spin 
Miniprep kit (Qiagen) according to manufacturer’s protocol. In brief, the bacteria were lysed 
under alkaline conditions. The lysate was subsequently neutralised and adjusted to high-salt 
binding conditions. The DNA was bound to a silica matrix, following a wash, the DNA was 
eluted and stored at -20°C.
2.1.13. DNA sequencing
All DNA constructs cloned into plasmids were sequenced using Big Dye™ Terminator 
Cycle Sequencing Kit (Applied Biosystems). Every sequencing reaction contained 50-100ng 
of template DNA, 2.5pmol specific forward or reverse primer, 2pl BigDye Premix 
containing Ampli Taq DNA polymerase, 3 pi Better buffer and dH20  to make the reaction up 
to lOpl.
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The amplification protocol consisted of 25cycles as follows:
Denaturation: 96°C for 30 seconds
Annealing: 50°C for 15 seconds
Extension: 60°C for 4 minutes
The DNA was precipitated by adding 2pl of 3M Sodium acetate pH5.2, 2pl of 125mM 
EDTA and 50pl ice cold 100% ethanol. The reaction tubes were incubated for 10 minutes at 
room temperature and DNA was centrifuged at 13,000 rpm for 30 minutes. The supernatant
was discarded and the pellet washed with 200pl 70% (v/v) ethanol. Sequencing was carried
out using an ABI model 377DNA sequencer (PerkinElmer; Central Biotechnology 
Services).
2.1.14. Plasmid dephosphorylation
To prevent self ligation of linearised plasmids during cloning, a dephosporylation step was 
carried out. This step was particularly important when the plasmid was cut with a single 
enzyme (generating sticky ends) or with enzymes forming blunt ends. A shrimp alkaline 
phosphatase (SAP, Promega) was used in this study. SAP removes phosphate groups from 
the 5’ends of DNA and RNA and thus prevents re-ligation.
Plasmid DNA digested with restriction enzymes was incubated with SAP at 37°C for 15 
minutes in lxSAP reaction buffer in a final volume of 50pl. The enzyme was inactivated by 
heating to 65°C for 15 minutes. The plasmid DNA was immediately used for ligation or 
stored at -20 °C.
2.2. Mammalian cell expression
All tissue culture was carried out under sterile conditions in a flow cabinet. All tissue culture 
reagents were obtained from Invitrogen Life Technologies unless otherwise stated. The cells 
were grown in a humid atmosphere at 37°C and 5% CO2.
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2.2.1. Media
RPMI-1640 (Roswell Park Memorial Institute 1640) was used for cell culturing. It was 
supplemented with 50U/ml penicillin/streptomycin, 2 mM L-glutamine and ImM sodium 
pyruvate and 10% (v/v) foetal calf serum (FCS). This medium would be called “RPMI- 
complete” for short. Hygromycin B (0-6-Amino-6-deoxy-L-glycero-D-galacto- 
heptopyranosylidine-(l-2-3)-0-P-D-talopyranosyl-(l-5)-2-dexy-N3-methyl-D-stretamine; 
A.G. Scientific, Inc.) was used as a selective agent for transfection. Depending upon the 
stage of cell selection different amounts of hygromycin B were added: 400pg/ml for 
selection medium, lOOpg/ml for transfected cells. Non-transfected CHO cells were grown in 
hygromycin B free media.
2.2.2. CHO cells
Chinese Hamster Ovary (CHO) cells were used to express the anti-complement therapeutics. 
A frozen aliquot of the cells was taken from the liquid nitrogen and was rapidly thawed and 
resuspended in warm RPMI-complete. The cells were centrifuged at 300xg for 5 minutes. 
The cell pellet was resuspended in 5ml of RPMI and cultured in T25 tissue culture flasks. To 
subclone or expand adherent cells, the cells were washed with sterile saline and lifted from 
the flask surface using Trypsin-EDTA. The detached cells were diluted in to RPMI- 
complete and transferred into new flasks for expansion.
2.2.3. Transfection of CHO cells
The vector pDR2AEFla used for mammalian expression contains the high expression 
promoter for Elongation Factor la  and multiple cloning site next to it. In addition to the 
gene for ampicillin resistance, it carries a hygromycin resistance allowing selection in 
eukaryotic cells.
CHO cells were transfected using JetPEI™DNA Transfection reagent (Poly plus 
Transfection). It is a water-soluble polymer, which forms stable aggregates with DNA.
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Transfection was carried out in 6  well-plate or T25 tissue culture flasks, according to 
manufacturer’s instructions. Plasmid DNA (3pg or 5pg) was mixed with transfection agent 
and incubated for 25 minutes at room temperature to allow formation of JetPEY/DNA 
complexes. The complexes were then applied to the cells. The cells were incubated with the 
transfection mix in Hygromycin B-free medium for 24-48 hours at 37°C and 5% CO2. The 
media was replaced with selective media containing 400pg/ml Hygromycin B. Mock 
transfected cells were used to monitor the selection. When these non-transfected cells had 
died, the CHO cells were maintained in media with 100pg/ml Hygromycin B. The efficiency 
of transfection and protein expression was confirmed by western blot analysis on tissue 
culture supernatant. Once the protein expression is confirmed, the cells were cloned out.
2.2.4. Cloning by limiting dilution
To select high expressing transfected CHO cells, the cells were cloned out by limiting 
dilution in 96-well plates. lOOpl of medium was placed in the wells. Cells from a tissue 
culture flask were resuspended to 500 cells/ml medium. 200pl of cell suspension was added 
to the first three columns. The cells were diluted in 1:2 serial dilution across two 96-well 
plates to achieve final dilution of 0.26 cell per well. The cloned cells were cultured for 10 
days. The supernatant from wells containing a single colony was screened by ELISA or 
western blot. Cells expressing highest levels of protein were expanded. The same assay was 
applied for cloning hybridoma cells.
2.2.5. Storage of CHO cells
To freeze down, CHO cells (transfected or non-transfected) harvested from a T80 flask were 
centrifuged at 300xg for 5 minutes and resuspended into 2ml of freezing medium (10 % 
DMSO/FCS). The cells were aliquoted into two cryovials (Greiner) and frozen in an 
isopropanol-containing Freezing container (Nalgene) placed at -70°C. The container 
provides l°C/min cooling rate which together with the DMSO prevented the formation of
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ice crystals in the cells. After 24 hours at -80°C, the cells were transferred into liquid 
nitrogen for long-term storage.
2.2.6. High-density expression systems
For efficient protein expression, transfected cells were seeded in a two-compartment 
bioreactor CELLine AD 1000 or HYPERF/as& expression systems.
2.2.6.I. Two-compartment bioreactor CELLine AD1000 for CHO cell culture
CELLine AD 1000 (Integra Biosciences) has two compartments separated by lOkDa semi- 
permeable cellulose-acetate membrane. This allows the cells, cellular products and protein 
to remain in the cell compartment and a concurrent continuous removal of any inhibitory 
waste product. The compartment contains a polyethylene teraphthalate matrix that provides 
a surface for cell attachment. Transfected cells were maintained in transfected cell medium 
(15-17ml) in the cell compartment.
To inoculate the flasks, the membrane was wetted by placing 50ml media in the medium 
compartment and 2.5x107 cells in 15ml RPMI-complete medium containing 1 00pg/ml 
hygromycin B were placed into the cell compartment. A further 950ml RPMI medium was 
added to the medium compartment. The media in both compartments was changed 10 days 
after the inoculation and then every 7 days. The medium harvested from the cell 
compartment was centrifuged at lOOOxg for 5 minutes and the supernatant was collected and 
stored at -20°C. The protein production was assessed by ELISA or Western blot. Prior to 
any protein purification, the cell culture supernatant was centrifuged at 6000xg for 1 0  
minutes at 4°C and filtered through a 0.22pm filter.
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2.2.6.2. HYPERFlask for CHO cell culture
CHO cells expressing anti-complement therapeutics were also maintained in HYPERF/as# 
cell culture vessels (Sigma-Aldrich). These flasks contain ten gas permeable polystyrene 
growth surfaces that allow air exchange between the layers. CHO cells (lxlO7) expressing 
fusion proteins were diluted in 100ml RPMI medium containing lOOpg/ml hygromycin B. 
The cell suspension was transferred into the HYPERF/as& cell culture vessel. The flask was 
capped and laid on its side to allow the solution to distribute between layers. This ensured 
that each layer of the flask received the same volume of liquid. The flask was then filled 
with 450ml of RPMI-complete medium containing lOOpg/ml Hygromycin B. The tissue 
culture supernatant was harvested and replaced with fresh medium every six days. The 
protein production was assessed and the supernatant was stored as described for CELLine 
AD 1000 flask.
2.3. Protein purification
Fusion proteins, complement plasma proteins C3 and C5, and antibodies were purified using 
chromatography techniques.
2.3.1. Buffers and solutions
The buffers used for protein purification are listed in table 2.3
2.3.2. Clarification of supernatant
Prior to any purification, cell culture supernatant was clarified by centrifugation at 6000xg 
for 10 minutes. Cell culture supernatant and plasma were filtered using 0.22pm filter before 
applying over chromatography columns.
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Name Contents
Tris buffered saline (TBS) lOmM Tris, 150mM NaCl, 0.01% (w/v) sodium 
azide, pH7.4
Phosphate buffered saline (PBS) 8.2mM Na2HP04,1.5mMKH2P04,137mMNaCl, 
pH 7.4
Coupling buffer 0.2M Na HC03,0.5M NaCl, pH8.3
Glycine 0.1M Glycine/HCl pH2.5
Diethylamine 20mM Dyethylamine in PBS
IgM binding buffer 20mM Na2HP04, 0.8M (NH4)2S04, pH7.5
IgM elution buffer 20mM Na2HP04, pH7.5
IgM regeneration buffer 20mM Na2HP04, pH7.5, 30% isopropanol
Source Q buffer lOmM K2HP04, 5mMEDTA, 0.5mM PMSF, 5mM 
Benzamidine, pH7.8
Source Q elution buffer lOmM K2HP04, 5mMEDTA, 0.5mM PMSF, 5mM 
Benzamidine, lMNaCl, pH7.8
Mono S running buffer 20mM NaP04, pH6
Mono S elution buffer 20mM NaP04,1M NaCl, pH6
Table 2.3
2.3.3. Protein A and G chromatography
To purify antibodies or OmCI-Fc, serum or tissue culture supernatant was passed over 
prepacked 5ml protein A or G columns (GE Healthcare). Protein A and G are bacterial 
proteins used for purification of many antibody isotypes from a variety of species. The 
column was run using an AKTA Prime system (GE Healthcare). Each run consisted of a 2 
column volume (10ml) equilibration with TBS, a supernatant load, 6  column volume wash 
with TBS and a 4 column volume elution with Glycine pH2.5. The elution was collected in
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lml fractions neutralised with lOOpl 1M Tris/HCl pH 10. The column was washed with HC1 
pHl .5 and equilibrated in TBS
2.3.4. IgM purification
HiTrap™ IgM Purification HP prepacked column (GE Healthcare) was used to purify IgM. 
The column was operated with Akta Prime liquid chromatography system. The column was 
equilibrated with 5 column volumes of IgM binding buffer. Tissue culture supernatant from 
hybridoma cells producing IgM anti-OmCI mAb containing 0.8M ammonium sulphate was 
loaded onto the column. The unbound protein was washed out with 15 column volumes of 
IgM binding buffer. IgM was eluted using 12 column volumes of IgM elution buffer. The 
column was regenerated with 7 column volumes of IgM regeneration buffer. The elution 
fractions were assessed by SDS-PAGE.
2.3.5. Gel filtration
Gel filtration chromatography was used to separate proteins based on their size and to 
estimate the molecular weight of OmCI-Fc and CRIg-CD59 fusion proteins. The 
chromatographic matrix consists of porous beads and the size of the bead pores defines the 
size of molecules that may be fractionated. The proteins that are too large to enter the beads 
pores are eluted from the column first. Smaller molecules are able to enter the pores and are 
retained by the column. Gel filtration chromatography was performed on Superdex 200 
column using an Akta Purifier system. The protein was eluted at a flow rate of 0.5ml/min 
with a 1.5 column volumes. The elution buffer was chosen to preserve the protein activity. 
Fractions (0.5ml) were collected and small aliquots were taken for SDS-PAGE analysis. The 
estimation of the molecular weight is based on the assumption that the protein is globular in 
shape.
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2.3.6. Affinity chromatography
Affinity chromatography was used to purify fusion proteins (OmCI-Fc and CRIg-CD59), 
complement protein C5 and antibodies (rabbit anti-OmCI polyclonal antibody, anti-OmCI 
monoclonal antibody of IgM isotype). OmCI-Fc was purified on an anti-OmCI antibody 
column while anti-CD59 antibody was used to purify CRIg-CD59 fusion proteins. Anti­
mouse C5 antibody (BB5.1) was used to generate an affinity column for mouse C5 
purification. Prior to the affinity purification, the polyclonal anti-OmCI rabbit serum was 
passed over a protein A column to isolat the immunoglobulin fraction. This was then 
subjected to OmCI affinity chromatography and the specific anti-OmCI antibody was 
purified.
2.3.6.1. Generation of affinity columns
Affinity columns were generated using prepacked NHS-activated Sepharose (5ml or 1ml 
HiTrap columns) from GE Healthcare. The antibody/protein to be bound were dialysed into 
coupling buffer two times for 7 hours at 4°C. Before coupling the antibody, the column was 
washed with 6  column volumes of ice-cold ImM HC1. The antibody/protein (30mg for 5ml 
column and lOmg for 1ml column) was injected and column incubated for 30 minutes at 37 
°C. The column was then washed with 6  column volumes of 0.5M ethanolamine, 0.5M 
NaCl, pH8.3 to block the remaining active sites, followed by washing with 6  columns 
volume of 0,1M acetate, 0.5M NaCl, pH4. These steps were repeated three times. The 
column was then equilibrated in TBS and stored at 4 °C.
2.3.6.2. Protein purification using affinity columns
To purify proteins, cell culture supernatant or serum (for C5 purification) was passed over 
an affinity column. The column was run using an AKTA Prime system (GE Healthcare). 
Each run consisted of a 2 column volume (10ml) equilibration with TBS, a supernatant load, 
5 column volume wash with TBS and a 4 column volume elution with glycine pH2.5 (for 
OmCI-Fc and OmCI) and diethylamine/PBS pHl 1 (for CRIg-CD59 proteins and mouse C5).
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The elution was collected in 1ml fractions neutralised with lOOjul 1M Tris pH 10 (when 
eluted with glycine pH2.5) or 1M Tris pH7 (when eluted with diethylamine/PBS pHl 1). The 
column was equilibrated in TBS. All buffers and supernatant were filtered through a 0.22pm 
filter prior to use.
2.3.7. Purification of mouse C3
Two-step PEG4000 cut was used to precipitate mouse plasma proteins prior to C3 
purification on anion and cation exchange chromatography. Ion exchange methods separate 
proteins based upon their differences in charge, anion exchange columns bind negatively 
charged proteins while cation exchange columns binds positively charged proteins. Proteins 
were separated using an increased salt gradient. Mouse EDTA-plasma (32 ml) was mixed 
with 8 ml of 20% (w/v) PEG4000 dissolved in Source Q running buffer to achieve a 4% 
PEG4000 cut. The mixture was stirred at 4°C for 1 hour. The pellet was harvested by 
centrifugation at 16900xg for 15 minutes. The supernatant was retained and mixed with 20% 
(w/v) PEG4000 to achieve 15% cut. After 1 hour stirring at 4°C, the precipitate was 
harvested by centrifugation as before. The pellet was resuspended in 32ml in Source Q 
running buffer and loaded onto a prepacked anion exchange Source Q column (GE 
Healthcare). The column was connected to an AKTA Purifier System (GE Healthcare). The 
proteins were separated using a 0-0.5M NaCl gradient over 15 column volumes. The C3 
containing peak was identified by SDS-PAGE (section 2.4.4) and haemolysis assay (section 
2.7.2.5). The C3 containing fractions were pooled, dialysed into Mono S running buffer and 
loaded onto a cation exchange Mono S column. The proteins were separated by a 0-0.5M 
NaCl gradient over 30 column volumes. C3 was identified by SDS-PAGE and haemolysis 
assay and dialysed into PBS for storage at -80°C for further studies.
2.3.8. Dialysis of proteins
Fractions containing protein of interests were combined and dialysed in PBS. The dialysing 
tubing used, had a molecular weight cut off of 12-14 kDa.
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2.4. Characterisation of purified proteins
Measuring protein concentration and determination of purity.
2.4.1. Buffers
Buffer Contents
Sodium Dodecyl Sulphate (SDS) stacking 
gel buffer
0.5M Tris, 0.4% (w/v) SDS, pH6 .8
SDS resolving gel buffer 1.5M Tris, 0.4% (w/v) SDS, pH8 .8
Non-reducing loading buffer 0.1M Tris, 10% (v/v) glycerol, 2% (w/v) 
SDS, 0.01% bromophenol blue, pH6 .8
Reducing loading buffer 5% (v/v) p-mercaptoethanol in non-reducing 
buffer
Running buffer 25mM Tris, 191mM glycine, 1% (w/v) SDS
Coomassie stain 0.2% (w/v) Coomassie blue R250 in 45 % 
(v/v) Methanol, 10 % (v/v) acetic acid in 
dH20
Destaining buffer 20% (v/v) Methanol, 8 % (v/v) acetic acid in
dH20
Gel drying buffer 20% (v/v) Methanol, 4 % (v/v) glycerol in 
dH20
Transfer buffer 25mM Tris, 191mM glycine, 20 % (v/v) 
Methanol
Coating buffer for ELISA 0.1MN2CO3, 0.1MNaHCO3, pH9.6
ELISA developing solution 1 OPD tablet, 1 urea hydrogen peroxide 
tablet dissolved in 20ml dH20
2.4.2. Protein concentration
The absorbance of proteins at 280nm was measured on NanoDrop ND-1000 
Spectrophotometer and the concentration was calculated using the following equation:
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Concentration (mg/ml) = Absorbance at 280 nm /Extinction coefficient when the pathlength 
is 1cm.
The extinction coefficients of fusion proteins were determined using ExPASy (Expert 
Protein Analysis System) proteomics server (Table 2.4)
Fusion protein Extinction coefficient
OmCI-Fc 1.3
CRIg-CD59 1.1
CD59-CRIg 1.1
CRIg-hinge IgG3-CD59 1.1
CD59-hinge IgG3- CRIg 1.1
CRIg-hinge IgG2a-CD59 1.1
CD59-hinge IgG2a- CRIg 1.1
CD59-CRIg (cleavable) 1.1
Mouse C3 1 .0
Mouse C5 1 .0
Antibodies 1.4
Table 2.4 Extinction coefficients of the proteins purified in this thesis
2.4.3. SDS-PAGE analysis
Electrophoretic separation of proteins was carried out using BioRad gel apparatus. The 
concentration of acrylamide was chosen depending on the proteins to be separated. Higher 
percentage gel was used for low molecular weight proteins while high molecular weight 
molecules were run on low percentage gel. Typically gels were poured with a 4 % 
acrylamide stacking gel and 7.5-15 % acrylamide separating gel (table 2.5 and table 2.6). In 
general, the protein or protein mixture of interest was mixed with either non-reducing or 
reducing loading buffer and boiled for 5 minutes. The samples were loaded into the wells of 
the SDS PAGE gel within a running tank (BioRad) containing buffer. The gel was subjected 
to electrophoresis at 2 0 0 V until the dye front had reached the bottom of the gel.
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4% stacking gel amount
Stacking buffer (ml)
40% acrylamide (ml)
10% Ammonium persulphate (pi) 
dH20  (ml)
TEMED (pi)
1 .2 ml 
506ul 
50pl 
3.19ml 
5 pi
Table 2.5 Content of 4% stacking gel
Percentage resolving 
gel -»
7.5% 1 0 % 1 1% 12.5% 15%
Resolving gel buffer 
(ml)
3.75 3.75 3.75 3.75 3.75
40% acrylamide (ml) 2 .8 3.75 4.2 4.5 5.62
10% Ammonium 
persulphate (pi)
150 150 150 150 150
dH20  (ml) 8 .2 7.3 6 .8 6.5 5.4
TEMED (pi) 15 15 15 15 15
Table 2.6 Content of resolving gel
2.4.3.1. Coomassie Blue staining
To visualise 2-5 pg of protein, SDS PAGE gels were stained with Coomassie Blue R250. 
Following electrophoresis the gel was incubated with Coomassie Blue R250 stain with
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agitation for 30 minutes. Coomassie was removed and the gel was incubated with destaining 
solution with agitation until the background staining was reduced and the protein bands 
appeared visible. The gel was then incubated with drying solution for 30 minutes and placed 
between wet acetate gel drying films (Promega) and stretched within a gel-drying frame 
overnight to dry by evaporation.
2.4.3.2. Silver staining
To visualise between 100ng-2pg of protein, SDS PAGE gels were silver stained. The gel 
was treated as followed:
• Rinsed in dP^O
• Incubate for 20-30 minutes in 50% (v/v) methanol, 10 % (v/v) acetic acid
• Incubate for 20-30 minutes in 5% (v/v) methanol, 7 % (v/v) acetic acid
• Rinsed in dP^O
• Incubate in 5% (v/v) glutaraldehyde for 20-30 minutes
• Washed in dPfeO, 3x15 minutes
• Soaked in DTT (5pg/ml in dPhO) for 20-30 minutes
• Rinsed in dt^O
• Stained with 0.1% (w/v) AgNC>3 in dPfeO for 20-30 minutes
• Rinsed in dPpO
• Developed in 0.28M Na2C03 containing 0.0185%
Development was stopped by adding lg citric acid (solid)
All incubation steps were carried out at room temperature with 
Following the silver staining procedure, gels were soaked in gel 
as described.
2.4.4. Western blot analysis
Western blot analysis was used to specifically identify proteins separated by SDS-PAGE. 
Following the electrophoresis, the gel was placed in a tray containing transfer buffer. The lx
(v/v) formaldehyde;
agitation (on a rocker), 
drying buffer and dried
95
nitrocellulose membrane, 2 x blotting paper and 2 x fiber pads were soaked in transfer buffer. 
One fiber pad was placed on one side of an open holder cassette. One blotting paper was 
then placed on the top of the fiber pad, followed by the gel. The nitrocellulose membrane 
was placed on the top of the gel followed by the second blotting paper and fiber pad. The 
cassette was placed into the electrode module with the nitrocellulose membrane closer to the 
anode and the gel closer to the cathode. The electrode module was placed into a buffer tank 
Mini Trans Blot Cell (Bio-Rad) which was filled with transfer buffer. The transfer was run 
at 100V for 1 hour. After the transfer was complete, the membrane was blocked with PBS, 
5% (w/v) non-fat dried milk for 30 minutes at room temperature. The blot was washed and 
incubated with relevant antibody at concentration of 4pg/ml diluted in the blocking buffer 
overnight at 4C. The blot was washed and probed with an appropriate secondary antibody 
conjugated with horseradish peroxidise (HRPO) diluted 1/1000 in blocking buffer. The 
specific primary and secondary antibodies used to detect different proteins are listed in 
Table 2.7.
Western blot for protein 
detection
Primary antibody Secondary antibody
OmCI and OmCI-Fc Rabbit anti-OmCI pAb Anti-Rabbit Ig HRPO
OmCI-Fc - Anti-mouse Ig HRPO
CRIg-CD59 fusion 
proteins
Rat anti-mouse CRIg mAb 
Rat anti-mouse CD59 mAb 
(mCD59a-7)
Rat anti-mouse CD59 mAb 
(Mel-4)
Anti-rat Ig HRPO
CRIg-CD59 fusion 
proteins
Mouse anti-mouse CD59 
mAb (7A6)
Anti-mouse Ig HRPO
Table 2.7 Antibodies used for protein detection
This incubation was carried out at room temperature for one hour and was followed by a 
washing step. All washings were performed in 3 steps of 20 minutes each using PBS 0.1% 
Tween 20/ (v/v). A final wash of 20 minutes in PBS was carried out prior the developing 
step. Blots were developed using ECL™ Western Blotting Detection Reagents (GE 
Healthcare). The reagents were mixed 1:1 and the membrane was incubated for 2 minutes.
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The membrane was removed and the blot was exposed to Amersham Hyperfilm™ ECL (GE 
healthcare) and developed in a Compact x2 developer (X-Ograph Ltd).
For densitometry analysis of the Western blot images, ImageJ 1.43u (Wayne Rasband 
National institute of health, USA, Windows version) was used.
2.4.5. Dot blot
Proteins (l-2pl) were applied directly on a nitrocellulose membrane as a dot. The membrane 
was allowed to dry and then was blocked at room temperature for one hour in 5% milk/PBS. 
The blots were probed and developed as with Western blots.
2.4.6. ELISA
ELISAs were used to identify and quantify recombinant fusion proteins (OmCI-Fc and 
CRIg-CD59) and to screen hybridoma cells and serum for presence of antibodies. ELISA 
plates (96-well plates, Nunc) were coated with lOOpl per well of a protein or antibody at 3- 
5pg/ml in coating buffer. The wells were blocked with 200pl of 1% BSA/PBS (w/v) and 
incubated with the sample of interest or standard in an appropriate dilution (lOOpl per well). 
The wells were incubated with lOOpl of detection antibody at 4pg/ml followed by lOOpl of a 
HRPO conjugated secondary antibody at 1/1000. The ELISA was developed using ELISA 
developing solution prepared with o-phenylenediamine dihydrochloride (OPD; 
SIGMAFM/ST OPD; Sigma Life Science). The reaction was stopped with 50pl of 10% 
H2SO4. Absorbance was read at 490nm.
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ELISA Capture Test sample or 
protein
Detection 
antibody or test 
antibody
Secondary
antibody
Quantification of 
pOmCI and 
OmCI-Fc; Half- 
life;
MBI-Om3 Cell culture 
supernatant, 
purified protein or 
serum of mice 
injected with 
OmCI proteins
Rabbit anti-OmCI Anti-rabbit Ig 
HRPO
Quantification of 
CRIg-CD59 
proteins in tissue 
culture
supernatant or 
mouse plasma
Mouse anti- 
mCD59 mAb 
(7a6)
Cell culture 
supernatant or 
pure protein
Rat anti-mCRIg 
mAb or rat anti- 
mCD59 mAb 
(mCD59a-7)
Anti-rat Ig HRPO
Screening for 
production and 
detection of 
mouse anti-OmCI 
Ab
Rabbit anti-OmCI 
Rabbit anti-OmCI
OmCI
OmCI
(negative
screening)
Mouse serum or 
cell culture 
supernatant
Anti-mouse Ig 
HRPO
Screening for rat 
anti-mCRIg and 
anti-mCD59 Ab -
CRIg-CD59
CD59-Fc
Rat serum or cell
culture
supernatant
Anti-rat Ig HRPO
Table 2.7 ELIS As for detection and quantification of recombinant proteins and 
antibodies.
2.4.7. Estimation of protein molecular weight
The molecular weight of fusion proteins was determined using their mobility in SAS PAGE 
or in the matrix of gel filtration column.
2.4.7.I. Mobility in SDS PAGE
To calculate apparent molecular mass of fusion proteins by their relative mobility a 7.5% 
SDS PAGE was used. To generate a standard curve, protein standards with known 
molecular weight were used (Protein Ladder, New England Biolabs). Relative mobility for
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each standard was determined by measuring the distance from the top of the separating 
(resolving) gel to the middle of the dye front in millimetres, measuring the distance from the 
top of the gel to the middle of the band, and dividing the second measurement by the first. 
This is Rf. It is between 0 and 1. Rf was plotted versus log molecular mass and standard 
curve was generated. Rf for each fusion protein was calculated and the molecular mass was 
determined using the standard curve.
2.4.7.2. Mobility in Superdex 200
To determine the molecular weight of fusion proteins, the Superdex 200 column was 
calibrated with standards of known apparent molecular weight (Gel filtration high molecular 
weight calibration kit, GE Healthcare) using the manufacturer’s protocol. Briefly, Blue 
Dextran 2000 at concentration of 1 mg/ml (100 pi) was loaded onto the column to determine 
the void volume (V0). A mixture of the standard proteins (lOOpl) was then applied onto the 
column and the elution volumes (Ve) of the proteins were determined. An elution volume 
parameter Kav was calculated (Kav= (Ve-Vo)/(Vc-Vo); Vc is the geometric volume of the 
column). Kav was plotted versus molecular mass and standard curve was prepared. Kav for 
each fusion protein was calculated and the molecular weight was determined from the 
standard curve.
2.5. Generation of monoclonal antibodies (mAbs)
Mice or rats were used to generate mAbs.
2.5.1. Medium
RPMI 1640 supplemented with 50U/ml penicillin/streptomycin, 2mM L-glutamine and 
ImM sodium pyruvate was used as hybridoma culture medium. Depending upon the stage of 
hybridoma developing HAT (Hypoxanthine, Aminopterin, Thymidine) or HT
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(Hypoxanthine, Thymidine) was added. The percentage of FCS varied depending on the cell 
culture system used.
Medium for hybridoma 
cell culture
Additives Use
HAT medium lxHAT; 15% 
FCS
Selection of hybridoma cells
HT medium 1XHT; 15% FCS Cloning and expansion of hybridoma cells 
post-culture with Aminopterin
Hybridoma medium 15% FCS Culture of hybridoma cells
CL1000 complete 10% Low Ig FCS Culture of hybridoma cells in a High 
density CL1000 system-cell compartment
CL 1000 incomplete - Culture of hybridoma cells in a High 
density CL1000 system-media 
compartment
2.5.2. Immunisation protocol
Female BALB/C mice or Lewis rats were immunized with 50pg of antigen. The antigens 
used in this project were pOmCI (for generation of anti-OmCI mAbs) and CRIg-CD59 
(generation of anti-CRIg and anti-CD59 mAbs). The antigen for immunization was diluted 
in saline (100 pi final volume) and mixed with lOOpl of Freund’s complete adjuvant (Sigma 
Life Science), using two glass Hamilton syringes connected with a luer fitting. Emulsion 
was prepared by repeated passage of the oil-water mixture through the narrow-bore syringe 
connector. A droplet test was performed to monitor the quality of the emulsion. The antigen 
was administrated subcutaneously. Two booster immunizations were carried out with the 
same dose of antigen emulsified in Freund’s incomplete adjuvant (Sigma Life Science) at 
three-week intervals. Ten days after the final injection, the mice were tail-bled and sera were 
tested for antibody titer by ELISA, further boost were carried out if the titre was low. A final 
intraperitoneal (ip) injection of 50pg of antigen in 200pl saline (without adjuvant) was 
performed four days before the fusion experiment.
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2.5.3. Droplet test
The quality (thickness) of antigen emulsion was assessed using droplet test [371]. A drop of 
the mixture (adjuvant and antigen) was place in a Petri dish with cold water and the integrity 
of the drop was observed. The emulsion was ready to administrate when the drop retained its 
shape.
2.5.4. Preparation of splenocytes
The mouse or rat which had been challenged with antigen was sacrificed by cervical 
dislocation. The spleen was harvested, placed in a vessel containing ice cold RPMI 1640 and 
kept on ice. The spleen was transferred in a Petri dish containing 2ml RPMI 1640 and the 
excess fat and fibrous tissue was removed. Single cell suspension was prepared by pressing 
the spleen using the plunger of a lOml-syringe and passing it through a cell strainer (40pm, 
Falcon™BD). The cell suspension was collected in a 50 ml-falcon tube. The splenocytes 
were washed three times in cold RPMI 1640. All handling of cells was performed in a 
laminar flow hood.
2.5.5. Preparation of myeloma cells
SP2/0-Agl4 (SP2/0) myeloma cells were cultured before the fusion. SP2/0 cells in an 
exponential growth phase were harvested by centrifugation at 145xg for 5 minutes. The cells 
were washed in cold serum-free RPMI 1640.
2.5.6. Preparation of macrophage
Macrophages were used as a feeder layer to produce soluble factors that increase hybrid 
growth. To obtain peritoneal macrophages, a BALB/C mouse was sacrificed 24 hours prior 
the cell fusion. 10 ml of cold serum-free RPMI was injected into the peritoneal cavity using
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21-guage needle. The medium was then withdrawn. The medium containing peritoneal 
macrophages was centrifuged at 145xg for 5 minutes and washed with RPMI. The cells were 
resuspended in HAT or HT containing medium and plated in 24-well plates (for fusion) or in 
96-well plates (for cloning). The cells were checked for contamination at the fusion at time 
of cloning.
2.5.7. Cell fusion
Hybriomas were produced by fusing spleen cells from the immunised BALB/C mouse or 
Lewis rat with myeloma SP2/0 cells (2.5x107) using polyethylene glycol 1500 (PEG, 
Roche). Washed myeloma and spleen cells were mixed, peletted and drained of all medium. 
PEG (1.5ml) was added slowly to the dry cell pellet over a 1-minute period with gently 
agitation and then kept without agitation for a further 1 minute. The fusion suspension was 
then diluted with 50 ml of warm RPMI 1640 medium; the first 20ml was added drop-wise 
over several minutes. The cells were spun down and the pellet resuspended in HAT- 
containing medium. The cells were plated in 24-well plates containing peritoneal 
macrophages as feeder cells. At day 10 the wells were screened for the desired antibody by 
ELISA.
Cells from wells that came up positive on ELISA were cloned by limiting dilution method 
(Method 2.2.4) and transferred to 96-well plates with feeder cells. The HAT medium was 
replaced by HT (Hypoxanthine Thymidine) containing RPMI 1640.
2.5.8. CELLine CL1000
CELLine CL 1000 high density system was used to scale up the antibody production. 
CELLine CL1000 is similar to CELLine AD100 (section 2.2.6.1) but it does not have 
polyethylene teraphthalate matrix (required for culturing adherent cell). The procedures for 
cell seeding and culturing are identical to these explained in section 2 .2 .6 .1 .
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2.5.9. Isotyping of mAbs
2.5.9.I. Isotyping of mouse mAbs
Roche Applied Science’s IsoStrip Mouse Monoclonal Antibody Isotyping Kit was used to 
determine the isotype of the anti-OmCI monoclonal antibodies. Culture supernatant (150pl) 
containing test antibody was added to a development tube containing coloured latex. An 
isotyping strip was placed into the tube and incubated until a blue band appear in either 
kappa or lambda section and in the class or subclass sections of the strip.
2.5.9.2. Isotyping of rat mAbs
An antibody-based rat immunoglobulin isotyping ELISA kit (Southern biotechnology 
associate) was used to determine the isotype of rat anti-mouse CRIg and anti-mouse CD59a 
antibodies. 96-well plates were coated with 3pg/ml CRIg-CD59 or CD59-Fc fusion proteins 
diluted in coating buffer (lOOpl per well) and incubated for one hour at 37°C. The plates 
were washed with ELISA washing buffer. The wells were blocked with 1% BSA/PBS for 
one hour at 37°C followed by incubation with hybridoma supernatant. The binding of the 
antibody to the antigen was detected with HRPO-conjugated anti-rat immunoglobulin 
secondary antibody. The ELISA was developed by adding substrate solution (OPD). The 
reaction was stopped with 50pl of H2SO4 and the absorbance was measured at 490nm.
2.6. Protein manipulations
2.6.1. Labelling with horseradish peroxidase (HRPO)
Monoclonal antibodies were conjugated with HRPO using EZ-Link® Plus Activated 
peroxidase kit (Pierce) following the manufacturer’s instructions. Monoclonal antibody 
(lmg) was dialysed into carbonate buffer (0.1M N2CO3, 0.1M NaHCOs), pH9.4 and was 
added to the lyophilized activated peroxidase. Sodium cyanoborohydride (lOpl) was added
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to the mixture. Following 1 hour incubation at room temperature, a quenching buffer was 
added and allowed to react for additional 15 minutes.
2.6.2. Chemical cross-linking of CRIg-3-CD59 and CD59-3-CRIg
A chemical cross-linker 1,8-bis (maleimido) diethylene glycol (BM(PEG)2; Pierce 
Biotechnology) was used to improve dimerisation of CRIg-3-CD59 and CD59-3-CRIg and 
to link the sulfhydryl groups (-SH) in the hinges from different molecules. BM(PEG)2 is a 
bismalemide crosslinker for conjugation between sulfhydryl groups (-SH). It has a spacer 
arm with polyethylene glycol groups. Reaction of a sulfhydryl to the malemide group results 
in formation of a stable thioether linkage resistant to reducing agents and physiological 
buffer conditions. Prior to cross-linking, fusion protein (170pl) at concentration of 6 mg/ml 
(in PBS/5mMEDTA) was mixed with 17pl of the mild reducing agent 2- 
Mercaptoethylamine.HCl (2-MEA; Thermo Scientific) at concentration of 6mg/100pl. The 
reaction was incubated for 90 minutes at 37°C. 2-MEA selectively reduces hinge-region 
disulphide bonds. The reaction was cooled down to room temperature and 2-MEA was 
separated from the fusion protein using HiTrap™ Desalting column (GE Healthcare) and 
AKTA Prime system. The run consisted of column equilibration with PBS/5mM EDTA, 
loading of fusion protein containing 2-MEA and elution with PBS/5mM EDTA buffer. The 
buffer and the sample were filtered through a 0.22pm filter prior to use. The peak fractions 
were pooled and concentrated to 2mg/ml using Vivspin500 MWCO 10,000 (GE Healthcare)
BM(PEG)2 was dissolved in dimethylsulfoxide (DMSO) to achieve 5mM final 
concentration. The cross-linker was added to the fusion proteins at two-fold molar excess 
(0 .1  mM of BM(PEG)2 to 0.05mM of protein). Following incubation of 1 hour at room 
temperature the reaction was passed over a desalting column using PBS as a running buffer. 
The efficiency of dimerisation was assessed by SDS PAGE on 7.5% gel.
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2.6.3. Papain digest
For cleavage of CD59-2a-CRIg and CD59-3-CRIg, immobilised papain (Pierce, Rockford, 
IL, USA) was used according to manufacturer’s protocol. The immobilised papain (200pl) 
was washed in digestion buffer containing 20mM Na2HPC>4, lOmM EDTA and 20mM 
cysteine, pH7.0. Digestion buffer (lOOpl) was added to lOOpl of the reagents (1 mg/ml) and 
this was mixed with the immobilised papain. The reaction was incubated at 37°C and test 
samples were withdrawn at 30 minutes, 1 hour, 2 hours and 19 hours for analysis. The 
cleavage efficiency was assessed by SDS-PAGE on 15% gel.
2.6.4.3C rhinovirus protease digest
For cleavage of CD59-CRIg cleavable reagent, recombinant human rhinovirus protease 3C 
(HRV 3C; Novagen, Darmstadt, Germany) was used. CD59-CRIg cleavable reagent (50pg) 
was incubated with lpl (2 units) of the enzyme for 16 hours at 4C in presence of protease 
cleavage buffer supplied with the enzyme. The lOx protease cleavage buffer contained 1.5M 
NaCl, 0.5M Tris-HCl with pH7.5. The protease (2000U/ml) was supplemented with 150mM 
NaCl, 50mM Tris-HCl, ImM EDTA, 0.5mM reducing agent THP and 50% glycerol, pH8.0. 
The cleavage efficiency was assessed by SDS-PAGE on 15% gel.
2.6.5. Labelling of CD59-2a-CRIg
CD59-2a-CRIg was labelled with the amine-reactive fluorescent labelling dye HiLyte™ 488 
SE using AnaTag™ HiLyte Fluor™ 488 Protein Labeling Kit (AnaSpec). The labelling was 
performed according to the manufacturer’s protocol. CD59-2a-CRIg diluted PBS was mixed 
with 1M bicarbonate buffer (buffer B) at 1/10 (v/v) ratio to obtain pH9. The HiLyte™ 488 
SE was dissolved in 30pl DMSO and was added to CD59-2a-CRIg. The reaction was mixed 
thoroughly. The reaction mixture was wrapped in foil to protect from direct light and 
incubated on a rotator for 1 hour at room temperature. The protein conjugate was purified on 
a pre-packed desalting column equilibrated with 25ml of elution buffer. The buffer was 
allowed to drain to the top frit and the reaction mixture was loaded on the column. When the
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entire sample entered the column, 10ml of the elution buffer was added. The coloured 
material separated into two bands. The faster-running band contained the labeled CD59-2a- 
CRIg (CD59-2a-CRIg/488) and the slower-running band contained the free dye. The labeled 
protein was collected and the degree of substitution (DOS) of the conjugate was calculated 
using the following equation:
DOS= Molar concentration of Dye / Molar concentration of the protein 
Molar concentration of dye=(A499 x dilution factor)/s HiLyte Fluor™ 488 
Molar concentration of the protein=((A28o-0.19 x A499) x dilution factor / ) /s c D 59-2a-CRig 
Where: A499 is the maximum absorbance of the dye measured at 499nm 
A280 is the absorption of the labelled protein at 280nm 
£ HiLyte Fluor™ 488= 68,000 cm'1 M'1 is the extinction coefficient of the dye 
£ CD59-2a-CRig = 36,000 cm'1 M'1 is the extinction coefficient of the CD59-2a-CRIg
2.7. Functional analysis
The functional analysis of OmCI-Fc and CRIg-CD59 fusion proteins and the ability of 
purified mouse C3 and C5 to restore complement activity.
2.7.1. Buffers and reagents
Buffer Contents
Complement Fixation Diluent (CFD; Oxoid) 2.8mM Barbituric acid, 145.5mM NaCl, 
0.8mM MgCl2, 0.8mM CaCl2, 0.9mM 
Sodium Barbital, pH7.2
Alternative pathway (AP) buffer 5mM Sodium barbitone, 150mM NaCl, 
7mM MgCl2, lOmM EGTA
Terminal pathway (TP) buffer lOmM EDTA, PBS
Biacore running buffer lOmM HEPES, 150mM NaCl, 0.005% (v/v) 
Surfactant P20, pH7.4
FACS buffer 1% (w/v) Bovine Serum Albumin (BSA), 
PBS
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2.7.2. Classical pathway haemolysis assay
2.7.2.1 Preparation of erythrocytes
Sheep erythrocytes were used for human and rat classical pathway haemolysis assays and 
rabbit erythrocytes were used for mouse assays. The cells were washed into CFD and diluted 
to 4% (v/v). To sensitise rabbit erythrocytes, mouse anti-rabbit erythrocyte polyclonal serum 
was diluted 1/500 in CFD and incubated 1:1 with cells for 30 minutes at room temperature. 
Sheep erythrocytes were sensitised by 30-minute incubation at 37°C with equal volume of 
amboceptor (rabbit anti-sheep erythrocytes, Behring Diagnostics) diluted 1/250 in CFD.
2.1.22. Titration of serum for inhibition assays
To establish the amount of mouse, rat and human serum required to cause 70% lysis a 
haemolysis assay was carried out using a serum titration. The serum was diluted and 1:2 
dilution series were set up beginning at 1/5 for mouse serum and 1/10 for human and rat 
serum. Each concentration (50pl) was incubated with 50pl antibody coated erythrocytes and 
50pl CFD in a round-bottom 96-well plate. Control wells were incubated for 100% lysis in 
which the serum was substiuted for 0.01% (v/v) Triton and 0% lysis in which the serum was 
substituted for 50pl CFD. Each concentration was analysed in duplicate. The plate was 
incubated for 30 minutes at 37°C. The remaining erythrocytes were peletted by 
centrifugation at 900xg for 5 minutes. The supernatant (lOOpl) from each well was 
transferred into a flat-bottom 96-well plate. The absorbance at 415nm was measured and 
percentage lysis (haemoglobin released) was calculated as follows:
% lysis=100x(Test A415- 0 % a 415) / ( 1 0 0 %  A415- 0% A 415)
The concentration of serum giving 70%-80% lysis was used in subsequent assays.
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2.123. Function of OmCI and OmCI-Fc
To compare the function of pOmCI and OmCI-Fc, the proteins were diluted and 1:2 serial 
dilutions were prepared starting from 84nM of OmCI-Fc and 102nM of pOmCI. Antibody- 
coated erythrocytes (50pl) were incubated with 50pl of the OmCI proteins from the dilution 
series and 50pl of serum (human, mouse or rat) diluted to give 70%-80% lysis in the 
absence of inhibition. Controls for 100% and 0% lysis were included. Each incubation was 
carried out in duplicate. The assays were incubated at 37°C for 30 minutes. Following the 
incubation the remaining cells were pelleted and the absorbance at 415 was measured. The 
percentage lysis was calculated and plotted against the log of concentration (x-axis). The 
concentration of inhibitor causing 50% lysis (EC50) was determined using GraphPad Prism5 
software.
2.7.2.4. Functional analysis of mouse C5
Antibody sensitised rabbit erythrocytes (50pl) were incubated with 1 in 2 serial dilutions 
(50pl) of C5 deficient serum (DBA2, mouse strain with naturally occurring C5 deficiency) 
or C5 deficient serum reconstituted with the purified C5 at physiological concentration 
(50pg/ml). Serial dilution of serum from wild type mouse (BalbC) was also used as a 
positive control for complement-mediated lysis. The assay was carried out in CFD. 
Complement-mediated killing of the rabbit erythrocytes was determined after 30 minutes 
incubation at 37°C by measuring the haemoglobin release of the cells at 415nm. 100% and 
0% lysis controls were also included. Maximum lysis was obtained by adding 0.01%Triton 
to the target cells. For 0% lysis-CFD was added to the erythrocytes. The percentage of lysis 
was calculated as described.
2.1.23. Assay for identification of C3-containing fractions
Elution fractions obtained from anion- and cation-exchange chromatography (section 2.3.7) 
were screened for presence of mouse C3 using classical pathway haemolytic assay.
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Antibody sensitised rabbit erythrocytes (50pl) were incubated with 22% C3 deficient mouse 
serum (45|xl) and 5jnl of each elution fraction for 30 minutes at 37°C. Controls for 0% and 
100% lysis were included. Percentage of lysis was determined.
2.7.3. Alternative pathway haemolysis
The capacity of the CRIg-CD59 fusion proteins to inhibit complement was assessed using 
alternative pathway assay.
2.7.3.I. Titration of rat serum
Guinea pig erythrocytes (GPE) were washed into AP buffer and diluted to 2% (v/v). To 
establish the amount of serum needed to cause 90% lysis, rat serum diluted in 10-fold 1:2 
serial dilution beginning at 1 in 2. The serum (50jll1) from dilution series was incubated with 
50pl GPE and 100pi AP buffer. Control wells containing either 50pl of 0.01% (v/v) Triton 
or AP buffer instead of serum were included to obtain 100% and 0% lysis respectively. The 
assay was carried out in duplicate. The plate was incubated at 37°C for one hour. The 
absorbance at 415 was measured and percentage of lysis was calculated as described for the 
classical pathway haemolysis assay.
2.7.3.2. Function of CRIg-CD59 fusion proteins
To compare the function of CRIg-CD59 fusion proteins, they were diluted in a 1:2 serial 
dilution. The dilution series began with 150pg/ml of CD59-CRIg, CD59-3-CRIg, CRIg-3- 
CD59 and with 80pg/ml of CRIg-CD59. GPE (50pl) were incubated with 50pl of the 
inhibitor proteins from the concentration titre and 50pl of anti-CRIg (generated in this 
project) or anti-CD59 (7a6) antibodies (300pg/ml). Rat serum (50pl) at concentration that 
caused 90% lysis in absence of inhibition was added to the wells. Controls for 100% and 0%
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lysis were included. The plate was incubated at 37°C for one hour and absorbance at 415 
was measured. The percentage of lysis was determined.
2.7.4. Terminal pathway assay
2.7.4.1. Generation of C5b-7 sites on GPE using C8 depleted human serum
GPE were washed and resuspended in CFD at 4% (v/v). C8 depleted human serum, 
generated by passing normal human serum over monoclonal anti-C8  affinity column 
(generated previously in house), was diluted in CFD to prepare two 1:2 serial dilutions 
beginning at 1 in 2 and 1 in 3. GPE (50pl) were incubated with 50pl of the serum from 
dilutions. The plate was incubated for 30 minutes at 37°C. The serum concentration causing 
15% lysis was used to generate GPE-C5b-7. GPE were incubated for 30 min at 37°C with an 
equal volume of C8 depleted human serum at a dose that gives 15% of lysis. The resulting 
cells (GPE-C5b-7) were washed and resuspended at 2% in TP buffer.
2.7.4.2. Generation of C5b-7 sites on GPE using purified C5b-6 and C7 human proteins
GPE were washed and resuspended in CFD at 2% (v/v). GPE (2ml) were incubated with 
15pg C5b-6 for 5 minutes at 37°C, followed by lOpg C7 for 15 min at 37°C. The GPE-C5b- 
7 were washed and resuspended in 2ml TP buffer.
2.7.4.3. Titration of mouse serum
To develop the terminal pathway assay, C3 deficient mouse serum was used. The mouse 
serum was diluted in TP buffer and two 1:2 dilution series beginning at 1 in 2 and 1 in 3 
were prepared. The amount of mouse serum that gave 50% lysis was determined by 
incubating 50pl of GPE-C5b-7 for 30 min at 37°C with 50pl dilutions of mouse serum and 
50pl TP buffer. Percentage of lysis was determined as described for the classical pathway.
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2.7.4.4. Function of CRIg-CD59 fusion proteins
The function of CRIg-CD59 was assessed in three different terminal pathway assays listed 
in table 2 .8 .
Terminal pathway Source of C5b-6 and Source of C8 and Presence of CRIg-
haemolysis assay C7 C9 CD59 proteins
Assay 1: In absence of Purified human C3 deficient mouse Throughout the
C3 proteins serum assay
Assay 2: Non-wash C8  depleted human C3 deficient mouse Throughout the
assay in presence of serum serum assay
C3
Assay 3: Wash assay C8 depleted human C3 deficient mouse Washed before the
in presence of C3 serum serum addition of C8 and
C9
Table 2.8 Terminal pathway haemolysis assays
To assess the function of the terminal pathway CRIg-CD59 inhibitors, these reagents were 
diluted in TP buffer and 1 in 2 or 1 in 3 dilution series were prepared. As a control, a 1:3 
serial dilution of CRIg-fH fusion protein was used.
Assay 1 and 2: GPE-C5b-7 (50pl) were incubated with 50pl of dilutions of CRIg-CD59 
fusion proteins for 10 minutes at room temperature. The predetermined concentration of 
mouse C3 deficient serum (usually 1/3000; 50 pi) was then added to the wells and incubated 
for 30 minutes at 37°C.
Assay 3: GPE-C5b-7 (50pl) were incubated with 50pl of dilutions of CRIg-CD59 fusion 
proteins for 30 minutes at37°C. The cells were pelleted and washed with TP buffer. The 
predetermined concentration of mouse C3 deficient serum (usually 1/3000; 50pl) and 50pl 
of TP buffer were added to the wells and incubated for 30 minutes at 37°C.
Controls, 0% (buffer only) and 100% (0.1% triton) were included in all three assays. 
Following pelleting of cells by centrifugation, lysis was quantified by measuring absorbance 
at 415nm. Percentage of lysis was calculated as described.
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2.7.5. Binding OmCI-Fc and pOmCI to C5
The ability of pOmCI and OmCI-Fc to bind human and mouse C5 was assesed by surface 
plasmon resonance (SPR) using Biacore ® T100 instrument (GE Healthcare). The binding 
of a molecule in the soluble phase (the analyte) to a ligand molecule immobilised on a 
sensor surface was directly measured. In Biacore ® the samples are delivered to the sensor 
surface using a micro-fluidic system. The sensor surface is a glass slide coated with thin 
gold film mounted in a plastic carrier. Binding events cause changes in the refractive index 
at the surface layer. The value is plotted as response units (RU). For carboxymethylated 
dextran-coated chip (CM5) used in this study, 1000RU correspond to lng protein/mm2 
sensor surface [372].
2.7.5.1. Preparation of pOmCI and OmCI-Fc surface
Fifty RU of pOmCI was amine coupled to the chip surface of flow cell 2 (CM5 chip, 
BIAcore) using 1-ethyl-3(3-dimethyl aminopropyl) carbodiimide/N-hydroxy-succinimide as 
instructed by the manufacturers (NHS/EDC coupling kit; BIAcore). The immobilization was 
performed at lOOpg/ml in acetate buffer, pH 4.0. Flow cell 1 was activated with NHS/EDC 
but left uncoated as negative control. Both Flow cells were deactivated with 0.1M 
ethanolamine pH8.5.
OmCI-Fc was amine coupled to the chip surface of flow cell 4 NHS/EDC coupling kit. The 
immobilization was performed at 3.5pg/ml in acetate buffer, pH 4.5 using the 
immobilization wizard control template, with target immobilization set at 150 RU. Flow cell 
3 was activated with NHS/EDC but left uncoated as negative control. Both Flow cells were 
deactivated with ethanolamine.
2.7.5.2. Binding of OmCI-Fc and pOmCI to human and mouse C5. Affinity analysis
To assess the affinity of pOmCI and OmCI-Fc with C5, human and mouse C5 were diluted 
in a 5-fold 1:2 serial dilution in a biacore running buffer. Each concentration was injected
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across the OmCI-Fc and pOmCI surface with 180 second contact time followed by a 300 
second dissociation buffer, flow rate lOpl/min. The C5 concentration began at 54nM. A 
regeneration cycle was run after each concentration. One cycle contained consecutive 30 
second pulses of 20mM diethylamine in PBS, pHll followed lOmM Glycine-HCl, pH2.5 
(BIAcore). Each cleaning cycle began and finished with the high pH buffer. Each protein 
concentration was injected in duplicate or triplicate. Data were evaluated using Biacore 
evaluation software. The affinity interaction was analysed by 1:1 Langmuir binding.
2.7.6. MBI-Oml-OmCI binding interaction
To investigate the interaction of MBI-Oml (anti-OmCI mAb) with OmCI, Bicore 3000 
instrument was used. The experiments performed are listed in table 2.9. The ligands were 
diluted in lOmM citrate buffer pH4.5 immobilised on CM5 chip using amine coupling 
(section 2.7.5.1). Bicore running buffer was used to dilute analyte 1 and analyte 2. The 
regeneration cycle, consisting of two injections of glycine pH2.5, was run after each MBI- 
Oml-OmCI binding interaction. The biacore analysis was perfomed at flow rate of 
lOpl/min.
Ligand/RU
immobilised
Analyte 1 Analyte 2
MBI-Oml 1000RU OmCI (20pg/ml and 200pg/ml) -
Protein A 500RU MBI-Oml (500pg/ml) OmCI (200p,g/ml)
Human C5 4000RU OmCI (200pg/ml) MBI-Oml (lOOpg/ml)
Table 2.9 Experiments carried out to characterise MBI-Oml-OmCI interaction
2.7.7. Binding CRIg-CD59 proteins to mouse C3b and iC3b
The ability of CRIg-CD59 fusion proteins to bind mouse C3b and iC3b was assessed by 
SPR using Biacore ® T100 instrument.
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2.7.7.1. Preparation of C3b surface
Human C3b was amine coupled on flow cell 2 of CM5 sensor chip using NHS/EDC 
coupling kit. The immobilization was performed at 3.3pg/ml in acetate buffer, pH 4.5 using 
the built-in immobilization wizard control template, with target immobilization set at 100 
RU. Flow cell 1 was activated with NHS/EDC but left uncoated as negative control. Both 
Flow cells were deactivated as above.
Mouse C3b was generated by cleavage of mouse C3 by alternative pathway convertase 
assembled on the chip surfaces. An alternative pathway convertase was formed from the 
covalently immobilised human C3b together with a mixture of factor B and factor D 
(CompTech, Inc) injected across the chip surfaces at concentration of 200 pg/ml and 5 
pg/ml respectively for 120 seconds at flow rate of 10 pl/min. Mouse C3 at a concentration of 
400pg/ml was immediately injected for 120 seconds at flow rate of 5pl/min. C3bBb 
complex (alternative pathway convertase) cleaved mouse C3 to C3b deposited on the chip 
surface. Injections of a mixture of factor B and factor D and mouse C3 were repeated until 
approximately 800RU of mouse C3b was deposited on the chip surface. Convertases was 
decayed by injection of DAF (16|Lig/ml) for 30 seconds. The surface was stabilised by a 30 
second injection of 0.1 M acetate buffer containing 1M NaCl, pH4.0 to remove any loosely 
bound mouse C3b. Biacore running buffer supplemented with ImM MgCl2 was used as 
running or dilution buffer.
2.7.7.2. Preparation of iC3b surface
Mouse iC3b surface was prepared by cleavage of C3b (coated on the chip surface) with 
factor I and factor H as a co-factor. Human factor I (CompTech, Inc) at concentration of 
5fig/ml and human factor H (68pg/ml) diluted in biacore running buffer were injected across 
the C3b surface for 300s at 5pl/min. The surface was regenerated by a 30 second injection of
0.1M acetate buffer containing 1M NaCl, pH4.0.
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2.7.7.3. Binding of CRIg-CD59 proteins to C3b and iC3b. Affinity analysis
To measure binding affinity of fusion proteins for mouse C3b, two-fold dilution series of 
CRIg-CD59 fusion proteins were prepared in a biacore running buffer and injected 
sequentially over the C3b or iC3b chip surface for 120s. Data was collected at 25 °C at a 
flow rate of 20pl/min. The proteins were allowed to dissociate for 180s. The surface was 
regenerated between binding cycles by a 30s injection of 0.1 M acetate buffer containing 1M 
NaCl, pH4.0. Each concentration was injected in duplicate. Data from a reference cell was 
subtracted to control for bulk refractive index changes. The equilibrium dissociation 
constant for fusion proteins was determined by using steady-state analysis.
2.7.8. Binding of CRIg-2a-CD59 to C3b-opsonised red blood cells-flow cytometry
CD59 deficient mouse erythrocytes were washed into CFD containing 0.1% (w/v) gelatin 
and diluted to 4% (v/v). polyclonal Rabbit anti-mouse erythrocytes (generated in house) was 
diluted 1 in 12.5 and incubated 1:1 with the mouse erythrocytes for 30 minutes on ice. The 
antibody-sensitised cells were washed into CFD/gelatin and diluted to 2% (v/v). To coat in 
C3b/iC3b, the antibody sensitised mouse erythrocytes were exposed to 20% C6-/- mouse 
serum diluted in CFD at 37°C for 30 minutes. C3-/- mouse serum was used as a negative 
control for C3 deposition. The cells were washed and resuspended in CFD/gelatin.
C3b/iC3b deposition was confirmed by flow cytometry. Cells (5pi) incubated with C6 or C3 
deficient mouse serum were transferred into 96-well plate (round bottom) and washed. The 
cells were incubated with 100pi of anti-mouse C3 antibody (Clone 3/26, HyCult) at 
concentration of lOpg/ml for 30 minutes at room temperature. The plate was washed and 
lOOpl of Phycoerythrin (PE) conjugated anti-rat IgG antibody (Jackson ImmunoResearch 
Laboratories) diluted 1:100 was added. After 20-minute incubation at room temperature the 
cells were washed and resuspended. FACS buffer was used to wash and resuspend the cells 
and to dilute the antibodies. The cell suspension was transferred to FACS tubes (BioRad) 
and fluorescence intensity was measured on FACSCalibur flow cytometer (Becton 
Dickenson, Oxford, UK), using CELLquest software.
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CD59 deficient erythrocytes (20pl) coated in C3b/iC3b along with cells that had been 
exposed to C3-/- serum were transferred into 96-well plate (round bottom) and washed in 
CFD. The cells were incubated with lOOpl of CD59-2a-CRIg monomer or dimer (separation 
is explained in section 2.3.5) at concentrations of 50pg/pl, 20pg/pl and Opg/pl (diluted in 
CFD/gelatin) for 30 minutes at 37°C. The wells were washed and resuspended in FACS 
buffer. Cell suspension (5pl) was transferred into a new plate and CD59-2a-CRIg binding 
was detected by incubating the cells with lOOpl of rat anti-CD59 mAb at concentration 
lOpg/ml diluted in FACS buffer. The plate was incubated for 30 minutes at room 
temperature and washed. PE conjugated anti-rat IgG antibody was then added and allowed 
to react with the cells for 20 minutes at room temperature. The cells were washed and 
fluorescence intensity was measured.
2.7.9. Binding of anti-CD59 mAb (mCD59a-7) to mouse -flow cytometry
CD59 sufficient and deficient mouse erythrocytes (0.05%) were washed in FACS buffer and 
incubated with mCD59a-7 mAb (lOpg/ml in FACS buffer) for 30 minutes at room 
temperature. Following washing step, the cells were incubated with lOOpl of PE conjugated 
anti-rat IgG antibody diluted 1:100. After 20-minute incubation at room temperature the 
cells were washed and resuspended. The fluorescence intensity was measured as described 
in section 2.7.8.
2.8. In vivo and ex vivo analysis
2.8.1. Animals
DBA2 (DBA/201aHsd) and C57B1/6 mice were obtained from Harlan Laboratories™. 
CD59-/- mice have been previously generated [373]. The animals were maintained 
according to Home Office guidelines within the Biomedical Services Unit at School of 
Medicine, Cardiff University.
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2.8.2. In vivo clearance of OmCI-Fc and pOmCI in DBA2 mice
pOmCI was mixed with OmCI-Fc and diluted in PBS. Male DBA2 mice (n=3) were injected 
iv with 200jil of the mixture containing 75jag of OmCI-Fc and 150jag of pOmCI. The 
animals were tail bled at the following time points 5, 10 and 30 minutes, 1, h, 12, 25, 48, 72 
and 96 hours post injection. The blood (20pl) was collected in tubes coated in lithium 
heparin (Microvette ® CB300 blood collection system). Presence of pOmCI and OmCI-Fc 
in plasma was assessed by Western blot. Test mouse plasma (0.25 j l x 1) along with plasma 
from a naive mouse was subjected to electrophoresis on 11% polyacrylamide gel and 
transferred to a nitrocellulose membrane. Mixture (0.25pi) of purified pOmCI and OmCI-Fc 
at concentration of 150pg/2ml and 75pg/2ml (assuming 2ml blood in mouse) respectively 
was used as a positive control. The blot was developed using affinity-purified rabbit 
polyclonal anti-OmCI Ab (4pg/ml) followed by anti-rabbit Ig-HRPO (1:1000) as described 
in section 2.4.5. Protein levels were determined by densitometry analysis using ImageJ 
1.43u (Wayne Rasband National institute of health, USA, Windows version) and presented 
as percentage of purified pOmCI or OmCI-Fc mixture used as a positive control.
2.8.3.7/i vivo half-life of OmCI-Fc and pOmCI in C57B1/6 mice
Two groups of 5 C57B1/6 mice were injected iv with 500pg of pOmCI or 200pg of OmCI- 
Fc. The animals were tail bleed at the following time points 5, 10 and 30 minutes, 1, h, 12, 
25, 48, 72 and 96 hours post injection. The blood (20pl) was collected in tubes coated in 
lithium heparin (Microvette ® CB300 blood collection system). Pharmacokinetic analysis of 
the proteins was performed by determining the plasma concentration of injected proteins by 
ELISA (section 2.4.6 table 2.7) using pOmCI or OmCI-Fc standard curves respectively. For 
each time point the protein concentration was calculated and expressed percent of the 
injected dose against time. The log of the percentage protein (y-axis) was plotted against the 
time in hours (x-axis). The data was analysed using two-compartment model. The half-life 
was calculated from the slope (determined using GraphPad Prism 5) of the linear region of 
the curve.
p half-life =0.693/-slope
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2.8.4. In vivo complement inhibitory activity of OmCI-Fc and pOmCI
The in vivo complement inhibitory activity (CH50) of OmCI-Fc and pOmCI was assessed in 
C57B1/6 mice. The animals were injected with either OmCI-Fc or pOmCI. A third group of 
mice received pOmCI followed by injection OmCI-Fc to study the combine effect of these 
reagents. Blood was collected at various time points. Serum samples were obtained by tail 
vein section and collected in capillary tubes (Microvette ® CB300 blood collection system). 
Blood was allowed to coagulate at room temperature for 10 minutes and serum was 
collected after centrifugation at full speed for lOminutes in a benchtop centrifuge. C5 
activity or complement activity was measured. Doses of OmCI-Fc and pOmCI used in these 
experiments are listed in table 2.10.
pOmCI 
injection at time 
0 hour
OmCI-Fc injection 
at time 1 hour
Route of 
administration
Mice
per
group
Activity
measured
200pg - iv 5 Complement
- 300pg iv 5 Complement
200pg 50pg iv 1 C5
200pg 150pg iv 1 C5
200pg 300|ig iv 5 Complement
200pg - sc 2 Complement.
- 300pg sc 2 Complement
Table 2.10 Experiments carried out to determine haemolytic inhibitory capacity of 
OmCI-Fc and pOmCI. Route and dose of OmCI reagents injected in mice and activity 
measured
2.8.4.I. Complement activity
For each animal, serum was diluted in CFD and 1 in 2 dilution series beginning at 22% (v/v) 
serum was prepared. Serum (50pl) from each concentration was incubated with 50pl 
antibody coated rabbit erythrocytes (described in section 2.7.2.1) in a round-bottom 96-well 
plate for 20 minutes at 37°C. To establish 0% and 100% lysis, 50pl rabbit erythrocytes were
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incubated with 50pl CFD and 50pl 0.01% Triton. The assay was carried out in duplicate. 
Following the incubation the cells were pelleted by centrifugation at 900xg for 5 minutes. 
Supernatant (80pl) from each well was transferred to a flat-bottom 96-well plate and the 
absorbance at 415nm was measured. Percentage lysis was calculated as described in section 
2.7.2.2 and was plotted against log of serum concentration (%) used. Haemolytic activity 
was quantified by the amount of the test serum necessary to kill 50% of antibody-sensitised 
rabbit erythrocytes (CH50). CH50 was determined as described in Complement Methods 
and Protocols [374, 375] and expressed as percent of the activity prior to pOmCI or OmCI- 
Fc administration (at time -1 hour).
% haemolytic activity=100x(% serum collected at time -1 hour causing 50% lysis / % serum 
collected at various time points causing 50% lysis)
2.8.4.2. C5 activity
Experimental serum collected at various time points from animals injected with OmCI-Fc 
and pOmCI was diluted and one in two dilution series beginning at 10% (v/v) was prepared. 
Serum (25pi) from each concentration was incubated with 50pl antibody coated rabbit 
erythrocytes and 25pi of 25% C5 deficient mouse serum (obtained from C5 deficient DBA2 
mice) in a round-bottom 96-well plate for 20 minutes at 37°C. All the dilutions were 
performed in CFD. Percentage haemolysis and CH50 were determined as described in 
section 2.8.5.1.
2.8.5. Induction of antibody-dependent experimental autoimmune encephalomyelitis 
(ADEAE)
Mice were immunised sc at a single site close to the base of the tail with 200pl of an 
emulsion containing 50pg recombinant mouse myelin oligodendrocyte glycoprotein 
consisting of amino acids 1-117 of the extracellular Ig domain (rMOG; provided by Dr. H 
Reid, Monash University, Clayton, Victoria, Australia) in complete Freund’s adjuvant
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supplemented with 2.5mg/ml Mycobacterium tuberculosis H37 Ra (Difco Labs, Detroit, MI, 
USA) on day 0. Mice also received 200ng pertussis toxin (endotoxin of Bordetella pertussis; 
Sigma) ip in PBS on days 0 and 2. On day 8 mice were injected with 500pg mouse anti­
mouse MOG mAb clone Z12 [223]. Mice were weighed and monitored daily for signs of 
clinical disease, scored as followed: 0, no clinical signs; 1, tail atony; 2, hind-limb weakness; 
3, hind-limb paralysis; 4,moribund; 5,dead. Animals that achieved a clinical score of 2 (day 
11) at monitoring were divided in two groups (n=2) and injected with 200pl of lOOpg of 
CD59-2a-CRIg or PBS iv. Mice were sacrificed via anaesthesia with ip injection of sodium 
pentobarbitone 15 minutes or 3 hours after injection and perfused via the aorta with PBS 
with outflow through the transected renal vein. The Spinal cord was promptly removed, 
embedded in optimum cutting temperature (OCT) compound (Raymond A Lamb Limited, 
Eastbourne, UK), snap-frozen on dry ice and stored at -80°C until required. Transverse 
spinal cord sections (10pm) were cut using a cryostat and mounted onto glass slides. The 
sections were allowed to dry for one hour at room temperature and stored at -80°C.
2.8.6. Induction of atherosclerosis
Male ApoE-/-/CD59-/- double knock out mice were fed on a high-fat diet containing 21% 
(w/w) pork lard supplemented with 0.15% (w/w) cholesterol (Special Diet Services, 
Whitham, UK) for 8 weeks starting at 8 weeks of age. Animals were housed in a specific 
pathogen-free environment. Mice were injected with 200pl of200pg CD59-2a-CRIg or PBS 
iv. Body weights were measured and animals were sacrificed 30 minutes or 1 hour post 
administration. At sacrifice, blood samples were collected via cardiac puncture. The mice 
were anaesthetised with sodium pentobarbitone via ip injection. After arterial perfusion with 
PBS via the abdominal aorta with outflow through the incised jugular veins, brachiocephalic 
arteries were removed with a piece of the aortic arch and the stump of the right subcavian 
artery still attached to aid orientation during histological processing. These were 
immediately embedded in OCT compound and snap-frozen in liquid nitrogen. This 
experiment was carried out in collaboration with Dr. Tim Hughes who harvested the 
brachiocephalic arteries. Serial transverse sections, of 7pm thickness, were cut along the 
brachiocephalic artery, starting from the proximal end.
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2.8.7. Immunohistochemical analysis
Frozen sections from the spinal cord or brachiocephalic artery from mice with ADEAE and 
atherosclerosis respectively (for C3 deposition and CD59-2a-CRIg targeting) and liver (for 
anti-CRIg mAb analysis) were left to air dry for 20 minutes before fixation in ice-cold 
acetone for 10 minutes on ice. Spinal cord from a naive mouse was used as a negative 
control in the ADEAE experiment and for anti-CRIg mAb characterisation. Sections were 
washed in PBS before marking with a pap pen and blocking in 10% Normal goat serum 
diluted in 30 min at room temperature. The sections were stained for C3b deposition or 
analysed for ex vivo or in vivo CD59-2a-CRIg targeting. Sections were then incubated with 
the relevant Abs, isotype control or CD59-2a-CRIg diluted in 1%BSA/PBS for 1 h at room 
temperature (Table 2.11). In between antibody incubations, the slides were washed three 
times in PBS for five minutes each. Following incubation with the secondary fluorescently 
labelled antibody for 30 minutes at room temperature, the slides were counterstained with 
DAPI (diamidino-2-phenylindole; Sigma-Aldrich) diluted 1:400 in 1%BSA/PBS for 20 
minutes. Incubations with antibodies, CD59-2a-CRIg reagent and DAPI were performed at 
room temperature in a humid chamber. Following washing in PBS and H20 the sections 
were air dry and mounted in Vectashield (Vector Laboratories) to prevent fading of the 
fluorescent signal. Fluorescence microscopy and digital image collection were carried out 
using Nicon ECLIPSE 80/ fluorescence microscope and a Nikon Digital Camera 
DXml200F.
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Purpose Targeted reagent Detecting antibody Fluorescently 
labelled antibody 
(Secondary 
antibody)
C3 deposition 5pg/ml Rat anti-mouse 
C3 clones 2/11 and 
11H9 (HyCult 
Biotechnology) or rat 
IgGl (Caltag 
Laboratories) isotype 
control
Alexa Fluor ® 594 
donkey anti-rat 
IgG (H+L) (1:100; 
Invitrogen)
CD59-2a-CRIg ex 
vivo targeting
lOOpg/ml CD59-2a- 
CRIg/488 (section 
2.6.5)
- -
CD59-2a-CRIg in 
vivo targeting
5pg/ml rat anti-mouse 
CD59 mAb (mCD59a- 
7) or rat IgGl (Caltag 
Laboratories) isotype 
control
Alexa Fluor ® 488 
goat anti-rat IgG 
(H+L) (1:100; 
Invitrogen)
Anti-CRIg mAb 
characterisation
- 5pg/ml rat anti-mouse 
CRIg mAb or rat IgGl 
(Caltag Laboratories) 
isotype control
Alexa Fluor ® 488 
goat anti-rat IgG 
(H+L) (1:100; 
Invitrogen)
Table 2.11 Reagents, antibodies and their working dilutions used for 
immunohistochemical analysis.
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Chapter 3. Cloning and expression of anti-terminal pathway therapeutics
The aim of the work described in this chapter was to clone and express a set of therapeutic 
agents with potential to inhibit the terminal pathway, these were based either on OmCI or 
CD59. Two types of anti-complement therapeutics were designed in this research study. 
OmCI-Fc is a long-lived reagent and CD59-CRIg proteins were engineered to target the site 
of pathology.
The C5 inhibitor OmCI, is a small protein which is cleared from the body within 30 minutes 
when injected into experimental animals. This has restricted its therapeutic application only 
to acute disease and conditions. In order to develop a long-lived reagent suitable for therapy 
of chronic complement-mediated disease, DNA technology was used in this project to join 
together the nucleotide sequences encoding for the tick protein, OmCI, and the mouse Fc of 
IgG2a so that it was expressed as an antibody-like OmCI-Fc fusion protein. The generation 
of Fc fusion proteins is a strategy employed to increase the serum half-life of protein drugs. 
Linking of immunoglobulin Fc fragment to complement regulators has been shown 
previously to increase the half-life of complement regulators and generate effective agents 
for anti-complement therapy [319, 320, 327].
The second type of anti-complement reagents makes use of the terminal pathway inhibitor, 
CD59. The MAC regulator has previously been generated in soluble form, however it is a 
poor inhibitor of complement in a whole serum, a consequence of its small size and its 
predisposition to bind plasma lipoproteins [376]. To overcome this limitation, CD59 was 
modified in such a way as to specifically deliver its complement inhibitory activity to the 
sites of complement activation where it is most needed. This was achieved in this project 
using the complement receptor, CRIg. CRIg binds complement activation products C3b and 
iC3b. To develop this efficient and targeted inhibitor, the DNA encoding the functional 
domain of mouse CD59 was linked to the extracellular domain of mouse CRIg in a chimeric 
molecule, thus combining the properties of both CD59 and CRIg. It has been shown 
previously in other CD59-containing constructs that the orientation of the protein moieties 
within the chimeric molecule and the distance between CD59 and the target surface affected 
its therapeutic capacity [330, 370, 377]. CD59 was functionally active when fused to the N- 
terminus of CD59-Crry molecule, however it worked better when linked to the C-terminus 
of CR2 (CR2-CD59). To address this, DNA constructs encoding CD59 fusion proteins in
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different orientations were designed and generated in the current study. The CRIg-CD59 
reagents were further modified to increase the targeting efficiency. To achieve this, the 
ability of antibodies to associate into dimers was utilised and the hinge of mouse IgG3 and 
IgG2a was incorporated within the CRIg-CD59 chimeric molecule to promote dimerisation. 
Two antibody hinge domains were tested. IgG3 has the longest upper hinge among the 
mouse antibody, therefore potentially providing flexibility to the chimeric molecule which 
may be beneficial for the function [378]; IgG2a core hinge has three cysteines able to form 
three disulfide inter-chain bonds [379] which may result in more stable CRIg-CD59 dimer.
The detailed design of these agents will be introduced and the strategies that were used to 
clone these agents into the expression system of choice will be explained step-by-step. 
Furthermore, generation of stable lines secreting these proteins and approaches used to 
optimise the yield in static culture systems will be discussed. The purification and functional 
characterisation of these agents will be described in Chapter 5.
DNA technology has transformed modem science. Advances in DNA technology including 
polymerase chain reaction (PCR), recombinant DNA techniques, gene therapy, and DNA 
microarray have already begun to shape medicine and biotechnology. DNA technology 
allows for the production of biological products including drugs at bulk quantities. By 
putting human, animal or plant genes into the genetic material of bacteria, mammalian or 
yeast cells, these cell systems can be used as protein factories to produce recombinant 
proteins for medical and therapeutic use. The design and production of recombinant proteins 
(including therapeutic proteins) are processes involving methods and techniques from 
different fields of basic science- molecular biology, biochemistry, microbiology, and cell 
biology. Recombinant proteins are proteins encoded by DNA that has been artificially 
generated. Moreover DNA from two or more sources can be incorporated into a single 
recombinant molecule to create one recombinant fusion protein. The approach offers an 
opportunity to create highly efficient therapeutics which combine the functional properties 
derived from each of the original proteins. This attractive strategy was used in this project to 
generate targeted drugs based on the complement inhibitor CD59.
Once the DNA encoding the protein of interest is generated it is amplified using PCR to 
provide material for further manipulations. The amplification products can be “cut” with 
restriction endonucleases and “glued” into “carrier molecule” using DNA ligase. This is
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used as a “transport vehicle”. In order to transfect cells for expression of recombinant 
protein or drug, the DNA encoding the molecule has to be replicated and purified. This 
usually can be done in bacterial cells such as E. coli. This organism has been studied for 
many years by molecular biologists and it is now known that its genome contains 4.2 million 
base pairs. The bacterium also possesses extrachromosomal DNA molecules known as 
plasmids that can replicate independently of the nuclear DNA. These plasmids are closed 
single pieces of supercoiled DNA which can be stably inherited by daughter cells. They 
have the ability to replicate to high copies within each bacterial cell. Therefore the plasmids 
can be used as a “transport vehicle” known as a “vector”. The introduction of recombinant 
plasmid into bacterial cells is referred to as transformation. Replicating the vector will 
amplify the DNA of interest inserted into the plasmid. This will generate enough material 
for further manipulations. Plasmid vectors are also used to transfer DNA from the 
prokaryotes to eukaryotic cells to generate the recombinant proteins. In order to achieve 
correct glycosylation and to avoid contamination with bacterial toxins, a mammalian cell 
line was chosen to express the recombinant therapeutic proteins. For this project Chinese 
Hamster Ovary (CHO) cells were used. These cells are one of the most popular hosts for 
production of therapeutics. They are able to perform appropriate and efficient post- 
translational modifications of complex proteins and the glycosylation pattern of recombinant 
proteins produced in CHO cells is very similar to that of native proteins [380]. Glycosylation 
is particularly essential for Fc fusion proteins (OmCI-Fc in this project). It is crucial for the 
structure and many effector functions of the antibody Fc domain [381-384].
3.1. Design of anti-complement therapeutics
The experiments described in this chapter are:
1. Generation of a soluble, long-lived anti-complement therapeutic: OmCI-Fc (Fig.3.1).
• Cloning cDNA encoding the soft tick salivary protein, OmCI, into the pDR2 
expression vector which also contains DNA encoding the mouse IgG2a Fc 
domain.
• Transfection of CHO cells with the engineered plasmid constructs and analysis of 
protein expression.
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Bulk production of OmCI-Fc
2. Generation of targeted anti-complement therapeutics: CRIg-CD59, CD59-CRJg, 
CRIg-3-CD59*, CD59-3-CRIg*, CRIg-2a-CD59*, CD59-2a-CRIg*, and finally the 
cleavable control protein CD59-CRIg. These agents are illustrated schematically in 
Fig 3.2. (* 3 stands for hinge o f mouse IgG3 and 2a stands for hinge of mouse 
IgG2a).
• Cloning cDNA encoding extracellular domain of mouse CRIg into the 
pDR2AEFla vector to generate CRIg-pDR2 vector.
• Cloning cDNA encoding extracellular domain of mouse CD59a into CRIg-pDR2 
vector.
• Cloning cDNA encoding the hinge region of mouse IgG2a or IgG3 into CRIg- 
CD59-pDR2 vector between CRIg and CD59.
• Transfection of CHO cells with the engineered plasmid constructs and analysis of 
protein expression.
• Bulk production of CD59-CRIg fusion proteins.
OmCI
Fig. 3.1 Schematic diagram of OmCI-Fc. To generate the chimeric antibody-like 
molecule, the Fab fragments of mouse IgG2a were replaced with OmCI. Two molecules of 
OmCI were linked to Fc portion of mouse IgG2a antibody. Fc comprises hinge, CH2 and 
CH3 domains of the antibody molecule.
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N- terminus -C
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N- terminus -C
Fig.3.2 Diagram of CD59 containing fusion proteins. To generate CD59 targeted 
reagents, the extracellular domain of mouse CD59 was fused directly or through a hinge 
(taken from mouse IgG3 or IgG2a) either to amino (N-) (A) or carboxy (C-) terminus (B) of 
the extracellular domain of mouse complement receptor CRIg.
3.2. Generation of OmCI-Fc
Fc fusion proteins are promising dimers designed to be effective as a long-term agents in 
vivo [385]. The aim of this project is to increase the molecular weight and prolong the half- 
life of the C5 inhibiting protein, OmCI, to generate a powerful long lasting anti-complement 
drug (Fig.3.1). This will be achieved by linking OmCI to Fc antibody domain to increase the 
molecular weight of the protein and also bind to the FcRn, to protect the Fc coupled 
molecule from degradation via a recycling mechanism. Thus OmCI-Fc is an antibody-like 
molecule with the C5 binding protein replacing the Fab arms (Fig.3.1). The expression 
vector was engineered to contain DNA encoding OmCI upstream of DNA encoding the
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hinge region of mouse IgG2a, CH2 and CH3 domains (Fig.3.3). For efficient protein 
production in mammalian a CD33 signal peptide was used [386].
150OmCI
OmCI 5 ’ OmCI 3’
5’ CAGGCTAGCGACTCCGAAAGCGACTGCACTGGA 3’ GGGGTAGAGTTCCTGACGAGATCTCGC 5’
N hel X bal
Promotor,elongation factor la (EFla)
Ampicillin
resistance
.CD33 leader 
sequence
OmCI-Fc
pDR2AEFla
Hygromycin
resistance
Poly A
Fig. 3.3 Schematic representation of the expression plasmid pDR2AEFla encoding 
OmCI-Fc fusion protein. A. OmCI cDNA was amplified. The sequences and positions of 
primers used for amplification o f OmCI are shown. The incorporated restriction sites are 
underlined. B. The OmCI cDNA digested with restriction enzymes was ligated into plasmid 
in a frame with sequence encoding Fc portion of mouse IgG2a. CD33 leader sequence was 
used for efficient expression o f OmCI-Fc.
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3.2.1. Cloning strategy
The strategy used to generate plasmid encoding OmCI-Fc protein was shown in Fig.3.4. The 
Fc domain of mouse IgG2a was cloned in pDR2AEFla (Fig.3.4A) to create the Fc-pDR2 
construct. DNA encoding OmCI was amplified from a plasmid containing modified 
(mutated) OmCI sequence and was cloned into the expression vector upstream of the Fc- 
encoding DNA. Native OmCI expressed in the soft tick is a nonglycosylated protein. 
However two possible N-linked glycosylation sites are present in the cDNA sequence 
(Asn78 and Asnl02) [175] and will result in a glycosylated product when produced in 
mammalian cells such as CHO. This post-translational modification was shown to have a 
negative effect on the ability of OmCI to inhibit the complement cascade [175]. Therefore, 
the OmCI cDNA was modified by Dr Miles Nunn (Centre for Ecology and Hydrology, 
Oxford, United Kingdom) who first described OmCI [175] and provided as a gift. Two 
mutations, substituting Asn78 and Asnl02 for Gin were introduced (Fig.3.5) to abolish post- 
translational glycosylation in CHO cells.
In order to accomplish efficient expression and correct folding of the fusion protein, the 
signal sequence of CD33 needed to be cloned upstream of, and in frame with, DNA 
encoding the mature OmCI protein. To do this, a commercial vector called Signal plgPlus 
(SIgpIg, R&D Systems) was used as a ‘vehicle’ to ‘pick up’ the CD33 leader sequence (Fig. 
3.6B). DNA encoding OmCI was ligated into Sigplg and DNA encoding CD33 signal 
peptide in frame with OmCI DNA was subsequently subcloned into the Fc-expression vector 
by PCR.
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OmCI-Fc-pDR2AEF 1 a
OmCI-Signal plgplus
Fc-pDR2AEFla
Fc-pDR2AEFla
pDR2AEFla 
6.4 kbp
Signal plgplus 
6.341 kbp
OmCI 3’
FcIgG2a fw 
FcIgG2arev
pDR 5’
Fc 
pDR3’
+ CD33 LS-OmCI
CD33LS
OmCI
CD33 LS 
(leader sequence)
+ OmCI ----------- ►
5’pigpDR2
CD33LS 
OmCI 5’
OmCI
Fig.3.4 Generation of OmCI-Fc encoding construct. Cloning strategy. A. DNA encoding 
the sequence of OmCI was cloned into Signal plgplus vector in frame with and downstream 
of the CD33 leader sequence. B.DNA encoding the Fc of mouse IgG2a was ligated into 
pDR2AEFla to generate Fc-pDR2 vector. C. Signal plgplus vector encoding OmCI was 
used as a template to amplify sequence encoding CD33 leader sequence-OmCI. The PCR 
product was cloned into Fc-pDR2 vector in frame with and upstream of the DNA encoding 
IgG2a Fc. Positions of primers used for cloning and sequencing are shown with dotted 
arrows.
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taagagctcaaaatgctggttttggtgaccctgattttctccttttctgcgaacatcgca 
OmCI 5' primer
tatgctgacagcgaaagcgactgcactggaagcgaacctgttgacgccttccaagctttc
.D--S--E--S--D--C--T--G--S--E--P--V--D--A--F--Q--A--F-
agtgagggcaaagaggcatatgtcctggtgaggtccacggatcccaaagcgagggactgc
• S • • E • • G • • K* • E • -A*•Y • •V • • L • •V • ■R • •S • •T • •D • •P • •K* -A- •R • • D • •C •
ttgaaaggagaaccagccggagaaaagcaggacaacacgttgccggtgatgatgacgttt
• L •• K-•G •• E ••P •-A*•G •• E •• K*•Q ••D ••N •• T •• L ••P ••V ••M ••M ••T •• F •
caa
aagaatggcacagactgggcttcaaccgattggacgtttactttggacggcgcaaaggta
• K*• N ••G ••T ••D ••W •*A-• S ••T •• D ••W ••T ••F ••T ••L ••D ••G ••A ■•K ••V •
Q caa
acggcaacccttggtaacctaacccaaaatagggaagtggtctacgactcgcaaagtcat 
•T •-A-•T •• L ••G ••N •• L ••T ••Q ••N ••R •• E •-V-•V ••Y ••D ••S ••Q ••S ••H • 
Q
cactgccacgttgacaaggtcgagaaggaagttccagattatgagatgtggatgctcgat
• H • •C • •H • -V* • D • • K • -V- • E • •K • • E • -V* •P • *D* •Y • -E- •M • •W • •M • -L- •D •
gcgggagggcttgaagtggaagtGgagtgctgGcgtGaaaagGttgaagagttggcgtGt
•A--G--G--L--E--V--E--V--E--C--C--R--Q--K--L--E--E--L--A--S-
OmCI 3' primer 
ggcaggaaccaaatgtatccccatctcaaggactgctaggcggcc 
•G ••R ••N ••Q ••M ••Y ••P ••H •-L-•K ••D ••C •
Fig.3.5 Nucleotide and amino acid sequence of OmCI. The positions of primers used for 
amplification and restriction site incorporation are shown in green. The codons for Asn (N) 
at positions 78 and 102 (highlighted in blue) were mutated to codons encoding for glutamine 
(Q) (shown in red).
3.2.I.I. Cloning of DNA encoding mouse IgG2a Fc
Fc, consisting hinge region, Ch2 and Ch3 of mouse IgG2a (Fig.3.7) was previously cloned 
into pDR2AEFla vector in our lab. Briefly, DNA encoding the Fc of IgG2a was amplified 
from a hybridoma cell line secreting monoclonal mouse IgG2a antibody. The Fc was 
amplified using sense primer FcIgG2a fw and anti-sense-FcIgG2a rev (primers listed in 
Table 3.1). FcIgG2a fw contained a BamHI restriction site at the 5’ end and overlapped the 
DNA encoding the hinge of IgG2a. Primer FcIgG2a rev introduced a Smal restriction site at 
the 3’ end.
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cn  CQ v i  Cl. U  U
Ampicillin
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HSVTK
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SV40 Poly A
pDR2AEFla 
6.4 kbp
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CD33
signal
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Xa
i Z i d X w R o Z f l i
CMV Promotor
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► fl ori
ColEI ori
SV40 ori
TK Poly A , TK promotor
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resistance
Fig.3.6 Vectors used for cloning. A. pDR2AEFla expression vector. B. Signal plgplus 
expression vector encoding CD33 leader sequence.
The amplification product was purified, digested with relevant enzymes and ligated in to 
pDR2AEFla to generate Fc-pDR2 construct (Fig.3.4 B). Chemically competent cells DH5a 
were transformed with the construct by heat shock and bacterial colonies were screened for 
presence of the insert (Chapter 2, sections 2.1.10 and 2.1.11). A positive colony was selected 
and expanded and the plasmid was purified by QIAquick® spin miniprep purification kit. 
The fidelity o f the Fc sequence was confirmed by sequencing Chapter 2, sections 2.1.13).
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Fig.3.7 Diagram showing domains of mouse IgG heavy chain used in OmCI-Fc.
Positions of the primers (FcIgG2a fw and FcIgG2a rev) used to amplify DNA encoding the 
Fc portion of mouse IgG2a, composed of hinge and constant domains 2 and 3 (Ch2 and Ch3) 
are shown.
3.2.I.2. Cloning of DNA encoding OmCI
cDNA encoding OmCI (450 bp) was amplified by PCR from the plasmid encoding OmCI 
(Fig.3.5 and Fig.3.8A). OmCI 5’ and OmCI 3’ primers used for the amplification contained 
Nhel and Xbal restriction sites respectively (Table3.1; Fig.3.3A). The PCR product was gel- 
extracted and purified using QIAquick PCR purification kit (Qiagen). After restriction with 
the relevant enzyme, the sequence was cloned into Signal pig Plus (Sigplg) (Fig.3.8B) 
vector in frame with and immediately downstream of the CD33 signal peptide sequence. 
Bacterial chemically competent cells DH5a were transformed and colonies screened by 
PCR using primers located in Table 2.2 Chapter 2 (Section 2.1.11, Fig.3.8C). A positive 
colony was grown up and plasmid encoding CD33 signal peptide-OmCI was purified using 
QIAprep <D spin Miniprep kit (Qiagen). OmCI-SigpIg vector was then used as a template to 
amplify a sequence encoding CD33 signal peptide-OmCI. Both, sense primer 5’pig pDR2 
and anti-sense primer OmCI 3’ used for this PCR reaction incorporated Xbal restriction sites 
at 5’ and 3’ ends of the amplification product. The position of the primers is shown in 
Fig3.4. CD33 signal peptide-OmCI DNA sequence was then purified from the plasmid 
template using QIAquick PCR purification kit (Qiagen), digested with Xbal (Fig.3.8D) and 
ligated into Fc-pDR2 previously restricted with Xbal and Spel, OmCI-encoding DNA was 
in frame with and upstream of the Fc DNA. The usage of Spel restriction enzyme to digest 
Fc-pDR2 was possible since it generates ‘sticky ends’ compatible with Xbal (used in CD33
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signal peptide-OmCI digest). Chemically competent cells DH5a were transformed using 
heat shock. Bacterial colonies were screened by PCR for expression of the insert (Fig.3.8E). 
A positive colony was selected, grown up and plasmid DNA was purified. 
Sequencing confirmed that no errors had been introduced by PCR.
Construct Primer name and sequence Incorporated 
restriction sites
OmCI 5’ CAGGCTAGCGACTCCGAAAGCGACTGCACTGGA Nhel
OmCI 3’ CGCTCTAGAGCAGTCCTTGAGATGGGG Xbal
5’pig pDR2 CGATCTAGATAACTAGAGAACCCACTG Xbal
FcIgG2a fw CGCGGATCCGGTGGTGGTGGCAGTGGTGGT BamHI
FcIgG2a rev GCGCCCGGGTCATTTACCTGGAGTCCTGGAGAAGC Smal
pDR5’ CAAGCCTCAGACAGTGGTTC -
pDR3’ ATGTCTGGATCGGTGCGGGGC -
Table 3.1 Primers used for generating OmCI-Fc fusion protein. The primer name and 
primer sequence are listed. The introduced restriction sites are shown in boldface.
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Fig.3.8 Generation of OmCI-Fc. PCR amplification and bacterial screening. A. DNA
encoding OmCI (450bp) amplified and visualised by gel electrophoresis. B. Signal plgplus 
(Sig pig) vector was digested with Nhel and Xbal restriction enzyme and 3 pi of the reaction 
was loaded on agarose gel. C. PCR screen of colonies containing Sig pig vector encoding 
OmCI. Primers 5’pig pDR2 and OmCI 3 ’ were used for the amplification. A band with an 
identical size (~600bp) appeared in 9 out o f 10 tested colonies. However only the band with 
the highest intensity (indicated by asterisk) came up positive for insert after sequence 
analysis. D. DNA encoding CD33 signal peptide-OmCI, obtained by PCR from Sig pig 
vector encoding OmCI was digested with Xbal and visualised by gel electrophoresis. E. 
DNA encoding CD33 signal peptide-OmCI was subcloned into Fc-pDR2 vector in a frame 
with Fc. Competent bacterial cells were transformed and bacterial colonies tested by PCR 
for insert. Primers pDR2 5’and OmCI 3’ were used for the amplification. Positive colony is 
indicated by asterisk.
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3.2.2. Transfection
For expression, CHO cells were transfected with plasmid encoding OmCI-Fc fusion proteins 
using JetPEI cationic polymer transfection reagent (Poly Plus Transfection) according to the 
manufacturer's instructions as described in Chapter 2, section 2.2.3. Stable lines were 
established by selection with 400 pg/ml Hygromycin B over the course of 4 days. 
Expression of the recombinant proteins in supernatant was confirmed at day five by western 
blot analysis (section 2.4.4, Fig.3.9A). The transfected cells were cloned out by limiting 
dilution. The clones were screened for OmCI-Fc expression by ELISA and Western blot 
(Fig.3.9B). The methods used for screening were explained in Chapter 2, sections 2.4.4 and
2.4.6. The cells expressing high levels o f protein were selected and expanded.
175  —
Fig.3.9 Western blot analysis for OmCI-Fc expression and clone selection
A. OmCI-Fc expression. Tissue culture supernatant from CHO cells expressing OmCI-Fc 
was harvested and subjected to SDS-PAGE on 7.5% gel under nonreducing conditions and a 
western blot was carried out using affinity purified rabbit anti-OmCI polyclonal antibody. 
Molecular weight markers are shown on left. OmCI-Fc appeared as a band with molecular 
weight of 83 kDa. The additional, higher molecular weight band is likely to represent protein 
aggregates. B. Clone screening. CHO cells expressing OmCI-Fc were cloned out by limiting 
dilution in 96-well plate. Tissue culture supernatant from wells containing a single colony 
was subjected to western blot. The three tested clones expressed similar levels of OmCI-Fc.
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3.2.3. Large-scale protein expression
To scale up OmCI-Fc production two high-density cell culture systems were tested. The 
selected clones expressing OmCI-Fc were expanded and transferred into either a two- 
compartment bioreactor CELLine AD 1000 (Integra Bioscinece) or High Yielding 
Performance Flask (Coming ®HYPERFlask Cell culture vessel).
3.2.3.I. Integra CELLine ADlOOOflasks
CELLine AD 1000 consists of two compartments separated by a lOkDa semi-permeable 
cellulose acetate membrane (Fig.3.10). The cells were cultured in the small compartment 
and the medium compartment was filled with medium as described in section 2.2.6.1. The 
membrane allowed a continuous diffusion of nutrients into the cell compartment and 
removal of waste products. Efficient gas transfer was ensured by a silicone membrane which 
forms the cell compartment base. The cell compartment contains a polyethylene terephtalate 
matrix design to allow adherent cells such as CHO cells to attach. This technology allows 
the culture of large number of cells in a small volume resulting in a high concentration of 
secreted protein.
CHO cells secreting OmCI-Fc were harvested from T80 flasks in log phase of growth. They 
were peletted and resuspended in 15ml of RPMI medium supplemented with 10% low Ig 
FCS. The cells were then inoculated into CL ADlOOOflask. Ten days later tissue culture 
supernatant form the cell compartment was harvested and tested for OmCI-Fc. The presence 
of OmCI-Fc was confirmed by western blot analysis (Fig.3.11) and the yield quantified by 
ELISA using a standard curve. For western blot analysis, the proteins were separated on 
7.5% gel and transferred to a nitrocellulose membrane. The membrane was probed with 
affinity purified rabbit anti-OmCI polyclonal antibody (generated in house). As expected, 
two bands were detected. The band with approximate molecular weight of 90kDa was 
OmCI-Fc (Fig.3.11). The higher molecular weight band was probably an aggregation 
product.
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Fig.3.10 Schematic representation of CELLine AD1000. CELLine A D I000 is a high
density tissue culture system consisting o f cell and medium compartments. The cells are 
cultured in high density in the cell compartment and fed by nutrients from the medium 
compartment passing over a semi-permeable membrane. The protein of interest is secreted 
in the cell compartment. Efficient gas transfer of the cell compartment is ensured by a 
silicone membrane. The medium is gassed via the lid.
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Fig. 3.11 Western blot analysis of cells expressing OmCI-Fc fusion protein. Supernatant 
was harvested from CHO cells expressing OmCI-Fc cultured in CELLine AD 1000 (lanel) 
flask and HYPERFYasA: vessel (lane 2), proteins were separated on a 7.5% gel and 
transferred to nitrocellulose membrane. The western blot was probed with rabbit anti-OmCI 
polyclonal antibody. OmCI-Fc was detected in the supernatant from both types of high- 
density culture systems. OmCI-Fc appeared as a major band with approximate molecular 
weight of 90kD in both supernatants (indicated with arrow). High molecular weight 
aggregates were seen on both lanes.
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3.2.3.2. HYPERFlask  vessel
The second type high-density culture system used in this project was HYPERFlask. The 
vessel consists of ten individual flaskettes (Fig.3.12). The bottom of each layer has a 
polystyrene cell growth surface allowing for gas exchange directly into the medium. The 
multi-layer design permits the growth of ten times as many cells as a normal T175 flask 
resulting in increase yield of the expressing recombinant protein.
-TV L -C\.
]  <— Polystyrene top surface
Culture medium
jT \ . -r\. -r\.
Culture medium
External air space for gas 
exchange between layers
Culture medium
Ultra-thin permeable 
polystyrene film
Fig.3.12 Schematic representation of three of the HYPERFlask vessel's ten culture 
layers. The air gaps between each layer allow gas exchange through the ultra-thin bottom 
growth surfaces.
CHO cells secreting OmCI-Fc were into HYPERFlask vessel. The tissue culture supernatant 
was harvested every six days and replaced with fresh medium as described in section
2.2.6.2. Protein production was confirmed by western blot analysis (Fig.3.11). Similarly to 
OmCI-Fc obtained from the CELLine AD 1000 flask, two bands were observed after 
probing with Rb anti-OmCI. OmCI-Fc appeared as a band with apparent molecular weight 
of 90kDa. This result suggested that OmCI-Fc fusion protein expressed in CELLine AD 
1000 flask and HYPERFlask had an identical molecular mass and a similar level of 
aggregate formation.
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To determine the level of OmCI-Fc expression, a quantitative ELISA was performed on 
tissue culture supernatant arising from both culture systems. The assay was described in 
method section 2.4.7. OmCI-Fc was calculated using a standard curve (Fig.3.13). The 
analysis revealed that the cells cultured in the HYPER Flask produced OmCI-Fc at 
concentrations 4pg/ml. However 450ml tissue culture supernatant was obtained every six 
days giving 1800pg of the recombinant protein per harvest contrasting with the weekly yield 
of 10.5pg in the CELLine AD1000 (Table3.2).
High density cell Volume harvest OmCI-Fc Total OmCI-Fc
culture system per week (ml) concentration yield per week
(pg/ml) (ng)
CELLine AD1000 15 0.7 10.5
UYEERFlask 450 4 1800
Table 3.2 OmCI-Fc production using high-density cell culture systems
The higher concentration of OmCI-Fc expressed in the HYPER Flask, could be explained by 
the difference in the number of cells cultured in the two systems. Thirty million cells could 
be cultured in CELLine AD 1000, whereas this number could reach 200x106 in a single 
HYPERFlask. HYPER Flask was more efficient in terms of protein production and 
therefore was used to bulk-up OmCI-Fc fusion protein.
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Fig.3.13 ELISA analysis of OmCI-Fc expression level of CHO cells cultured in 
CELLine AD1000 flask and HYPERF/as£ vessel. Tissue culture supernatant, 15ml and 
450ml was harvested from CELLine AD 1000 flask and HYPERFlask vessel respectively. 
Serial dilutions from the tissue culture supernatant and pure OmCI-Fc were prepared and 
added to ELISA plate coated with mouse anti-OmCI mAb. OmCI-Fc was detected with 
affinity purified rabbit anti-OmCI polyclonal antibody. A standard curve was generated from 
the pure OmCI-Fc (A). The amount of tissue culture supernatant added to the wells was 
plotted (X-axes) versus the absorbance at 490nm (Y-axes) (B). Higher level of OmCI-Fc 
was detected in tissue culture supernatant from HYPERF/as£ vessel (open square) 
comparing to CELLine AD 1000 flask (black circle). To determine the concentration of 
OmCI-Fc, a cubic-spline curve was fitted to the standards and the unknown values were 
interpolated from the standard curve. The analysis was performed using GraphPad Prism 5.0 
software.
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3.3 Generation of fusion proteins consisting of CRIg and CD59
To generate fusion proteins, the extracellular domain of mouse CRIg was linked to either the 
N terminus or the C terminus of mouse CD59a. DNA encoding the membrane-anchoring 
domains was excluded from these constructs as illustrated in Fig.3.14.
3.3.1 Construction of expression plasmids
3.3.1.1 CRIg-CD59, CRIg-3-CD59 and CRIg-2a-CD59
To generate CRIg-CD59, CRIg-3-CD59 and CRIg-2a-CD59 fusion proteins (Fig.3.2A), 
DNA encoding extracellular domain of murine CRIg was required. Total RNA was isolated 
from mouse liver and RT-PCR was performed. The cDNA generated by RT-reaction was 
used as template to amplify the extracellular domain (including the signal sequence) of 
mouse CRIg (Fig.3.14). The PCR was carried out using primers containing restriction sites. 
The forward primer CRIg amino5’ introduces Xbal and the reverse primer CRIg amino3’ 
introduced a BamHI restriction site (Fig.3.15A). Following purification of the PCR product 
(Fig.3.15C), it was digested with Xbal and BamHI and ligated into pDR2AEFla vector. 
Chemically competent cells DH5a were transformed using heat shock. Bacterial colonies 
were screened by PCR for inclusion of the insert. A positive colony was selected, grown up 
and plasmid DNA was purified. The DNA sequence of the insert was checked by 
sequencing analysis.
DNA encoding the 72 N-terminal amino acids of mouse CD59a was amplified from a vector 
that had previously been engineered in house to contain mouse CD59a encoding sequence 
(Fig.3.15B and C). PCR primers containing BamHI and EcoRV restriction sites were used. 
The reverse primer was designed to introduce a stop codon prior to Asp-74, to which the 
GPI anchor attaches (Fig.3.15B) and thus deleting the GPI-addition signal sequence from the 
CD59 DNA construct. The DNA obtained from this PCR did not contain the CD59 leader 
sequence. The PCR product was extracted from the agarose gel and digested with BamHI 
and EcoRV. The plasmid containing CRIg sequence (CRIg-pDR2) was also subjected to the 
same digestion procedure followed by a dephosphorylation step (Method 2.1.14). The
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CD59a insert was ligated into CRIg-pDR2 in frame and downstream of CRIg to create a 
construct encoding CRIg-CD59 fusion protein.
CRIg amino 5'
gagctaccagcacttccaggttcttcagcagcaagaggatggaaggatgaatagaagtag
Signal sequence — 
cttcaaataggatggagatctcatcaggcttgctgttcctgggccacctaatagtgctca
IgV -> CRIg carboxy 5' 
c c t a t ggc caccccaccc taaaaacac c tgagagtgtgacagggacc tggaaaggagatg
tgaagattcagtgcatctatgatcccctgagaggctacaggcaagttttggtgaaatggc 
V--K--I--Q--C--I*-Y--D--P--L--R--G--Y*-R--Q--V--L--V--K--W*•
tggtaagacacggctctgactccgtcaccatcttcctacgtgactccactggagaccata 
L ••V**R* *H* *G* • S • *D • • S ••V**T ••I••F**L • *R • *D* • S • *T • • G* *D •*H*•
tccagcaggcaaagtacagaggccgcctgaaagtgagccacaaagttccaggagatgtgt 
I--Q*-Q--A* *Y*-R*-G--R* *L*-K-*V**S*-H--K--V--P*-G*-D--V-•
ccctccaaataaataccctgcagatggatgacaggaatcactatacatgtgaggtcacct 
S* *L* *Q*•I•*N*’T* *L* *Q* *M* *D* *D* *R* *N* *H-*Y* *T* *C* *E*•V**T••
- IgV
ggcagactcctgatggaaaccaagtaataagagataagatcattgagctccgtgttcgga 
w . . q . . T . . p . . D . . q . . N . . q . - v -I--R-- D - -K*-I--I**E*-L--R--V--R-•
aatataatccacctagaatcaatactgaagcacctacaaccctgcactcctctttggaag
CRIg
caacaactataatgagttcaacctctgacttgaccactaatgggactggaaaacttgagg 
A--T--T--I--M--S--S--T--S--D--L--T--T--N--G--T--G--K--L--E-- 
amino/carboxy 3' Trans membrane domain
agaccattgctggttcagggaggaacctgccaatctttgccataatcttcatcatctccc 
E--T-•I•-A--G
intracellular
tttgctgcatagtagctgtcaccataccttatatcttgttccgctgcaggacattccaac 
domain ->
aagagtatgtctatggagtgagcagggtgtttgccaggaagacaagcaactctgaagaaa
Fig.3.14 Nucleotide and amino acid sequence of mouse CRIg. Variable region (IgV) of 
CRIg is shown in boldface. The signal sequence is highlighted in green. The positions of 
primers used for amplification and restriction site incorporation are shown in red. To 
generate vector construct encoding fusion protein with CRIg fused to the N-terminus of 
CD59 (CRIg-CD59 or CRIg-hinge-CD59) CRIg encoding DNA was amplified using 
primers CRIg amino 5’ and CRIg amino 3’. The PCR product contained sequence encoding 
the signal peptide (in green) and IgV. To generate reagents in reverse orientation (CD59- 
CRIg or CD59-hinge-CRIg), primers CRIg carboxy 5’ and CRIg carboxy 3’ were used. This 
gave rise to DNA encoding IgV of CRIg but not the signal peptide. For these reagents CD59 
signal peptide was used. Primer CRIg carboxy 3’ adds stop codon to the 3’ end of the PCR 
product.
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The common BamHI restriction site in both CRIg and CD59 cDNA formed a link between 
the DNA fragments (Fig.3.15D). DH5a chemically competent bacteria were transformed 
and colonies screened by PCR for insert expression. A positive colony was selected, grown 
up and plasmid DNA was isolated. The sequence was checked for fidelity.
A
CRIg amino 5
Signal peptide 1 118 H IgV-type domain o f  CRIg K Transmembrane
domain
s ’ GCrCT CT AG ACC AGGTT CTTCAGC AGC AA G3 ’ 
X b a l 5 ’ G AACT CCT CT GGT AACG ACCGCCT AGGGAC5’ 
BamHI
— ■ GPI anchor site
C-terminal signal peptide 
for attaching GPI anchor
N-terminal Signal 
peptide
i 73 74
L Mature CD59a s  D
5 ’ GCGGG AT CCCT C ACATGCTACCACT GTTTC3 ’ 
Bam HI
3 ’ GGTCAAATT GAACACATT GTTT ATTCT AT AGATGs’ 
Stop E co R V
CD59 carboxy 5 ’: CD59 carboxy 3 ’:
pDR2AEFla
Fig.3.15 CRIg-CD59: construction of expression plasmid. Schematic diagrams of mouse 
CRIg (A) and mouse CD59 (B). The sequences and positions of primers used for 
amplification of extracellular domains o f CRIg and CD59a are shown. The incorporated 
restriction sites are underlined. The stop codon is shown in boldface. The amplification 
products were visualised by gel electrophoresis (C), digested with appropriate enzymes and 
ligated into expression vector pDR2AEFla to create CRIg-CD59 encoding construct (D).
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In order to generate CRIg-3-CD59, cDNA, encoding hinge of mouse IgG3 was amplified by 
PCR. Total RNA was isolated from mouse spleen and reverse transcribed. The generated 
cDNA was used as a template to PCR-amplify the hinge of IgG3 (Fig.3.16A). The primers 
used for this PCR amplification step were designed to add BamHI restriction sites to 5’ and 
3’ end of the hinge. The size of the amplification product was confirmed on agarose gel 
(Fig.3.16B). The PCR product and the plasmid encoding CRIg-CD59 were subjected to 
restriction with BamHI (this will cut the link between CRIg and CD 5 9 in the plasmid, CRIg- 
CD59-pDR2) followed by a ligation step (Fig.3.16C). The hinge was cloned between and in 
the same reading frame as CRIg and CD59. The construct was processed as described 
previously.
To generate CRIg-2a-CD59, cDNA encoding hinge domain of mouse IgG2a was obtained 
from a hybridoma cell line expressing mouse IgG2a. Total RNA was prepared and RT-PCR 
was carried out to generate cDNA. cDNA was used as a template for PCR to amplify the 
hinge of IgG2a. Both primers used for this reaction contained restriction sites for BamHI 
(Fig.3.16A). The PCR product was digested with BamHI enzyme after being visualised on 
agarose gel (3.16B). The cDNA encoding the hinge was ligated into CRIg -CD59-pDR2 
vector, between CRIg and CD59 (Fig.3.16C). In both cases (CRIg-3-CD59 and CRIg-2a- 
CD59), after the cloning of the hinge, the orientation was confirmed by PCR using one 
primer specific for the insert and a second one complementary to a sequence outside of the 
insert. Sequence fidelity was confirmed.
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pDR 2A EFla
pDR 2AEFla
pDR2AEFla
pDR2AEFla
Hinge (H)
Mouse IgG2a or IgG3
B
Hinge of IgG
IgG2a: 5c g c g g a t c c a a a a t t g a g c c c a g a g 3 3g a t t g g a g a a c c c a c c t g g t a g g c c t a g g c g c 5 '
BamHI BamHI
BamHI
+£hP
BamHI
IgG3: S rG C GGATCCAGAATCGAGCCTAGAATACCCA 3 
BamHI
3' c c a t t g t a g a a c c c a c c a g g g a g g c c t a g g c g c  s ' 
Bam HI
Fig.3.16 CRIg-3-CD59, CRIg-2a-CD59, CD59-2a-CRIg and CD59-2a-CRIg: 
construction of expression plasmid. Schematic diagrams of mouse IgG cloning strategy.
The sequences and positions of primers used for amplification the hinges are shown. The 
primers for IgG2a are boldfaced. All primers incorporated BamHI restriction sites 
(underlined). The amplification products were visualised by gel electrophoresis (B), digested 
with appropriate enzyme and ligated into linearised expression vector pDR2AEFla encoding 
CRIg-CD59 (C) and CD59-CRIg (D).
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3.3.I.2. CD59-CRIg, CD59-3-CRIg and CD59-2a-CRIg
The orientation of the proteins in hybrid molecules may affect their function, for example 
CD59 may function well at the carboxy terminus of a chimeric protein but it is less efficient 
at the amino terminus [330], To address this I designed fusion proteins in the reverse 
orientation where CD59 was linked to the N-terminus of CRIg (Fig.3.2B).
To create CD59-CRIg, CD59-3-CRIg and CD59-2a-CRIg fusion proteins, sequence 
encoding the signal peptide and a truncated form of mouse CD59a (C-terminal residue 
Lys72) was obtained from mouse liver RNA. RNA was reverse transcribed and full-length 
cDNA was generated. This was used as a template to PCR-amplify CD59a encoding 
sequence (Fig.3.17A). The PCR was carried out using primers containing restriction sites. 
The forward primer CD59 amino5’ incorporated Xbal and the reverse CD59 amino 3’ 
primer incorporated a BamHI restriction site. Following purification of the PCR product 
(Fig.3.17C), it was digested with Xbal and BamHI and cloned into pDR2AEFla vector. 
Chemically competent cells DH5a were transformed using heat shock. Bacterial colonies 
were screened by PCR for expression of the insert. A positive colony was selected, grown 
up and plasmid DNA was purified. The DNA sequence of the insert was checked by 
sequence analysis. DNA sequence encoding the extracellular domain of mouse CRIg was 
obtained from total RNA isolated from mouse liver as described before. The primers used to 
amplify the CRIg-encoding sequence were designed to insert restriction sites and a stop 
codon (Fig.3.17B). The CRIg PCR product (Fig.3.17C) and plasmid containing CD59a 
sequence (CD59-pDR2) were subjected to digestion with BamHI and EcoRV. The CRIg 
encoding sequence was cloned into CD59-pDR2 in frame and downstream to CD59. The 
common BamHI restriction site in both CRIg and CD59 cDNA formed a link between the 
DNA fragments (Fig.3.17D). DH5a chemically competent bacteria were transformed and 
colonies screened by PCR for insert expression. A positive colony was selected, grown up 
and plasmid DNA was isolated. The sequence was checked for fidelity.
CD59-3-CRIg and CD59-2a-CRIg were generated using an identical approach to that 
described above (Section 3.3.1.1; Fig.3.16 A and D).
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GPI anchor site
C-terminal signal peptide 
for attaching GPI anchor
73 74N-terminal Signal 
peptide Mature CD5 9a
5 GGCTCTAG ACTCACATGCTACCACTGTTTC5 
X b a l BamHI
Signal peptide
(S)
1 118 
H IgV-type domain o f  CRIg K Transmembrane
domain
CGCGGATCCGGCCACCCCACCCT AAAAACAC3 
BamHI
3TGAACTCTGGTAACGACCGATTCTATAOATGs 
stop EcoR V
Fig.3.17 CD59-CRIg: construction of expression plasmid. Schematic diagrams of mouse 
CD59 (A) and mouse CRIg (B) cloning strategies. The sequences and positions of primers 
used for amplification of extracellular domains of CRIg and CD59a are shown. The 
incorporated restriction sites are underlined. The stop codon is shown in boldface. The 
amplification products were visualised by gel electrophoresis (C), digested with appropriate 
enzymes and ligated into expression vector pDR2AEFla to create CD59-CRIg encoding 
construct (D).
3.3.I.3. Generation of cleavable CD59-CRIg
Soluble CD59 and soluble CRIg were required as controls for various assays used to assess 
function of the chimeric reagents. To create control soluble CD59 and CRIg which were 
identical to those in the constructs described above, but NOT fused to other domains, a
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cleavable CD59-CRIg protein was designed. This agent was expressed as a CD59-CRIg 
fusion protein with a protease cleavage recognition site for the human rhino virus 3C 
protease introduced between CD59 and CRIg. This enzyme specifically cleaves between the 
Gin and Gly residues of the recognition sequence of IleGluValLeuPheGln/GlyPro. The 
cleavable reagent was generated in a similar way to CD59-CRIg fusion protein. Briefly, 
sequence encoding the signal peptide and the 72 N-terminal amino acids of mouse CD59a 
was obtained by PCR from mouse liver full-length cDNA. CD59 amino 5’ primer used for 
generating CD59-CRIg fusion protein was used as a sense primer. It contains Xbal 
restriction site. The anti-sense primer contains BamHI restriction site. This primer also 
contained a sequence incorporating a protease cleavage recognition site of the 3C protease 
before the BamHI site (Fig.3.18). The PCR product was digested with appropriate restriction 
endonucleases and cloned into pDR2AEFla vector. The construct was processed as 
described for CD59-CRIg construct.
3.3.2. Transfection
For expression, CHO cells were transfected with vector constructs encoding CD59 fusion 
proteins using JetPEI cationic polymer transfection reagent (Poly Plus Transfection) 
according to the manufacturer's instructions and as described in method 2.2.3. Stable lines 
were established by selection with 400 pg/ml Hygromycin B. Expression of the recombinant 
proteins in supernatant was confirmed by western blot probed with anti-CD59 or anti-CRIg 
mAb (Fig.3.19). This assay revealed that the transfection was successful. CD59-CRIg and 
CRIg-CD59 proteins appeared as a single band, while two bands were seen for the fusions 
containing antibody hinge. The bands are likely to represent different oligomeric forms of 
the proteins: monomers and dimers. The transfected cells were cloned out by limiting 
dilution and cells expressing high levels of protein were detected using western blot analysis 
(Fig.3.19C). The selected clones were expanded and transferred into the two-compartment 
bioreactor CELLine AD 1000. Cell culture supernatant was harvested weekly.
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Fig. 3.18 Cleavable CD59-CRIg: construction of expression plasmid. Schematic 
diagrams of cloning strategy to introduce a human rhinovirus 3C protease site. The 
sequences and positions of primers used for amplification of extracellular domains of mouse 
CD59a (A) and CRIg (B) are shown. The incorporated restriction sites are underlined. The 
PreScission recognition site is encoded by the antisense primer for CD59 (shown in grey 
box). The stop codon is shown in boldface. The amplification products were digested with 
appropriate enzymes and ligated into expression vector pDR2AEFla to create a cleavable 
CD59-CRIg-encoding construct (C). The protease recognition site is shown in grey.
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Fig. 3.19 Western blot analysis for protein expression and clone selection. Tissue culture 
supernatant from CHO cells expressing CRIg-CD59, CRIg-CD59, CRIg-IgG3 hinge-CD59, 
CD59-3-CRIg, CRIg-2a-CD59 and CD59-2a-CRIg, (A) and cleavable CD59-CRIg (B) was 
subjected to SDS-PAGE and the proteins were transferred onto a nitrocellulose membrane. 
The blot was probed with anti-CD59 mAb (A) or anti-CRIg mAb (B). Molecular mass 
markers are shown to the right o f each panel. One band of 40kDa was observed for CRig- 
CD59 (A), CD59-CRIg (A) and CD59-CRIg cleavable reagent (B). CRIg-hinge-CD59 and 
CD59-hinge-CRIg gave two forms with molecular weights corresponding to monomeric and 
dimeric forms. Example of screening o f cells expressing CRIg-CD59 and CD59-CRIg 
fusion proteins (C). Transfected cells were expanded and cloned out by limiting dilution in 
96-well plate format. Tissue culture supernatant from wells containing single colonies was 
subjected to western blot analysis. The three tested CRIg-CD59 producing cell clones gave 
positive result. One out of ten tested wells containing CD59-CRIg did not express this 
protein.
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3.3.3. Large-scale expression of CRIg-CD59 fusion proteins
To achieve high levels of protein expression, CHO cells producing CRIg-CD59 fusion 
proteins were harvested from T80 flasks and cultured in high-density culture systems. 
CELLine AD 1000 and HYPERF/tf.s£ flasks, introduced earlier in this chapter, were 
inoculated with cells expressing fusion proteins (see section 2.2.6). Protein expression was 
confirmed by western blot analysis (Fig.3.20). The culture supernatant was centrifuged at 
700xg for 5 min in order to separate dead cells from the culture medium. The tissue culture 
was stored at -20°C until used for purification
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Fig. 3.20 Western blot analysis of tissue culture supernatant form cells cultured in 
high-cell density cell systems. Tissue culture supernatant from CHO cells cultured in high- 
density cell culture systems expressing CRIg-CD59 constructs with or without the IgG3 or 
IgG2a hinge was subjected to SDS-PAGE and the proteins were transferred to a 
nitrocellulose membrane. The blot was probed with anti-CD59 mAb. Molecular mass 
markers are shown to the right o f each panel. One band of 40kDa was observed for CRIg- 
CD59, CD59-CRIg and CD59-CRIg cleavable. CRIg-2a-CD59 and CD59-2a-CRIg gave 
two forms with molecular weights corresponding to monomeric and dimeric forms.
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3.4. Discussion
Complement has been implicated in a number of diseases. It either causes or exacerbates 
pathology. Reagents which inhibit complement have shown benefit in many models of 
diseases. Many of these therapeutics block complement systemically, and thus suppress vital 
complement functions such as opsonisation. Complications including infection and immune 
complex disease may arise after long-term treatment. I have designed drugs which may 
retain the physiologically important complement functions (such as opsonisation) and 
suppress only pathological ones. Here I describe agents which neutralise late events of 
complement activation and MAC formation. MAC is intimately involved in host tissue 
destruction and pathology of diseases such as multiple sclerosis, myasthenia gravis, 
rheumatoid arthritis, age-related macular degeneration [211, 224, 328, 365, 387-389].
For protein therapeutics to be effective, they must be synthesised in biologically active 
forms with correct folding and post-translational modifications, including glycosylation. 
Such modifications are performed accurately in mammalian cells. For this reason 
mammalian cells have been extensively utilised as a host for protein production [390, 391]. 
CHO cells were chosen to generate the anti-complement therapeutics in this study. Despite 
the advantages, the major challenge in using CHO cells was that the yields of proteins 
produced were relatively low. To achieve high protein expression, two high-density culture 
systems were tested and contrasted.
To generate soluble long-lived complement blocking agent, the Fc portion of mouse IgG2a 
antibody was fused to C5 inhibitor, OmCI. Plasmid encoding OmCI-Fc was generated and 
CHO cells were successfully transfected. Protein expression was confirmed with western 
blot analysis. The protein production was scaled-up using high-density cell culture systems. 
Out of the two culture systems tested, the HYPERF/as& flask demonstrated better yields and 
was therefore used for production of OmCI-Fc. However, overall level of OmCI-Fc 
expression remained low. In future studies this could be improved by engineering the vector 
and host cell or by changing the format of transfection- from stable to transient. Large-scale 
transient gene expression has been proved to be more efficient in the production of many 
therapeutic proteins especially at the early development phase [392-394]. The choice of the 
vector and particularly the promoter driving the expression could be crucial in terms of 
protein production rate [395]. The fusion proteins including OmCI-Fc were expressed under
153
i
promoter for human EFla. To increase the levels of protein expression a promoter from 
Chinese hamster EFla could be used. The level of protein expression driven by sequences 
from the Chinese hamster EFla gene was found higher than expression controlled by a 
human EFla promoter [396].
The targeted anti-complement therapeutics were generated by joining DNA sequences 
encoding the extracellular domains of mouse CRIg and CD59a. It has previously been 
shown that orientation of the protein domains within chimeric fusion proteins may cause 
loss of function [330]. In order to generate an optimally-targeted reagent, constructs 
encoding fusion proteins in different orientations were engineered (Table 3.3). CRIg was 
linked either to the amino (N-) or carboxy (C-) terminus of CD59.
N-terminus Spacer C- terminus Fusion protein
CRIg - CD59a CRIg-CD59
CD59a - CRIg CD59-CRIg
CRIg Hinge IgG3 CD59a CRIg-3-CD59
CD59a Hinge IgG3 CRIg CD59-3-CRIg
CRIg Hinge IgG2a CD59a CRIg-2a-CD59
CD59a Hinge IgG2a CRIg CD59-2a-CRIg
CD59a Human Rhinovirus 3C CRIg CD59-CRIg
protease recognition site cleavable
Table 3.3 CD59 containing targeted reagents
In addition to restriction of function caused by blockade of one or other protein terminus, 
function may be sterically restricted due to the close proximity of the two molecules. To 
avoid steric hindrance, the hinge region of mouse IgG3 or IgG2a was introduced to distance 
CRIg from CD59. The Ig hinge consists of three parts: an upper hinge permitting Fab 
rotation and movement; a core hinge containing possible interchain disulfide bonds; and a 
lower hinge allowing Fc movement. In addition to distancing the two moieties, it was 
expected that the hinge would promote dimerisation and introduce avidity effects and thus 
better surface localisation and targeting as is the case with native antibody. Mouse IgG3 
hinge was initially chosen as it possessed a long upper hinge (14 amino acids), which 
theoretically would provide high flexibility. However, experiments described in Chapter 5 
illustrated that this hinge, which contains a single cysteine residue capable of forming one
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disulfide bridge, did not promote efficient dimerisation. Despite its long upper hinge (14aa) 
it has been found that mouse IgG3 hinge has a rigid structure, possibly due to a Pro-Pro-Gly 
sequence near the inter-chain disulfide bond [378]. This sequence can cause a turn of a 
polyproline helix that restricts the motion of the Fab arms. To increase flexibility and 
improve dimerisation, additional constructs comprising the hinge of mouse IgG2a were 
generated [397]. The “core” hinge of IgG2a contains three cysteines that could form three 
separate disulfide bridges [379]. I hypothesised that this would increase the chance of 
formation of stable dimers.
To compare function of the reagents, a control fusion protein was also engineered. Cleavable 
CD59-CRIg fusion protein was generated by incorporating the human rhinovirus 3C 
protease recognition site immediately after the CD59 sequence. This will allowed generation 
of soluble CD59 and soluble CRIg, which will be used as control proteins when testing 
function of CD59 and CRIg units within the fusion proteins (described in later chapters).
Plasmids encoding all CD59 fusion proteins (listed in Table 3.3) were purified and used to 
transfect CHO cells. Stable cell lines were generated by selection and protein expression was 
confirmed by Western blot. The blot was developed with either anti-CD59 or anti-CRIg 
monoclonal antibodies (generation of the anti-CRIg antibody is described in Chapter 4). 
CRIg-CD59, CD59-CRIg and cleavable CD59-CRIg gave rise to single bands with apparent 
molecular weight of 40kDa. The modified reagents containing antibody hinge migrated as 
two bands. The lower band with apparent molecular mass of 45kD represented a monomeric 
form. Incorporation of the hinge increased the molecular mass of CRIg-hinge-CD59 and 
CD59-hinge-CRIg monomers compared to the CRIg-CD59 and CD59-CRIg reagents. The 
higher band (83kDa) is likely to represent a dimeric form of the reagent, the result of 
disulfide bond formation between hinges from two molecules.
In summary, this chapter describes the cloning strategy, successful generation and large- 
scale expression of anti-terminal pathway therapeutics. Their purification and functional 
characterisation is detailed in the following chapter.
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Chapter 4. Production of monoclonal antibodies against OmCI, mouse CRIg and 
mouse CD59
4.1 Introduction
The aim of this project was to generate and characterise anti-complement therapeutics. This 
Chapter describes the production of monoclonal antibodies (mAbs) specific to the anti­
complement reagents generated in the study. These antibodies would provide essential tools 
for purification and characterisation of the therapeutics. In section 4.2 the production, 
characterisation and the purification of anti-OmCI monoclonal antibodies is discussed, 
whereas section 4.3 is focused on anti-CRIg and anti-CD59 mAbs.
Activation and clonal expansion of antigen-specific B cells is one of the body’s protective 
mechanisms against foreign antigen. Each B cell clone secretes its unique (monoclonal) 
antibody that recognizes a specific binding site (epitope) on the antigen surface. Their high 
specificity and high sensitivity makes monoclonal antibodies indispensable tools for 
research, diagnostics and therapy. The generation of monoclonal antibodies involves in vitro 
and in vivo procedures (Fig.4.1). The technology for monoclonal antibody production from 
hybridoma cells (hybridomas) was first described in 1975 [398]. The hybridomas are hybrid 
cells generated by the fusion of cancer cells, such as myeloma, with B-lymphocytes 
(splenocytes) from the spleen of animals challenged with the target antigen. The hybrid cells 
possess the key features of both parental cell types, immortality and specific antibody 
secretion respectively. Cloning of hybridoma cells by limiting dilution ensures isolation of 
clones producing antibodies identical in their epitope-binding region.
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Fig. 4.1 Diagram showing the typical steps for monoclonal antibody production. These 
include antigen challenge of animals, splenocyte preparation and fusion with immortal 
myeloma cells to generate antibody producing hybridoma cells. Three round of clonal 
selection are usually necessary to generate clones producing specific monoclonal antibodies.
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4.2 Anti-OmCI monoclonal antibodies
4.2.1 Generation of hybridomas secreting anti-OmCI antibodies
Antibodies specific to OmCI were of the utmost importance for purifying and characterising 
the OmCI-Fc reagent. Two types of recombinant OmCI were used in the experiments: 
pOmCI (produced in yeast Pichia methanolica) [175] and the fusion protein, OmCI-Fc, 
developed in this project.
Female BALB/c mice were immunized with pOmCI (Method 2.5). Sera were analysed for 
OmCI specific antibodies on a pOmCI coated ELISA plate (Fig.4.2). The mouse with the 
highest anti-OmCI Ab titre was sacrificed and spleen harvested (Method 2.5.4). Splenocytes 
were fused with SP2/0 myeloma cells (Method 2.5.7). Fused cells were distributed into 24- 
well tissue culture plates containing peritoneal macrophages as feeder cells harvested from 
the peritoneum of a normal BALB/c mouse. The hybridomas were grown for ten days in 
HAT medium (medium supplemented with hypoxanthine, aminopterin and thymidine) and 
tissue culture supernatant was tested for anti-OmCI antibody production by ELIS As.
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Fig.4.2 Pre-fusion ELISA screen of sera from mice immunised with pOmCI. Serum 
from three test mice or from a naive mouse was tested by ELISA for immunoreactivity with 
OmCI. The spleen from the mouse with highest antibody titer against OmCI (open diamond) 
was used for fusion.
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4.2.2. ELISA for screening hybridoma cells secreting anti-OmCI mAbs
Supernatants from the hybridoma cells were screened for specific antibody production by 
ELISA. Three different ELISAs were developed (Fig.4.3).
A direct ELISA was initially used for screening (Fig.4.3A). Hybridoma supernatant was 
incubated on a plate coated with pOmCI. Bound antibody was detected with HRP- 
conjugated anti-mouse Ig. Two OmCI-specific clones were selected and two monoclonal 
antibodies were developed. The antibody subclass was determined using Iso Strip test 
(Roche) using the method recommended by the manufacturer. The analysis revealed that the 
mAbs were of IgGl (MBI-Oml) and IgM (MBI-Om2) isotype. The characterisation of the 
antibody, discussed in section 4.2.4, showed that the mAb obtained from this screening 
selectively bound denatured antigen (directly coated on the plate or transferred to 
membranes by western blot) but not in conditions which preserved the native conformation 
of OmCI (captured on ELISA plate or flowed across biacore chip). This antibody selectivity 
can be attributed to the set up of the screening assay.
To generate mAb which recognised the native conformation of OmCI, the hybridoma cells 
were screened on a capture ELISA (“positive” screening) (Fig.4.3BI). To maintain the 
native conformation of OmCI, the antigen was captured on the plate coated with affinity- 
purified rabbit anti-OmCI polyclonal antibody. Tissue culture supernatant from hybridoma 
cells was added to the wells. The bound antibody was detected with HRPO-conjugated anti­
mouse Ig, similarly to the previous ELISA. To confirm the specificity of the antibodies a 
“negative” screening was also performed (Fig.4.3BII). This was identical to the positive 
screening but instead of antigen (pOmCI) the wells were incubated with buffer only. The 
clones with positive response to pOmCI and negative to the buffer were selected. Four 
hybridoma clones passed both levels of selection and four anti-OmCI monoclonal antibodies 
were obtained. The isotype of the antibodies were determined as described before. One of 
the specific monoclonal antibodies was identified as IgG2b and the remaining three 
belonged to IgGl isotype. To assess whether IgG2b (MBI-Om3) was suitable for purifying 
OmCI-Fc reagent, this antibody was further characterised.
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Fig. 4.3 ELISA based strategies for screening hybridoma supernatant for OmCI 
reactivity. OmCI (3|ig/ml) was coated directly (A) or captured with rabbit anti-OmCI 
polyclonal antibody (pAb) (B) on an ELISA plate. Antibody-containing tissue culture 
supernatant (lOOpl) was added to the wells and antibody binding was detected with HRPO 
conjugated anti-mouse Ig. Washing steps are indicated with a dotted line. The antigen was 
denatured when coated directly on the plate and one monoclonal antibodies against 
denatured OmCI was developed (A). To ensure identification of hybridomas secreting 
antibodies recognizing native antigen, OmCI was captured with specific pAb (BI). The 
specificity of the screening approach was increased by introducing second “negative” 
screening steps (BII).
All six hybridoma clones which gave a positive signal on ELISA were cloned three times by 
limiting dilution (Detailed method in Chapter 2, section 2.2.4) on peritoneal macrophages 
from a normal BALB/c mouse as feeder cells after which they were clonal.
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4.2.3. Large-scale production of Anti-OmCI antibodies
As a result of cell fusion and cloning, six clones secreting monoclonal antibodies 
recognising OmCI were obtained. Three clones secreting anti-OmCI mAbs: MBI-Oml 
(IgGl), MBI-Om2 (IgM), MBI-Om3 (IgG2b) were expanded and high expression level of 
the antibody was achieved using Two-compartment bioreactor CELLine technology (Integra 
Biosciences CL1000 flasks). This cell culture system is similar to CELLine AD 1000 
(section 2.5.8) but does not contain a polyethylene terephtalate matrix. To avoid bovine Ig 
contamination from the FCS in the medium when purifying the antibody, ultra low bovine 
immunoglobulin FCS was used. The CELLine CL1000 high expression system requires 
only small amount of serum containing media therefore the usage of ultra low bovine 
immunoglobulin FCS was economical. Cell culture supernatant was collected weekly and 
the monoclonal antibodies were purified.
4.2.4. Purification of Anti-OmCI antibodies
4.2.4.I. Purification of anti-OmCI mAbs of IgG isotype (MBI-Oml and MBI-Om3)
Protein A and protein G affinity chromatography are the most commonly used approaches 
for IgG purification. Protein A and protein G are both bacterial proteins (from 
Staphylococcus aureus and Group G Streptoccocus, respectively), which bind to the Fc 
portion of IgG. A Protein G column was used to purify the antibodies of IgG isotype as the 
Fc of mouse IgGl and IgG2b have higher affinity for protein G than to protein A. The 
method was described in Chapter 2, section 2.3.3. The supernatant containing anti-OmCI 
IgG was passed over the column, the column was washed and bound protein was eluted 
using elution buffer. The absorbance at 280nm was used to identify fractions that contained 
protein. These fractions were combined and the antibody was dialysed against PBS. The 
purity of the protein was assessed by SDS-PAGE. The proteins were visualised using 
Coomassie blue staining. A typical antibody pattern was observed (Fig.4.4). MBI-Oml and 
MBI-Om3 migrated as one prominent band under non-reducing conditions. As can been 
seen from Fig4.4, two distinct bands corresponding to the heavy and light chains were 
observed under reducing conditions. As may be noted from the figure, the heavy chain of
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MBI-0m3 appeared as a double band under reducing conditions. This may suggest that 
MBI-Om3 was not clonal.
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Fig.4.4 SDS PAGE analysis of purified monoclonal antibodies against OmCI. mAbs of 
IgG class were purified by chromatography on protein G column and subjected to SDS- 
PAGE analysis under non-reducing and reducing conditions and proteins were stained with 
Coomassie Blue. MBI-Oml and MBI-Om3 appeared as one prominent band under non­
reducing condition. The antibodies migrated as two bands under reducing condition, 
corresponding to the light (L) and heavy (H) chains of antibody. The difference in molecular 
weight between the antibodies may be due to the isotype difference or difference in 
glycosylation.
4.2.4.2. Purification of MBI-Om2 (IgM)
Two chromatography-based methods were tested in order to purify anti-OmCI monoclonal 
antibody of IgM isotype.
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The first approach used to purify MBI-Om2 was affinity chromatography. Supernatant 
containing the monoclonal antibody was passed over the OmCI column, generated 
previously (Method 2.3.6). The column was washed with Tris buffer and bound antibody 
was eluted with a buffer with low pH. No protein was obtained from the elution. The 
presence of anti-OmCI IgM in the run through was tested by ELISA and compared to the 
initial supernatant (Fig.4.5). Further optimisation of the assay (using higher dilutions of the 
test supernatant) was required and for this reason the degree of supernatant depletion could 
not be assessed accurately. The negative result obtained from the affinity purification can be 
accounted for by a weak interaction between OmCI and MBI-Om2. However it is more 
likely that MBI-Om2 cannot recognise the native OmCI when coupled to Sepharose matrix 
on the column.
—0—medium 
control
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Dilution of tissue culture supernatant
Fig.4.5 ELISA of the purification of anti-OmCI IgM mAb by OmCI column. To assess 
the degree of supernatant depletion brought about by the OmCI column and hence the 
expected yield, an ELISA was carried out as follows. The plate was coated with OmCI, 
blocked and incubated with a sample of supernatant from before and after the column (1:2 
serial dilutions). The plate was probed with anti-mouse IgM HRPO. Anti-OmCI IgM 
antibody was detected in both the pre column supernatant and the run through. It A higher 
dilution of the tissue culture supernatant was required for more accurate analysis.
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The second strategy performed to purify MBI-Om2 was based on thiophilic chromatography 
on a prepacked thiophilic adsorption medium, 2-mercaptopyridine coupled to Sepharose™ 
High Performance (HiTrap™ IgM Purification HP; GE Healthcare). This approach relies 
upon the affinity of a sulphur-containing ligand, immobilized on a matrix, for 
immunoglobulins in the presence of high concentrations of lyotropic salts. Elution of IgM is 
mediated by removal of these salts [399]. The tissue culture supernatant was adjusted to a 
high salt (0.8M ammonium sulphate) concentration before applying on the column. The 
supernatant was passed over the column which had been preequilibrated with binding buffer 
pH 7.5. Unbound protein was washed away with binding buffer and bound IgM was eluted 
by decreasing the ionic strength of the buffer. Fractions containing protein were identified 
by their absorbance at 280nm, combined and dialysed against PBS. SDS-PAGE analysis 
revealed that the eluted protein contained IgM antibody (Fig.4.6). Multiple bands found on 
the gel indicated low purity of the preparation (Fig.4.6). Additional purification steps such as 
gel filtration were required to achieve pure IgM preparation and for this reason the antibody 
was not characterised further.
kDa ( —p_ 5(H+L) kDa
. 7 5 - * 175" I
83- m
Xi1cnoo
6 2 -  * 6 2 - 1
4^ 1 1 47 -JS
3 2 - 32-'>,
2 8 -
I
i00(N
N on-reducing Reducing
Fig. 4.6 SDS PAGE analysis of the purification of anti-OmCI IgM mAb. The product 
from HiTrap IgM Purification HP was resolved on a 7.5% gel under non-reducing and 
reducing conditions and Coomassie stained. The major, high molecular band indicated as 
5(H+L) is likely to represent IgM pentamer. Two main bands with apparent molecular 
weight of 20 kDa and 80kDa were seen under non-reducing conditions. These corresponds 
to IgM heavy (H) and light (L) chains. Multiple bands were also found indicating that the 
product was not pure.
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4.2.5. Characterisation of anti-OmCI mAbs
In order to develop a tool to purify and characterise the OmCI-Fc protein, the selected anti- 
OmCI monoclonal antibodies were analysed. An important feature for good antibodies is 
their ability to recognise the antigen in native conformation. The specificity of MBI-Oml 
and MBI-Om3 was evaluated by Western blot analysis and ELISA. In addition to that a SPR 
analysis was performed to characterise MBI-Oml. To be able to test the specificity of the 
antibodies, they were conjugated with Horseradish peroxidase (HRPO) using EZ-link Plus 
Activated Peroxidase (Pierce) as described in method section 2.6.1.
4.2.5.1. Characterisation of MBI-Oml (IgGl)
4.2.5.1.1. Western blot analysis
pOmCI protein and tissue culture supernatant containing OmCI-Fc were subjected to SDS- 
PAGE and transferred to nitrocellulose membrane. The membrane was probed with MBI- 
Oml-HRPO (Fig.4.7). Single bands with molecular weight of 83kDa and 17kDa were found 
for OmCI-Fc and pOmCI respectively. This suggested that the antibody raised against 
pOmCI was reactive with both OmCI and OmCI-Fc fusion protein.
4.2.5.I.2. Capture ELISA
As shown by Western blot and direct ELISA, MBI-Oml binds antigen that has been directly 
immobilised on the surface (plastic plate or on nitrocellulose membrane following SDS 
PAGE). To check whether MBI-Oml was able to bind the antigen in its native 
conformation, a capture ELISA was performed. Rather than the antigen being directly 
attached to the plate, it was captured by polyclonal anti-OmCI antibody or by its ligand C5. 
C5 and the polyclonal antibody were able to bind the antigen and thus maintain its native 
shape on the plate. However, MBI-Oml failed to bind OmCI captured on the plate in this 
way. This result suggested that the monoclonal antibody was specific to denatured but not to 
native OmCI. However, as this was the first antibody generated, there was no positive
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control that could be used to confirm that OmCI was indeed captured on the plate. This 
encouraged further analysis o f the binding.
Fig.4.7 Western blot analysis of MBI-Oml-HRPO binding to OmCI and OmCI-Fc.
pOmCI (pure protein) or OmCI-Fc (supernatant) was resolved by SDS-PAGE and 
transferred to a nitrocellulose membrane. The membrane was probed with MBI-Oml- 
HRPO.
4.2.5.I.3. Surface Plasmon Resonance (SPR)
To confirm that the result obtained from the capture ELISA was real and the antibody 
recognised only the denatured antigen, the MBI-Oml/OmCI interaction was further 
analysed using SPR. MBI-Oml (1000RU) was covalently immobilized through free amines 
to a carboxy-methylated sensor chip. pOmCI (lpM  and lOpM) diluted in a biacore running 
buffered saline was injected across the mAb surface. Having the antigen in solution 
minimized the risk of masked or altered epitopes due to immobilization of the antigen to a 
surface. Fig.4.8A showed that pOmCI bound MBI-Oml in a dose dependent manner. 
Nevertheless crude fitting of the curves to a 1:1 interaction model indicated 100-1000-fold 
weaker than normal antibody binding. This might be due to a non-specific binding to the 
chip matrix or that antibody was denatured during purification. To orientate the mAb and to 
analyse the interaction from the ‘opposite direction’, 500RU of protein A was immobilised
on a chip and MBI-Oml was captured. Either pOmCI or running buffer was injected 
(Fig.4.8 B).
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Fig.4.8 Biacore analysis of MBI-Oml binding to pOmCI. pOmCI was flowed over a 
chip immobilized with the mAb. The binding response was fitted to 1:1 Lqngmuir binding 
model to obtain the dissociation constant (Kd=0.9|jM) (A). To orientate anti-OmCI mAb, it 
was captured with protein A onto the chip surface. OmCI (grey) or buffer control (black) 
was flowed across the surface. No difference between the test sample and the negative 
control was observed in terms of binding (B). OmCI was captured on a chip with C5 and the 
mAb loaded over the chip. No binding was detected (C). The result from this experiment 
demonstrate that anti-OmCI mAb did not recognise native OmCI.
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No detectable antigen-antibody binding was observed since the binding profile for the 
antigen and the buffer control were exactly the same. An identical result was achieved when 
the antibody was flowed across pOmCI captured by C5 (Fig.4.8 C). Human C5 (4000RU) 
were immobilized to the chip surface and used to capture pOmCI. MBI-Oml was then 
flowed across the antigen surface. No binding was detected.
These SPR assays replicated the findings from the capture ELISA experiments. In light of 
the above, it is therefore clear that MBI-Oml specifically recognises denatured antigen 
(when coated on a plate or transferred onto a membrane) but not the native form (captured 
on the plate or flowed across biacore chip). For this reason MBI-Oml was of limited use. 
This result stimulated the generation o f the subsequent anti-OmCI mAbs.
4.2.5.2. Characterisation of MBI-Om3 (IgG2b)
The double screening approach gave rise to four clones producing OmCI-reactive antibody. 
The antibody that gave the best signal on the capture ELISA (MBI-Om3), was purified and 
characterised. The Western blot analysis shown in Fig.4.9 demonstrated that MBI-Om3 was 
able to react with pOmCI and OmCI-Fc.
Fig.4.9 Western blot analysis of MBI-Om3-HRPO binding to OmCI and OmCI-Fc.
pOmCI (pure protein) or OmCI-Fc (supernatant) was resolved by SDS-PAGE on 15%gel 
(pOmCI) or 7.5% gel (OmCI-Fc) and transferred to a nitrocellulose membrane. The 
membrane was probed with MBI-Om3-HRPO.
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One of the reasons to develop anti-OmCI mAb was to enable purification of the OmCI-Fc 
fusion protein. To do so the antibody needed to be coupled to the matrix of a 
chromatography column. The capacity of MBI-Om3 immobilised on a solid phase to bind 
OmCI-Fc was verified in ELISA format. MBI-Om3 was used to capture OmCI-Fc (present 
in tissue culture supernatant) on to the plate. Using an antibody to bind OmCI-Fc on a plate 
will retain the antigen in its native form. The binding was then detected with rabbit anti- 
OmCI polyclonal antibody. The analysis revealed that MBI-Om3 antibody was able to 
recognise OmCI-Fc fusion protein in a dose dependent manner (Fig.4.10). Most importantly, 
the results indicated that this monoclonal antibody, coupled to chromatography column had 
potential to bind OmCI-Fc protein and to purify it from tissue culture supernatant. This 
antibody was used to generate an affinity column that was able to purify OmCI-Fc as 
described in Chapter 5. For this reason the last three anti-OmCI mAbs generated during the 
double screening were not characterised at this time.
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Fig.4.10 ELISA to assess binding of MBI-Om3 to OmCI-Fc. The plate was pre-coated 
with various concentrations of MBI-Om3 and lOOpl of tissue culture supernatant containing 
OmCI-Fc fusion protein were added. The plate was then incubated with rabbit anti-OmCI 
polyclonal Ab following by incubation with anti-rabbit Ig-HRPO. The test antibody coated 
on the plate bound OmCI-Fc in a dose dependent manner. The medium background control 
is presented with a dotted line.
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4.3. Rat anti-mouse CRIg and rat anti-mouse CD59a monoclonal antibodies
To purify and characterise the CRIg-CD59 reagents, availability of good mAbs was an 
indispensable requirement. Anti-CRIg and -CD59 mAbs were generated by immunising rats 
with recombinant CRIg-CD59 fusion protein (generation of CRIg-CD59 was described in 
Chapter 3). Supernatants from the hybridoma cells were screened on a plate coated with the 
antigen used for immunisation. A second ELISA, with CD59-Fc coated on the plate, was 
also performed in order to discriminate the cells producing anti-CRIg Ab from those 
secreting antibody specific for CD59. The ability of the antibodies to bind native CRIg and 
CD59 (expressed on cells) was validated.
4.3.1. Generation of rat anti-mouse CRIg and rat anti-mouse CD59a monoclonal 
antibodies
Female Lewis rats (10-12 weeks old) received 50pg CRIg-CD59 fusion protein initially 
emulsified in Freund’s complete adjuvant, followed 2 weeks later by similar booster 
injection emulsified in Freund’s incomplete adjuvant. Two more booster injections were 
administered at 2-week intervals. After the third immunisation, the rats were test bled and 
the serum tested for reactivity with CRIg-CD59. The animal showing the strongest reactivity 
with the antigen was selected for fusion (Fig.4.11). This animal was given a final 
immunisation by the ip route with 50pg of CRIg-CD59 fusion protein diluted in PBS and 2 
days later the spleen was harvested. The splenocytes were isolated and fused with mouse 
myeloma SP2/0 cells using polyethylene glycol as fusogen as described in Chapter 2. The 
cell mixture was plated in 24-well plates containing a feeder layer of mouse peritoneal 
macrophages. Hybridomas were selected by growing in HAT medium. 10-12 days following 
the fusion, the cell supernatant was screened. Cells were harvested from the selected wells 
and plated out at limiting dilution into wells containing feeder cells. Screening and cloning 
were repeated to obtain monoclonal populations.
170
3.5 test rat 1
test rat 2
8  2-5
^  9< 2
A - test rat 3
naive rat
0.5
100000100001000100
Dilution of rat serum
Fig. 4.11 ELISA to test specific antibody titre of rats immunised with CRIg-CD59 
fusion protein. Rats immunised with CRIg-CD59 or non-immunised (open diamond) were 
bled and serum samples were incubated in wells coated with CRIg-CD59 antigen. The 
binding was detected with anti-rat IgG-HRPO. The rat with the highest antibody titer (open 
triangle) was boosted and the spleen harvested.
4.3.2. Screening ELISA
The hybridomas were screened for anti-CRIg and anti-CD59 antibodies by ELISA. Because 
the rat was immunised with CRIg-CD59 fusion protein, it was possible that the antibodies 
produced by the hybridomas could be reactive to either CRIg or CD59. To identify the 
specificity of the antibodies, double screening was performed. ELISA plates were coated 
with purified CRIg-CD59 or CD59-Fc fusion protein (generated previously in-house). 
Supernatant from growing hybridoma cells was added and the binding of the antibody to the 
coated antigen was detected by HRPO labelled anti-rat Ig. The specificity of the antibodies 
was determined by comparing the binding signal of each well to CRIg-CD59 and CD59-Fc. 
The antibodies that reacted with both, CRIg-CD59 and CD59-Fc, proteins were initially 
assumed to be CD59-specific and these that bound CRIg-CD59 only as CRIg-specific. 
Hybridomas producing anti-CD59 and anti-CRIg antibodies were selected and cloned at 
least three times by limiting dilution. Stable clones were expanded. Three monoclonal
antibodies were generated: one against CRIg and the remaining two against CD59 (named 
mCD59a-7 and mCD59a-8). ELISA-based isotype analysis (Method 2.5.9.2) was performed 
using HRPO-labelled secondary antibodies specific for rat immunoglobulins: IgM, IgGl, 
IgG2a, IgG2b and IgG2c. The analysis revealed that the three mAbs were of IgGl isotype.
The cells producing mCD59a-7 and the anti-CRIg antibodies were expanded for large-scale 
antibody production (as described for anti-OmCI mAbs). The two mAbs were purified and 
further characterised.
4.3.3. Purification of rat anti-mouse CRIg and rat anti-mouse CD59a monoclonal 
antibodies
The anti-CRIg mAb and mCD59a-7 were of rat IgGl subclass and were therefore purified 
using protein G affinity chromatography (as described for anti-OmCI mAb of mouse IgG 
isotype). The purified mAbs were subjected to SDS-PAGE analysis. As shown in Fig.4.12, 
the antibodies migrated as a single band under non-reducing conditions. Two bands, 
representing the heavy and the light chains, were found on the reducing. The result of the 
purity analysis demonstrated that purification using HiTrap protein G column yielded very 
pure preparations.
4.3.4. Characterisation of rat anti-mouse CRIg and rat anti-mouse CD59a monoclonal 
antibodies
The reason for generating anti-CRIg and anti-CD59 mAbs was to develop tools to 
characterise the CD59-CRIg reagents. Therefore an extensive analysis of the anti-CRIg and 
mCD59a-7 antibodies was needed. The ability of mAbs to bind recombinant and native 
antigens was verified.
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Fig.4.12 SDS-PAGE analysis of purified rat monoclonal antibodies specific to mouse 
CRIg or CD59a. Purified anti-CRIg (lane 1) and anti-CD59 (lane 2) Abs were 
electrophoresed under non-reducing and reducing conditions. The proteins were stained with 
Coomassie Blue. One band as observed under non-reducing condition. This consisted of two 
heavy and two light chains (H2L2). Two bands corresponding to the heavy (H) and light (L) 
chains of the antibodies were found under reducing conditions.
4.3.4.I. Characterisation of anti-CD59 mAb
The specificity of rat anti-mouse CD59 (mCD59a-7) mAb was confirmed by FACS analysis. 
CD59a deficient and sufficient mouse erythrocytes were isolated from CD59-/- or WT mice. 
The cells were washed and resuspended in FACS buffer (1% BSA, PBS). After incubation 
with serial dilutions of mCD59a-7, the cells were pelleted. The unbound antibody was 
washed out and mCD59a-7 bound to the cells was detected with phycoerythrin-conjugated 
donkey anti-rat Ig, cells were analysed by flow cytometry. The result clearly demonstrated 
that mCD59a-7 was able to bind the cells expressing CD59 but not the erythrocytes derived 
from CD59 deficient mouse (Fig.4.13).
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Fig.4.13 Flow cytometry histogram for binding of rat anti-mouse CD59a mAb 
(mCD59a-7) to mouse CD59 sufficient and deficient erythrocytes. Erythrocytes were 
isolated from wild type and CD59 deficient mice and incubated with 6pg/ml of mCD59a-7 
monoclonal antibody, followed by incubation with phycoerythrin-conjugated donkey anti-rat 
Ig. The binding was analysed by flow cytometry. mCD59a-7 bound CD59 expressing cells 
(solid line) and no detectable reactivity was observed with CD59-/- erythrocytes (filled 
area). Antibody isotype control is the dotted line.
4.3.4.2. Characterisation of anti-CRIg mAb
The specificity of the anti-CRIg mAb was analysed by western blot and 
immunohistochemistry. To check whether the antibody recognised CRIg but not a neo­
epitope formed after the fusion with CD59, CRIg containing fusion proteins (different to the 
one used for the antigen challenge, CRIg-CD59) were subjected to SDS-PAGE and 
transferred to nitrocellulose membrane (Fig.4.14). The membrane was probed with the 
purified anti-mouse CRIg mAb. The fusion proteins migrated as two forms -monomers and 
dimers. The antibody was able to detect CRIg in both forms of all fusion proteins. 
Furthermore it recognised a fusion protein CRIg-2a-factor H, which did not contain CD59. 
These data suggested that the antibody-binding site is exclusively within the CRIg moiety of 
the hybrid molecules but not in CD59 or in the join between them.
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Fig.4.14 Western blot analysis of monoclonal antibody against mouse CRIg. CRIg-2a- 
CD59, CD59-2a-CRIg and CRIg-2a-fH were subjected to SDS PAGE under non-reducing 
conditions and transferred to a membrane by Western blot. The blot was incubated with the 
test anti-CRIg mAb. Molecular weight markers are shown on the left. The test antibody 
recognised the monomeric and dimeric forms of all three fusion proteins. It reacted with N- 
terminal and C-terminal CRIg (within CRIg-2a-CD59 and CD59-2a-CRIg respectively). The 
monoclonal antibody also bound in CRIg-2a-fH, a negative control fusion protein, which did 
not contain CD59.
To investigate whether the anti-CRIg mAb recognised a native antigen, 
immunohistochemistical analysis was performed. CRIg is a complement receptor expressed 
on resident macrophages and Kupffer cells in the liver [161]. Therefore a liver from a BalbC 
mouse was harvested and frozen sections were prepared. The tissue was stained for CRIg 
using the anti-CRIg mAb. An isotype control was also included. The microglia in brain 
tissue do not express CRIg therefore frozen section from mouse spinal cord was used as a 
negative control. The anti-CRIg antibody specifically bound liver but not spinal cord tissue 
(Fig.4.15). The analysis demonstrated that anti-CRIg mAb specifically binds denatured 
(shown by western blot) as well as native CRIg (shown by immonohistochemistry).
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Fig.4.15 CRIg staining. Immunostaining was performed on sections obtained from mouse 
liver (positive control tissue) and spinal cord (negative control tissue) using monoclonal 
anti-CRIg antibody (green channel) at a concentration of 3.5|ig/ml. DAPI staining (blue 
channel) was used to detect the nuclei. The anti-CRIg antibody specifically recognised CRIg 
expressed in liver. No staining was found in the control tissue or when isotype control 
antibody was used.
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4.4. Discussion
Specific antibodies are key tools for the purification and characterisation of newly generated 
recombinant proteins. The main focus of the work in this chapter was the development of 
antibodies specific for complement regulators; this involved generation of hybridomas 
secreting antibody specific for pOmCI, OmCI-Fc, CRIg and CD59, followed by their 
purification and characterisation. These antibodies were important not only for efficient 
purification of the recombinant complement inhibitors but also for in vitro, ex vivo and in 
vivo characterisation of these therapeutic agents.
Conventional hybridoma technology was used to generate the monoclonal antibodies. The 
first steps were antigen preparation and antigen challenge of animals. Mice and rats were 
used for generation of hybridomas secreting specific antibody. The choice of species 
depended on the origin of the antigen used for immunisation. The immune system usually 
does not respond to self-antigens. Rats are not used for the production of antibodies to rat 
proteins and mice for antibodies to mouse proteins. For this reason mice were used for 
production of antibodies to soft tick glycoprotein OmCI and rats for the generation of 
antibodies to mouse CRIg and mouse CD59.
Six hybridoma clones producing mouse anti-OmCI mAbs were selected and the isotype of 
the antibodies was determined. The specificity of the antibodies was found to be dependent 
on the design of the screening approach. Three ELISAs were developed for detection and 
selection of OmCI reactive antibodies. Two antibodies, of IgGl and IgM isotypes, which 
recognised denatured OmCI, were generated when the hybridoma clones were screened on a 
pOmCI-coated plate. Many studies have demonstrated a tendency of immobilised proteins to 
undergo conformational changes and denaturation as a consequence of their binding to the 
plastic surface [400-402]. The pOmCI coated directly on the plate was presumably partially 
or completely denatured and therefore the selected antibodies from this screening turned out 
to be to be specific for the denatured protein. The denaturation problem was overcome by 
capturing pOmCI using specific rabbit polyclonal antibody on the plate and thus maintaining 
its native conformation. A double screening approach was introduced to select clones 
producing antibodies that are highly specific to OmCI. The specificity of the clones was 
verified on a “negative” control ELISA incubated with buffer instead of pOmCI (Fig4.3). 
The double screening approach proved to be particularly effective for identifying positive
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hybridoma clones which were reactive against native OmCI. Hybridomas from the four 
original fusion wells were taken successfully through the cloning process and four highly 
specific anti-OmCI mAbs were developed and one of IgG2b isotype was purified and 
characterised.
The isotype of the antibodies was important for the choice of purification strategy. The 
antibodies of the subclasses IgGl (MBI-Oml) and IgG2b (MBI-Om3) were readily purified 
by protein G affinity chromatography and the purification of IgM (MBI-Om2) required 
thiophilic chromatography followed by further polishing steps. Because an additional 
purification step such as gel filtration was required to obtain pure MBI-Om2, only the two 
other mAbs of IgG isotype were further characterised. Methods such as ELISA, western blot 
and biacore analysis were used to characterise the antibodies. The result from the detailed 
analysis revealed that MBI-Oml recognised denatured OmCI, but not native protein. MBI- 
Om3 was specific to native OmCI. Furthermore, it was able to capture OmCI-Fc on the 
ELISA plate indicating that it might also work well for affinity chromatography. MBI-Om3 
proved to be the key tool in the purification of OmCI-Fc fusion protein and its in vivo 
characterisation.
A similar approach was used to generate anti-mouse CRIg and anti-mouse CD59a mAbs. 
When rats were immunised with CRIg-CD59 recombinant fusion protein, two kinds of 
antibodies were produced in the animals. One set of antibodies was elicited by CRIg in the 
fusion protein, and the other was elicited by CD59. Both antibody types would be useful 
tools in this project. In order to identify and discriminate such antibodies, two different 
fusion proteins, CRIg-CD59 and CD59-Fc, were used as coating antigens in the screening 
ELISA. Two clones producing antibodies reactive with both CRIg-CD59 and CD59-Fc were 
obtained. These were considered as CD59 specific antibodies (mCD59a-7 and mCD59a-8). 
mCD59a-7 was purified and its specificity for native protein was confirmed by flow 
cytometry using CD59-deficient and sufficient mouse erythrocytes.
Among the hybridomas screened on the two fusion proteins, one clone reacted with CRIg- 
CD59, but not with CD59-Fc antigen. The antibody secreted from the cells was considered 
as CRIg specific. It was purified and its capacity to interact with recombinant antigen was 
analysed by Western blot. The mAb was able to detect CRIg in a number of fusion proteins, 
including protein that did not contain CD59 moiety (CRIg-factor H). This suggested that the
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epitope for this mAb was located within CRIg but not in CD59. Furthermore the anti-CRIg 
mAb recognised native CRIg as shown from the immunohistochemical analysis of mouse 
liver.
In conclusion, two monoclonal antibodies specific for mouse CD59a and one against mouse 
CRIg were generated and characterised. These antibodies would be used to characterise the 
anti-complement therapeutics generated in this project.
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Chapter 5. Purification and biochemical characterisation of anti-complement
therapeutics
The generation and expression of the anti-complement reagents was described in Chapter 3. 
The focus is now moved to the purification and biochemical characterisation of OmCI-Fc 
and CRIg-CD59 fusion proteins and their ligands (complement proteins C3 and C5). To 
assess CRIg-CD59 targeted inhibitory activity, soluble CRIg and soluble CD59 are required. 
This Chapter explains the generation of control proteins containing CRIg and CD59 but not 
fused to each other.
5.1. OmCI-Fc
5.1.1. Purification of OmCI-Fc
Different chromatographic methods could be employed for purifying Fc fusion proteins and 
the choice of the approach depends on the type of the protein. As a potential therapeutic it is 
necessary that OmCI-Fc is of high purity, that it has functional activity and is in sufficient 
amount for in vitro and in vivo analysis. A thorough study was carried out to determine the 
optimal purification approach and two chromatography strategies were investigated and 
compared.
5.1.1.1. Purifying via the Fc portion
Protein A and protein G chromatography (described in Chapter 4) is based on the affinity 
interaction of the Fc domain with these bacterial proteins and can be employed for 
purification of Fc fusion proteins. Fc of mouse IgG2a (used in OmCI-Fc) has good affinity 
for protein G and A. However the bovine antibodies present in the FCS used to supplement 
cell culture media also have a good affinity for protein G and will compete with OmCI-Fc 
for binding to the column. To avoid contamination with bovine immunoglobulins, CHO 
cells expressing OmCI-Fc were cultured in medium supplemented with low Ig FCS. The
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tissue culture supernatant was passed over the protein 5ml G or protein A column, the 
column was washed and bound protein was eluted at low pH (pH2.5). No protein was found 
in any of the fractions when absorbance at 280nm was measured. Elution with high pH 
buffer (PBS containing diethylamine, pH 11) was then tested and again no protein was 
detected in any of the eluted fractions.
To confirm that OmCI-Fc did not bind to protein G and protein A and to determine whether 
it bound but could not be dissociated during the elution step, an ELISA was performed. The 
analysis showed a very little depletion of the supernatant after it had passed through protein 
A column (Fig.5.1A). A similar result was obtained with protein G (data not shown). As this 
method gave no purified OmCI-Fc protein, another chromatography approach was 
investigated. Anti-OmCI antibody columns were generated and used for OmCI-Fc 
purification.
5.1.1.2. Purifying via the OmCI domain
Specific polyclonal and monoclonal anti-OmCI antibodies were tested for their suitability to 
purify OmCI-Fc.
5.1.1.2.1. Polyclonal anti-OmCI affinity chromatography
Immunoglobulins from rabbit anti-OmCI polyclonal serum were purified on a protein G 
column (Method 2.3.3) and 30 mg was used to prepare an anti-OmCI affinity column (5ml 
HiTrap). Supernatant containing OmCI-Fc was passed over the column, the column was 
washed with TBS and bound protein was eluted with glycine pH 2.5. When no protein was 
found in the eluate, a buffer with a high pH (PBS containing 20mM diethylamine, pH ll) 
was run over the column. No protein was detected in any of the eluted fractions. ELISA- 
based analysis was carried out to assess the degree of OmCI-Fc depletion. Similarly to the 
result obtained with protein A and G chromatography, a very little depletion of the run 
through was seen when compared to the tissue culture supernatant prior the purification 
(Fig.5.1B).
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Fig.5.1 ELISA to determine efficiency of purification of OmCI-Fc. To assess the degree 
of supernatant depletion achieved by protein A (A), polyclonal anti-OmCI (B) and 
monoclonal anti-OmCI (C) affinity chromatography, an ELISA was carried out as follows. 
The plate was coated with rabbit anti-OmCI polyclonal antibody, blocked and incubated 
with a sample of supernatant from before and after the column (1:2 serial dilutions). The 
plate was probed with anti-mouse IgG HRPO. OmCI-Fc was detected in both the pre 
column supernatant and the run through. Very little difference was seen between the two 
supernatants suggesting that OmCI-Fc failed to bind the protein A or the polyclonal anti- 
OmCI column (A and B). Only a small amount of protein was detected in supernatant after 
passing over the monoclonal affinity column. The monoclonal affinity column was adopted 
as the method for purification of OmCI-Fc from supernatant.
5.1.1.2.2. Monoclonal anti-OmCI affinity chromatography
The antibody (MBI-Om3, IgG2b) that recognised native OmCI and passed the double 
screening test analysis (explained in Chapter 4, section 4.2.4) was used to generate an 
affinity column. MBI-Om3 (27mg) was coupled to prepacked Sepharose. Tissue culture 
supernatant from cells expressing OmCI-Fc cultured in UYVERFlask was loaded onto the
column. The unbound protein was washed out and the protein associated with the anti-OmCI 
Ab was eluted with a glycine buffer (pH 2.5). The fractions containing eluted protein were 
identified, neutralised, pooled and dialyzed against PBS. An ELISA analysis was conducted 
to determine the efficiency of purification. Almost no OmCI-Fc was detected in the run 
through (Fig.5.1C).
5.1.2. Biochemical characterisation of OmCI-Fc
The purity of OmCI-Fc isolated from tissue culture supernatant using anti-OmCI 
monoclonal antibody (MBI-Om3) column was verified by SDS-PAGE. The molecular 
weight of the recombinant protein was determined using its relative mobility in the gel and 
by gel filtration chromatography.
5.1.2.1. SDS-PAGE characterisation of OmCI-Fc
The overall purity and the molecular weight of the recombinant protein purified on an anti- 
OmCI column was determined by SDS-PAGE. OmCI-Fc eluted from the affinity column 
and dialysed in PBS was subjected to SDS-PAGE on a 7.5% gel. The protein was visualised 
by staining with Coomassie blue (Fig.5.2). Two bands were seen under non-reducing 
condition. This was consistent with the result obtained from the western blot analysis of the 
tissue culture supernatant (Chapter 3, Fig.3.11).
The apparent molecular mass of the protein was estimated using its relative mobility. The 
calculation for protein molecular mass is explained in section 2.4.7.1 of Chapter 2. The 
major band was with apparent molecular weight of 90 kDa, agreeing with the mass predicted 
for OmCI-Fc. A higher molecular weight band was also observed. Initially this band was 
defined as a product of aggregation since there was reactivity with antibody specific for 
OmCI on Western blot analysis (Fig.3.11)). However, three bands were seen under reducing 
conditions (Coomassie staining, Fig.5.2), when only one was expected for pure OmCI-Fc. 
The band with the highest intensity (51 kDa) represented the polypeptide backbone of 
OmCI-Fc. The molecular weight of the two additional bands corresponded very well with a
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C5 profile under reducing conditions: a-chain (127±5 kDa) and P-chain (74±2kDa) [403]. It 
is likely that the OmCI-Fc expressed from the CHO cells bound bovine C5 from the FCS in 
tissue culture medium. It appeared that the first band seen on the Western blot represents the 
OmCI-Fc while the higher molecular weight band was mostly bovine C5 and a bit o f OmCI- 
Fc aggregating material. This suggests that the anti-OmCI mAb (MBI-Om3) used in this 
analysis but also used to purify OmCI-Fc binds the free Fc fusion protein and also the C5 
complex. There is good possibility that bovine C5 has been co-purified with OmCI-Fc.
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Fig.5.2 SDS-PAGE of purified OmCI-Fc fusion protein. Purified OmCI-Fc was subjected 
to SDS-PAGE on a 7.5% under non-reducing (lanel) and reducing conditions (lane2) and 
stained with Coomassie Blue. The protein migrated as two bands under non reducing 
conditions (lane 1). The band, indicated with arrows, with apparent molecular weight of 
90kDa corresponded to OmCI-Fc. The additional higher molecular band (indicated with 
dotted arrow) was likely to represent bovine C5 from the cell growing medium, co-purified 
with OmCI-Fc. Three bands were visible under reducing conditions. The polypeptide chain 
of OmCI-Fc is indicated with arrows. The higher molecular weight bands represent the a - 
and p-chain of bovine C5. Molecular weight markers are shown on the left.
5.I.2.2. Gel filtration of OmCI-Fc
Gel filtration was used to remove C5 contamination from OmCI-Fc protein and as an 
alternative way to determine the apparent molecular weight of the fusion protein.
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This method separates the proteins and peptides based on their size. Separation was achieved 
using a porous matrix of dextran chains covalently linked to highly cross-linked agarose 
particles (Superdex) to which the molecules have different degrees of access. Smaller 
molecules have greater access and larger molecules are excluded from the matrix. Therefore 
proteins are eluted from the column in decreasing order of size, with the largest molecules 
(bovine C5 in this case) eluting from the column first.
Gel filtration also allows an estimation of the molecular weight of protein or multiprotein 
complexes. The molecular weight estimation is based on the assumption that the proteins 
have a globular shape. The column was calibrated using Gel filtration High Molecular 
Weight Kit (GE Healthcare) containing Blue dextran 2000 (2000kDa, for column void 
volume determination), Ovalbumin (43kDa), Conalbumin (75kDa), Aldolase (158kDa), 
Ferritin (440kDa), and Thyroglobulin (669kDa) (Fig.5.3). The molecular weight of proteins 
was determined by comparing their elution volume parameter (Kav) with the values obtained 
from the calibration standards. Kav was calculated as follows:
Kav=(V e“ V o)/(V c-V q)
V0 is elution volume of molecules larger then the largest pores in the matrix and 
therefore remains in the buffer and pass straight through the packed bed.
Vc is the geometric volume of the column.
Ve is elution volume.
To measure the molecular weight and to remove bovine C5, OmCI-Fc purified from tissue 
culture supernatant on an anti-OmCI column was applied to a Superdex 200 10/300GL 
column (GE Healthcare) equilibrated with PBS. Eluted proteins were detected by monitoring 
their UV absorbance at 280nm. Three peaks were detected (Fig.5.4A). Peak fractions were 
pooled and the purity of the protein was analysed by SDS-PAGE on a 7.5% gel (Fig.5.4B). 
The protein was visualised by silver staining. Aggregates and C5 were eluted in the first two 
peaks, traces of OmCI-Fc were also visible. The majority of OmCI-Fc protein was eluted in 
the third peak with characteristic elution volume of 12.30ml (between 440kDa-ferritin and 
158-aldolase), corresponding to apparent molecular weight of 174kDa. The molecular mass 
obtained from the gel filtration was greater than the molecular mass measured by SDS- 
PAGE analysis (Table 5.1). The variation could be explained by a non-spherical shape of the 
fusion proteins. No aggregates or C5 were detected in the OmCI-Fc peak. Using gel
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filtration chromatography as a polishing purification step C5 and aggregates free OmCI-Fc 
protein preparation was obtained.
Reagent Mass based on 
amino acid 
sequence 
(kDa)
Experimental 
mass SDS-PAGE 
(kDa)
Experimental mass 
Gel filtration 
(kDa)
OmCI-Fc 83 83 174
CRIg-CD59 30 33 93.68
CD59-CRIg 30 33 87.11
CRIg-3-CD59 m/d 32/64 39/94 110/295
CD59-3-CRIg m/d 32/64 39/94 123/276
CD59-2a-CRIg m/d 32/64 40/96 118/280
CRIg-2a-CD59 m/d 32/64 40/96 n/a
Cleavable CD59-CRIg 30 33 96
Table 5.1 Experimental molecular mass of anti-complement reagents determined by 
SDS-PAGE and Gel filtration analysis or based on the amino acid sequence, m,
monomer; d, dimer; n/a, not available;
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Fig.5.3 Calibration of SD200 gel filtration column. A.Gel filtration chromatography of a 
series of protein molecular mass standards on a pre-packed Superdex 200 column. Standards 
were: thyroglobulin (669kDa), ferritin (440kDa), aldolase (158 kDa), ovalbumin). The 
elution volume Ve of ferritin is shown on the histogram. B. Standard curve. The standard 
curve for a particular gel filtration media is a plot of Kav of the standards versus log of their 
molecular weight, and the data shown here has been derived from panel A. The curve was 
used estimate the molecular mass of anti-complement reagents.
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Fig. 5.4 Gel filtration chromatography of OmCI-Fc. To remove aggregates OmCI-Fc 
purified on affinity column was loaded on Superdex 200 column equilibrated in PBS. A. Gel 
filtration profile o f OmCI-Fc. Three peaks were eluted (indicated with a numbers from 1 to 
3). The peak fractions were pooled and analysed by SDS-PAGE on 7.5% gel. The protein 
was visualised by silver staining (B). Each peak is indicated with its corresponding number. 
OmCI-Fc was eluted as peak 3 at 12.30ml between Ferritine and Aldolase and corresponds 
to 174kDa apparent molecular weight. No contamination of C5 was detected. C5 was eluted 
early, in peaks 1 and 2. Trace of OmCI-Fc was also found in these peaks.
5.2. CRIg-CD59 fusion proteins
Seven CRIg-CD59 fusion proteins have been generated: CRIg-CD59 (CD59 at C-terminus), 
CD59-CRIg (CD59 at N-terminus), CRIg-3-CD59 (CD59 at C-terminus and hinge o f mouse
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IgG3 introduced) CD59-3-CRIg (CD59 at N-terminus and hinge of mouse IgG3), CRIg-2a- 
CD59 (IgG3 hinge replaced by IgG2a hinge), CD59-2a-CRIg (IgG3 hinge replaced by 
IgG2a hinge) and cleavable CD59-CRIg (a peptide linker containing cleavage sites for 
protease which enables the liberation of the two separate proteins). The generation and 
expression of the reagents were discussed in Chapter 3.
5.2.1. Purification of CRIg-CD59 fusion proteins
Anti-CD59 affinity column was used to purify CRIg-CD59 fusion proteins. To generate an 
affinity column, 28mg of purified anti-CD59a mAbs (7a6) (Fig.5.5) were coupled to 
prepacked NHS-activated sepharose.
kDa kDa
M8 r , 148 r i
98 98 - *
64 * 64 ¥ -
50 50 Heavy chain
36 36 m m Light chain
Nonreduced Reduced
Fig. 5.5 SDS-PAGE analysis of anti-mouse CD59 mAb. Anti-mouse CD59 mAb was 
purified on protein G column and visualised on SDS-PAGE (under reduced and non-reduced 
conditions) by Coomassie staining.
Supernatant containing CD59 fusion protein was passed over the column. The column was 
washed with TBS and the fusion protein was eluted at high pH. Protein-containing fractions 
were identified, combined and dialysed against PBS and analysed by Western blot. The blot 
was developed with a rat anti-mouse CD59 mAb. The efficiency of purification is shown in 
Fig.5.6, where CRIg-CD59 is illustrated as an example. As may be noted in the figure CRIg-
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CD59 was not detected in the run through, suggesting that the supernatant was completely 
depleted (Fig.5.6).
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Fig. 5.6 Western blot analysis of purification of CRIg-CD59 fusion proteins. Tissue 
culture supernatant from cells expressing CRIg-CD59 was loaded onto an anti-CD59 affinity 
column. The column was washed and the bound protein was eluted at high pH. The fractions 
containing CRIg-CD59 were identified by absorption at 280 nm. Samples from the peak 
fractions (1), tissue culture supernatant (2) and the run through (3) was subjected to western 
blot analysis. Membranes were probed with rat anti-mouse CD59 mAb (mCD59a-7). No 
detectable level of the protein was found in the run through. This result suggested that 
purification was highly efficient. Arrows indicate CRIg-CD59. Molecular weight marker is 
shown on left.
The concentration of the reagents was calculated by measuring absorbance at 280nm and the 
rate of protein expression was determined. Table 5.2 shows the amount of purified protein 
produced per week in CELLine AD 1000 and HYPERFlask. The data revealed that the rate 
of protein production was greater in HYPERFVas'A:, which was consistent with the result 
obtained from OmCI-Fc expression discussed in Chapter 3 (section 3.2.3.2, table 3.2). The 
purified proteins were concentrated and analysed by SDS-PAGE (Fig.5.7).
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Reagent Yield (pg/weekly harvest)
CELLine AD 1000 (20ml HYPERF/ax* (500ml harvest) 
_______harvest)____________________________________
CRIg-CD59 93 700
CD59-CRIg 900 NA
CRIg-3-CD59 300 900
CD59-3-CRIg 180 875
CRIg-2a-CD59 125 NA
CD59-2a-CRIg NA NA
Table.5.2 High-density tissue culture system and production of recombinant proteins 
expressed as pg per harvest. NA-not assessed
5.2.2. Biochemical characterisation of CRIg-CD59 fusion proteins
5.2.2.1. SDS-PAGE analysis of CRIg-CD59 fusion proteins
CD59 containing fusion proteins were analysed by SDS PAGE on 7.5% gel. The apparent 
molecular mass of the proteins was estimated using their relative mobility (Rf) as described 
in Chapter 2. The result is summarised in Table 5.1.
As can be noted in Fig. 5.7, the CRIg-CD59 fusion protein, the construct in reverse 
orientation CD59-CRIg and the cleavable CD59-CRIg migrated as a single band with 
apparent molecular weight of 34kDa under nonreducing conditions. This confirmed the 
western blot analysis of crude supernatant, where one band of apparent molecular weight of 
33kDa was detected with anti-CD59 mAb in the supernatant.
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Fig.5.7 Purification of CRIg-CD59 fusion proteins. Proteins were purified by anti-CD59 
affinity chromatography, subjected to SDS-PAGE on a 7.5% gel and stained with 
Coomassie Blue. A. SDS-PAGE analysis of fusion proteins CRIg-CD59 and CRIg-3-CD59 
under non-reducing conditions. CRIg-CD59 migrated as a single band. Two bands were seen 
for CRIg-3-CD59. The major band had approximate molecular weight of 33kDa. The faint 
band (indicated with arrows) is likely to represent a dimeric form of the protein. B. SDS- 
PAGE analysis of fusion proteins CD59-CRIg, CD59-3-CRIg, CD59-2a-CRIg and cleavable 
CD59-CRIg under non-reducing (left) and reducing conditions (right). Two bands were seen 
for CD59-3-CRIg and CD59-2a-CRIg under non-reducing condition. The arrows indicate 
the dimeric forms. All proteins migrate as a one band under reducing conditions. Loading is 
indicated above lanes.
The reagents containing antibody hinge: CRIg-3-CD59, CD59-3-CRIg and CD59-2a-CRIg 
and CRIg-2a-CD59 were resolved into two bands with molecular mass identical to this 
observed by western blot analysis o f cell culture supernatant (Chapter 3). This result 
suggested that the proteins existed as two forms. The smaller band had apparent molecular 
weight of 39kDa (CRIg-3-CD59 and CD59-3-CRIg) and 40kDa (CD59-2a-CRIg), slightly 
higher than CRIg-CD59 or CD59-CRIg proteins. This band is likely to represent monomeric 
configuration of the proteins. The increase in molecular mass of CRIg-3-CD59, CD59-3- 
CRIg, CD59-2a-CRIg and CRIg-2a-CD59 was due to the IgG hinge incorporated in the
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chimeric molecule. The second band found on Western blot and SDS-PAGE analysis had 
molecular weight of 94kDa for CRIg-3-CD59 and CD59-3-CRIg and 96kDa CD59-2a- 
CRIg, approximately double the size of the monomeric band indicating that CRIg-3-CD59, 
CD59-3-CRIg and CD59-2a-CRIg were assembled into dimers as expected. Reagents with 
N-terminal CD59 are shown in Fig.5.7B. Under reducing conditions all tested proteins 
migrated as a single band with the following molecular weights: 36kDa-CD59-CRIg, 
38kDa-CD59-3-CRIg, 37kDa-CD59-2a-CRIg and 36kDa-the cleavable CD59-CRIg. The 
fact that dimers were observed only in presence of a hinge domain and could be altered 
under reducing conditions means that disulphide bonds formed between hinges were 
responsible for holding two fusion proteins together. SDS-PAGE analysis revealed that 
approximately 40% of CD59-2a-CRIg was assembled in a dimer, whereas only 5% of the 
protein, containing IgG3 hinge was dimerised (Fig.5.7). The molecular weight obtained by 
SDS-PAGE analysis was slightly higher than the molecular weight from the amino acid 
sequence (Expert Protein Analysis System) (Table 5.1). This difference could be explained 
by post-translational modifications such as glycosylation. CRIg-CD59 fusion proteins 
possess two potential N-linked glycosylation sites, one in the CRIg moiety and one in CD59.
5.2.2.2. Gel filtration analysis of CRIg-CD59 fusion proteins
Analytical gel filtration was used to confirm the ratio of monomer and covalent dimer and to 
precisely calculate their molecular weights.
Samples were loaded on Superdex 200 column equilibrated in PBS. CRIg-CD59 and CD59- 
CRIg were eluted as a single peak. The reagents containing hinge of antibody gave a distinct 
profile shown in Fig.5.8. Two peaks were observed for CRIg-3-CD59, CD59-3-CRIg and 
CD59-2a-CRIg suggesting that these proteins indeed existed in two forms- monomer and 
covalently associated dimer (Fig.5.8 A and B). To prove that two peaks represent different 
oligomeric organization of the same protein, western blot analysis was performed 
(Fig.5.8C). Both elution peaks were recognized by anti-CD59 mAb and gave bands 
corresponding to the molecular weight of a monomer and dimer of the analysed fusion 
protein.
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Fig.5.8 Gel filtration chromatography of CD59-CRIg (N-terminal CD59) fusion 
proteins. A. Gel filtration profile. CD59-CRIg was eluted as a single peak. Two peaks were 
observed for CD59-3-CRIg and CD59-2a-CRIg. The earlier eluted peak represents a dimer 
and the late represents a monomer. Elution position of protein standards and their molecular 
weights are indicated. B. Gel filtration elution profile of CD59-2a-CRIg and SDS-PAGE 
analysis. Elution fractions across (indicated with dotted double arrow) the dimer and 
monomer peaks were analysed by SDS-PAGE. The first peak contained dimer and the 
second-monomeric CD59-2a-CRIg. C. Western blot analysis of pooled fractions.
194
To measure the relative amount of monomer to dimer, peak area was measured and the 
percentage of monomer and dimer was calculated. From the profile I calculated that the 
approximately 95% of CD59-3-CRIg was a monomer and only 5% of the protein was 
assembled in disulphide-bonded dimer. In agreement with SDS-PAGE analysis, the 
percentage of dimer dramatically increased when the IgG3 hinge was replaced by hinge of 
IgG2a antibody, 45% of the protein dimerised, confirming that the IgG2a hinge increased 
the efficiency of dimer formation.
Gel filtration was used to determine the molecular weight of CRIg-CD59 fusion proteins. 
CRIg-CD59 and CD59-CRIg were eluted as a single peak from Superdex 200, with 
characteristic elution volume of 13.58ml and 13.73ml respectively. The approximate 
molecular mass was calculated using Kav as described previously and the molecular mass 
obtained was 93.69kDa (CRIg-CD59) and 87.1 lkDa (CD59-CRIg). Each CRIg-3-CD59, 
CD59-3-CRIg and CD59-2a-CRIg was eluted as two peaks with characteristic volume lower 
than predicted. The molecular mass calculated from gel filtration was larger than the mass 
achieved from SDS-PAGE (Table 5.1).
5.2.3. Generation of soluble CD59 and soluble CRIg
Proteins containing both CD59 and CRIg but not fused to each other were required to 
control for delivering CD59 to the cell surface. To prepare the control reagents comprising 
only soluble CD59 or soluble CRIg, CD59-CRIg (cleavable) and CD59-2a-CRIg were 
subjected to cleavage with 3C human rhino virus (HRV) protease or papain respectively. The 
generation of the cleavable CD59-CRIg was described in Chapter 3. It is expressed as fusion 
protein with a protease cleavage recognition site of the 3C HRV protease introduced 
between CD59 and CRIg. The cleavage was performed in presence of 0.0ImM reducing 
agent Tris (hydroxypropyl) phosphine (THP), using recombinant 3C HRV protease 
(Novagen) following the manufacturer’s protocol. After 16 hours incubation with the 3C 
HRV protease at 4°C, the cleavable CD59-CRIg was subjected to SDS-PAGE analysis to 
assess the cleavage efficiency. As seen in Fig 5.9A, the majority of the fusion protein was 
split to its components CD59 and CRIg. Only small amount of the dimeric protein remained 
intact.
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To investigate the effect of the reducing agent, THP, on CD59, a Western blot analysis was 
performed (Fig.5.9B). The three-dimensional structure of the CD59 molecule is maintained 
by five disulfide bonds [404]. Presence of THP might reduce the disulfide bonds holding the 
molecule and thus impair the protein structure. The functional activity o f CD59 depends on 
the binding interaction with C8 and C9 in regions exposed during assembly of MAC. For 
this reason conformational alterations in CD59 caused by breaking the disulfide bridges are 
likely to affect its function.
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Fig. 5.9 CD59-CRIg cleavage with 3C rhinovirus protease (3C HRV). A. SDS-PAGE 
analysis illustrating fusion protein cleavage. CD59-CRIg (cleavable) was digested with 3C 
HRV protease. After separation on 15% gel, the proteins ware visualised with Coomassie 
Blue. B. Western blot analysis of CD59-CRIg (cleavable) reagent following digest. CD59- 
CRIg cleaved with 3C HRV protease was subjected to Western blot analysis under non­
reducing (lane 1) and reducing conditions (lane 2). Rat anti-mouse CD59 mAb was used to 
detect the proteins. The higher molecular weight bands are likely to represent aggregates. 
The arrows indicate the positions o f the non-cleaved fusion protein and digestion products 
CRIg and CD59.C. Amino acid sequence o f the 3C rhinovirus protease cleavage site. The 
cleavage site (3C) is indicated with arrow and the amino acids are shown in bold.
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To analyse whether CD59 lost conformational epitopes after being exposed to THP, the 
cleaved CD59-CRIg fusion protein was resolved on a 15% gel and transferred to a 
nitrocellulose membrane. A rat anti-mouse CD59 mAb was used for detection. As seen in 
Fig. 5.9B, the mAb was not able to recognise CD59 under reducing conditions confirming 
that it specifically binds a conformational epitope within the antigen. Under non-reducing 
conditions, a major band was seen on the western blot corresponding to the intact CD59- 
CRIg. This suggests that the fusion protein was not completely reduced and a small portion 
remained noncleaved (also seen in Fig 5.9A). Only a very faint band was obtained for the 
cleaved CD59, indicative for conformational changes and epitope loss.
The second fusion protein used to generate soluble CD59 and CRIg was the CD59-2a-CRIg 
construct and as it has an IgG2a hinge introduced between the CD59 and CRIg domain it 
was possible to use papain to cleave this reagents [405,406]. Papain is a thiol-endopeptidase 
that has a sulphydryl group in the active site, hence a reducing agent such as cysteine is 
necessary for its activation. As discussed earlier, a reducing agent can also facilitate 
undesirable reduction of the disulphide bonds within the fusion protein. To minimise the 
negative effect that cysteine may have on CD59 function, the duration of the cleavage 
reaction was carefully monitored and reduced. Due to the limited supply of CD59-2a-CRIg, 
the CD59-3-CRIg reagent was used to determine the minimum time required for papain 
cleavage. This reagent was chosen because IgG3 requires similar papain digestion 
conditions as IgG2a [406]. CD59-3-CRIg was incubated with agarose-immobilised papain 
(Pierce) at 37 °C in a shaking water bath. The reaction was performed in the presence of 
20mM cysteine.HCl. Aliquots were taken at various time and analysed by SDS-PAGE and 
Western blot (Fig.5.10). SDS-PAGE analysis demonstrated that CD59-3-CRIg was almost 
entirely cleaved to soluble CRIg and CD59 within an hour of incubation time (Fig.5.10A). 
To investigate whether cysteine affected the CD59 structure the proteins were subjected to 
western blot analysis. Probing with rat anti-mouse CD59 mAb confirmed that the majority 
of CD59-3-CRIg was cleaved and soluble CD59 was generated one hour after incubation 
(Fig.5.10B). The analysis revealed that the antibody epitope on CD59 remained intact 
suggesting cysteine did not have a dramatic effect on the CD59 conformation.
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Fig.5.10 Papain digest of CD59-3-CRIg. CD59-3-CRIg was used to determine the 
minimum time required for generation o f soluble CRIg and CD59. The fusion protein was 
incubated with immobilised papain. Aliquots were removed from the reaction after 30 
minutes, 1, 2, 3 and 19 hours and subjected to SDS-PAGE on 15% gel under nonreducing 
conditions (A) and a Western blot was carried out using rat anti-mouse CD59 mAb (B). 
Molecular weights in kDa are indicated on the right. The arrows indicate the anticipated size 
of the intact fusion proteins and its cleavage products.
Following the same protocol, CD59-2a-CRIg was subjected to a papain digest for one hour 
at 37°C. Papain digest o f the IgG2a and IgG3 antibodies results in formation o f Fab and Fc 
fragments, but no (Fab)2 [406]. For this reason no CD59 dimers were expected. The cleavage 
efficiency was analysed by SDS-PAGE and Western blot analysis (Fig. 5.11 A and B). 
Consistent with the CD59-3-CRIg digest, one-hour incubation with papain was sufficient to 
dissociate most o f the fusion protein and generate soluble CRIg and CD59. The cleaved 
reagent, containing soluble CD59, soluble CRIg and very small percentage of intact 
monomer and dimer, was dialysed in PBS.
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Fig.5.11 Generation of soluble CRIg and CD59. A. SDS-PAGE analysis illustrating 
papain cleavage of CD59-2a-CRIg. CD59-2a-CRIg was subjected to a papain cleavage for l 
hour at 37°C. After separation on 15% gel, the proteins were visualised with Coomassie 
Blue. Arrows indicate the positions o f non-cleaved CD59-2a-CRIg monomer and dimer and 
released CRIg and CD59. B. Western blot analysis o f CD59-2a-CRIg following digest. 
CD59-CRIg cleaved with papain for 1 hour was subjected to Western blot analysis under 
non-reducing condition. Rat anti-mouse CD59 mAb was used to detect the proteins. Arrows 
indicated the positions of the non-cleaved CD59-2a-CRIg dimer and digestion product 
CD59. C. Amino acid sequence o f the hinge region of mouse IgG2a. The hinge region is 
composed by core hinge flanked by upper and lower hinge. The positions of disulfide bonds 
(S-S) responsible for protein dimerisation are indicated. The papain (P) cleavage sites are 
indicated in bold.
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5.3. Purification of ligands for anti-complement reagents
To characterise the ability of OmCI-Fc and CRIg-CD59 fusion protein to bind their ligands, 
mouse C5 and C3 were purified.
5.3.1. Purification of mouse C5
OmCI inhibits complement by binding C5 and preventing it from being cleaved by the 
convertase. To confirm that the recombinant proteins were functional, binding to mouse and 
human C5 was analysed.
C5 was purified by affinity chromatography. An anti-C5 HiTrap column was prepared by 
coupling anti-mouse C5 mAb (BB5.1) to prepacked Sepharose. Mouse serum (10ml) was 
passed over the column. The column was washed with Tris buffer saline and C5 was eluted 
at high pH. The profile of mouse C5 purification is shown on Fig.5.12A. The fractions 
across the protein peak were analysed by SDS PAGE on 10% gel under non-reducing and 
reducing conditions (Fig.5.12B). The apparent molecular weight of C5 was 200kD (non­
reducing condition) and the a- and p- chain showed molecular mass of 115kD and 83kD 
(reducing condition). A minor contamination was detected across the peak fractions. The 
fractions containing C5 were pooled and immediately dialysed against PBS. The protein 
concentration was determined by measuring absorbance at 280nm.
The functional activity of the affinity purified C5 was assessed by haemolysis assay 
described in detail in Chapter 2, section 2.7.2.4. Antibody-sensitised rabbit erythrocytes 
were attacked by C5-deficient mouse serum and the ability of the purified mouse C5 to 
restore complement killing was analysed. C5 was able to restore the complement activation 
of the C5-/- serum and lysed the target cells via the classical pathway (Fig.5.12C). This 
suggested that C5 obtained from mouse serum in affinity purification was functionally active 
and that affinity purification of C5 from mouse serum did not destroy its haemolytic 
function. The difference in level of lysis caused by the wild type serum and the C5-/- serum 
with C5 added back was probably due to difference in level of complement activation in the 
different mouse strains used in this experiment.
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Fig.5.12 Purification of C5 from mouse plasma. A. Profile o f affinity purification of C5. 
Mouse plasma was passed over an anti-mouse C5 affinity column. C5 was eluted in a single 
peak. Peak fractions were analysed by SDS-PAGE (B). Coomassie staining revealed a band 
of intact C5 with apparent molecular mass o f 210-220kDa under non-reducing condition and 
bands at 115kDa and 83kDa, corresponding to the intact G5 and a-and p- chains (indicated 
with arrows), respectively under reducing condition. A minor contamination (probably 
albumin) was seen in fractions across the peak. The ability o f C5 to restore the complement 
cascade in C5 deficient mouse serum was assessed by the ability of the serum to lyse 
antibody-sensitised rabbit erythrocytes (C). The cells were incubated with serial dilutions of 
C5 deficient mouse serum (open circle), C5 deficient serum reconstituted with the purified 
mouse C5 at concentration of 50 pg/ml (black diamond) added back or dilutions of wild type 
serum (black triangle). The purified C5 was able to restore complement-mediated lysis of 
the C5 deficient serum.
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5.3.2. Purification of mouse C3
Mouse C3 was necessary to assess the ability of CRIg within fusion proteins to bind its 
ligands C3b and iC3b. C3 was purified from plasma using anion- and cation exchange 
chromatography. Ion-exchange chromatography separates proteins on the basis of their 
charge type and on the basis of relative charge strength (strongly anionic from weakly 
anionic). The anion exchange elution profile is shown in Fig.5.13A. The fractions were 
screened by SDS-PAGE on a 10% gel under reducing condition analysis (Fig.5.13B) and C3 
was identified. This was confirmed by haemolysis assay (Fig.5.13C). Briefly, antibody 
sensitised rabbit erythrocytes were incubated with C3 deficient mouse serum, unable to lyse 
the cells. Complement mediated lysis occurs only by adding back functional active C3. 
Sample (lOpl) of each Source Q fractions was added to the cells. The fractions (C6-C11) 
containing mouse C3 were able to restore the haemolytic activity of C3 deficient mouse 
serum. The C3-containing peak was dialysed against 20mMNaPO4 pH6.0 and subject to 
cation exchange chromatography on Mono S column with a gradient of 0 to 500mM NaCl 
over 20 column volumes (Fig.5.14A). The peak containing C3 was identified by SDS-PAGE 
(Fig.5.14B) analysis and presence of C3 was confirmed by haemolysis assay (Fig.5.14C).
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Fig.5.13 Purification of mouse C3 by anion exchange chromatography.
A. Chromatogram of the anion exchange of mouse C3. The product from the 15% cut of 
mouse plasma was loaded onto Source Q column. The proteins were separated using an 
increasing salt gradient, presented as a change in conductivity (%B; gray). B. SDS-PAGE 
analysis of the Source Q fractions. The elution fractions were loaded on 10% gel under 
reducing conditions. The protein was visualized by staining with Coomassie Blue. The 
fraction number is shown above each lane. Fractions C7 to C ll  showed typical C3 profile, 
a -  and p-chains are indicated with arrows. C. Haemolytic activity of Source Q fractions. 
Fractions positive for C3 on SDS-PAGE and adjacent fractions were analysed on haemolysis 
assay. Antibody-sensitised rabbit erythrocytes were incubated with C3 deficient mouse 
serum and fraction samples was added. Fractions from C6 to C l 1 (bold) were able to restore 
complement activity to the C3-deficient serum and were processed further.
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Fig. 5.14 Purification of mouse C3 by cation exchange chromatography.
A. Chromatogram of the cation exchange of mouse C3. Source Q fractions C6-C11 were 
pooled, dialysed against 20mMNaPO4 pH6.0 buffer and loaded onto Mono S column. The 
proteins were separated using an increasing salt gradient, presented as a change in 
conductivity (%B, gray). B. SDS-PAGE analysis of the Mono S fractions. The elution 
fractions were loaded along with a protein sample before being loaded on the column (Pre 
MonoS) on 10% gel under reducing conditions. The protein was visualized by staining with 
Coomassie Blue. The fraction number is shown above each lane. Fractions A13 to A15 
showed typical C3 profile, a -  and p-chains are indicated with arrows. C. Haemolytic activity 
of MonoS fractions. Fractions positive for C3 on SDS-PAGE and adjacent fractions were 
analysed on haemolysis assay. Antibody sensitised-rabbit erythrocytes were incubated with 
C3 deficient mouse serum and fraction samples were added. Fractions from A13 to A15 
(bold) were able to restore complement activity o f the C3 deficient serum and were dialysed 
against PBS and stored at -80°C until needed.
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5.4. Discussion
Data in this chapter illustrate the purification and biochemical analysis of OmCI-Fc and 
CD59-CRIg proteins. A number of different methods for purifying the anti-complement 
therapeutics were investigated. Protein A and G are usually used for purification of Fc- 
fusion proteins. However, the use of protein A and G column resulted in no OmCI-Fc being 
purified from tissue culture supernatant. It has been described in the literature that some 
fusion proteins show different ability of binding to the same stationary phase despite being 
of the same isotype [407]. This effect is attributed to a steric hindrance on the protein A 
surface [407]. Purification by antibody affinity chromatography was then tested. Polyclonal 
rabbit anti-OmCI column failed to purify OmCI-Fc fusion protein. Different anti-OmCI 
mAb were generated and one was successfully used to purify this anti-complement reagent. 
After the purification of the Fc-based construct, it was necessary to demonstrate that the 
fusion protein was structurally sound and biologically active. The purity of the protein was 
analysed by SDS-PAGE. OmCI-Fc migrated as a band with molecular weight of 90kDa 
under non-reducing condition and 51kDa (polypeptide backbone) under reducing. The 
analysis revealed a contamination with bovine C5 from the FCS in the cell-growing 
medium. This was removed by a gel filtration step.
The second part of the chapter deals with the purification and the biochemical analysis of 
targeted CD59-CRIg fusion proteins. CD59-CRIg, CRIg-CD59, CD59-3-CRIg, CRIg-3- 
CD59, CD59-2a-CRIg, CRIg-2a-CD59 and cleavable CD59-CRIg were purified from 
culture supernatant by affinity chromatography. The molecular mass of fusion proteins was 
determined by SDS-PAGE analysis and gel filtration and compared to the mass calculated 
based on amino acid sequence. SDS-PAGE analysis was also used to control the quality of 
purified proteins. Gel filtration chromatography clearly revealed that CRIg-CD59, CD59- 
CRIg and cleavable CD59-CRIg were monomeric, whereas CRIg-3-CD59 and CD59-3- 
CRIg and CD59-2a-CRIg were eluted as two peaks meaning that they exist in two forms- 
monomer and dimer. Calibration of the gel filtration column allowed the generation of a 
standard curve used to determine the molecular weight of the recombinant proteins. The 
molecular mass obtained from gel filtration has found to be higher than the mass calculated 
from the SDS-PAGE analysis and the molecular weight from the electrophoresis was larger 
than the mass estimated from the amino acid sequence (Table 5.1). This could be explained 
with enhanced level of post-translational modification. CRIg-CD59 fusion proteins
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contained two potential N-linked glycosylation sites-one within CRIg and one in the CD59 
moiety. In addition, the high content of proline, serine and threonine predispose to O-linked 
glycosylation [408]. This could result in highly glycosylated proteins with increased 
molecular mass. The Fc domain of IgG (used in OmCI-Fc) is also highly glycosylated.
The discrepancy in the molecular weight obtained from SDS-PAGE and gel filtration 
analysis could be explained with a high hydration of the particle in solution, characteristic 
for extended molecules with large specific surface accessible to the solvent. Extended 
molecules have larger Stokes radius (Stokes-Einstein radius, hydrodynamic radius, radius of 
the hydrated molecules in solution) and therefore larger resistance to motion compare to 
spherical molecules (Stoke radius identical to the effective radius) with the same molecular 
weight. It might be that the CD59-CRJg proteins have hydrodynamic radius larger than the 
effective radius and therefore are eluted earlier than expected for globular proteins with their 
molecular mass. The monomeric CRIg-CD59 were eluted substantially earlier than 
ovalbumin, a 43kDa globular protein and OmCI-Fc was eluted before the aldolase (158kDa) 
(Fig.5.4 and Fig.5.8).
As revealed by the analysis, the ratio of monomer to dimer within the CD59-2a-CRIg and 
CD59-3-CRIg preparations was different. This means that IgG3 and IgG2a hinge could offer 
different levels of protein dimerisation. The difference could be explained by the different 
number of cysteins found in the two hinges. IgG2a hinge has three cystiens and a potential 
to form three hinge disulphide bonds, whereas IgG3 has only one. It is highly likely that the 
two additional cysteines in the IgG2a hinge increased the efficiency of assembling disulfide- 
bonded dimers and/or their stability. The formation of disulfide-bonded dimers would 
increase the avidity of the reagent to the target (C3b/iC3b coated) surface which might be 
extremely beneficial for therapy.
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Chapter 6. In vitro functional analysis of OmCI-Fc and CD59-CRIg fusion proteins
The aim of the work in this chapter was to characterise the function of the anti-complement 
therapeutics in vitro. OmCI-Fc and CD59-CRIg are chimeric proteins. Linking two 
molecules in one fusion protein may alter the way in which OmCI-Fc and CD59-CRIg bind 
their ligands. For this reason it is vital to assess the ability of the reagents to bind C5 (for 
OmCI-Fc) and C3b/iC3b (for CD59-CRIg). Furthermore, measuring the affinity of CD59- 
CRIg fusion proteins for C3b will address the important question whether dimerisation 
improves the binding capacity of these reagents. To confirm that the targeting strategy 
works, the ability of CD59-CRIg agents to bind C3b-coated will be evaluated by flow 
cytometry. Haemolysis analysis will be undertaken to assess the ability of OmCI-Fc and 
CD59-CRIg reagents to prevent complement activation. As a result of these in vitro 
analyses, the best anti-complement fusion proteins will be expanded and selected for in vivo 
testing.
6.1. In vitro characterisation of OmCI-Fc
6.1.1. Binding of OmCI-Fc and pOmCI to C5; affinity analysis.
Surface plasmon resonance (SPR) was used to measure the affinity of OmCI-Fc for mouse 
and human C5 and to investigate whether the fusion to antibody Fc domain affected the C5 
binding capacity of OmCI. The experiments were carried out on a Biacore T100. The 
method is described in detail in Chapter 2, section 2.7.5. Briefly pOmCI or OmCI-Fc was 
amine coupled on CM5 biacore chip. For efficient amine coupling the ligand must be 
positively charged and therefore diluted in immobilization buffer 0.1-1 units in pH below its 
pi. The optimal pH for OmCI-Fc and pOmCI coupling was determined in a pre­
concentration injection. Fifty resonance units (RU) of pOmCI (lOOpg/ml) were immobilised 
on the chip surface using a manual protocol in lOmM acetate pH4.0 as a dilution buffer. One 
hundred and fifty RU of OmCI-Fc (3.5pg/ml in lOmM acetate pH4.5) were coupled on the 
chip surface using the immobilisation wizard. The remaining free covalent-binding sites of 
the carboxymethylated dextran surface were blocked (Fig.6.1).
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Fig.6.1 Sensograms illustrating preparation of the chip surface. All steps were 
performed at a flow rate of 5pl/min at 25°C. A. Immobilisation of OmCI. The chip surface 
was prepared using manual immobilisation. The surface was cleaned by injecting 50mM 
NaOH and activated with N-hydroxysuccinimide (NHS) and l-ethyl-3(3- 
dimethylaminopropyl)-carbodiimide hydrochloride (EDC), mixed 1:1. OmCI, diluted in 
acetate buffer pH4.0, was injected until 36RU were immobilised. The surface was blocked 
with ethanolamine. B. Immobilisation of OmCI-Fc. OmCI-Fc diluted in acetate buffer 
pH4.5 electrostatically adhered to the chip. The surface was cleaned with 50mM NaOH and 
activated as above. OmCI-Fc, diluted in acetate buffer pH4.5, was injected until 150RU 
were immobilised. The surface was blocked.
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To compare the ability of OmCI-Fc and pOmCI to bind its ligand, mouse and human C5 
were separately flowed across the two immobilised chip surfaces. C5 was gel-filtered on a 
SD200 column in biacore running buffer immediately before analysis to remove any 
aggregates which might give unreliable data. Serial dilutions twofold were prepared with a 
starting concentration of 54nM for both proteins. Each dilution was injected in duplicate or 
triplicate across OmCI-Fc and pOmCI surfaces. The dissociation equilibrium constant (K d) 
was calculated using Biacore 3000 evaluation software. The binding of OmCI-Fc and 
pOmCI to mouse and human C5 is shown in Fig.6.2.
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Fig.6.2 SPR sensograms illustrating the OmCI-C5 interaction. pOmCI (A) and OmCI-Fc 
(B) were immobilised on a sensor surface and a dilution series of five different 
concentrations of human and mouse C5 was injected over the surface. Binding experiments 
were performed two times. The protein binding interaction is shown in resonance units with 
a grey line. The binding response was fitted to 1:1 Langmuir binding model (shown with 
black dotted line) to derive kinetic rate and affinity constants.
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OmCI-Fc and pOmCI bound human and mouse C5 with high, nanomolar affinity. While no 
difference in the binding profile was observed, the evaluation of the affinity data showed 
changes in binding properties occurring as a result of engineering OmCI. Table 6.1 presents 
a summary of the affinity data obtained from the interactions. The affinity of OmCI-Fc for 
C5 was lower than pOmCI. The Kd values of OmCI-Fc and pOmCI with human C5 were 
greater than those obtained with the mouse protein. pOmCI had an affinity with mouse C5 of
0.4 ±0.24nM, while the Kd with human C5 was 4.7±1.26nM. A similar observation was 
made for the Fc protein. OmCI-Fc had enhanced binding affinity with mouse C5 (K d =5.3 
±1.13nM) when compared to the human protein (K d= 10.1 OnM).
Ligand Analyte Kd (nM) Rmax (RU)
OmCI-Fc hC5 11±0.82 32.02 ±16.5
mC5 5.3 ±1.13 101 ±7.1
pOmCI hC5 4.7±1.26 29.4±4.17
mC5 0.4 ±0.24 72 ±4.3
Table 6.1 Affinity values obtained from SPR analysis. Kd is the dissociation equilibrium 
constant, the greater the number the lower the affinity. Rmax is the anticipated maximum 
response for each protein (surface saturation); m-mouse; h-human;
6.1.2. Complement inhibitory activity of OmCI-Fc
Having shown that both recombinant proteins bound C5, the abilities of OmCI-Fc and 
pOmCI to inhibit complement from various species were assessed in CP haemolysis assays. 
Antibody-sensitised sheep erythrocytes (EAsh) were used for the rat and human complement 
assay and sensitised rabbit erythrocytes (EArb) were the target for mouse complement. The 
assays are described in detail in method 2.7.2. Briefly, EAsh or EArb were exposed to 
human, rat or mouse serum at concentrations that caused 70% lysis and a dilution of OmCI- 
Fc or OmCI (1:2 serial dilution). Haemoglobin release from the cells was measured and 
complement-mediated lysis was determined. Approximately one third the mass of OmCI-Fc 
is contributed by the Fc domain, for this reason the results are presented in molar
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concentration of OmCI moiety. Percentage lysis was plotted against inhibitor concentration 
in nM and the amount of inhibitor causing 50% lysis was calculated (IH50).
pOmCI and OmCI-Fc effectively inhibited lysis by all three species of sera tested (mouse, 
rat and human) in a dose dependent manner (Fig.6.3). OmCI-Fc and pOmCI showed a 
different profile of complement inhibition, consistent among the assays. Both inhibitors 
followed a sigmoidal dose-response curve, however the OmCI-Fc curve was shallower than 
the curve obtained for the pOmCI. Nevertheless, both proteins were highly potent at 
preventing cell lysis with IH50 in the range of 1.7-7. InM. OmCI-Fc provided 50% inhibition 
of mouse complement at 6 . InM and pOmCI had IH5o=7 .1nM. The amount of pOmCI 
required to achieve 50% cell lysis by human and rat serum, was 1.9nM and 2.7nM 
respectively. OmCI-Fc at 1.7nM provided 50% cell protection in the human assay and 
2.0nM OmCI-Fc was sufficient to achieve the same effect in the rat assay. A direct 
comparison with the mouse assay was not appropriate because of the different target cells 
used in this assay. Table 6.2 compares the inhibitory activities of OmCI-Fc and pOmCI.
Source of 
complement
OmCI-Fc
nM SD
pOmCI
nM SD
Human 1.67 0.008 1.94 0 .1
Rat 2 .0 1 0.46 2.67 0 .1
Mouse 6.13 0.4 7.06 0.008
Table 6.2 Concentrations of OmCI-Fc and pOmCI resulting in 50% inhibition of cell 
lysis (IHso). SD, standard deviation of two ''human and mouse assay) or four measurements 
(rat assay).
I
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Fig.6.3 Complement inhibitory activity of OmCI-Fc and pOmCI. Antibody sensitised 
sheep erythrocytes were incubated with a dilution of OmCI-Fc and pOmCI and attacked by 
rat (A) or human (B) complement. Antibody sensitised rabbit erythrocytes were used to test 
the effect of pOmCI and OmCI-Fc on mouse complement (C). Both, OmCI-Fc and pOmCI 
inhibited lysis in a dose dependent manner. Each data point represents the mean value ±SD 
of a single experiment performed in triplicate.
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6.2. In vitro characterisation of CD59-CRIg fusion proteins
The capacity of CD59-CRIg fusion proteins to target to complement-opsonised cells in order 
to provide protection from complement mediated-killing was studied in vitro using SPR and 
flow cytometry. The unifying feature of these analyses is that C3 activation was promoted 
generating C3b-coated surfaces. The ability of the reagents to deliver effective complement 
inhibition was analysed by haemolysis assays.
6.2.1. SPR analysis
The capacity of CD59-CRIg to “target” to complement activation products was first 
analysed in vitro using a Biacore T100). Affinity analysis was performed to study the 
interaction of mouse CRIg within CRIg-CD59 fusion proteins with its natural ligands, 
mouse C3b and iC3b. The following questions were asked.
1. Does CRIg within CRIg-CD59 fusion proteins bind C3b and iC3b?
2. Does the orientation of CRIg within CRIg-CD59 affect binding to C3b?
3.. Does the distance between CRIg and CD59 impact on binding?
4. Does dimerisation of CRIg-CD59 translate into increased binding avidity?
To address these questions, mouse C3b and iC3b were coated onto a biacore chip.
6.2.1.1. Preparation of the C3b surface
To investigate the potential of CD59-CRJg fusion proteins to target cells tagged with C3 
fragments, a C3b “opsonised” chip surface was prepared to resemble a C3b-coated cell.
A small nidus of human C3b was first immobilised on the chip surface (~50RU). An initial 
alternative pathway C3 convertase was assembled on the sensor chip by injecting mixture of 
fB and fD across the nidus of human C3b in the presence of Mg2+ (ImM) (Fig.6.4). This C3 
convertase (containing human C3b) was able to cleave mouse C3 resulting in deposition of
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mouse C3b on the surface. This procedure was repeated. Each cycle, comprising injection of 
fB and fD to form convertase on both mouse and human C3b, followed by mouse C3, 
gradually increased the amount of C3b deposited on the chip, (~700RU).Once C3b was 
deposited, DAF was flowed across the surface to dissociate any active convertase and non- 
covalently bound C3b was removed using regeneration buffer.
Deposition of mC3b
RU
hfB+hfD DAF
AP AP 
cycle cycle C3b
(deposited)
800- hffi+hfD
700-
600
13000 1500010000 11000 12000 14000 16000 17000
Time
Fig.6.4 Preparation of a mouse C3b surface. A mouse C3b “opsonised” chip surface was 
generated via the AP using the C3 convertase. A small nidus of human C3b was 
immobilized onto a CM5 biacore chip and used as initial target to build a C3bhUBb 
convertase by injecting human factor B and factor D. Mouse C3 was flowed across the 
convertase surface and C3b was generated which bound covalently to the chip. The AP was 
amplified by repeated cycling o f fB and fD followed by mouse C3. Convertases and non- 
covalently bound C3b were decayed by injection of DAF and regeneration buffer.
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6.2.1.2. Preparation of iC3b surface
iC3b is a C3b degradation product generated by cofactor mediated factor I cleavage of C3b. 
Factor I in the presence of factor H (cofactor) was used to cleave mouse C3b deposited on 
the sensor chip. The deposition of iC3b was explained in section 2.7.7.2. Briefly human 
factor H and factor I were injected across the C3b surface resulting in release of C3f and 
generation of iC3b bound to the chip surface (Fig.6.5).
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Fig. 6.5 Preparation of a mouse iC3b surface and binding of CRIg-3-CD59. A mouse 
iC3b surface was generated by cleaving C3b, previously deposited on the chip. Human 
factor I and factor H were injected over the C3b surface. This resulted in generation of iC3b 
bound to the chip and C3f released in the fluid phase. fH alone was then injected to confirm 
that no C3b was left on the surface. A second injection of fH and fl verified that C3b was 
entirely converted to iC3b. CRIg-3-CD59 was flowed over the surface and binding was 
detected.
To confirm that C3b was entirely converted to iC3b, factor H alone was flowed over the 
surface prior to and after the combined fH/fl injection. Because fH can bind only C3b and 
not iC3b, the absence o f binding to the chip indicated when there was no C3b left. This was 
further verified when a second injection o f fH/fl was applied and no binding or release o f C3
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fragments was observed. Once the iC3b surface was created, CRIg-3-CD59 was flowed 
across the chip. The positive interaction indicated that CRIg retained its ability to react with 
iC3b after being fused to CD59.
6.2.1.3. Interaction of CRIg-CD59, CD59-CRIg, CRIg-3-CD59 and CD59-3-CRIg with 
C3b
The affinity of CD59-fusion proteins for mouse C3b was assessed and compared between 
constructs; initially four fusion proteins were tested. CRIg-CD59, CD59-CRIg, CRIg-3- 
CD59 and CD59-3-CRIg were diluted in biacore running buffer and two sets of 1:2 serial 
dilutions were prepared. The concentration series began at 181 pg/ml for CRIg-CD59 and at 
727pg/ml for CD59-CRIg, CRIg-3-CD59 and CD59-3-CRIg. Increasing concentration of 
fusion proteins were flowed across the C3b surface. The surface was regenerated. Data from 
the reference cell and a blank buffer inject were subtracted to eliminate bulk refractive index 
changes and evaluated using Biaevaluation T100 evaluation software. The equilibrium 
dissociation constant for fusion proteins was determined by using steady-state analysis, 
followed by nonlinear fitting analysis. The apparent Kd values of the interactions are listed 
in Table 6.3 and the SPR profiles for equilibrium binding and their corresponding steady- 
state analysis are shown in Fig 6.6.
Reagent KD(pM)
CRIg-CD59 2.3
CD59-CRIg 6
CRIg-3-CD59 NA
CD59-3-CRIg 5.2
CD59-2a-CRIg monomer 5
CD59-2a-CRIg dimer 0.7
Table 6.3 Kd for interaction of CD59-CRIg fusion proteins with C3b. Kd is the
dissociation equilibrium constant, the greater the number the lower the affinity. NA, not 
assessed;
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CRIg-CD59 had a KD of 2.3pM (Fig.6.6 A). The same reagent with CRIg at the C-terminus 
(CD59-CRIg) had a three-fold weaker affinity with the surface (KD=6pM) (Fig.6.6 B).
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Fig.6.6 Equilibrium binding of CD59-CRIg fusion proteins to C3b. Representative SPR 
sensorgrams of the interaction between C3b and either CD59-CRIg (A), CRIg-CD59 (B), 
CD59-3-CRIg (C), CRIg-3-CD59 (D) and CD59-3-CRIg crosslinked (XL). Each protein 
was injected across the surface at a range of concentrations as indicated on each sensorgram. 
When possible, inset plots show the corresponding steady-state affinity analysis.
217
This suggests that orientation of CRIg has an effect on binding to C3b. N-terminal CRIg 
binds tighter to its ligand. The affinity of CD59-CRIg was comparable to CD59-3-CRIg 
(K d=  5.2pM) (Fig.6.6 D), implying that the space between CD59 and CRIg was not of high 
importance in terms of binding of C-terminal CRIg to C3b. The fourth reagent tested, CRIg- 
3-CD59, demonstrated a slightly different binding profile (Fig.6.6 C). The interaction had a 
fast observed association rate (similar to the other reagents) but a slower rate of dissociation. 
However, accurate determination of Kd could not be achieved using the steady-state model 
because the interaction did not reach equilibrium. A possible reason for this could be a 
heterogeneous binding interaction.
6.2.1.4. Interaction of chemically cross-linked (XL) CD59-3-CRIg with C3b
As described in Chapter 5, the fusion proteins with an IgG3 hinge contained 5% dimer. To 
investigate whether the different binding profile observed for CRIg-3-CD59 was due to the 
presence of monomer and dimer in the protein preparation, and to test the hypothesis that 
dimerisation improved binding and targeting, the percentage of dimer was increased and the 
C3b binding affinity was re-evaluated.
A cross-linking strategy was developed to enhance dimerisation of CRIg-3-CD59 and 
CD59-3CRIg proteins (Fig. 6.7A). Bisamalemide cross-linker, BM(PEG)2 ( 1,8-bis 
(malemido) diethylene glycol; Thermo Scientific) was used to link sulphydryl groups (-SH) 
of the IgG3 hinge domain of monomeric fusion proteins to form a dimer. The cross-linking 
condition was optimised and explained in details in Chapter 2, section 2.6.2.
A two-fold molar excess of crosslinker to CD59-3-CRIg fusion protein provided the highest 
percentage of dimerisation and was selected as the final reaction condition. As assessed by 
SDS-PAGE analysis, the dimerisation was increased by 30% and approximately 35% of the 
protein was assembled in a dimer (Fig.6.7 B).The affinity of CD59-3-CRIg XL with C3b 
was studied. As with the other CD59-CRIg fusion proteins, a serial dilution of CD59-3- 
CRIg XL was prepared, starting at 363 pg/ml, and was flowed across the C3b coated chip 
surface. The binding sensorgram is shown on Fig 6.6 E. Similarly to CRIg-3-CD59 
interaction (Fig.6.6 C), the injection time of CD59-3-CRIg XL was not sufficient for the
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binding reaction to reach equilibrium. The Kd was estimated at 1.4 pM using steady state 
analysis although this was likely a significant under-estimate due to the unusual and 
heterogenous kinetics which made it difficult to reach equilibrium. It was clear that 
crosslinking increased binding significantly (at least 3.7-fold as estimated by Kd) when 
compared to CD59-3-CRIg; a portion o f the bound ligand bound very stably with a slow off- 
rate.
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Fig.6.7 Chemical crosslinking of CD59-3-CRIg fusion proteins. A. Schematic diagram 
representing CRIg-3-CD59 crosslinking. Crosslinking reaction o f CRIg-3-CD59 or CD59-3- 
CRIg with BM(PEG)2 ( 1,8-bis (malemido) diethylene glycol) was performed in PBS 
(pH7.5) containing 5mM EDTA. The reaction mixture was incubated for one hour at room 
temperature and the excess o f nonreacted reagent was removed by a desalting column. B. 
SDS-PAGE analysis of dimerisation. The efficiency of crosslinking was assessed by SDS- 
PAGE analysis under non-reducing conditions. Proteins before and after the crosslinking are 
visualised using Coomassie Blue. Monomer and dimer are indicated.
6.2.1.5. Interaction of monomeric and dimeric forms of CD59-2a-CRIg with C3b
The effect of dimerisation on binding to C3b was further analysed. SPR was used to 
establish the affinity of CD59-2a-CRIg monomer and dimer for mouse C3b.
The generation o f CD59-2a-CRIg proteins was explained in Chapter 3. We hypothesised 
that the three sulfhydryl groups present in IgG2a hinge (compared to only one cysteine in 
IgG3 hinge) would lead to a higher percentage of stable dimers being formed. SDS-PAGE
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analysis and gel filtration explained in Chapter 3 confirmed this and revealed that 45% of 
the protein was assembled in dimer.
Using gel filtration chromatography, CD59-2a-CRIg monomer and dimer were separated on 
Superdex 200 column (Fig.5.8B) and their affinity to C3b was analysed. Similarly to the 
other reagents, the monomer and dimers were diluted in a 1:2 serial dilution in biacore 
running buffer. Each concentration was flowed over the C3b coated chip in duplicate 
(Fig.6.8). The affinity was calculated as described for the other CD59-CRIg reagents. The 
affinity of the monomer (Ko=5pM) was comparable to the other reagents with CRIg at C- 
terminus. The affinity (K d) of the dimer was 0.7pM or 7-fold greater than the monomer. 
The analysis demonstrated that the dimerisation dramatically increased the affinity of the C- 
terminal CRIg for C3b. This is probably due to an increased avidity of the dimer for 
deposited C3b. These data suggested that both CRIg molecules in CD59-2a-CRIg dimer 
were able to bind simultaneously to separate C3b molecules and contribute to avidity.
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Fig.6.8 Equilibrium binding of monomeric and dimeric form of CD59-2a-CRIg with 
C3b. SPR sensograms of the interaction between C3b and (A) monomeric or (B) dimeric 
forms of CD59-2a-CRIg. Inset plots show steady-state affinity analysis for each reaction. 
The highest and the lowest concentration o f fusion proteins flowed across the surface are 
indicated.
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6.2.I.6. Interaction of CRIg-3-CD59 with iC3b
CRIg-3-CD59 protein was used to assess whether CRIg within fusion proteins was able to 
bind iC3b. Serial dilution o f the fusion protein was flowed across the iC3b chip surface (Fig. 
6.9). The analysis revealed that CRIg-3-CD59 bound iC3b. The affinity of CRIg-3-CD59 for 
iC3b could not be determined due to a heterogeneous binding interaction.
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Fig. 6.9 Representative sensogram of equilibrium binding between CRIg-3-CD59 and 
mouse iC3b. CD59-3-CRIg (1:2 serial dilution) was injected across the iC3b surface. The 
highest and the lowest concentrations o f the fusion protein in pM are indicated.
6.2.2. Binding to C3b-opsonised target cells as analysed by flow cytometry
The SPR analyses revealed that increased dimerisation o f the reagents translated into 
improved targeting. Flow cytometry was next performed to confirm this observation. The 
ability o f CD59-2a-CRIg monomer and dimer to target C3b-coated red blood cells was 
assessed.
CD59-2a-CRIg was selected for analysis because the dimeric form o f the reagent 
demonstrated increased C3b binding affinity (Biacore analysis). Furthermore it became 
evident from functional analysis explained in section 6.2.2 that this orientation of CD59 was 
beneficial for complement inhibition (haemolytic assays). Prior to flow cytometric analysis,
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the CD59-2a-CRIg was gel filtered using a Superdex 200 column to separate monomer and 
dimer.
The ability of CD59-2a-CRIg to target sites of complement activation (C3b/iC3b deposition) 
on the cell surface was assessed following method 2.7.8. Antibody-sensitised CD59- 
deficient erythrocytes were coated in C3b/iC3b via the classical pathway using 20% C6 
deficient mouse serum to prevent MAC formation and cell lysis. CD59-/- cells were chosen 
as target in order that anti-CD59 antibody could be used to detect CD59-2a-CRIg bound to 
the cells. C3 deposition was confirmed by flow cytometric analysis using anti-mouse C3 
antibody (clone 3/26). C3 fragments were deposited on the cells incubated with C6 deficient 
mouse serum but not on cells exposed to C3 deficient serum or in absence of serum 
(Fig.6.10 A).
Either the monomeric or dimeric form of CD59-2a-CRIg was added to the cells and allowed 
to interact for 30 minutes at room temperature. Binding of the reagent to the erythrocytes 
was detected with anti-mouse CD59 monoclonal antibody (aCD59a-7). Flow cytometry 
plots illustrating representative examples of CD59-2a-CRIg interaction to C3b-positive and 
C3-negative control erythrocytes are shown in Fig.6.10 B and C. The dimeric CD59-2a- 
CRIg bound the C3b-coated red blood cells in a dose dependent manner. No binding was 
detected in absence of C3 or serum (Fig.6.10 B and D). In contrast to the dimer, the 
monomer showed binding to erythrocytes in presence and absence of C3 deposition 
(Fig.6.10 C). The binding to complement-coated cells was greater than to the “bare” cells. 
As seen from Fig.6.10 D, more binding to C3-opsonised cells was detected for the monomer 
compared to the dimer.
6.2.3. Complement Inhibition
The ability of CRIg-CD59 fusion proteins to inhibit complement and to protect erythrocytes 
from killing was assessed in vitro using variety of haemolysis assays.
222
BD
£ 500
a 375
33 250 
°125 
010 10
£ 1672 
ol254 -
=  836 -
1 0 ‘
FL2
103 104
°  418 -
*-1226-
g  817 -
=  408 ‘
103 104
10J 104
■  RBC exposed to C6-/-serum □  RBC exposed to C3-/-serum
___________P=0.21______________
' ' t  '■ ________ P=0.05_________
l l  l l  M l  l l  m
50pg/ml 20pg/ml 50pg/ml 20pg/ml Opg/ml
Dimer Monomer
Fig.6.10 Targeting of CD59-2a-CRIg to C3-opsonised red blood cells. A. C3 deposition. 
Antibody-sensitised CD59-/- mouse erythrocytes were incubated with C6-/- (dotted line), 
C3-/-(black line) mouse serum or buffer (filled area). Deposition of C3b was detected using 
rat-anti mouse C3 mAb. B. Representative binding profile of CD59-2a-CRig dimer to C3b- 
coated cells. CD59-2a-CRIg dimer (40pg/ml) was added to the C3b-opsonised or control 
cells. Binding of recombinant proteins was detected using anti-CD59 mAb, CD59-2a-CRIg 
dimer bound the C3b-coated cells (dotted line). No binding was detected to the cells treated 
with C3-/- serum (black line) or with no serum (filled area). C. Representative binding 
profile of CD59-2a-CRIg monomer to C3b-coated cells. CD59-2a-CRIg monomer bound the 
C3b-opsonised red blood cells (dotted line). Less binding was observed to the cells treated 
with C3-/- serum (black line) or with no serum (filled area). D. Analysis of CD59-2a-CRIg 
binding to red blood cells. Data are mean ±SD of two determinations.
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6.2.3.1. Alternative pathway haemolysis assay
The capacities of CRIg-CD59 fusion proteins to inhibit complement AP activation and to 
protect cells from complement-mediated lysis were compared using a haemolysis assay. The 
assay is described in detail in Chapter 2, section 2.7.3. Briefly, GPE were target cells and rat 
serum was the source of complement. GPE were incubated with 1:2 serial dilution of the 
CD59-CRIg fusion proteins and rat serum at concentration sufficient to cause 90% lysis. To 
determine whether inhibition was due to CRIg or CD59, either anti-CD59 or anti-CRIg 
blocking antibodies were used to prevent one or other function.
As shown in Fig 6.11 A, CRIg-CD59, CD59-CRIg, CRIg-3-CD59 and CD59-3-CRIg were 
equally effective at inhibiting AP-mediated lysis of GPE. To assess whether the inhibition 
was due to the CRIg domain or to CD59 function, either CRIg or CD59 was blocked using 
specific anti-CRIg or anti-CD59 monoclonal antibodies. As expected, blockade of CRIg 
restored cell lysis and abolished the protective effect of all four agents (Fig.6.11 B). This 
may be due to either the complement regulatory function of CRIg, or due to inhibition of 
targeting as CRIg no longer binds the membranes.
The importance of the CRIg targeting domain for CD59-CRIg complement inhibitory 
efficacy was further investigated in the same AP assay using blocking anti-CD59 antibody. 
When the CD59-CRIg reagents were preincubated with anti-CD59 antibody the protective 
effect of the CD59-CRIg and CD59-2a-CRIg was abolished (Fig. 6.12 A and B). Blockade 
of the CD59 moiety in CD59-3-CRIg only partially reduced the capacity of the reagent to 
inhibit complement (Fig. 6.12 C). In contrast to the N-terminal CD59, the presence of the 
CD59 blocking antibody did not have any effect on inhibition when CD59 was located at the 
C-terminus of CRIg-CD59 or CRIg-3-CD59 (Fig. 6.12 D and E). This result suggests that 
CD59 at N-terminus inhibits complement with greater efficiency and thus provides better 
protection to the target cells.
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Fig. 6.11 CRIg effect on alternative pathway inhibition. GPE were incubated with rat 
serum and the ability of CD59-CRIg, CD59-3-CRIg, CRIg-CD59 and CRIg-3-CD59 to 
prevent alternative pathway-mediated haemolysis was determined. All four reagents were 
able to inhibit complement and to protect cells from complement mediated killing (A). To 
test whether this was a specific effect, CRIg was blocked using specific anti-CRIg 
monoclonal antibodies. Blockade of CRIg restored cell lysis and abolished the protective 
effect of all four agents (B).
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Fig. 6.12 CD59 effect on alternative pathway inhibition. GPE were incubated with rat 
serum and the ability of CD59-CRIg (A), CD59-2a-CRIg (B), CD59-3-CRIg (C), CRIg- 
CD59 (D) and CRIg-3-CD59 (E) in presence or absence of CD59 blocking antibody to 
prevent alternative pathway-mediated haemolysis was determined. All five reagents in 
absence of anti-CD59 mAb were able to inhibit complement and to protect cells from 
complement mediated killing. Blocking CD59 completely abolishes the protective effect of 
CD59-CRIg (A) and CD59-2a-CRIg (B) and only partially o f CD59-3-CRIg (C). The 
antibody did not have a significant effect on CRIg-CD59 (D) and CRIg-3CD59 (E) mediated 
inhibition
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6.2.3.2. Terminal pathway haemolysis assays
Both CRIg and CD59 functions were analysed in the AP haemolysis assay. It is likely that 
CRIg has a double effect. It inhibits complement activation due to blockade of C3/C5 
binding, but also targets the CRIg-CD59 proteins to the cell surface. To exclude the CRIg- 
driven complement inhibition and to specifically study only CRIg-mediated targeting and 
CD59-driven inhibition of MAC formation, a terminal pathway haemolysis assay was 
performed.
The ability of CRIg-CD59, CD59-CRIg, CRIg-3-CD59, CD59-3-CRIg, CRIg-2a-CD59 and 
CD59-2a-CRIg to target complement and inhibit the terminal pathway was assessed in a 
reactive-lysis system on GPE bearing preformed human C5b-7 sites in presence or absence 
of C3b on the same cells. C5b-7 sites were generated on the target red blood cells by adding 
purified C5b-6 and C7 proteins or C8 depleted human serum, in the latter case C3b was also 
deposited on the target cell surface. The cells were then incubated with dilutions of mouse 
serum as a source of C8 and C9 and haemolysis was measured. The formation of C5b-7 sites 
and lysis development are described in detail in Chapter 2, sections 2.7.4.1 and 2.7.4.2.
6.2.3.2.I. CD59-CRIg function on cells bearing C5b-7 sites in absence of C3b
The ability of CD59 within fusion proteins to inhibit the terminal pathway was analysed on 
GPE bearing C5b-7 sites generated by incubation with purified terminal pathway 
components (Chapter 2, section 2.7.4.2). The cells were pre-incubated with 1:3 serial 
dilutions of CRIg-CD59 fusion proteins, followed by addition of C3 deficient mouse serum 
to develop lysis at a predetermined concentration which causes 50-60% lysis in the absence 
of inhibition. To exclude any non-specific protein effects on cell lysis, a dilution series of 
CRIg-fH (generated in house) was used as a negative control. This protein contains CRIg 
but has no terminal pathway regulatory activity. Haemoglobin release from the cells was 
measured and percentage lysis was determined.
All CD59-CRIg fusion proteins inhibited the terminal complement pathway in a dose 
dependent manner. CD59-CRIg, CD59-3-CRIg and CD59-2a-CRIg had equal capacity to 
protect the target cells from complement-mediated lysis (Fig.6.13). In contrast, constructs
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with CD59 at the C-terminus (CRIg-CD59, CRIg-3-CD59 and CRIg-2a-CD59) had 
decreased complement inhibitory function. This complement inhibitory capacity of the C- 
terminal CD59 was not observed in the AP haemolysis test. However the assay used here 
was specifically designed to study the terminal pathway and small changes in its activity 
could be detected. Nevertheless the data obtained by the two assays strongly suggests that 
the position and/or the orientation of CD59 within fusion proteins was important for its 
inhibitory function.
6.2.3.2.2. CRIg-CD59 function on cells bearing C5b-7 sites in presence of C3b
All tested CD59-CRIg fusion proteins demonstrated ability to block the terminal pathway. 
To investigate the capacity of reagents to target C3b deposition and then to inhibit MAC 
formation (i.e. in addition to working from the fluid phase), GPE were incubated with C8- 
depleted human serum to allowed C3b deposition and the generation of C5b-7 sites on the 
cell surface. Wash and non-wash haemolysis assays were used to assess the ability of the 
reagents to target C3 fragments and to physically bind to the cells to inhibit complement. In 
the first, non-wash assay, the reagents were present throughout, whilst they were washed out 
before subjecting the cells to complement attack in the second assay. Two proteins 
containing both CD59 and CRIg but not fused to each other were used as controls as they 
have no capacity for delivering CD59 to the cell surface. Generation of the control proteins 
was explained in Chapter 5, section 5.2.3.
For the non-wash assay the C5b-7 sites were generated on GPE using C8-depleted human 
serum. The cells were pre-incubated with 1:2 serial dilutions of CRIg-CD59 fusion proteins, 
followed by addition of C3 deficient mouse serum in a predetermined concentration causing 
50-60% lysis. Percentage lysis was determined.
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Fig.6.13 Terminal pathway regulatory function of CD59-CRIg fusion proteins. Guinea 
pig erythrocytes on which C5b-7 complex was preformed were attacked with C3 deficient 
mouse serum. The ability of C-terminal (closed circle) and N-terminal CD59 (open circle) 
within CRIg-CD59 and CD59-CRIg (A), CRIg-3-CD59 and CD59-3-CRIg (B) and CRIg- 
2a-CD59 and CD59-2a-CRIg (C) to inhibit MAC formation was assessed. CD59 located at 
the N-terminus of the protein was more effective complement inhibitor compared to the C- 
terminal CD59.
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In agreement with previous experiments, CD59-CRIg, CD59-3-CRIg and CD59-2a-CRIg, 
containing CD59 at N-terminus were more effective inhibitors than the reagents in reverse 
orientation. As revealed in Fig.6.14, CD59-3-CRIg was less effective than CD59-CRIg and 
CD59-2a-CRIg. Among the reagents with C-terminal CD59, only CD59-3-CRIg showed no 
complement inhibition and cell protection.
The soluble CD59 derived from CD59-CRIg cleavage with 3C HRV protease did not inhibit 
complement in this assay (Fig.6.15A). This result suggests that CD59 treated with the 
reducing agent THP not only lost the antibody epitope (suggested by the Western blot), but 
also lost the binding sites for C8 and C9 and was rendered non-functional. In contrast to the 
cleaved CD59-CRIg, the soluble CD59 generated after papain digest of CD59-2a-CRIg was 
able block complement and protect the cells in a dose dependent manner (Fig.6.15C).
The capacity of CD59-CRIg fusion proteins to target complement and block the terminal 
pathway was further explored. The wash assay allows the targeting ability of the reagents to 
be studied. Only reagents directly bound to the cell surface would be able to provide cell 
protection. GPE C5b-7 were prepared as described for the non-wash assay. Dilutions of 
CD59-CRIg, CRIg-CD59, CD59-2a-CRIg, CRIg-2a-CD59, CD59-3-CRIg, CRIg-3-CD59 
and the two control proteins in PBS/1 OmM EDTA were then added and incubated for 30 
minutes at 37°C. Cells were washed once by centrifugation in PBS/EDTA prior to the 
addition of the selected dilution of mouse C3 deficient serum required to develop 
haemolysis. Percentage lysis was measured as described above. The non-wash revealed that 
CD59-CRIg, CRIg-CD59, CD59-2a-CRIg, CRIg-2a-CD59 and CD59-3-CRIg are able to 
inhibit complement to a different extent. However, after washing the GPE C5b-7, only the 
reagents containing IgG2a remained bound to the cells and inhibited MAC-deposition 
(Fig.6.16). This was in agreement with the SPR analysis which showed that CD59-2a-CRIg 
had high affinity for a C3b-coated chip surface (section 6.2.1.1.3.3, table 6.3).
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Fig.6.14 Targeting and terminal pathway regulatory function of CD59-CRIg fusion 
proteins in non-wash assay. GPE on which C3b and C5b-7 was deposited were generated 
using C8-/- human serum; these were then incubated with C3 deficient mouse serum to 
develop MAC. The ability o f C-terminal (closed circles) and N-terminal CD59 (open 
circles) within CRIg-CD59 and CD59-CRIg (A), CRIg-3-CD59 and CD59-3-CRIg (B) and 
CRIg-2a-CD59 and CD59-2a-CRIg (C) to target C3-coated cells and inhibit MAC formation 
was assessed. CD59 located at the N-terminus of the protein was more effective complement 
inhibitor compared to the C-terminal CD59.
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Fig.6.15 Targeting and terminal pathway regulatory function of CD59-2a-CRIg and 
control proteins in non-wash and wash assay. Guinea pig erythrocytes with C3b and C5b- 
7 on their surface were incubated with intact CD59-2a-CRIg (black diamonds), papain 
digested CD59-2a-CRIg (open triangles) and CD59-CRIg cleaved with 3C RHV protease 
(black squares) to allow binding C3b-coated cells. Lysis was developed with C3-deficient 
mouse serum. Ability to inhibit MAC formation was assessed in non-wash (A and C) and 
wash (B and D) assays. The intact fusion protein was able to provide cell protection in both 
assays, while this effect was lost in the wash assay after CD59-2a-CRIg was cleaved with 
papain (D). CD59-CRIg treated with 3C HRV protease did not inhibit complement in any of 
the assays (A and B).
Similarly to the result obtained from the non-wash assay, the cleaved CD59-CRIg (the 
cleavable reagent) did not inhibit the terminal pathway (Fig.6.15 B). However in contrast to 
the non-wash assay, the other control protein obtained from the papain cleavage of CD59- 
2a-CRIg lost its inhibitory activity in the wash assay indicating that CRIg was essential for 
targeting CD59 to the cells (Fig.6.15 D).
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Fig.6.16 Targeting and terminal pathway regulatory function of CD59-CRIg fusion 
proteins in wash assays. C3b was deposited on Guinea pig erythrocytes and C5b-7 complex 
was preformed using C8-/- human serum to activate complement. MAC was developed 
using C3 deficient mouse serum. The ability o f C-terminal (closed circle) and N-terminal 
CD59 (open circle) within CRIg-CD59 and CD59-CRIg (A), CRIg-3-CD59 and CD59-3- 
CRIg (B) and CRIg-2a-CD59 and CD59-2a-CRIg (C) to target C3-tagged cells and inhibit 
MAC formation was assessed. After washing the target cells only CD59-2a-CRIg and CRIg- 
2a-CD59 remained bound to the surface and provided protection.
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6.3. Discussion
OmCI inhibits the complement system by blocking C5 activation. It has been previously 
shown that one molecule of pOmCI binds one molecule of human C5 with a high affinity 
comparable to antigen-antibody interaction [176]. Here, the ability of OmCI to bind mouse 
and human C5 after the fusion with Fc was assessed and compared to pOmCI. It has 
previously been shown in the literature that fusion of proteins to Fc fragments can causes 
steric hindrance and render the protein of interest less active [327]. Therefore it was 
important to check that the OmCI within the fusion protein could still bind its ligand, C5. 
Biacore analysis of OmCI with or without the Fc domain revealed that attachment to the Fc 
reduced the affinity of OmCI-Fc for human C5 ~2-fold and for mouse C5 ~13-fold. This is 
probably due to steric hindrance in the OmCI-Fc, which affects the interaction of OmCI with 
its ligand. I suggest that the access of C5 to the first OmCI was normal, but access to the 
second OmCI site was sterically hindered resulting in a weak interaction so the overall 
affinity representing both interactions was reduced. Nevertheless, the respective affinities 
of llnM  and 5.3nM are still in the order of antibody/antigen affinity. Interestingly, as 
determined by the Rmax (table 6.1), pOmCI and OmCI-Fc were able to bind more mouse 
C5 molecules when compared to human C5. A possible explanation could be that the second 
molecule of mouse C5 bound weakly to OmCI-Fc while the second human C5 was not able 
to interact with the fusion protein.
Notwithstanding the fact that the overall affinity for C5 was lower, OmCI-Fc was as 
effective as pOmCI at inhibiting complement-mediated lysis when used in equimolar 
amounts. The concentration of OmCI-Fc and pOmCI that inhibited complement-mediated 
lysis by 50% (IH50) was calculated and compared. IH50 is the most widely used measure of 
drug inhibition. The analysis revealed that slightly less OmCI-Fc was needed to bring about 
50% inhibition of cell lysis in all assays compared to pOmCI. However OmCI-Fc 
demonstrated different kinetic of complement inhibition compared to pOmCI with the two 
OmCI moieties binding C5 with different affinity (suggested by the SPR analysis) and 
therefore a direct comparison of OmCI-Fc and pOmCI activity using IH50 was inappropriate.
In addition to IH50, other key factors, describing the effect of pOmCI and OmCI-Fc on 
complement, are the steepness of the dose response curve and the threshold dose level for 
inhibiting MAC formation. Increase in the concentration of the inhibitors resulted in a
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decrease in the number of the C5 molecules able to form MAC. However, only a single C5 
molecule is needed to form a MAC and even a very small amount of C5 was sufficient to 
cause cell lysis. For this reason a noticeable anti-complement effect was not observed until 
“the last” C5 molecule had been neutralised. pOmCI bound tightly to C5 and therefore a a 
small increase in drug concentration resulted in a dramatic increase in complement 
inhibition and a steep dose response curve. In contrast to pOmCI, the inhibitory effect of 
OmCI-Fc increased much more slowly with increasing the drug concentration. This could be 
explained with the weaker OmCI-Fc-C5 interaction (with one OmCI-arm binding C5 with 
the expected affinity and second-binding with lower affinity). Therefore the OmCI-Fc 
response curve was less sharp with higher threshold dose level (the point at which 
complement inhibition first appear) when compared to pOmCI.
The inhibitory effects of pOmCI and OmCI-Fc on the complement system also differed in 
the threshold dose level of these two reagents. pOmCI had a lower threshold compared to 
OmCI-Fc. The difference in the threshold effect and the steepness of the dose response 
curve could be explained with the lower overall affinity of OmCI-Fc to C5 when compared 
to pOmCI. pOmCI bound more tightly to C5 leading to rapid complement inhibition 
(demonstrated by the steeper slope and the low threshold).
Targeted reagents comprised of the sole membrane regulator of MAC assembly, CD59, and 
the complement receptor, CRIg, were comprehensively characterised in vitro in order to 
select the optimal CD59-CRIg anti-complement reagent to take for further analysis in vivo.
The C3b/iC3b-targeting activity of the CRIg domain was assessed by SPR and flow 
cytometry. The SRP analysis revealed that CRIg within fusion proteins was able to bind C3b 
and iC3b.The dimeric proteins with CRIg located at the N-terminus showed higher C3b 
binding affinity than the proteins in reverse orientation. This implies that positioning of the 
receptor with regards to CD59 was of high importance for CRIg function. Even though the 
Kd of CRIg-3-CD59 interaction with C3b could not be calculated, the binding profile 
revealed that this reagent dissociated more slowly from the surface compared to CRIg- 
CD59. This was due either to the longer spacing domain between the CRIg and CD59 
domains, providing greater conformational flexibility, or to the 5% dimerisation which 
occurred in the presence of the IgG3 hinge. Two strategies were tested to increase the 
dimerisation. First, CD59-3-CRIg and CRIg-3-CRIg were chemically cross-linked to
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generate homodimers and secondly, the IgG3 hinge was replaced with the hinge from 
IgG2a. Although dimerisation was incomplete, replacing the hinge offered an advantage 
over chemical cross-linking and approximately 45% of the protein was assembled in a 
dimer. It was found than the C-terminal CRIg within CD59-2a-CRIg dimer bound C3b with 
high affinity similar to the N-terminal CRIg within CRIg-CD59 molecule. In other words, 
the low C3b affinity of the C-terminal CRJg was overcome by increasing the C3b binding 
avidity through dimerisation.
The targeting capacity of CD59-2a-CRIg reagent was verified by flow cytometry. The 
CD59-2a-CRIg dimer specifically bound C3b/iC3b deposited on the erythrocyte surface 
while the monomeric form interacted with the cell in the absent of C3 fragments. An 
enhanced binding of CD59-2a-CRIg monomer with C3b/iC3b coated cells was observed 
which could be an additive effect of CD59-2a-CRIg monomer binding to C3b and the 
unknown ligand simultaneously. The result suggests that CD59-2a-CRIg binds to a cell 
ligand different to C3b (or iC3b) and the epitope for this is sterically hindered in the dimeric 
reagent.
The ability of CD59-CRIg fusion proteins to target to a surface and/or to inhibit complement 
activation was explored using alternative and terminal pathway haemolysis assays. All 
proteins were effective at inhibiting the AP. This was not surprising since during my PhD it 
became evident that CRIg itself could inhibit the AP [167]. The observation was confirmed 
using anti-CRIg blocking antibody capable of abolishing the complement inhibitory effects 
of the reagents. However blocking CRIg binding to C3b/iC3b deposited on the cell surface 
did not only suppress its AP inhibitory activity but also prevented CRIg-mediated targeting 
of CD59 to the surface. The importance of CRIg-mediated targeting for complement 
inhibitory activity of the CD59-CRIg reagents was proved by blocking inhibitory function of 
CD59. It was demonstrated that CD59 at the N-terminus in particular, contributed to the 
complement inhibitory capacity of the whole protein. The conclusion from this experiment 
was that both CD59 and CRIg function better when located at the N-terminus of the fusion 
proteins. Interestingly, in contrast to other agents, CD59 at the N-terminus of CD59-3-CRIg 
reagent showed only minimal effect on complement. This could be due to restricted 
flexibility of the IgG3 hinge which prevented CD59 from free movement. In addition to that 
it was also possible the CRIg at C-terminus in this reagent functioned well compared to the 
other reagents with such orientation (CD59-CRIg and CD59-2a-CRIg). This could be due to
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space between CRIg and CD59 provided by the IgG3 hinge. The hinge moved apart the two 
moieties of the chimeric molecule and thus prevented any steric hindrance within CRIg. The 
difference in function between N- and C-terminal CD59 was not unexpected. It was 
previously shown that positioning CD59 relative to CR2 within CR2-CD59 is important for 
its function. In contrast to results obtained in this study, C-terminal CD59 was found more 
active than N-terminal CD59 [330]. This difference could be due to the different 
complement receptor used for targeting.
The effect of CRIg-CD59 specifically on the terminal complement pathway was assessed. 
Firstly, the inhibitory effect of the CD59-CRIg reagents was studied in the absence of C3b 
on the target cell surface, then it was studied when C3b was present on the membrane, 
enabling targeting via CRIg. This enabled the dissection of CD59 inhibitory function and 
CRIg targeting.
A difference in function between proteins containing CD59 at N- or C-terminus, with N- 
terminal CD59 being more active, was also seen in terminal pathway assays in the absence 
of C3 (so only CD59, not CRIg was active on the target cells). While this assay studied only 
CD59 function, the combined effect of CRIg-mediated targeting and CD59 function was 
investigated in different terminal pathway specific haemolysis assays (non-wash and wash) 
in present of C3b. Using C8-depleted serum to deposit C3b/iC3b and C5b-7 and C3 
deficient serum to finish off the assay, allowed to study CD59-driven complement inhibition 
and CRIg-mediated targeting in absence of CRIg complement suppression.
In a non-wash assay where the reagents were present throughout and C3b was deposited on 
the target cells, the complement inhibitory activity of the CD59-CRIg, CD59-3-CRIg and 
CD59-2a-CRIg was increased when compared to CRIg-CD59, CRIg-3-CD59 and CRIg-2a- 
CD59 respectively. The result further confirmed that CD59 at N-terminus of the protein was 
functionally more active than the C-terminal CD59. In contrast to the other terminal pathway 
assays, where the ligands for CRIg were not present on the cell surface, here CD59-3-CRIg 
and CRIg-3-CD59 reagents showed reduced or no functional activity respectively. This may 
be related to the rigid nature of the IgG3 hinge that prevents the simultaneous interactions of 
the C3 fragments and MAC components. It is very likely that upon binding of CRIg to 
C3b/iC3b on the cell surface, CD59 was held at distance from the cell membrane. The IgG3
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hinge did not allow the cell surface-bound reagent to move freely in a more favourable 
orientation for interaction with C8 and C9.
In a wash assay, when the inhibitors not bound to the target cells were removed, the 
complement-blocking capacity of the untargeted CD59 (CD59-2a-CRIg cleaved with papain 
and CRIg-CD59 digested with 3C protease) was completely lost whereas CD59-2a-CRIg 
retained its complement inhibitory activity even after washing of the erythrocytes. This 
demonstrated that the increased avidity effect of CRIg targeting successfully delivered 
CD59 to the target cells. In contrast to the non-wash assay, the two dimer-containing 
reagents CRIg-2a-CD59 and CD59-2a-CRIg showed similar complement inhibitory activity. 
This suggests that the good targeting through the N-terminal CRIg compensated for the less 
effective complement inhibition via the C-terminal CD59 to achieve identical overall anti­
complement effect of CRIg-2a-CD59 and CD59-2a-CRIg reagents.
The data in this Chapter demonstrate that CD59 at the N-terminus was more effective at 
protecting erythrocytes than C-terminal CD59, and that CRIg at the C-terminus had lower 
C3b-binding affinity. However the effect of the dimerisation balanced functional activities 
of C- and N-terminus CRIg and CD59, and CD59-2a-CRIg and CRIg-2a-CD59 
demonstrated equal capacity to protect the target cells from complement attack. In contrast 
to the IgG2a hinge, the hinge of IgG3 restricted the flexibility of CD59-3CRIg and CRIg-3- 
CD59 molecules and thus reflected on the overall complement inhibitory activity of these 
reagents. The in vitro targeting analysis revealed CD59-2a-CRIg reagent as a promising 
therapeutic. This protein expressed as a dimer (45%) and provided efficient targeting 
through increased avidity to C3b/iC3b and good cell protection from complement-mediated 
killing. The project will therefore now focus upon CD59-2a-CRIg.
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Chapter 7. In vivo and ex vivo functional analysis of OmCI-Fc and CD59-CRIg fusion
proteins
The specific features of the OmCI-Fc and CD59-CRIg fusion proteins which are essential 
for therapy were explored in vitro (Chapter 6). The focus is now moved to analysis of the 
reagents ex vivo and in vivo. Chapter 7 opens with a section describing the pharmacokinetic 
parameters of OmCI-Fc and the establishment of a dosing regimen for anti-complement 
treatment. The Chapter continues with in vivo and ex vivo analysis of the most promising 
CD59-CRIg fusion protein characterised in Chapter 6, CD59-2a-CRIg. The capacity of 
CD59-2a-CRIg to target complement activation in tissues will be assessed.
7.1. OmCI-Fc
7.1.1. Clearance of OmCI-Fc in mice
It was previously shown that that pOmCI given to experimental animals bound C5 and 
circulated as a complex. However, free pOmCI was rapidly cleared from the circulation; 
consequently, it had a short half-life in vivo. Only a trace amount was detected in plasma 30 
minutes post iv administration in C5 deficient mice [176]. The short half-life of pOmCI 
would limit its therapeutic use to acute disease and clinical conditions such as I/R. The 
purpose of generating OmCI-Fc was to create a soluble drug with extended circulating half- 
life for treatment of chronic disorders. To determine whether fusion to the Fc domain of 
antibody prolonged the circulating half-life of OmCI, OmCI-Fc was injected into C5 
deficient or sufficient mice and its presence in the circulation and half-life were investigated 
by Western blot analysis and ELISA.
7.1.1.1. OmCI-Fc elimination in the absence of C5
To assess the affect of Fc fusion on clearance of OmCI, a mixture of OmCI-Fc (75 pg) and 
pOmCI (150pg) was administered iv in C5 deficient mice. At specific times following
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administration, plasma samples were harvested (Fig.7.1A) and analysed for the presence of
OmCI-Fc and pOmCI by Western blot (Fig.7.1B).
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Fig.7.1 Clearance of OmCI-Fc and pOmCI in the absence of C5. A. Schematic 
representation of the experimental protocol. C5 deficient mice were given a mixture of 
150pg pOmCI and 75pg OmCI-Fc iv. Plasma was collected at specific times post 
administration. B. Western blot analysis o f pOmCI and OmCI-Fc illustrating clearance from 
the circulation. Plasma samples (lp l)  from the experimental animals along with serum from 
a naive mouse and a mixture o f purified pOmCI and OmCI-Fc were subjected to SDS- 
PAGE on a 15% gel. The proteins were transferred to a nitrocellulose membrane and 
detected with rabbit anti-OmCI polyclonal antibody. Arrows indicate the position of pOmCI, 
OmCI-Fc monomer and dimer. A background band (probably mouse Ig) with molecular 
weight similar to the mass of OmCI-Fc was present in the plasma. For this reason, the 
OmCI-Fc monomer (visible when the protein is denatured by SDS) was used as an 
indication o f OmCI-Fc presence in the serum. The blot is representative of three animals. C. 
Densitometry analysis of western blot. Protein levels were evaluated by densitometric 
analysis o f scanned autoradiographs using ImageJ software. The results are representative 
from three animals and are presented as percentage of proteins injected into the animals.
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Fc fusion proteins are generally expressed as disulphide-linked dimers. However 
nondisulfide-linked dimers can also be formed [409] and due to the non-covalent nature of 
the bond it dissociates and appears as monomer when analysed by Western blot. OmCI-Fc 
monomer and dimer were seen when the plasma samples were subjected to Western blot 
analysis (Fig.7.1B). Densitometric analysis was performed to evaluate the pOmCI and 
OmCI-Fc levels in the circulation (Fig.7.1 C). A band with molecular mass identical to the 
OmCI-Fc dimer was observed across the Western blot. This band was also apparent in the 
naive serum indicating that this was a background band on the blot. For this reason the 
OmCI-Fc monomeric form was used to analyse the OmCI-Fc presence in the circulation. 
OmCI-Fc was detected at all time points including five days after administration. In contrast 
to OmCI-Fc, pOmCI was present in the serum only for a short time period after 
administration. Trace amounts of the protein were detected at one hour after injection and it 
was fully cleared after six hours. This result indicated that the Fc domain of mouse IgG2a 
significantly decreased the elimination rate of OmCI.
7.1.1.2. Half-life OmCI-Fc in the presence of C5
Small molecules such as pOmCI are cleared by the kidneys and excreted in the urine. Higher 
molecular weight molecules, such as OmCI-Fc are cleared through the kidneys more slowly 
and liver clearance takes over as the molecular weight increases.
To measure the half-life, an important pharmacokinetic parameter, of OmCI-Fc and compare 
it to pOmCI, these proteins were injected into C57B1/6 mice iv. The animals were divided 
into two groups (n=5) and received 500pg (6pMols) of OmCI-Fc or 200pg (12pMols) 
pOmCI intravenously. The presence of two OmCI molecules per fusion protein was taken 
into account when calculating the OmCI concentration in pMols. Blood samples were 
collected at various time points and plasma levels of OmCI-Fc and pOmCI quantified by 
ELISA (Chapter 2, section 2.4.6 and 2.8.4). The protein concentration was expressed as a 
percentage of initial dose injected and was plotted against time in hours (Fig.7.2).
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Fig.7.2 In vivo half-life of OmCI-Fc and pOmCI in C5-sufficient mice. A. Schematic 
diagram of the two-compartment model. The proteins enter the central compartment where 
they reach equilibrium before equilibrating with the peripheral compartment. B. Graph 
showing typical profile of the two-compartment model with plasma concentration plotted 
against time. The model is characterised by a rapid distribution (a-) phase followed by an 
elimination (P-) phase. The extrapolation o f the elimination line back to the y axis, gives 
CPO, a theoretical point representing the concentration that would have existed at the start if 
the dose had been instantly distributed. The time needed for the concentration to drop by 
50% can be calculated from this new straight line and the terminal slope; this is the 
elimination half life. Likewise, a similar procedure could be performed on the a phase: the 
distribution half life. C. p-phase (elimination) half-life of OmCI-Fc and pOmCI. Groups of 
five mice were injected iv with pOmCI or OmCI-Fc. The concentration o f the OmCI 
proteins in mouse plasma was measured by ELISA. The log of the proteins remaining in the 
circulation was expressed as a percent o f the injected dose against time (hours after 
injection). The inset shows percentage pOmCI and OmCI-Fc remaining in the circulation 
one hour after injection.
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The half-life of the reagents was calculated based on the two-compartment body model 
(Fig.7.2A and B). The model was based on two assumptions. The first assumption was that 
the body is represented as a central compartment (vascular space and well-perfused organs 
such as liver and kidney) and peripheral compartments (poorly perfused tissues such as 
muscle, lean tissues, and fat). The second assumption was that drug elimination follows 
linear, first order kinetics.
Upon iv administration into the central compartment, drugs rapidly distribute into peripheral 
compartments and their concentration in the first compartment rapidly decreases. This is the 
initial phase (a-phase) of distribution of the protein into extracellular fluid. Distribution into 
peripheral compartment continues until the drug concentration in both compartments reaches 
and maintains equilibrium. At the same time the drug is slowly cleared from the body via the 
central compartment and the concentration in both compartments decreases proportionally as 
the elimination in plasma continues. This elimination phase (P-phase) starts immediately 
after drug administration and occurs alongside the drug distribution. It represents the true 
plasma clearance, therefore p-phase half-life (ti/2p) was calculated and used to assess the 
clearance of OmCI-Fc and pOmCI. The half-life was determined using the terminal slope of 
the elimination (p-) phase using the following equations:
Integrated first-order rate law: 
ln[Cp]= -kt+In [CpO] or Cp=CpOe ~kt 
In [CpO/2] = In CpO-k x ti#
In (CpO/(2xCpO))=-k x im 
ln2=k* ti/2 
ti/2= ln2/k 
ti/2=0.693/k
ti/2 -half-time of elimination, the time taken for the plasma concentration to fall to half to its 
original value.
CpO- start concentration
CpO/2-concentration at time when half of CpO is cleared from circulation 
k-the slope of the elimination phase
The maximum plasma concentration of pOmCI and OmCI-Fc was observed at 5 minutes 
(first bleeding time point) after zv administration and remained almost unchanged over the
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next 10 minutes (Fig.7.2.C). Clearance of OmCI-Fc from the plasma was significantly 
slower than that of the pOmCI (P=0.001). The half-life of OmCI-Fc was 96 hours whereas 
pOmCI was cleared much more rapidly and demonstrated a half-life of 38 hours, 
presumably due to its complex with C5 [176].
7.1.2. In vivo inhibitory activity
To assess OmCI-Fc functional activity in vivo, the fusion protein was given to mice and its 
impact on systemic complement activity was studied. A comparison with pOmCI was made 
to investigate how the fusion to Fc of antibody modified the complement inhibitory capacity 
of the reagent in vivo. The combine effect of pOmCI and OmCI-Fc on complement was also 
studied to establish a strategy for effective complement inhibition.
7.1.2.1. pOmCI and OmCI-Fc- individual effect on complement inhibition
To assess the ability of OmCI-Fc to block C5 in vivo and to investigate whether the 
prolonged half-life translated in to extended complement inhibition, OmCI-Fc (300pg) and 
pOmCI (200pg) were injected into C57bl/6 (n=5 in each group) mice through the tail vein. 
Higher dose of OmCI-Fc was used because the OmCI moieties contribute only one third of 
the molecular mass of the protein. The animals were tail bled before being given any 
reagents, and also at different time points post-injection. A schematic representation of the 
experimental plan is shown in Fig.7.3.A. Complement activity was assessed by haemolysis 
assay and quantified by the amount of the test serum necessary to kill 50% of antibody- 
sensitised rabbit erythrocytes (CH50). The serum complement activity was expressed as 
percent of the activity prior to pOmCI or OmCI-Fc administration (Fig.7.3B).
A single injection of pOmCI and OmCI-Fc was able to completely block the complement 
system at the first hour after injection when no complement activity was detected. An 
increase in the serum haemolytic activity (66%) was measured over the next 12 hours in the 
mice injected with pOmCI while the complement activity remained very low (15%) in mice 
injected with OmCI-Fc. The pOmCI treated animals had restored their haemolytic activity
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48 hours after the drug administration while only 57% activity was measured at the same 
time point in OmCI-Fc injected mice.
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Fig.7.3 Effect of OmCI-Fc and pOmCI on complement haemolytic activity in vivo. A.
Schematic representation of the experimental protocol. C57B16 mice were injected with 
pOmCI 200pg or OmCI-Fc (300pg) through the tail vein. Blood was collected at specific 
time point post administration (indicated with tick marks). A pre-injection serum sample 
(time -1) was also harvested. B. Serum haemolytic activity. CH50 was determined by 
haemolysis assay. The results are expressed as percent complement activity compared with 
the activity pre-administration. Results are means o f determinations from five animals, and 
vertical bars represent standard deviations.
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7.1.2.2. pOmCI and OmCI-Fc-cooperative effect on complement inhibition
To establish an effective and potentially less expensive strategy to therapeutically inhibit 
complement, the cooperative effect of pOmCI and OmCI-Fc was studied in vivo. pOmCI, 
produced in yeast or bacteria [175], is less expensive than OmCI-Fc produced in 
mammalian expression system. pOmCI was shown to block C5 for over an hour after 
administration. OmCI-Fc was as effective as pOmCI at inhibiting complement in vitro 
(Chapter 6), and demonstrated longer half-life and extended complement inhibitory activity 
when compared to pOmCI. The advantages of both reagents pOmCI, being an inexpensive 
and powerful C5 inhibitor and OmCI-Fc being a powerful complement blocker with 
extended half-life, was combined in a single therapeutic strategy that could be of benefit to 
patients with complement driven disorders.
The approach was modelled in C57B1/6 mice. The two proteins were injected iv 
sequentially. A bolus of pOmCI was given to the animals to block all circulating C5 and 
provide initial complement inhibition. As shown in Fig.7.1, free OmCI was rapidly cleared 
from the circulation meaning that the excess of OmCI (not bound to C5) was eliminated. To 
block C5 generated in the liver and to maintain complement inhibition, the mice were 
injected with OmCI-Fc which should circulate and ‘mop up’ any newly-synthesised C5. The 
animals were tail bled before being given any reagents, and also at different time points 
post-injection. C5 or serum complement activity was monitored.
A preliminary experiment was carried out to assess whether OmCI-Fc was able to block 
complement in vivo in a dose-dependent manner and to establish the dose range of OmCI-Fc 
required for effective complement inhibition. Two mice were injected with OmCI (200pg) 
to achieve rapid systemic C5 inhibition [176] followed by iv injection of OmCI-Fc at 
concentrations of 50pg or 150pg one hour later to determine the optimal dose sufficient to 
maintain good complement inhibition. A schematic representation of the experimental plan 
is shown in Fig.7.4.A.
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Fig.7.4 Effect of pOmCI and OmCI-Fc on C5 activity in mice. A. Schematic 
representation of the experimental protocol. C57B1/6 mice were given 200pg OmCI 
intravenously at time 0. One hour later the mice were injected with 50pg (n=l) or 150pg 
(n=l) OmCI-Fc through the tail vein. Blood was collected at specific time point post 
administration (indicated with tick marks). Test serum sample at lh  was harvested 
immediately before OmCI-Fc administration. A pre-injection serum sample (time 0) was 
also harvested. B. C5 activity was determined by haemolysis assay. Haemolytic activity in 
the test mouse serum was assessed using antibody sensitised rabbit erythrocytes in presence 
of C5-/-mouse serum. Results are expressed as percentage C5 activity compared with pre­
injection levels.
C5 activity was assessed by haemolysis assay in presence of 8% C5 deficient mouse serum 
and quantified by the amount of the test serum necessary to kill 50% of antibody-sensitised 
rabbit erythrocytes (CH50). The C5-deficient serum provided a source of complement
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(except C5 component) and allowed the use of a small amount of the experimental serum 
without affecting C5 activity. C5 activity of the test samples was expressed as percent of C5 
activity prior to pOmCI and OmCI-Fc administration (Fig.7.4 B).
As shown in Fig.7.4B, injection of OmCI was able to completely block C5 activity 
measured one hour after administration. C5 was inhibited for 11 hours after OmCI-Fc 
injection with the higher dose of OmCI-Fc providing more effective complement inhibition; 
this was best demonstrated at 48 hours after treatment when C5 activity was 28% of pre­
treatment levels in the mouse which received 150pg OmCI-Fc. At 96 hours time point, C5 
reached normal level of activity.
To investigate whether increasing the dose of OmCI-Fc would result in extended 
complement inhibition, five mice were injected with 200pg of pOmCI and 300pg of OmCI- 
Fc following the timeline illustrated in Fig.7.4A. Serum samples were removed at intervals. 
Complement activity was assessed by haemolysis assay and quantified as described above. 
The serum complement activity was expressed as percent of the activity prior the treatment 
and compared to the mice that received pOmCI or OmCI-Fc alone (Fig.7.5).
The mice that received the combined pOmCI and OmCI-Fc treatment showed complete 
complement inhibition at the first hour after OmCI injection. Very low complement activity 
{<21%) was detected over the first 24 hours after OmCI-Fc was given to the mice. As seen 
in Fig. 7.5 there was a dramatic reduction of complement function in these animals 
compared to the mice that received pOmCI alone. However no difference was observed 
between the groups that received pOmCI-OmCI-Fc and OmCI-Fc alone over the first 48 
hours of the experiment.
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Fig.7.5 Effect of OmCI treatment on complement haemolytic activity in vivo. Two
groups of mice were injected intravenously with 200pg of pOmCI (black squares) or 300pg 
OmC-Fc (open triangles) at time 0. A third group of animals received a combined treatment 
with pOmCI and OmCI-Fc (black circles) according to schematic illustrated in fig. 7.4. 
CH50 was determined by haemolysis assay. The results are expressed as percent 
complement activity compared with activity pre-administration. Results are means of 
determinations from five animals, and vertical bars represent standard deviations.
7.I.2.3. Routes of administration: subcutaneous versus intravenous
The biological activity of a protein drug and duration of its effect may depend on the route 
of administration. It is important that during the preclinical study, several routes of 
administration are tested.
To explore whether the route of administration affected inhibitory activity, pOmCI and 
OmCI-Fc were injected sc in C57B1/6 mice (two mice in each group). The animals were tail 
bled before reagent administration and then at different time points post-injection. 
Complement activity was quantified by CH50, expressed as percent lysis obtained before 
treatment as described before and compared to those values obtained from the previous 
experiment when the reagents were given iv. As seen in Fig.7.6A, single sc or iv injection of 
pOmCI provided complete complement inhibition one hour post administration.
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Fig.7.6 Comparison of sc and iv routes of administration of pOmCI and OmCI-Fc.
Mice (two mice in each group) were given with OmCI reagents sc. Inhibition data are 
plotted alongside those when the reagents were administered iv (obtained from previous 
experiment, fig.7.5). CH50 was determined by haemolysis assay. The results are expressed 
as percent complement activity compared with the pre-administration levels.
However inhibition lasted longer when the reagent was administered sc. No measurement 
was taken at 6 hours post iv injection o f pOmCI (Fig.7.6 A). Serum complement 12 hours 
after sc administration of pOmCI showed lower haemolytic activity than when pOmCI was 
given iv. The mice that received OmCI-Fc iv showed no detectable complement activity at 1 
hour after the drug administration while the same effect was achieved 12 hours after sc 
injection of this reagent.
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7.2. Targeting of CD59-CRIg in vivo and ex vivo
CD59-CRIg fusion proteins were designed to bind to cell surfaces under attack by 
complement. Among the six targeted reagents, CD59-2a-CRIg showed good therapeutic 
properties in vitro. For this reason this agent was taken for further analysis to assess whether 
it retained targeting function in vivo. Two animal models, antibody dependent experimental 
autoimmune encephalomyelitis (ADEAE) and the ApoE model of atherosclerosis, were 
chosen to investigate the ability of CD59-2a-CRIg to target C3b/iC3b deposition at the site 
of pathology. These models were selected as pathology in both models was shown to 
involve the terminal pathway and CD59-2a-CRIg reagent could provide valuable therapy.
7.2.1. ADEAE
The ADEAE mouse model was already established in our laboratory. ADEAE is an acute 
model of multiple sclerosis. Complement, and the terminal pathway in particular, has been 
shown to be essential for demyelination and axonal damage in this disease [224, 225]. The 
model is characterised by a disruption of the blood-brain barrier and thus allowing for the 
delivery of therapeutic reagents to the central nervous system (CNS). To investigate whether 
CD59-2a-CRIg was able to bind C3b and iC3b fragments in diseased spinal cord ex vivo and 
in vivo, ADEAE was induced in six CD59a deficient male mice as described (Chapter 2, 
section 2.8.6). A schematic of disease induction is illustrated in Fig 7.7. CD59a-/- animals 
were chosen in order that anti-CD59 antibody could be used for detection of CD59-2a-CRIg. 
Briefly, mice were immunised with emulsion containing rMOG in CFA supplemented with 
Mycobacterium tuberculosis. Before onset of disease (day 8), mice received anti-mouse 
MOG mAh (clone Z12, mouse IgG2a with high complement fixing capacity) [223]. The 
mice were monitored daily for development of disease symptoms which were scored as 
follows: 0, no disease; 2, hind limb weakness; 3, hind limb paralysis; 4, moribund and 5, 
dead. Disease signs were first apparent on day 10 and 100% of mice developed clinical 
disease. When the disease severity reached a clinical score of 2 (on day 11), four of the mice 
were injected with lOOpg CD59-2a-CRIg and the remaining two received PBS iv. The 
animals that received CD59-2a-CRIg were randomly divided in two groups, which were
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sacrificed at one or three hours after the drug administration. Spinal cord was harvested and 
frozen sections prepared.
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Fig.7.7 Induction of ADEAE. On day 0, mice (7 weeks old males) were immunised with 
200pl of 1:1 emulsion of rMOG (50pg) and CFA containing 2.5mg/ml Mycobacterium 
tuberculosis H37 Ra. Mice also received 200ng of pertussis toxin ip in PBS on days 0 and 2. 
Anti-MOG antibody (Z12) was injected ip at day 8. The animals were weighed and 
monitored daily for signs of clinical disease. 0, no clinical signs; 1, tail atony; 2, hind-limb 
weakness; 3, hind-limb paralysis; 4, moribund; 5,dead. Animals that had a clinical score of 2 
(day 11) at monitoring were injected with 200pl of lOOpg of CD59-2a-CRIg or PBS 
intravenously. The mice were sacrificed while under terminal anaesthesia and spinal cord 
was harvested one or three hours after CD59-2a-CRIg administration. The spinal cord was 
immediately frozen in OCT on dry ice.
7.2.1.1. Identification of ligands for CRIg, C3b and iC3b, in diseased tissue
Deposition of C3b and iC3b in spinal cord was assessed in ADEAE and in naive mice by 
immunohistochemical analysis. Two different rat anti-mouse C3 monoclonal antibodies, 
clones 11H9 and 2/11, were used to identify the site of complement activation (Fig.7.8). 
Initially, anti-C3 mAb clone 11H9 was used to detect C3 fragment deposition. It specifically 
recognises C3 and its break down products C3b, iC3b and C3d. To prove that the staining 
observed with 11H9 was due to the presence of the ligands for CRIg, C3b and/or iC3b, and
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not the further cleavage fragment C3d, anti-C3 mAh clone 2/1 lwas also used. This antibody 
does not bind C3d. Nuclei were visualised with the DNA counterstain DAPI (diamidino-2- 
phenylindole).
Staining with DAPI revealed subpial (underneath the pia mater) and perivascular infiltration 
of cells in ADEAE but not in healthy spinal cord (Fig.7.8 A). Staining for C3 fragments 
using both anti-C3 antibodies was negative in the spinal cord from a naive mouse (Fig.7.8 B, 
bottom panels). In contrast, C3 deposition was evident in ADEAE spinal cord. C3 fragments 
were deposited in the areas of cell infiltration. This deposition was specific, as an isotype 
control did not show any staining (not shown).
7.2.1.2. Ex vivo and in vivo targeting of reagents to demyelinating lesion
Having demonstrated deposition of CRIg ligands, C3b and iC3b, the ability of CD59-2a- 
CRIg to target the site of pathology was investigated ex vivo. Spinal cord cryosections from 
the mice with ADEAE and treated with PBS were incubated with CD59-2a-CRIg/488. 
Nuclei were stained with DAPI.
As seen from the merged images in Fig.7.8 C, CD59-2a-CRIg was clearly localised in areas 
of cell infiltration. This region correlated with C3b and iC3b deposition illustrated in Fig. 
7.8 B. No CD59-2a-CRIg staining was detected in spinal cord from a naive mouse indicating 
that CD59-2a-CRIg targeted specifically to C3 activation fragments.
To assess the capacity of CD59-2a-CRIg to target complement activation in vivo, spinal cord 
sections from ADEAE mice injected with CD59-2a-CRIg and from naive mice were probed 
with anti-CD59 mAb. No CD59-2a-CRIg was detected in the spinal cord at any of the time- 
points (data not shown). The directly conjugated CD59-2a-CRIg/488 reagent was not tested 
in vivo.
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Fig.7.8. Immunohistochemical analysis of spinal cord from mouse with ADEAE and 
naive mouse and ex vivo targeting of CD59-2a-CRIg. ADEAE was induced in CD59-/- 
mice. Spinal cord was isolated when the disease reached clinical score of 2. Schematic 
representation and DAPI staining (ADEAE and naive spinal cord section) with the area used 
for analysis indicated in dotted square (A). Representative lumbar cryosections were 
analysed for deposition of C3 fragments (B) and CD59-2a-CRIg localisation (C). C3b and 
iC3b deposition was assessed using two rat anti-mouse C3 mAbs, clone 11H9 binds C3 and 
its breakdown fragments and clone 2/11 interacts with C3b and iC3b. CD59-2a-CRIg ex vivo 
targeting was assessed using CD59-2a-CRIg conjugated with Ana Tag Hilyte fluor 488. 
Sections were counterstained with DAPI (blue) to reveal cell nuclei and provide a means of 
imaging the negative sections. Staining is shown as merged images. Images are taken x40 
objective and are representative of n=2.
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7.2.2. Atherosclerosis
The ApoE mouse model of atherosclerosis was already established in our laboratory. To 
investigate whether CD59-2a-CRIg was capable of targeting C3 activation in atherosclerotic 
plaques, ApoE-/-/CD59-/- double knockout mice on a high-fat diet received 200pg of CD59- 
2a-CRIg (three mice) or PBS (two mice) intravenously. The body weight was measured and 
the mice were sacrificed 30 minutes or 1 hour post- administration. Serum sample and 
brachiocephalic artery were harvested. Feeding a high fat, cholesterol-enriched diet for 8 
weeks to male ApoE-/- mice results in innominate/brachiocephalic plaque rupture with 
mural thrombosis and intra-plaque haemorrhage [410], The innominate/ brachiocephalic 
trunk is a small segment of artery situated between the ascending aortic arch and the 
bifurcation of the right subclavian artery from the right carotid artery (Fig.7.9A).
Frozen sections of brachiocephalic artery with plaques from mice injected with CD59-2a- 
CRIg and PBS were analysed for deposition of C3 fragments. Sections were also incubated 
with CD59-2a-CRIg/488 to study ex vivo targeting. In vivo targeting was assessed by 
staining of brachiocephalic artery sections obtained from mice injected with CD59-2a-CRIg 
with anti-CD59 mAb.
7.2.2.1. Identification of ligands for CRIg, C3b and iC3b, in diseased tissue
Deposition of C3 activation products in atherosclerotic plaques of ApoE-/-/CD59a-/- mice 
has already been demonstrated [242]. To confirm the presence of CRIg ligands, C3b and 
iC3b, in atherosclerotic brachiocephalic arteries in this experiment, frozen sections were 
stained with anti-C3 mAb clone 2/11.
The immunohistochemical analysis revealed that C3b or/and iC3b was deposited in the 
atherosclerotic plaques (Fig 7.9B). The control staining with an irrelevant isotype-matched 
monoclonal rat antibody instead of the specific antibody was negative. Comparison with a 
naive (non-diseased) vessel was not appropriate as no plaque would be formed for analysis.
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12.2.2. Ex vivo targeting of reagents to atherosclerotic plaques
To investigate whether CD59-2a-CRIg was able to bind to the C3b and iC3b detected in the 
tissue, brachiocephalic sections were incubated with CD59-2a-CRIg/488 ex vivo. The 
analysis revealed that the fusion protein bound to the tissue section within the plaque area 
(Fig.7.9 C). Moreover, the CD59-2a-CRIg staining pattern resembled that obtained with the 
anti-C3 mAb. This suggests that CD59-2a-CRIg interacts with C3b and iC3b deposited in 
the disease tissue.
To investigate whether CD59-2a-CRIg binding co-localised with the C3b and iC3b 
fragments, cryosections were double-stained. The brachiocephalic artery was incubated with 
anti-C3 mAb and with CD59-2aCRIg/488 simultaneously. The anti-C3 antibody bound the 
C3 fragments deposited in the plaques, but CD59-2a-CRIg protein could not be detected. It 
is possible that CRIg and the antibody competed for the same C3b/iC3b epitope, thus CD59- 
2a-CRIg was not able to interact with iC3b and C3b in presence of the anti-C3 antibody.
1.22.3. Plasma levels of CD59-2a-CRIg in treated atherosclerotic mice and in vivo 
targeting of reagent to atherosclerotic plaques
To study whether CD59-2a-CRIg could target C3 activation in vivo, mice were injected with 
the CRIg reagent or PBS and were sacrificed 30 minutes or 1 hour post administration. The 
presence of CD59-2a-CRIg in the circulation of experimental animals at the time of tissue 
harvest was assessed by ELISA. A dilution series of the serum samples collected from the 
experimental mice was prepared and incubated on ELISA plates coated with mouse anti­
mouse CD59 mAb. The CD59-2a-CRIg was detected with a non-competitive rat anti-mouse 
CD59 mAb. The serum concentration of CD59-2a-CRIg was calculated from a standard 
curve generated using pure CD59-2a-CRIg protein. As seen in Fig.7.10, CD59-2a-CRIg was 
present in the circulation at the two time points chosen in this experiment (30 minutes and 1 
hour after administration). The serum concentration of the reagent was between 28 and 
78pg/ml (Fig.7.10). No CD59-2a-CRIg was detected in the mouse injected with PBS.
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Fig.7.9 Deposition of C3b and iC3b and localisation of CD59-2a-CRIg in 
atherosclerotic brachiocephalic arteries ex vivo. The brachiocephalic artery, the third 
branch of the aorta and the first branch from the arch of the aorta, is indicated with a dotted 
square on the diagram of the proximal aorta (A) from diseased ApoE-/-/CD59a-/- mice (A). 
Frozen sections were stained with rat anti-mouse C3 mAb specific for C3b and iC3b (red) 
(B) and with CD59-2a-CRIg/488 (green) (C). Nuclei were stained with DAPI (blue). Inset 
image shows isotype antibody (rat IgG l) control staining. Merged images are presented.
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To assess whether CD59-2a-CRIg reagent was able to target C3b/iC3b fragments, 
brachiocephalic artery sections from mice injected with this reagent were incubated with rat 
anti-CD59 mAb followed by incubation with anti-rat IgG conjugated with alexa 488. CD59- 
2a-CRIg could not be localised and no immunoreactivity was observed in any of the time- 
points (data not shown).
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Mouse Time of harvest Body weight 
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CD59-2a-CRIg 
plasma level 
(pg/ml)
1 30min 35 28
2 1 hour 30 78
3 1 hour 48 30
4 PBS lhour 61 0
Fig.7.10 Identification of CD59-2a-CRIg in plasma of mice with atherosclerosis.
Atherosclerosis was induced in CD59-/-ApoE-/- mice. Animals 1, 2 and 3 received CD59- 
2a-CRIg and mouse 4 was injected with PBS. Body weight was measured and mouse 1 was 
sacrificed 30 minutes after the administration and mice 2, 3 and 4 were sacrificed one hour 
after injection. Serum samples were collected and subjected to ELISA. Dilution series (1:2) 
were prepared from the test serum and added to 96-well plate coated with mouse anti-mouse 
CD59 mAb. The assay was developed with rat mCD59a-7. Serum CD59-2a-CRIg 
concentration was determined from a standard curve. The calculated CD59-2a-CRIg levels 
along with the body weights are listed.
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f7.3 Discussion
Understanding the behaviour of drugs in a biological system is of high importance in 
treatment of disease. Pharmacokinetic parameters for protein drugs include measurement of 
circulatory half-lives, volumes of distribution, clearance rates and total bioavailability. One 
of these parameters (the in vivo half-life) was characterised for OmCI-Fc.
Clearance of protein drugs from the systemic circulation begins with passage through the 
capillary endothelia. Drugs are eliminated from the body through proteolytic, renal, hepatic, 
and receptor-mediated mechanisms. Small proteins (<30kDa) such as pOmCI and peptides 
are efficiently filtered by the glomerulus and then excreted. The liver also plays an important 
role in the removal of proteins from the systemic circulation. There are several strategies to 
reduce the clearance rates of proteins from peripheral blood circulation, such as covalent 
attachment of polyethylene glycol (PEG, PEGylation) [411], fusion to serum albumin or 
serum albumin binding receptor or fusion to the Fc portion of antibody.
Attachment of PEG increases the molecular weight of the protein and hence prolongs its 
circulating life. PEG is hydrophilic long chain molecule capable of forming a protective 
shield around the therapeutic reagent in aqueous solution, thus diminishing the 
immunogenicity of the drug [412]. However, the use of PEGylation is limited by the number 
and distribution of polyethylene glycol attachment sites such as lysyl e-amino groups 
(epsilon amino groups of lysine residues) and the high cost of PEGylation agents. 
PEGylation can also mask the effector function of the drug [413].
An alternative method to extend circulating half-life of a drug is fusion of the therapeutic to 
a protein with a long half-life or to a receptor which binds such a protein. Serum albumin 
with its half-life of up to 19 hours (in human blood) and its abundance is a suitable candidate 
as a carrier protein. Fusion of therapeutic reagents to serum albumin, or serum albumin 
binding receptor from Streptococcal protein G, extends circulating half-life when compared 
to the non-fused drugs (from two to four fold increase) [309, 414-416].
Here, I extended the half-life of OmCI by fusion to the Fc of mouse IgG2a antibody. The Fc 
region is the part of the antibody important for the half-life and the distribution of the 
molecule in the body. Fc binds to receptors on cells and modulates the serum half-life of the
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antibody. FcRn interacts with the Fc portion of IgG and other Fc molecules that are 
otherwise destined for degradation, and thereby selectively extends their half-lives in the 
circulation (Fig.7.11).
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Fig. 7.11 Schematic diagram showing FcRn recycling of OmCI-Fc and IgG. Endothelial 
cells internalize serum OmCI-Fc and IgG, which bind to FcRn in an acidic endosomal 
compartment. FcRn (in green) is a heterodimer consisting of a non-classical MHC-I-related 
glycoprotein noncovalently bound to |32-microglobulin. The Fc portion of OmCI-Fc and IgG 
bind with high affinity to FcRn at acidic pH (<6.5) but not at physiological pH (7.4). FcRn 
then recycles OmCI-Fc and IgG back into circulation, thus extending their serum half-life. 
Serum proteins without a recycling receptor are destined for lysosomal degradation. The 
figure is adapted from Roopenian and Ahreeram. Nature Reviews Immunology. 2007.
The proteins in the bloodstream enter the endothelial cells and endosomes via fluid-phase 
endocytosis as cells sample their environment. Fc containing molecules are able to bind 
FcRn expressed within the endosomes. Fc has a greater binding affinity for FcRn in the 
endosome (pH6.0-6.5) than at the cell surface (pH7.4) because a favourable interaction
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between Fc and FcRn is induced by the protonation of certain histidines (pKa=6.4) within 
the Fc domain at the lower pH [417, 418]. The binding to FcRn to Fc enhances the recycling 
of IgG back to the cell surface. This recycling mechanism decreases the amount of IgG that 
is degraded in the lysosomes. Dissociation of the Fc fragment from FcRn at the cell surface 
then releases IgG back in to the bloodstream.
In addition to increasing half-life due to the receptor-dependent rate of clearance, attaching 
an Fc fragment to OmCI increased the molecular weight of the reagent and thus reduced its 
clearance through the kidney. It is likely that the primary route of OmCI-Fc clearance 
(similar to antibodies) is via proteolytic catabolism.
The presence of pOmCI and OmCI-Fc was analysed in C5 deficient and C5 sufficient 
animals. In the absence of C5, pOmCI was rapidly cleared (within an hour) whereas, OmCI- 
Fc was apparent at 96 hours after administration (Fig.7.1). The half-life of OmCI-Fc and 
pOmCI was also determined in C5 sufficient mice. The reagents injected iv bind C5 and the 
complex circulates in the body thus the half-life determined is that of the complex, not free 
OmCI [176]. The plasma concentration-time profiles following iv administration were 
described by a two-compartment model with linear elimination where the drug half-life is 
independent of the concentration and the clearance is independent of the dose and dosing 
intervals. Small molecules such as pOmCI follow linear clearance (characterised by first- 
order kinetic). The half-life of an antibody is determined by the Fc portion. It is likely that 
the OmCI-Fc has a pharmacokinetic profile similar to an antibody molecule. It has been 
shown that many antibodies directed against cell-surface antigens exhibit non-linear (dose- 
dependent) pharmacokinetic behaviour whereas antibody specific to soluble antigens often 
exhibit linear behaviour (dose-independent) [419, 420]. OmCI-Fc binds plasma C5 and 
therefore it was assumed that it exhibited linear clearance because the primary route of 
clearance would be limited to catabolism.
Using the linear model of elimination, pOmCI had a half-life of 38 hours, while the half-life 
of OmCI-Fc was 96 hours, demonstrating that the fusion to Fc prolonged the half-life of 
OmCI/C5 complex 2.5-fold. The short-lived pOmCI would require frequent administration, 
while the longer circulating half-life in vivo of OmCI-Fc would reduce the frequency of 
injections to achieve comparable complement-inhibitory effects. This rapid decline in 
plasma concentration of pOmCI is indicative of rapid distribution of the drug into highly
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perfused organs such as liver, lung, spleen and kidney. It is important to note that the ELISA 
used here to quantify pOmCI and OmCI-Fc in plasma did not distinguish free molecules 
from those in complex with C5. As described earlier, OmCI-C5 is a long-lived complex and 
this explains the higher half-life values obtained here compared to other Fc fusion proteins.
Having established that OmCI-Fc had a long circulating half-life, the capacity of OmCI-Fc 
to inhibit complement in vivo in mice, and the optimum dose and route of administration 
was investigated and compared to pOmCI. The experiments revealed that the short-lived 
pOmCI (200pg) had a capacity to inhibit complement for approximately an hour, while the 
reagent with extended half-life, OmCI-Fc (300jng) demonstrated longer lasting complement 
inhibitory effect in vivo. Based on these data, a strategy using both pOmCI and OmCI-Fc 
was developed to effectively inhibit complement long-term. The iv injection of 200pg of 
pOmCI was chosen to block circulating C5 and to achieve rapid systemic C5 inhibition for 
an hour. A preliminary experiment measuring serum C5 activity in serum from mice treated 
with pOmCI followed by iv injection of 50jng or 150pg OmCI-Fc to wipe out the newly 
synthesised C5, demonstrated the ability of OmCI-Fc to block complement in vivo in a dose 
dependent manner. C5 activity of 70% was measured in the mouse treated with 50pg OmCI- 
Fc while only 28% was detected in the mouse that received the higher dose after 48 hours of 
the treatment. The percentage of C5 activity determined in this experiment did not 
necessarily directly translate to an equivalent percentage of circulating C5 level. This is due 
to the fact that only a single C5 molecule is needed to form a MAC and to observe any 
complement inhibition at this level, majority of the C5 molecules should be neutralised. For 
example 28% of C5 activity (measured here) was likely to correspond to lower (than 28%) 
protein level.
A separate experiment measuring total serum complement activity after iv administration of 
a combined pOmCI (200pg)/OmCI-Fc (300pg) dose revealed very low (27%) complement 
activity after the first 24 hours. However, a similar level of complement activity was 
detected in the mice that received OmCI-Fc alone. It is likely that the effect of OmCI-Fc in 
the combined staggered dose masked the pOmCI-mediated complement inhibition. This 
suggests that the pOmCI and/or OmCI-Fc concentration could be decreased. The lowest 
dose and optimal duration of the treatment remain to be determined. However if the 
maximum C5 concentration in plasma is 80pg/ml (C5 concentration range 50-80pg/ml [421,
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?422]) and plasma volume of a mouse is 3.5% of the body weight (3.5ml/100g) then the C5 
pool in a 25g mouse is 70pg. The molecular weight of C5 is 190kDa and the molecular mass 
of pOmCI is 17kDa, therefore 6.4pg of pOmCI would be needed to neutralise 70pg C5. The 
binding interaction pOmCI-C5 is very tight (as shown from the SPR analysis in Chapter 6; 
Kd of 0.4nM) meaning that this dose of pOmCI (approximately 0.4pM) should be sufficient 
to bind all C5 and oblate complement lytic activity in a mouse. Therefore the optimal 
strategy would be to inject mice with 6.5pg of pOmCI (30-lold less than the dose used in 
here) followed by OmCI-Fc given one hour later. The minimum effective does of OmCI-Fc 
needs to be determined experimentally by titrating the reagent in vivo.
Differing routes of administration of OmCI were also investigated. The iv and sc routes are 
the most frequently used routes of therapeutic administration. Because of gastrointestinal 
enzymatic degradation of the protein molecules, the oral route was not feasible. pOmCI and 
OmCI-Fc were given iv or sc to mice and their effect on complement activity was 
monitored. The analysis revealed that the reagents were efficiently delivered to the 
circulation and effectively blocked C5 after iv and sc injection. However pOmCI and OmCI- 
Fc absorption from the sc route was slow, with peak functional activity occurring 
approximately 1-6 hours after pOmCI administration and 12 hours post OmCI-Fc injection. 
Subcutaneous injection of pOmCI resulted in longer lasting complement inhibition when 
compared to iv administration. In contrast to pOmCI injected iv, pOmCI given to the animals 
sc gradually entered the circulation and provided extended complement inhibition. OmCI-Fc 
injected sc blocked C5 and showed level of complement activity similar to OmCI-Fc when 
given iv however there was an initial delay of an approximately 12 hours in this effect. 
OmCI-Fc took a longer time to reach the circulation and block C5 compared to the small 
pOmCI. Protein-based therapeutics given sc enter systemic circulation via the blood 
capillaries or lymphatic system depending on their molecular weight [423]. Proteins with 
molecular weights larger than 16kDa are predominantly absorbed by the lymphatic system, 
while smaller proteins are absorbed by blood capillaries. Proteins that enter systemic 
circulation via the lymphatic system require a longer time to reach maximum concentration 
( t m a x )  than protein drug absorbed via the blood capillaries [424]. In other words t m ax  is 
increased with increasing molecular mass of the therapeutic [423]. For example the 
absorption of antibody administered sc proceeds slowly and tmax ranges from 2 to 8 days
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[425]. Although additional experiments are required, the results suggested that sc 
administration might be advantageous in OmCI based anti-complement treatment.
Two animal models were chosen to study the ability of CD59-2a-CRIg to target to sites of 
complement activation, and localisation to C3b/iC3b in particular, was investigated. Mouse 
models of multiple sclerosis (ADEAE) and atherosclerosis (ApoE model) were selected 
because of the well-defined role of the complement and the terminal pathway in the disease 
pathology. Deposition of C3 fragments and binding of CD59-2a-CRIg to disease tissues 
were investigated by immunofluorescence microscopy.
ADEAE is an acute demyelinating model of MS. The disease was induced in CD59-/- mice 
on C57B1/6 background. C57B1/6 is one of the commonly used mouse strain in 
neuroimmunological disease including MS and CD59 deficiency was required because anti- 
CD59 mAb was used for CD59-2a-CRIg detection. ADEAE is characterised with severe 
pathology. This model was selected because the disruption of the BBB which allowed 
transport and localisation of CD59-2a-CRIg to the CNS. CD59-2a-CRIg targeting was 
analysed ex vivo and in vivo.
For the ex vivo analysis, CD59-2a-CRIg was labelled with a green fluorophor. This allowed 
direct detection without using antibody and thus reduced the washing steps and preserved 
CRIg-C3b/iC3b interaction. When diseased spinal cord sections were incubated with a 
directly labelled reagent, it was found that the CD59-2a-CRIg localisation pattern resembled 
those for C3b/iC3 deposition. The C3b and iC3b staining co-localised with cell infiltrates 
shown in the spinal cord from ADEAE mice but not from healthy animals. An additional 
experiment using a control protein is required to confirm that CD59-2a-CRIg spesificaly 
targets complement activation ex vivo.
For the in vivo targeting, CD59-2a-CRIg reagent was injected in ADEAE mice at day 11. 
The reagent could not be detected in the spinal cord one or three hours post administration. 
A possible reason for this could be that the time chosen to harvest tissue sample was not 
appropriate and more time was required for CD59-2a-CRIg to reach the site of pathology 
(spinal cord). Additional time points could be also included in order to determine the time 
frame in which the reagent reached the target. In addition to time, a physical obstacle could 
also account for negative in vivo targeting. The passage of compounds from the blood to the
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CNS is controlled by the brain capillary endothelial cells forming BBB. The restriction of 
brain penetration is due to the tight junctions between adjacent cells. However the integrity 
of the BBB is lost in animal models of multiple sclerosis [426, 427]. Furthermore, the anti- 
MOG antibody injected at day 8 amplifies the disease pathology through binding to MOG of 
the myelin sheath and triggering complement activation [223]. This means that the antibody 
needs to cross the BBB barrier in order to cause exacerbation of CNS inflammation and 
demyelination suggesting that the BBB was disrupted at the time of CD59-2a-CRIg injection 
at day 11. Another explanation for this result could be that the high number of washes 
during the staining had a detrimental effect on CD59-2a-CRIg binding to C3b and iC3b. 
This could be possibly avoided if CD59-2a-CRIg/488 was used for in vivo targeting.
The second model tested here was ApoE model of atherosclerosis. The disease was induced 
in ApoE-/- CD59-/- double knockout mice. ApoE, a glycoprotein synthesised mainly in the 
liver and brain, is a constituent of most of the lipoprotein. It functions as receptors that clear 
chylomicrons and very low-density lipoprotein remnants. ApoE is also synthesised by 
monocytes and macrophages in vessels and it plays a role in clearing cholesterol-rich 
lipoproteins from plasma to maintain cholesterol homeostasis [428, 429]. Targeted deletion 
of the gene for ApoE leads to impaired clearing of plasma lipoproteins and atherosclerosis. 
The pathogenesis of atherosclerotic lesions in these mice resembled that found in humans. 
The terminal complement pathway was found to contribute to the development of this 
disorder. The lack of CD59 in mice worsened disease pathology and increased the plaque 
area [242].
Similarly to ADEAE, deposition of CRIg ligands, C3b and iC3b, was shown in the diseased 
tissue (brachiocephalic artery) isolated from mice with atherosclerosis. The analysed C3 
fragments were found in the atherosclerotic plaques. Directly labelled CD59-2a-CRIg/488 
effectively target complement activation fragments when added to diseased tissue ex vivo. 
Double C3b/iC3b and CD59-2a-CRIg was also tested. It is very likely that the reagent 
competed with the anti-C3 antibody for the same C3b/iC3b epitope and therefore CD59-2a- 
CRIg was not able to interact with its ligands. This finding supported the observation that 
the anti-complement agent specifically targeted complement activation fragments deposited 
at the site of pathology.
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For in vivo analysis, CD59-2a-CRIg was administered iv into diseased mice and the high 
plasma levels (28-78pg/ml) of CD59-2a-CRIg detected at the time of sacrifice in the 
circulation confirmed the efficacy of injection. Similarly to the ADEAE model, CD59-2a- 
CRIg could not be detected at the site of pathology after intravenous injection. This could 
not be explained by the lack of the CRIg ligands within the atherosclerotic vessel. C3b and 
iC3b were found within the plaque beneath the endothelial wall as demonstrated by 
immunohistochemistry. It is highly likely that the intact vessel wall was an obstacle 
preventing CD59-2a-CRIg from reaching the target. The result obtained here could also be 
due to the high number of washes during the staining procedure as explained earlier for 
ADEAE model. This could be investigated by using directly labelled CD59-2a-CRIg/488 
reagent.
The analysis performed in this Chapter clearly demonstrated that CD59-2a-CRIg was able to 
target complement activation at the site of pathology. The reagent effectively targeted 
C3b/iC3b complement fragments ex vivo. Additional analysis is required to demonstrate that 
CD59-2a-CRIg is capable of targeting complement activation in vivo.
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Chapter 8. Final Discussion
The overall aim of the proposed study was to design and develop effective novel anti­
complement biologicals. Long-lived OmCI-Fc and targeted CRIg-CD59 reagents were 
generated and comprehensive characterisation was carried out in vitro, ex vivo and in vivo.
Complement is a central element of innate immunity, defending the host against pathogens, 
synchronising various events during inflammation, and linking innate and adaptive immune 
responses. However disturbance in complement regulatory mechanisms can turn 
complement from a defensive to an attacking system contributing to the pathology of many 
diseases. The potential therapeutic value of inhibiting complement was illustrated in Chapter 
1. Anti-complement therapy began with CVF in 1971 [430], a reagent used as a proof-of- 
concept that complement inhibition could reduce disease severity in many experimental 
models of complement-mediated pathologies. However, the strong antibody response and 
the uncontrolled complement activation occurring during CVF decomplementation restricted 
its in vivo use. Since then, many different anti-complement reagents ranging from small 
natural complement inhibitors (K-76COOH), synthetic serine protease inhibitors (FUT-175), 
antibody inhibitors of complement activation and recombinant soluble forms of complement 
regulators (sCRl) were developed. Despite the success of many of the anti-complement 
therapeutics their uses in vivo have been limited. Developing anti-complement therapeutic 
agents is a challenging task and various factors including rapid clearance of small reagents 
in vivo, broad-spectrum activities and low-specificity (FUT-175), side effects of systemic 
complement inhibition in long-term treatment and the point at which to inhibit complement 
should be taken into account. These aspects were considered when designing OmCI-Fc and 
CD59-CRIg reagents.
8.1. OmCI therapy
8.1.1. pOmCI: a powerful C5 inhibitor for treatment of acute disease and conditions
Several research advances, including knock-out animals lacking terminal pathway 
complement proteins (C5 and C6) or C5a receptor, C5-neutralising antibodies, and
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recombinant C5a receptor antagonists have provided strong evidence for the involvement of 
C5 and the terminal pathway in various disorders such as RA [210] and retinal disorders 
[431, 432]. The anti-C5 reagents, pOmCI and OmCI-Fc, described in this project represent 
promising therapeutics for such disorders. The small molecule, pOmCI (17kDa) is a 
powerful complement inhibitor and the therapeutic potential of small molecules inhibiting at 
the C5 level has been already proven. C5aR antagonist (ADC-1004) is a small molecule 
(9.5kDa) that was highly effective in preclinical studies and is now a candidate for clinical 
treatment in situations where IR injury is a risk, including acute myocardial infarction, 
stroke and transplantation. ADC-1004 prevented neutrophil activation thereby reducing 
inflammation and reducing the myocardial infarction in a porcine IR model [433]. Similarly 
to ADC-1004, the therapeutic potential of pOmCI was also shown in an acute model of rat 
myasthenia gravis, where a single injection of pOmCI was able to protect rats from disease 
development [324]. The ability of this reagent to bind tightly to C5 (also demonstrated in 
this project) effectively prevented MAC formation and C5a generation. Blocking C5a, a 
powerful chemoattractant, decreased the cellular infiltration and inhibited MAC, preventing 
direct tissue damage. pOmCI given to experimental animals rapidly formed a complex with 
C5 and thus turned off the destructive power of complement instantaneously. However, 
excess reagent which did not bind C5 was rapidly cleared from the circulation so that when 
C5 was resynthesised, complement activity was quickly restored. The high synthesis rate of 
C5, 70-134pg/kg per hour (in human) [434] and the short half-life of free pOmCI increased 
the frequency of administration required to achieve effective therapy in chronic disease. 
Therefore, reagents with a molecular size below the renal clearance threshold, such as 
pOmCI (17kDa) and ADC-1004 (9.5kDa), show good therapeutic effect only in acute 
diseases and conditions [435].
8.1.2. OmCI-Fc: an excellent long-lived reagent for treatment of chronic disease
The ability of OmCI to prevent C5a formation and inhibit the terminal pathway is an 
attractive proposition in therapy, as physical damage and proinflammatory effects caused by 
MAC and C5a-activated neutrophils would be prevented whilst key physiological functions 
of the complement system, such as protection from infection and immune complex 
solubilisation, would be sustained. Preserving the upstream events of the complement
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activation such as an opsonisation would diminish side effects in treatment of chronic 
disease when long-term anti-complement therapy is required. Many disorders with 
complement-driven pathology, (including MS, RA and SLE) are chronic and as such, 
require lifelong medication following diagnosis. To generate a long-acting mouse OmCI 
therapeutic suitable for chronic disorders, OmCI was fused to the Fc portion of mouse IgG2a 
and a long-lived OmCI-Fc fusion protein was created. Fusion of proteins to the Fc domain of 
antibody has been widely used to increase half-life of many therapeutic proteins, including 
CTLA-4 (Abatacept) and TNF-a receptor (Etanercept). Abatacept and Etanercept are now in 
the clinic for treatment of various inflammatory diseases such as severe RA, moderate to 
severe polyarticular-course juvenile RA, psoriatic arthritis, ankylosing spondylitis, moderate 
to severe plaque psoriasis, MS and SLE [436-440]. The Fc-fusion strategy was previously 
used in our laboratory to decrease the plasma elimination rate of recombinant complement 
regulators (the functional domains) such as DAF and CD59. The OmCI-Fc protein 
developed in this project was designed for therapy of mouse models of chronic disease. 
Unlike other therapeutics, including Soliris (anti-C5 mAb), the OmCI functional activity is 
not species-restricted and prevents complement activation in human, mice, rats and guinea 
pigs. One of the limitations of anti-complement therapeutics is the fact that many reagents 
created are based on human regulators so the capacity to test them in chronic animal models 
of disease is limited because of their immunogenicity and species selectivity [441]. For 
example, treatment of rat CIA with human sCRl could not continue beyond five days 
because of the immunogenicity of this human reagent in animals [304]. It is highly likely 
that pOmCI, as with most other salivary components of O. moubata, is poorly immunogenic, 
thus avoiding this issue. The lack of immunogenicity is useful to the tick as it evades the 
host immune system during blood feeding [442] and thus avoids generating a host immune 
response -especially in larger hosts, such as cattle, where thousands of ticks can infest a 
single animal. Moreover no anti-pOmCI IgM response was detected in rats after receiving 
this reagent [435]. The choice of mouse Fc used in this project will allow the reagent to be 
tested in mouse models of complement-driven diseases without generating an antibody 
response. The low immunogenicity and the capacity to bind C5 from different species will 
enable OmCI-Fc to be tested, and dose and frequency of administration to be established in a 
variety of preclinical models before applying it to the clinic.
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The comprehensive in vitro analysis undertaken in this research project revealed that the 
novel reagent OmCI-Fc is a hybrid molecule which retains good anti-complement activity. 
OmCI-Fc displayed a slower plasma clearance rate and achieved longer lasting complement 
inhibition in mice compared to pOmCI. OmCI-Fc when bound to C5 demonstrated 2.5-fold 
longer p-phase half-life compared to pOmCI-C5 complex. However, the true clearance rate 
of free OmCI-Fc and pOmCI was obtained in the absence of C5. While the majority (70%) 
of the free pOmCI was cleared within the first 5 minutes after drug administration, high 
levels (52%) of OmCI-Fc were measured 6 hours post administration. Circulating fusion 
protein was detected even on day five of the experiment (Fig.7.1) suggesting that OmCI-Fc 
was suitable for long-term therapy in chronic complement-mediated diseases. The extended 
plasma half-life of OmCI-Fc translated into longer lasting C5 inhibition and thus decreased 
the frequency of injections required to effectively block complement. Sometimes biological 
activity of a fusion protein can be significantly reduced relative to the nonfused protein due 
to steric hindrance or misfolding [327, 443]. The fusion of Fc to OmCI slightly reduced the 
C5 binding affinity, so I hypothesised that C5 bound with normal affinity to one OmCI 
moiety in the fusion protein, and following occupation of the first site, with a lower affinity 
to the second site. By binding to C5, both OmCI arms of the dimeric molecule were able to 
provide cell protection from complement attack. These unique features, high C5-binding 
affinity of pOmCI and the long lasting functional activity of OmCI-Fc, were combined to 
design a strategy to achieve long-term complement inhibition. C5 would be removed with a 
bolus of OmCI, which can be readily synthesised in high quantity, and second injection of 
the long-acting OmCI-Fc would be given to neutralise “newly” synthesised C5 thereafter for 
24 hours. The strategy was modelled in mice, however the high dose of OmCI-Fc used 
masked the effect that pOmCI had on complement (pOmCI-OmCI-Fc treatment and OmCI- 
Fc alone had similar effect on complement; fig.7.5), further experiments to titrate the dose of 
pOmCI and OmCI-Fc are required to determine the minimal effective concentration of the 
reagents. Establishing the minimal dose of pOmCI and OmCI-Fc which will deliver 
effective anti-complement therapy will diminish the cost of medication of chronic disease.
Testing different routes of administration is of high importance for delivering effective 
therapy especially when using drugs with short half-life such as pOmCI. pOmCI, injected iv 
bound C5 immediately and the excess was rapidly cleared from the circulation whereas a sc 
injection allowed the reagent to be gradually released into the circulation and neutralised C5
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for hours longer compared to the iv administration. Both, the sc and iv injections of OmCI- 
Fc resulted in complete C5 blockade. The route of administration did not affect the 
functional capacity of OmCI-Fc to block complement (duration of complement inhibition) 
but only had an impact on the time needed for the blocking effect to develop. OmCI-Fc 
delivered sc took longer to enter the circulation and to neutralize complement. Because sc 
injections are more convenient for repeated treatment and are able to maintain efficient 
complement inhibition, this route of administration could be considered for OmCI therapy of 
chronic disease. Other Fc fusion proteins, including Etanercept, have proved to be effective 
treatment for chronic diseases (for example RA) when administered sc.
8.1.3. OmCI: Prospects for therapy
I have successfully generated the long-lived anti-complement therapeutic, OmCI-Fc, and 
have established an OmCI-inhibition strategy. An optimal tactic for treating specific 
complement-mediated disease must be designed. Possible approaches to further increase the 
in vivo half-life and delivery strategies will be discussed.
I have shown that OmCI-Fc demonstrated a markedly increased half-life compared to 
pOmCI in C5 sufficient mice. Attaching Fc to other complement regulators has also been 
shown to prolong their circulating half-life; that of DAF was increased from 20 minutes to 
33 hours and Crry from 7 minutes to 53 hours [324, 327]. The half-life of free (uncomplexed 
with C5) pOmCI and OmCI-Fc was not determined in this study and direct comparison with 
DAF and Crry Fc fusion proteins could not be made. However free pOmCI was observed for 
only one hour after the administration in C5 deficient mice while OmCI-Fc was detected 
even at day five of the experiment (at 96 hours) suggesting that attachment of Fc greatly 
decreased the clearance rate of OmCI. As a long-term goal, the half-life of OmCI-Fc could 
be further extended which may result in increased therapeutic capacity. Certain 
modifications, such as substitution of amino acid residues located near the Fc-FcRn interface 
within in the Fc portion, have been shown to additionally extend the half-life of antibodies 
and Fc fusion proteins. It has been demonstrated in the mouse that mutations in the Fc which 
resulted in stronger binding to FcRn at pH6 whilst maintaining similar or weaker binding at 
pH7.4, translated into longer lived molecules [444]. Human IgGl, IgG2 and IgG3 Fc double
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mutants within the FcRn-binding domain (Thr250Gln and Met428Leu) also demonstrated 
increased binding affinity to human and rhesus monkey FcRn at pH 6 and increased half- 
lives in vivo (in rhesus monkeys) compared to the wild type forms [445]. A similar approach 
could be employed to further increase the half-life of OmCI-Fc. The Fc of mouse OmCI-Fc 
(generated in this study) can be easily modified, especially as the interaction site for FcRn 
on mouse IgG2a has been already mapped [446], and tested in animal models of 
complement mediated disease prior to developing an optimal human OmCI-Fc (with human 
Fc) reagent.
In addition to FcRn, Fc of IgG antibodies interact with FcyRs on various cell types. A 
correlation between the affinity of the Fc-FcyR interaction and the half-life of Fc coupled 
molecules has been observed [447]. Fc molecules with higher affinity for FcyR were cleared 
rapidly from circulation compared to those with reduced binding affinity. This has been 
illustrated with IL-2 fused to the Fc of human IgG4 [447]. This reagent had a longer serum 
half-life compared to the high affinity IL-2-Fc proteins derived from IgGl or IgG3 which 
were cleared from the circulation faster through enhanced interaction with FcR-expressing 
cells. The same effect on half-life was achieved by site-directed mutagenesis of the FcyR 
binding site in IgGl, reducing the affinity for the receptor. This approach could be utilised to 
additionally prolong the serum half-life of OmCI-Fc. It is important to note that the sites for 
FcRn and FcyR interactions on Fc of IgG are distinct, thus mutations that impact FcRn 
binding would not affect the interaction with FcyR [383, 384, 448-450].
OmCI-Fc has been designed for treatment of chronic disease. The administration route is 
critical for patients suffering from chronic disorders requiring long-term therapy; less 
invasive routes of delivery such as sc and intranasal (/.«.) would be preferential in such 
disorders. Although they have not yet been employed in routine clinical use, there is an 
interest in the development of Fc-fusion proteins for non-invasive pulmonary delivery. 
Pulmonary epithelial cells (upper and central airways) are known to express FcRn, which 
may facilitate efficient systemic absorption of Fc fusion proteins delivered to the lung (Fig. 
8.1). Whether FcRn is expressed in mouse lung is still not clear [451, 452] however high 
molecular weight Fc fusion proteins, such as Epo-Fc (120kDa) and follicle stimulating 
hormone-Fc (128kDa), have been successfully delivered at high concentration from the air 
space across the epithelial cells into the interstitium and to the circulation in neonatal rats,
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monkeys and human volunteers after oral or i.n. administration [453]. It is very likely that 
the pulmonary route would deliver OmCI-Fc (83kDa) to the systemic circulation.
OmCI-Fc Air space
Interstitium
Blood vessel (lumen
Fig 8.1 A schematic representation of OmCI-Fc pulmonary delivery. OmCI-Fc in the air
space is captured by FcRn on the airway epithelial cells. The transport vesicles containing 
OmCI-Fc bound to FcRn do not fuse with the degradative lysosomes, but pass through the 
epithelial cell in the apical to basolateral direction and release the OmCI-Fc to the interstitial 
space (neutral to slightly alkaline pH) and the circulation. The figure is adapted from 
Roopenian and Ahreeram. Nature Reviews Immunology. 2007.
It has been hypothesised that steric hindrance between the effector and Fc moieties within 
Fc-fusion proteins may alter the Fc-FcRn interaction and hampers protein transcytosis 
through the epithelial cells [454, 455]. Monomeric Epo-Fc and Factor IX- Fc (monomeric in 
respect to the therapeutic protein and dimeric in respect to Fc) delivered i.n. have shown 
improved therapeutic efficiency (2-10-fold) compared to the dimeric forms. Monomeric 
Factor IX- Fc is currently in phase II clinical trial for treatment of Hemophilia B [454, 455]. 
If needed monomeric OmCI-Fc could be generated to improve its delivery. In the light of 
this, the combined OmCI strategy explained in this project could be modified. OmCI would 
be injected sc while OmCI-Fc would be given i.n. to achieve less invasive and sustained 
treatment of complement-mediated disease (Fig.8.2).
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Fig.8.2 OmCI therapeutic strategy for less invasive treatment of complement-mediated 
disease. pOmCI will be injected sc at time 0 to neutralize C5 in circulation. This will 
provide 6-hours complete complement inhibition. OmCI-Fc will be given i.n. at intervals. Iv 
injection of OmCI-Fc blocked complement (80% complement inhibition) for 24 hours. It 
could be hypothesized that similar or even longer lasting C5 blockade will be achieved 
through i.n. administration of OmCI-Fc.
As described in Chapter 1, the complement system has been implicated in diseases and 
conditions with organ specific pathology including organ specific IR injury, 
glomerulonephritis, RA and CNS disorders. Therefore local delivery of therapeutics could 
be beneficial in such illness. The delivery of therapeutic proteins to the CNS to treat 
neurological disease and conditions, such as demyelination, Alzheimer’s disease and brain 
tumors, is a challenging goal. The BBB is formed from tight junctions between the capillary 
endothelial cells in the brain microvasculature, which prevents free diffusion of molecules 
across the membrane and prevent most molecules from reaching the CNS from the blood 
stream. Thus the BBB blocks drug entry to the CNS and therefore is the main obstacle for 
developing effective therapy [456]. Therapeutics can be introduced directly into the CNS by 
intracerebroventricular or intraparenchymal injections, however for multiple dosing 
regimens both delivery methods are invasive, risky and expensive techniques. A strategy for 
OmCI could be developed for effective complement inhibition specifically in the CNS. An 
increasing numbers of studies suggested that i.n. delivery provides a method for bypassing 
the BBB and directly delivering therapeutic drugs to the CNS. The exact mechanism of drug 
delivery has not been entirely understood and it is likely that a combination of pathways 
involving nerves (olfactory and trigeminal nerves) connecting the nasal passages to the brain 
and spinal cord and pathways involving the vasculature, cerebrospinal fluid and lymphatic 
system convey the therapeutics from the nasal cavity to the CNS through either intra- or
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extraneuronal routes [457]. It has been shown that 11-10 delivered i.n. suppressed neurologic 
symptoms in a rat model of MS while sc administration did not [458]. Similarly, the 
anticancer drug methotrexate administered i.n. was shown to be directly delivered to the 
cerebrospinal fluid (CSF) and more effectively reduced brain tumours in rats when 
compared to systemic administration [459]. Fig. 8.3 illustrates the route by which i.n. 
administered drugs could reach the CNS.
Nasal 
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Olfactory
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of drug distribution from the nasal cavity to CNS. Following i.n.
administration, drugs come into contact with the nasal mucosa, which is innervated by 
olfactory and trigeminal nerves. Drugs can be transported through the nasal mucosa to the 
CNS by entering perivascular channels in the lamina propria (connective tissue which lies 
beneath the epithelium) or via extracellular or intracellular mechanisms involving olfactory 
and trigeminal nerves. After reaching the lamina propria, drugs can enter channels created 
by olfactory ensheathing cells surrounding the olfactory nerves, where they can access the 
CSF and olfactory bulb. From the CSF, drugs can be distributed via bulk flow mechanisms 
and mix with brain interstitial fluid throughout the brain. Drugs can also enter perivascular 
spaces after reaching the brain to be rapidly distributed throughout the CNS. Drugs that 
entered perivascular spaces from the nasal mucosa can also exit these spaces in the brain. 
These same pathways in the reverse direction are involved in the clearance of the drug from 
the CNS to the periphery.
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Comparative analysis of i.n. and iv delivery of IFN-p (~18kDa) demonstrated that i.n. 
administration produced much higher concentration in the CNS with minimal systemic 
exposure, and achieved much higher degree of delivery of intact protein to CNS than did iv 
administration [460]. Drug uptake in the CSF and brain depends on its molecular weight; 
pOmCI (17kDa) has molecular weight similar to IFN-p and therefore it is possible that 
pOmCI administered i.n. could reach the CNS to provide local complement inhibition. 
Compared with traditional drug-delivery strategies, i.n. pOmCI delivery has advantages. 
This noninvasive route of administration causes less pain and it is easily conducted by the 
patients themselves. Potential side effects of the drugs on the peripheral system could be 
minimised and also smaller amounts of drugs are required to produce the desires 
concentrations of drugs in the CNS and thus reduce the treatment cost.
Another possible way to deliver OmCI therapy across the BBB and to the CNS is through 
receptor-mediated transport. In many neurological diseases and models, including EAE, the 
BBB is disrupted enabling therapeutic reagents to enter the CNS. However the BBB and 
capillary endothelium in particular express FcRn [461]. This receptor mediates reverse 
transcytosis of Fc containing molecules from the brain to the blood [462]. For this reason it 
is possible that OmCI-attached to Fc would not provide optimal therapy for CNS diseases 
(Fig 8.4). While FcRn only transports Fc molecules to the bloodstream, other receptors such 
as the insulin receptor (IR) and transferrin receptor 1 (TfRl) are also expressed in the BBB 
(on luminal and abluminal endothelial membranes), resulting in transport of their ligands in 
both blood-brain and brain-blood directions [463]. The ability of these receptors to transport 
their ligands across the BBB to the CNS has proved beneficial for drug delivery. Highly 
selective antibodies against human insulin receptor and mouse and rat TfRl have been 
generated and used as a “Trojan horse” to transport attached drugs across the BBB [464, 
465]. The human brain-derived neutrophic factor fused to mouse anti-human insulin receptor 
mAb was specifically delivered to the brain after iv injection into rhesus monkeys. 
Antibodies that bound TfR at sites distinct from the transferring binding site enabled the 
transcytosis of avidin (64kDa) and nerve growth factor (26kDa) to the CNS [466, 467]. This 
delivery strategy could be used for delivering OmCI therapy to treat complement driven 
neurological disease such as MS. When administered iv, the bifunctional OmCI-Anti-TfR 
protein would selectively bind TfRl, expressed at high levels on brain capillaries (TfRl 
expression in rat is restricted to brain capillaries) [468, 469], which are part of the BBB, thus
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enabling transport of the drug via endogenous transport systems for Tf across the BBB. 
Following penetration of OmCI into the brain, OmCI would initiate its pharmacological 
effect. Intranasal pOmCI delivery combined with iv administration of OmCI-anti-TfR could 
provide an effective and less invasive way protection to the CNS from complement 
mediated damage in the context of disease.
Endothelial
cell
Blood
Fig. 8.4 Schematic diagram of FcRn-mediated reverse transport. The cerebral vascular 
endothelial cells are joined by tight junctions that prevent the passive the passive diffusion 
of macromolecules across the BBB in the absence of specific transporters. In some 
neurological disorders such as MS, the BBB is disrupted and therefore protein drugs such as 
OmCI-Fc are able to reach the CNS. However, the FcRn expressed in BBB mediates reverse 
transcytosis of OmCI-Fc from the CNS back into the circulation. The figure is adapted from 
Roopenian and Ahreeram. Nature Reviews Immunology. 2007
8.2. CD59-CRIg therapy
8.2.1. CD59-2a-CRIg: a unique targeted anti-complement drug
Recombinant sCD59 (non-targeted) has been previously generated, however its therapeutic 
capacity has never been tested in vivo because of its low specific activity in the presence of 
serum and small size (12kDa) leading to rapid elimination [376, 470, 471]. Due to its short 
half-life, sCD59 would require frequent administration or continual infusion to control
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complement. sCD59 has been further engineered to improve its therapeutic efficacy. 
Attempts have been made to generate more active forms of sCD59 by designing chimeras or 
fusion proteins [327, 337]. sCD59, linked to a membrane “tag”, a chemically engineered 
lipid targeting peptide, (sCD59-APT542), significantly inhibited disease progression when 
delivered to the cell surface in a rat model of AIA [365]. This proved that targeting terminal 
pathway inhibition to the cell surface was a promising anti-complement strategy for in vivo 
therapy. Novel anti-complement therapeutics, based on CD59-CRIg, were generated in this 
project to deliver complement inhibition exclusively to disease sites. Targeting CD59 not 
just to any cell membrane, but specifically to the site of complement activation, will result in 
increased local concentration of the inhibitor at the pathophysiologically relevant sites 
relative to other parts of the body. My strategy was that linking the terminal pathway 
inhibitor, CD59, to the complement receptor, CRIg, would allow delivery and localisation of 
CD59-mediated complement inhibition to the target tissue while reducing the relative 
concentration of the reagent in other tissues and in blood.
The choice of ligand used for targeting, CRIg, was driven by the fact that C3 is a central 
molecule of the complement system and its activation fragments are abundant opsonins 
deposited at sites of complement activation. Upon activation, C3 is cleaved by C3 
convertase to a small C3a peptide and a large C3b fragment, which covalently attaches to the 
cell surface before degradation to iC3b and C3dg. C3 fragments are present at sites of 
pathology in various complement driven diseases and conditions such as RA [52, 53], MS 
[54] and atherosclerosis [55, 56]. These fragments can be targeted through C3 complement 
receptors such as CRIg and CR2. The use of a complement receptor to deliver targeted 
complement inhibition has already been shown to be an effective strategy to protect host 
tissue from complement attack. Several targeted anti-complement reagents have been 
generated and their efficacy tested in various animal models of disease with complement 
driven pathology. CR2-CD59, CR2-DAF, CR2-fH and CR2-Crry were discussed in Chapter 
1. These fusion proteins utilised the ability of the first four N-terminal SCRs of complement 
receptor CR2 to bind C3 fragments C3dg and, with lower affinity, to iC3b. A macrophage 
receptor CRIg was used here to target CD59 to the site of complement activation. CRIg 
binds iC3b as demonstrated by ELISA and flow cytometry [57]. However it also interacts 
with the first fragment generated upon the C3 activation, C3b. CD59-CRIg (generated in this 
project) and CR2-CD59 fusion proteins are design to bind to C3 activation fragments at the
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cell surface and to prevent MAC formation. The interaction with the first C3 activation 
product, C3b, enables CRIg-CD59 to come into action before CR2-CD59 and thus provides 
cell protection as soon as complement attack starts. C3b deposited on surfaces is regulated 
further by conversion to iC3b, if this regulation does not occur, complement activation 
continues and amplifies C3 deposition. Anti-complement therapy would therefore benefit 
from targeting the two earliest fragments of C3 activation; this will effectively localise more 
CD59-CRIg molecules to the site of complement activation and thus provide immediate and 
powerful protection.
In the presence of membrane bound complement regulators (CR1 or Crry), iC3b deposited 
on cell is further degraded to C3dg. The agents (based on CR2 or CRIg) given to patients or 
experimental animals will be circulating in the blood stream. Because of the expression of 
the complement inhibitor CR1 on human red blood cells, I believe that most of the C3b in 
the blood (on neighbouring blood cells and endothelial tissues) would be converted to C3dg 
[58-61], therefore it is likely that CR2-CD59 reagent will be mopped up to a greater extent 
than CRIg-CD59, which does not bind C3dg. For this reason CRIg-mediated targeting might 
be advantageous over CR2 targeting and provide more effective therapy as it will survive 
longer in the circulation. Whilst studies are limited, the in vivo therapeutic effect of CR2- 
CD59 (generated by others) was described only in one animal model a model of liver 
resection [472]. This reagent has shown to be protective against IR injury and induced 
enhanced liver regeneration; the reagent has not yet been tested in other models.
By binding its target, C3b, CRIg also turns off further activity in the AP. It selectively 
blocks the AP C3 and C5 convertases while leaving the CP and LP intact to mount host 
response to pathogens [166]. Thus the CRIg-CD59 agents provide a double-hit on the 
complement system, delivering both MAC inhibition and convertase blockade, this makes 
CD59-CRIg a potential treatment for disorders known to involve both the AP and the 
terminal pathway such as aHUS [253, 255, 473, 474], RA [197, 198, 201, 202, 205, 208, 
210, 211], AMD [328, 336, 475] and MS [218, 219, 221, 224, 225, 476]. For example, 
complement inhibition with CD59-CRIg may provide effective therapy and become the 
treatment of choice for aHUS associated with factor I mutations. Factor I cleaves C3b to 
generate iC3b and C3dg. Factor I mutations (10% of the aHUS cases) result either in 
quantitative or functional deficiency of factor I [477, 478]. A hypothesis could be made that 
reduced levels of iC3b and C3dg would be deposited in the kidney (the site of pathology) in
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such patients. Although C3 fragments deposition has not been investigated in such patients, 
animal studies revealed that the only C3 fragment found on the glomerular basement 
membrane of factor I deficient mice was C3b [479, 480]. In cases like this CR2 targeting 
would not be effective while CRIg would target C3b and deliver CD59 to the site of 
complement activation.
I generated monomeric CD59-CRIg reagents with different orientations of CD59 either at 
the N- or C-terminus. The functional analysis revealed that the CD59-CRIg reagent (with 
CD59 at N-terminus) had higher capacity to inhibit the terminal pathway while CRIg-CD59 
(with CD59 at the C-terminus) demonstrated better targeting. This suggested that the N- 
terminal position within the fusion molecule was favourable in terms of functional activity 
for both CD59 and CRIg domains. The monomeric CRIg-CD59 proteins (CRIg-CD59 and 
CRIg-3-CD59) had a structure similar to that of CR2-CD59, both reagents contained a CD59 
molecule linked to a single complement receptor molecule. CD59 was either directly linked 
to CRIg to create CD59-CRIg, or the hinge of IgG3 was used to join the two molecules. 
CR2-CD59 was generated using the Gly-Ser sequence, (GGGS)2, to link the two moieties in 
one hybrid molecule [330]. In contrast to CD59-CRIg, CD59 at the C-terminus within CR2- 
CD59 reagent blocked complement more effectively than the reagent in the reverse 
orientation. The difference in the CD59 functional activity could be possibly explained by 
the different linking sequences used within the fusion proteins. This hypothesis is illustrated 
in Fig.8.5.
When CD59 was linked to the C-terminus of CRIg via the hinge of IgG3, the CD59 
functional site could not be easily accessed due to steric constraints and rendered CRIg-3- 
CD59 less functional. Similarly, the CD59 active site within CRIg-CD59 (two moieties 
linked directly without linker sequence), was likely to be partially hidden because of the 
very short distance between the two parts of the molecule. The Ser-Gly linker used in CR2- 
CD59 distances CR2 and CD59 without restraining their flexibility and thus allowed CD59 
to function well when located at the C-terminus of the molecule. Despite the long upper 
hinge (an indication of flexibility), the mouse IgG3 hinge has been shown to be fairly rigid 
resulting in reduced segmental flexibility of the IgG3 antibody [378]. Segmental flexibility 
facilitates bivalent antigen binding. Similarly to antibodies, the lack of segmental flexibility 
was likely to cause steric hindrance of CD59 and CRIg. For this reason, the more flexible
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hinge of IgG2a was also used in this project. In addition to less restricted motion, the 
presence of IgG2a hinge caused a better dimersisation of the hybrid molecule.
Using this novel strategy to assemble two CD59-CRIg proteins, a unique anti-complement 
therapeutic reagent was generated. The presence of two CRIg moieties in a single dimeric 
molecule dramatically increased the C3b binding avidity of this reagent. To the best of my 
knowledge this is the first dimeric targeted reagent developed for anti-complement therapy. 
The increased targeting capacity of CD59-2a-CRIg will translate into improved therapy for 
disease.
8.2.2. CD59-2a-CRIg: Prospects for therapy
The encouraging in vitro and ex vivo data presented in this study using the dimeric CD59- 
2a-CRIg agent, will be extended to analysis of its in vivo therapeutical potential. Diseases 
with organ specific damage in which pathology is mediated in part by the terminal and/or 
the alternative pathway such as glomerulonephritis, MS and RA will benefit from local 
(injected directly into tissue of question) CD59-2a-CRIg application. Here I propose a 
strategy for treatment of RA in experimental models. Recombinant CD59 and CRIg reagents 
have already been shown to have a therapeutic effect in models of RA. Soluble CRIg (CRIg- 
Fc) injected sc demonstrated protective effect in animal models of RA [325]. Similarly, the 
membrane-targeted CD59-APT542 agent at concentration of 250pg given intra-articularly 
markedly inhibited disease progression in a mouse model of AIA [365]. Combining the 
function of the two molecules in one therapeutic would have an additive or synergistic 
effect. As explain earlier in this chapter, the delivery approach is of a high importance when 
designing a therapeutic approach. It has been demonstrated that local drug delivery into the 
knee (intra-articular) was more efficient than systemic administration [481]. Local delivery 
into the joint could be used for CD59-2a-CRIg. Such delivery would be advantageous over 
systemic administration. The diseased joint is a significant source of complement, local 
synthesis of complement components C3, Clq, Clr/s and complement activation have been 
demonstrated [482-484] and therefore an intra-articular administration would be an 
appropriate delivery strategy to achieve instant local complement inhibition.
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Fig. 8.5 Schematic representation of CRIg-CD59 and CR2-CD59 fusion proteins and 
binding to C8. A. In this project, CD59 was linked to the C- or N-terminus of CRIg directly 
or via the hinge o f mouse IgG3 antibody; and previously others have fused CR2 (SCR 1-4) 
to the N- or C-terminus o f CD59 through linker sequences, (GGGS )2  or SS(GGGGS)3 . In 
this hypothesis, the CD59-functional active site, shown in white, within fusion proteins 
containing CD59 at the N-terminus is not sterically hindered and is available for binding to 
C8. B. Because of steric restriction (due to the nature of the hinge and orientation o f the 
proteins with respect to each other), the CD59 active site within CRIg-3-CD59 cannot be 
accessed easily. This may explain the lower complement inhibitory capacity o f CRIg-3- 
CD59 reagent compared to CD59-3-CRIg. C. In contrast to the C-terminal CD59 within 
CD59-3-CRIg, the C-terminal CD59 in CR2-CD59 protein has its active site available for 
binding to C8. This is likely due to the Ser-Gly sequence linking the two moieties. This 
linker moves apart CD59 and CR2 without causing any steric constraints (seen with the 
antibody hinge linker) allowing CD59 to function.
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Once the therapeutic potential of the mouse CD59-2a-CRIg is demonstrated in animal 
models, then a human reagent will be engineered. Point mutations in human CRIg have been 
shown to markedly enhance affinity for C3b [325]. As a long-term goal, such mutations 
could be introduced into the CRIg domain to increase targeting potential further still and to 
generate the most effective human therapeutic agent by improving targeting efficiency.
8.3. Final thoughts
The field of anti-complement therapy is rapidly evolving. The reagents created in this 
research study offer excellent prospect of specific and safe control of complement in 
diseases and conditions where the complement system is the driving force. I not only 
generated novel anti-complement reagents but also developed a unique strategy to enhance 
targeting efficiency and thus improve the potency of the drug.
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